Datasets:

tasksource

/

nli4ct

like 1

Comparison

Eligibility

NCT01313039

NCT01031446

Nursing patients are not eligible for the primary trial or the secondary trial, due to potential harm to the father from the study interventions.

Contradiction

{'Clinical Trial ID': 'NCT01313039', 'Intervention': ['INTERVENTION 1: ', ' Single Arm', ' AZ6244: AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15'], 'Eligibility': ['Inclusion Criteria:', ' Female breast cancer patient > 18 years.', ' Patients must have biopsy-proven clinical Stage Ic-III invasive breast carcinoma with 10% ER expression by immunohistochemistry (IHC) analysis.', ' Patients must have a pre-treatment baseline core biopsy or incisional biopsy available for additional testing (ER, protein/gene expression analysis).', ' Patients must have sufficient tumor remaining following diagnostic biopsy that requires an additional definitive surgical procedure per the standard of care. Planned procedure may include lumpectomy or mastectomy as clinically indicated.', ' Patients must have an ECOG Performance Status of 0 - 1.', ' Patients must have the ability to understand and willingness to sign an English or a Spanish language written informed consent document.', 'Exclusion Criteria:', ' Male breast cancer patient.', ' Patients who are pregnant or breast-feeding are excluded from the study due to potential harm to the fetus or nursing infant from the study therapy. Patients of reproductive potential must consent to use of contraception or abstinence to be eligible for the study.', ' Patients may not have received prior chemotherapy or hormonal therapy for treatment of the current breast cancer.', ' Patients should not have known or strongly suspected BRCA mutation by history (genetic testing not required).', ' Patients will have pre-study testing, including history and physical exam, complete blood count, and measurement of renal and hepatic function. Patients will be ineligible for the study if significant abnormalities are detected, in accordance with good medical practice.'], 'Results': ['Outcome Measurement: ', ' Increase of ER Protein Expression in ER-Negative/Low Breast Cancer', ' To evaluate in a clinical neoadjuvant model whether MEK inhibitor AZD6244 can increase ER protein expression in ER-negative/low breast cancer, as measured by the "ER response rate" by both standard immunohistochemistry and Allred Score.', ' Time frame: 2 years', 'Results 1: ', ' Arm/Group Title: Single Arm', ' Arm/Group Description: AZ6244: AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15', ' Overall Number of Participants Analyzed: 1', ' Measure Type: Number', ' Unit of Measure: participants 1'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/4 (0.00%)']}

{'Clinical Trial ID': 'NCT01031446', 'Intervention': ['INTERVENTION 1: ', ' RAD001 and Cisplatin and Paclitazel', ' Cisplatin intravenously (IV) weekly for 3 weeks, then 1 week of rest; paclitaxel IV weekly for 3 weeks, then 1 week of rest. Everolimus (RAD001) po daily. One cycle = 4 weeks'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed invasive mammary carcinoma', ' Stage IV disease', ' Basal-like disease (triple-negative, hormone-refractory, HER2-negative)', ' No locally recurrent breast cancer', ' No symptomatic brain metastases', ' Patients with a history of brain metastases are eligible provided they are clinically stable for > 3 weeks after completion of radiotherapy and are not taking steroids or therapeutic anticonvulsants that are cytochrome P450 3A4 (CYP3A4) modifiers', ' Patients with asymptomatic brain metastases are eligible provided they are not taking prophylactic anticonvulsants that are CYP3A4 modifiers', ' PATIENT CHARACTERISTICS:', ' Pre- or post-menopausal', ' European Cooperative Oncology Group (ECOG) performance status 0-1', ' Life expectancy 6 months', ' Absolute neutrophil count (ANC) 1,000/mm^3', ' Platelet count 100,000/mm^3', ' Creatinine 1.5 times upper limit of normal (ULN)', ' Total bilirubin 1.5 times ULN ( 3 times ULN in the presence of liver metastasis)', ' Direct bilirubin will be measured in patients with Gilbert syndrome', ' serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) 1.5 times ULN ( 3 times ULN in the presence of liver metastasis)', ' Alkaline phosphatase 3 times ULN (in the presence of liver metastasis)', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment', ' Able to swallow and retain oral medication', ' No malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel', ' No concurrent uncontrolled illness including, but not limited to, any of the following:', ' Ongoing or active infection requiring parenteral antibiotics', ' Impaired lung function (chronic obstructive pulmonary disease or lung conditions requiring oxygen therapy)', ' New York Heart Association class III-IV congestive heart failure', ' Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within the past 6 months', ' Uncontrolled hypertension (systolic BP > 180 mm Hg or diastolic BP > 100 mm Hg, found on 2 consecutive measurements separated by a 1-week period and despite adequate medical support)', ' Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment [grade 3 according to NCI Common Toxicity Criteria for Adverse Events v3.0])', ' Uncontrolled diabetes (hyperosmolar state, ketoacidosis, etc.)', ' Psychiatric illness or social situations that would compromise patient safety or limit compliance with study requirements including maintenance of a compliance/pill diary', ' No symptomatic neuropathy grade 2', ' No other invasive cancer within the past 5 years except for completely resected basal cell or squamous cell carcinoma of the skin or successfully treated cervical carcinoma in situ', ' No hypersensitivity to paclitaxel or drugs using the vehicle Cremophor, Chinese hamster ovary cell products, or other recombinant human antibodies', ' No history of hepatitis B or C', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics', ' Recovered from prior therapy', ' Prior total cumulative life-time dose of doxorubicin 360 mg/m^2 or epirubicin 640 mg/m^2', ' No more than 4 prior chemotherapy treatments in the metastatic setting (not including endocrine therapy or single-agent biologic therapy)', ' At least 2 weeks since prior investigational drugs', ' At least 14 days since prior and no concurrent herbal or dietary supplements', ' At least 14 days since prior and no concurrent CYP3A4 inducers', ' At least 7 days since prior and no concurrent CYP3A4 inhibitors', ' Concurrent radiotherapy to painful bone metastases or areas of impending bone fracture allowed provided radiotherapy is initiated before study entry', ' No other concurrent anticancer therapy (chemotherapy, radiotherapy, surgery, immunotherapy, hormonal therapy, biologic therapy)'], 'Results': ['Outcome Measurement: ', ' Maximum Feasible Dose in Milligrams Per Meter Squared of Body Surface Area (mg/m2) of Cisplatin and Paclitaxel for Women With Metastatic Breast Cancer', ' The recommended dose for the Phase II trial will be the most prevalent dose delivered per week in Phase I that allows for safe and feasible administration of the medications.The maximum tolerated dose (MTD) is defined as the dose preceding that at which 2 or more of 3 patients experience dose-limiting toxicity (DLT) during the initial cycle of therapy. DLTs include Common Toxicity Criteria (CTC) Grade 4 neutropenia (absolute neutrophil count [ANC] < 0.5 x 10 9/L for > 5 days), febrile neutropenia (ANC < 1.0 x 10 0/L with fever > 38.5 degrees Centigrade) or documented infection associated with Grade 3-4 neutropenia, CTC Grade 4 thrombocytopenia < 25 x 10 9/L or CTC Grade 3 < 50-25 x 10 9/L thrombocytopenia with bleeding, and Grade 3-4 non-hematologic toxicity despite symptomatic therapy.', ' Time frame: at 8 weeks', 'Results 1: ', ' Arm/Group Title: RAD001 and Cisplatin and Paclitazel', ' Arm/Group Description: Cisplatin intravenously (IV) weekly for 3 weeks, then 1 week of rest; paclitaxel IV weekly for 3 weeks, then 1 week of rest. Everolimus (RAD001) po daily. One cycle = 4 weeks', ' Overall Number of Participants Analyzed: 3', ' Measure Type: Number', ' Unit of Measure: mg/m2 Cisplatin: 25', 'Paclitaxel: 80'], 'Adverse Events': ['Adverse Events 1:', ' Total: 9/55 (16.36%)', ' neutrophils2/55 (3.64%)', ' leukocytes1/55 (1.82%)', ' platelets1/55 (1.82%)', ' febrile neutropenia, ANC < 1.0 x 10e9L, fever 38.5 degrees Celsius1/55 (1.82%)', ' anemia2/55 (3.64%)', ' thrombocytopenia2/55 (3.64%)', ' ventricular tachycardia1/55 (1.82%)', ' pain-abdomen3/55 (5.45%)', ' diarrhea1/55 (1.82%)', ' nausea3/55 (5.45%)', ' vomiting3/55 (5.45%)']}

2f700407-8baf-4e5f-8fc0-378a294512f5

Single

Eligibility

NCT02287675

Informed consent is optional for entry in the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT02287675', 'Intervention': ['INTERVENTION 1: ', ' Lymphoseek', ' Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma and guiding sentinel lymph node biopsy using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.', 'INTERVENTION 2: ', ' Sulfur Colloid', ' Technetium Tc 99m Sulfur Colloid Injection is a radioactive diagnostic agent indicated for use as follows:', ' In adults, to assist in the:', ' localization of lymph nodes draining a primary tumor in patients with', ' breast cancer or malignant melanoma when used with a hand-held gamma counter.', ' evaluation of peritoneovenous (LeVeen) shunt patency in adults.'], 'Eligibility': ['Inclusion Criteria:', ' The subject must be female and 18 years of age or older.', ' The subject must be a preoperative clinical Tis, T1, T2, T3, T4, as well as clinical N0 and clinical M0 breast cancer', ' The subject must have a diagnosis of primary breast cancer.', ' The subject must be a candidate for surgical intervention, either with lumpectomy and SLNB or with mastectomy and SLNB, as the treatment of her breast cancer.', ' The subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 - 2', ' The subject must provide written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before participating in the study', 'Exclusion Criteria:', ' The subject has clinical or radiological or pathologic evidence of metastatic cancer, including any abnormal or enlarged clinical palpable lymph nodes or core biopsy/surgical biopsy/fine-needle-aspiration evidence of malignant cell within any lymph nodes.', ' The subject has a known hypersensitivity to vital blue dye (VBD) in a case where vital blue dye was planned for use during SLNB.', ' The subject has a positive pregnancy test or is lactating.', ' The subject has had prior surgery to the indicated breast or axilla.'], 'Results': ['Outcome Measurement: ', ' Injection Site Clearance for Lymphoseek and 99mTc-Sulfur Colloid (SC).', ' The rate of injection site clearance is the time from radiotracer injection to peak SLN radioactive level. Injection clearance rates will be determined by planar SPECT imaging and by SPECT/CT. Subjects will undergo standard sequential planar imaging at 30 to 60 seconds intervals until the sentinel lymph node is seen. Once a sentinel node is located, a SPECT/CT will be performed for higher resolution imaging in transaxial, coronal, and sagittal planes.', ' Time frame: 2 hours', 'Results 1: ', ' Arm/Group Title: Lymphoseek', ' Arm/Group Description: Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma and guiding sentinel lymph node biopsy using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.', ' Overall Number of Participants Analyzed: 18', ' Mean (Standard Deviation)', ' Unit of Measure: minutes 1.78 (0.85)', 'Results 2: ', ' Arm/Group Title: Sulfur Colloid', ' Arm/Group Description: Technetium Tc 99m Sulfur Colloid Injection is a radioactive diagnostic agent indicated for use as follows:', ' In adults, to assist in the:', ' localization of lymph nodes draining a primary tumor in patients with', ' breast cancer or malignant melanoma when used with a hand-held gamma counter.', ' evaluation of peritoneovenous (LeVeen) shunt patency in adults.', ' Overall Number of Participants Analyzed: 22', ' Mean (Standard Deviation)', ' Unit of Measure: minutes 0.045 (0.18)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/18 (0.00%)', 'Adverse Events 2:', ' Total: ']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

cebee448-235d-49ff-8e87-56639399548b

Single

Eligibility

NCT01073865

Females over the age of 18, whose last period was 2 years prior to randomisation are eligible for the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT01073865', 'Intervention': ['INTERVENTION 1: ', ' Zoladex 10.8 mg', ' ZOLADEX 10.8 mg (goserelin acetate): one subcutaneous depot injection into interior abdominal wall once every 12 weeks', 'INTERVENTION 2: ', ' Zoladex 3.6 mg', ' ZOLADEX 3.6 mg (goserelin acetate): one subcutaneous depot injection into interior abdominal wall once every 4 weeks'], 'Eligibility': ['Inclusion Criteria:', ' Female 20 years and pre-menopausal.Pre-menopausal defined as 1) last menses within 1 year of randomisation, and 2) E2 10 pg/mL and FSH 30 mIU/mL within 4 weeks of randomisation.', ' Hormone sensitivity (ER positive) of primary or secondary tumour tissue.', ' Histological/cytological confirmation of breast cancer and are candidates to receive hormonal therapy as therapy for advanced breast cancer.', 'Exclusion Criteria:', ' Patients who have received tamoxifen or other hormonal therapies as adjuvant therapy for breast cancer within 24 weeks before randomisation and/or who have received prior treatment with hormonal therapies for advanced breast cancer', ' Patients who have received LHRHa as adjuvant therapy for breast cancer within 48 weeks before randomisation', ' Patients who have relapsed during adjuvant hormonal therapy or within 48 weeks after completion of adjuvant hormonal therapy and/or'], 'Results': ['Outcome Measurement: ', ' Number of Patients With Progression-free Survival (PFS) at 24 Weeks', ' A patient is judged as progression-free survive at Week 24 if their PFS time is at least 24 weeks with no progression event prior to Week 24 (ie, overall visit response is complete response (CR), partial response (PR) or stable disease (SD) at a tumour assessment at least 24 weeks after randomization). Overall visit response is assessed according to the RECIST version 1.1. %PFS is the proportion of patients with PFS.', ' Time frame: 24 weeks after the first dosing', 'Results 1: ', ' Arm/Group Title: Zoladex 10.8 mg', ' Arm/Group Description: ZOLADEX 10.8 mg (goserelin acetate): one subcutaneous depot injection into interior abdominal wall once every 12 weeks', ' Overall Number of Participants Analyzed: 109', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 67 61.5%', 'Results 2: ', ' Arm/Group Title: Zoladex 3.6 mg', ' Arm/Group Description: ZOLADEX 3.6 mg (goserelin acetate): one subcutaneous depot injection into interior abdominal wall once every 4 weeks', ' Overall Number of Participants Analyzed: 113', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 68 60.2%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/108 (3.70%)', ' ANAEMIA 1/108 (0.93%)', ' ENTEROCOLITIS 0/108 (0.00%)', ' PERIODONTAL DISEASE 0/108 (0.00%)', ' VOMITING 0/108 (0.00%)', ' CHEST PAIN 1/108 (0.93%)', ' PNEUMONIA 0/108 (0.00%)', ' TETANUS 1/108 (0.93%)', ' HYPERURICAEMIA 0/108 (0.00%)', ' DECREASED APPETITE 0/108 (0.00%)', ' MUSCULAR WEAKNESS 0/108 (0.00%)', ' PAIN IN EXTREMITY 1/108 (0.93%)', ' DYSPNOEA 0/108 (0.00%)', 'Adverse Events 2:', ' Total: 8/113 (7.08%)', ' ANAEMIA 1/113 (0.88%)', ' ENTEROCOLITIS 1/113 (0.88%)', ' PERIODONTAL DISEASE 1/113 (0.88%)', ' VOMITING 1/113 (0.88%)', ' CHEST PAIN 0/113 (0.00%)', ' PNEUMONIA 1/113 (0.88%)', ' TETANUS 0/113 (0.00%)', ' HYPERURICAEMIA 1/113 (0.88%)', ' DECREASED APPETITE 1/113 (0.88%)', ' MUSCULAR WEAKNESS 1/113 (0.88%)', ' PAIN IN EXTREMITY 0/113 (0.00%)', ' DYSPNOEA 3/113 (2.65%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

d3f0dd2f-a5b9-4ff4-8a6b-65c9947cb710

Single

Adverse Events

NCT02187744

sepsis, due to the presence of an implanted device was a common adverse event in the primary trial

Contradiction

{'Clinical Trial ID': 'NCT02187744', 'Intervention': ['INTERVENTION 1: ', ' PF-05280014', ' Participants received a loading dose of 8 mg/kg of PF-05280014 on Cycle 1 Day 1. Subsequent infusions followed every 3 weeks with a dose of 6 mg/kg. Taxotere 75 mg/m2 and carboplatin AUC 6 were administered on Day 1 of each cycle.', 'INTERVENTION 2: ', ' Trastuzumab-EU', ' Participants received a loading dose of 8 mg/kg of trastuzumab-EU on Cycle 1 Day 1. Subsequent infusions followed every 3 weeks with a dose of 6 mg/kg. Taxotere 75 mg/m2 and carboplatin AUC 6 were administered on Day 1 of each cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed HER2 overexpressing invasive breast cancer.', ' Plan for definitive surgical resection of breast tumor (i.e., lumpectomy or mastectomy, and sentinel node (SN) biopsy or axillary lymph node dissection (ALND).', ' Plan for neoadjuvant chemotherapy.', ' Measurable disease in the breast after diagnostic biopsy, defined as longest diameter 2.0 cm.', 'Exclusion Criteria:', ' Bilateral breast cancer.', ' Inflammatory breast cancer.', ' Presence of known distant metastases.', ' Received prior treatment, including chemotherapy, endocrine therapy, biologic therapy, radiation or surgery with the exception of diagnostic biopsy for primary breast cancer.'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Steady State Drug Concentration Ctrough (Cycle 6 Pre-dose) >20 µg/mL at Cycle 5.', ' The percentage of participants with Cycle 5 Ctrough (Cycle 6 pre-dose) >20 μg/mL in each treatment group, the denominator being the number of participants in the per protocol population for each treatment group.', ' Time frame: Cycle 5', 'Results 1: ', ' Arm/Group Title: PF-05280014', ' Arm/Group Description: Participants received a loading dose of 8 mg/kg of PF-05280014 on Cycle 1 Day 1. Subsequent infusions followed every 3 weeks with a dose of 6 mg/kg. Taxotere 75 mg/m2 and carboplatin AUC 6 were administered on Day 1 of each cycle.', ' Overall Number of Participants Analyzed: 101', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 92.1 (85.0 to 96.5)', 'Results 2: ', ' Arm/Group Title: Trastuzumab-EU', ' Arm/Group Description: Participants received a loading dose of 8 mg/kg of trastuzumab-EU on Cycle 1 Day 1. Subsequent infusions followed every 3 weeks with a dose of 6 mg/kg. Taxotere 75 mg/m2 and carboplatin AUC 6 were administered on Day 1 of each cycle.', ' Overall Number of Participants Analyzed: 89', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 93.3 (85.9 to 97.5)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 7/113 (6.19%)', ' Febrile neutropenia 1/113 (0.88%)', ' Neutropenia 1/113 (0.88%)', ' Anaemia 0/113 (0.00%)', ' Pancytopenia 1/113 (0.88%)', ' Proctitis 1/113 (0.88%)', ' Device related sepsis 1/113 (0.88%)', ' Gastrointestinal infection 0/113 (0.00%)', ' Injection site abscess 1/113 (0.88%)', ' Tooth infection 0/113 (0.00%)', ' Hip fracture 0/113 (0.00%)', ' Blood creatinine increased 1/113 (0.88%)', 'Adverse Events 2:', ' Total: 6/112 (5.36%)', ' Febrile neutropenia 2/112 (1.79%)', ' Neutropenia 1/112 (0.89%)', ' Anaemia 1/112 (0.89%)', ' Pancytopenia 0/112 (0.00%)', ' Proctitis 0/112 (0.00%)', ' Device related sepsis 0/112 (0.00%)', ' Gastrointestinal infection 1/112 (0.89%)', ' Injection site abscess 0/112 (0.00%)', ' Tooth infection 1/112 (0.89%)', ' Hip fracture 1/112 (0.89%)', ' Blood creatinine increased 0/112 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

7a981da3-dc7f-4e1f-ae5b-26e5399ba2a5

Comparison

Eligibility

NCT00676793

NCT01931163

Patients with dysphagia cannot participate in the secondary trial, but may be eligible for the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00676793', 'Intervention': ['INTERVENTION 1: ', ' ECGC and Breast Cancer', ' Single arm for a phase II study of EGCG extract and breast cancer. Subjects are asked to take 4 polyphenol E (200mg) capsules daily with a meal for the duration of the study. Biomarkers are measured at baseline and then again at presurgery, the end point for the study.'], 'Eligibility': ['Inclusion Criteria:', ' Definitive biopsy demonstrating primary breast cancer', ' Residual breast cancer requiring additional surgical resection', ' Stage I, II or III disease', ' Patient has ability to give signed informed consent', ' Normal hepatic and renal function (creatinine<1.5, transaminases <1.5 times upper limit of normal).', ' ECOG Performance status of 0 or 1.', ' Age 21 years and less than 75', 'Exclusion Criteria:', ' Prior hormonal or surgical therapy for breast cancer', ' Abnormal liver function test', ' Liver or kidney problems that would interfere with metabolism of study drug', ' Any condition that would hamper informed consent or ability to comply with study protocol', ' Participation in another research study in the last three months', ' Known malignancy at any site other than breast', ' Recent consumption of green tea (5 or more cups per day, within one week prior to biopsy)', ' Allergy or intolerance to any component of green tea', ' Inability or refusal to comply with definitive surgical therapy'], 'Results': ['Outcome Measurement: ', ' Change in Serum VEGF in Breast Cancer', ' Change in serum VEGF from baseline to post treatment with polyphenon E.', ' Time frame: Baseline and 4 to 6 weeks', 'Results 1: ', ' Arm/Group Title: ECGC and Breast Cancer', ' Arm/Group Description: Single arm for a phase II study of EGCG extract and breast cancer. Subjects are asked to take 4 polyphenol E (200mg) capsules daily with a meal for the duration of the study. Biomarkers are measured at baseline and then again at presurgery, the end point for the study.', ' Overall Number of Participants Analyzed: 19', ' Median (Inter-Quartile Range)', ' Unit of Measure: pg/ml 270 (-142.5 to 581.25)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/32 (0.00%)']}

{'Clinical Trial ID': 'NCT01931163', 'Intervention': ['INTERVENTION 1: ', ' Everolimus Plus Cisplatin', ' Everolimus 10mg by mouth daily for 12 weeks; Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles'], 'Eligibility': ['Inclusion Criteria:', ' Female patients 18 years of age.', ' Clinical/pathological documentation of residual disease after neo-adjuvant therapy.', ' Patients with synchronous bilateral cancers are eligible only if:', ' Index cancer is triple-negative, defined as ER-, PR-, and HER2-.', ' HER2 negative tumors. HER2 negativity must be confirmed by one of the following:', ' FISH-negative (FISH ratio <2.2), or', ' IHC 0-1+, or', ' IHC 2-3+ AND FISH-negative (FISH ratio <2.2).', ' Estrogen receptor negative and progesterone receptor negative (<10% staining by IHC for estrogen receptor and progesterone receptor).', ' Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.', ' Adequate hematologic function, defined by:', ' Absolute neutrophil count 2 >1000/mm3', ' Platelet count 100,000/mm3', ' Hemoglobin >9 g/dL', ' Adequate liver function, defined by:', ' AST and ALT 2.5 x the upper limit of normal (ULN)', " Total bilirubin 1.5 x ULN (unless the patient has grade 1 bilirubin elevation due to Gilbert's disease or a similar syndrome involving slow conjugation of bilirubin).", ' Adequate renal function, defined by:', ' Serum creatinine 1.5 x ULN', ' Complete staging work-up 24 weeks prior to initiation of study treatment with computed tomography (CT) scans of the chest and abdomen/pelvis (abdomen/pelvis preferred; abdomen accepted), a CT scan of the head or MRI of the brain (if symptomatic), and either a positron emission tomography (PET) scan or a bone scan.', ' Adequate cardiac function, defined by a left ventricular ejection fraction (LVEF) value of >50% (or normal per institutional guidelines) by MUGA scan or echocardiogram (ECHO).', ' Patients with previous history of invasive cancers (including breast cancer) are eligible if definitive treatment was completed more than 5 years prior to initiating current study treatment, and there is no evidence of recurrent disease.', ' Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to start of treatment. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately.', ' Patient must be accessible for treatment and follow-up.', ' Women of childbearing potential must agree to use an acceptable method of birth control to avoid pregnancy for the duration of study treatment, and for 3 months thereafter.', ' Able to swallow and retain oral medication.', ' Patient must be willing to undergo breast biopsies as required by the study protocol.', ' All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry.', 'Exclusion Criteria:', ' Women who are pregnant or breastfeeding.', ' History of previously treated ductal carcinoma in situ (DCIS) is acceptable.', ' Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.', ' Known intolerance or hypersensitivity to Everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus);', ' Previous cancer (with the exception of non-melanoma skin cancer or cervical carcinoma in situ) in the past 5 years.', ' Patients who have any severe and/or uncontrolled medical conditions such as:', ' unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction 6 months prior to start of Everolimus, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease', ' Symptomatic congestive heart failure of New York heart Association Class III or IV', ' active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and chronic hepatitis (i.e. quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA),', ' known severely impaired lung function (spirometry and DLCO 50% or less of normal and O2 saturation 88% or less at rest on room air),', ' active, bleeding diathesis;', ' Patients may not receive any other investigational or anti-cancer treatments while participating in this study.', ' Concurrent severe, uncontrolled infection or intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.', ' Mental condition that would prevent patient comprehension of the nature of, and risk associated with, the study.', ' Inability to comply with study and/or follow-up procedures.', ' Patients who have received live attenuated vaccines within 1 week of start of Everolimus and during the study. Patient should also avoid close contact with others who have received live attenuated vaccines.', ' Examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella and TY21a typhoid vaccines;', ' Known history of HIV seropositivity;', ' Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing of study treatment. Highly effective contraception methods include combination of any two of the following (a+b or a+c or b+c):', ' Use of oral, injected or implanted hormonal methods of contraception or;', ' Placement of an intrauterine device (IUD) or intrauterine system (IUS);', ' Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository;', ' Total abstinence or;', ' Male/female sterilization. Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to treatment. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child-bearing potential.', ' Chronic treatment with corticosteroids or other immunosuppressive agents. Topical or inhaled corticosteroids are allowed;'], 'Results': ['Outcome Measurement: ', ' Tumor Response', ' Evaluate tumor response using RECIST criteria after 12 weeks of treatment at definitive surgery.', ' Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.", or similar definition that is accurate and appropriate.', ' Time frame: tumor response at 12 weeks after treatment', 'Results 1: ', ' Arm/Group Title: Everolimus Plus Cisplatin', ' Arm/Group Description: Everolimus 10mg by mouth daily for 12 weeks; Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles', ' Overall Number of Participants Analyzed: 22', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 22 100.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/22 (27.27%)', ' Thrombocytopenia 1/22 (4.55%)', ' leucocytopenia 1/22 (4.55%)', ' neutropenia 1/22 (4.55%)', ' papilledema 1/22 (4.55%)', ' Nausea 1/22 (4.55%)', ' hyperglycemia 1/22 (4.55%)']}

af677d94-a376-42ea-93fe-91963a071199

Single

Eligibility

NCT00981305

Only people who have previously been diagnosed with cancer and are currently receiving ongoing treatment for their primary tumor are eliglbe for the primary trial, as long as they are over the age of 20.

Contradiction

{'Clinical Trial ID': 'NCT00981305', 'Intervention': ['INTERVENTION 1: ', ' Lactate-containing Vaginal Lubricant', ' apply 3cc of lactate-containing vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)', ' Lactate-containing vaginal lubricant: vaginal applying at least 3cc of lactate-containing lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)', 'INTERVENTION 2: ', ' Placebo', ' apply 3cc of placebo vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)', ' Placebo vaginal lubricant: vaginal applying at least 3cc of placebo lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)'], 'Eligibility': ['Inclusion Criteria:', ' breast cancer survivors over 20 years-old', ' premenopausal at the time of diagnosis', ' treated with operation and chemotherapy', ' newly developed dyspareunia after cancer treatment', 'Exclusion Criteria:', ' recent (< 2 months) start or cessation of hormonal treatment (tamoxifen etc.)', ' depression or other psychological problems', ' active vaginal infection', ' evidence of cancer recurrence', ' previously use of lactate-containing lubricants', ' other chronic diseases which severely disturb the sexual life'], 'Results': ['Outcome Measurement: ', ' Change of Pain Score of Female Sexual Function Index', ' The Female Sexual Function Index (FSFI) is a 19-item self-reported instrument used for assessing key dimensions of female sexual function over the past 4 weeks with a total of six domains being analyzed. Each of the six specific domains (desire, arousal, lubrication, orgasm, satisfaction, and pain) analyzed in the FSFI is scored on a scale ranging from 1.2 to 6.0 (desire), 0 to 6.0 (arousal, lubrication, orgasm, and pain) or 0.8 to 6.0 (satisfaction), with higher scores indicating better performance. The total score, falling in a possible range from 2.0 to 36.0, is obtained by adding the six domain scores together.', ' Time frame: Baseline and 8 weeks', 'Results 1: ', ' Arm/Group Title: Lactate-containing Vaginal Lubricant', ' Arm/Group Description: apply 3cc of lactate-containing vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)', ' Lactate-containing vaginal lubricant: vaginal applying at least 3cc of lactate-containing lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)', ' Overall Number of Participants Analyzed: 50', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale 1.15 (1.59)', 'Results 2: ', ' Arm/Group Title: Placebo', ' Arm/Group Description: apply 3cc of placebo vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)', ' Placebo vaginal lubricant: vaginal applying at least 3cc of placebo lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)', ' Overall Number of Participants Analyzed: 57', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale 1.05 (1.54)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/50 (0.00%)', 'Adverse Events 2:', ' Total: 0/57 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

6579e25e-8dcf-44b5-a50d-7c84672cba89

Single

Adverse Events

NCT00451555

Cohort 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse events.

Contradiction

{'Clinical Trial ID': 'NCT00451555', 'Intervention': ['INTERVENTION 1: ', ' Enzastaurin + Fulvestrant QD + BID', ' Participants received Enzastaurin loading dose of 1125 mg, on Day 1 of Cycle 1 only then received Enzastaurin 500 mg orally (QD) once daily in a 28-day cycle.', ' Participants received enzastaurin loading dose of 1125 mg, on Day 1 of Cycle 1 only then received Enzastaurin 250 mg orally (BID) twice daily in a 28-day cycle.', ' Fulvestrant was given intramuscularly at a loading dose of 500 mg on Day 1 and 250 mg on Day 15 in Cycle 1. Subsequent doses of Fulvestrant 250 mg were given on Day 1 of Cycle 2 and every 28 days thereafter.', '.', 'INTERVENTION 2: ', ' Enzastaurin + Fulvestrant BID', ' Participants received enzastaurin (250 mg; 2 tablets) or placebo administered orally twice daily (BID) in a 28-day cycle, until disease progression. Fulvestrant was given intramuscularly at a loading dose of 500 mg on Day 1 and 250 mg on Day 15 in Cycle 1. Subsequent doses of Fulvestrant 250 mg were given on Day 1 of Cycle 2 and every 28 days thereafter.'], 'Eligibility': ['Inclusion Criteria:', ' Female participants with a histological-documented diagnosis of locally advanced or metastatic breast cancer. The primary or metastatic tumor must be estrogen response (ER) and/or parathyroid hormone receptor (PtR) positive.', ' Note: Hormone receptor positivity is defined as ER or PtR greater than 10 fmol/mg by biochemical assay or 10% positive cells by immunohistochemistry', ' Participants are resistant to aromatase inhibitors (AI) therapy', ' Females with postmenopausal status', ' Previous radiation therapy is allowed, but should have been limited', ' Measurable or non-measurable disease', ' Have a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) scale', ' Have adequate organ function', ' Have an estimated life expectancy of at least 24 weeks', ' Must sign an informed consent document', 'Exclusion Criteria:', ' Have had prior treatment with fulvestrant or enzastaurin', ' Are receiving concurrent administration of any other antitumor therapy, with the exception of gonadotropin-releasing hormone (GnRH) antagonists.', ' Have received treatment within the last 4 weeks with a drug that has not received regulatory approval for any indication at the time of study entry', ' Have received supplemental estrogen or progesterone within 4 weeks prior to study entry', ' Are hormone estrogen receptor (HER2)-positive', ' Are unable to discontinue use of anticoagulants', ' Have hypercalcemia', ' Have a second primary malignancy that is clinically detectable at the time of consideration for study enrollment', ' Have documented central nervous system (CNS) metastases, symptomatic pulmonary lymphangitis, or involvement of more than 1/3 of the liver', ' Have a serious concomitant systemic disorder', ' Have a serious cardiac condition', ' Are unwilling or unable to discontinue use of carbamazepine, phenobarbital, or phenytoin at least 14 days prior to study therapy', ' Are unable to swallow tablets.'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants Who Achieved a Best Response of Complete Response, Partial Response, and Stable Disease (CR+PR+SD) (Clinical Benefit Rate)', ' Clinical benefit rate is defined as the rate of confirmed CR, confirmed PR, and SD for 24 weeks duration and is the best response CR, PR, or SD as classified by the investigators according to the RECIST v1.1. CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of not-target lesions or appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameter since treatment started. Kaplan-Meier (KM) techniques were used to assess the time-to-event endpoints. Progressive Disease (PD) was defined as having at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase above nadir.', ' Time frame: Baseline to Measured Progressive Disease or Study Discontinuation (Up to 24 Weeks)', 'Results 1: ', ' Arm/Group Title: Enzastaurin + Fulvestrant QD + BID', ' Arm/Group Description: Participants received Enzastaurin loading dose of 1125 mg, on Day 1 of Cycle 1 only then received Enzastaurin 500 mg orally (QD) once daily in a 28-day cycle.', ' Participants received enzastaurin loading dose of 1125 mg, on Day 1 of Cycle 1 only then received Enzastaurin 250 mg orally (BID) twice daily in a 28-day cycle.', ' Fulvestrant was given intramuscularly at a loading dose of 500 mg on Day 1 and 250 mg on Day 15 in Cycle 1. Subsequent doses of Fulvestrant 250 mg were given on Day 1 of Cycle 2 and every 28 days thereafter.', ' .', ' Overall Number of Participants Analyzed: 94', ' Measure Type: Number', ' Unit of Measure: percentage of participants 43.6 (33.4 to 54.2)', 'Results 2: ', ' Arm/Group Title: Enzastaurin + Fulvestrant BID', ' Arm/Group Description: Participants received enzastaurin (250 mg; 2 tablets) or placebo administered orally twice daily (BID) in a 28-day cycle, until disease progression. Fulvestrant was given intramuscularly at a loading dose of 500 mg on Day 1 and 250 mg on Day 15 in Cycle 1. Subsequent doses of Fulvestrant 250 mg were given on Day 1 of Cycle 2 and every 28 days thereafter.', ' Overall Number of Participants Analyzed: 39', ' Measure Type: Number', ' Unit of Measure: percentage of participants 43.6 (27.8 to 60.4)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 17/94 (18.09%)', ' Anaemia 2/94 (2.13%)', ' Lymphadenopathy 0/94 (0.00%)', ' Angina pectoris 0/94 (0.00%)', ' Ischaemic cardiomyopathy 0/94 (0.00%)', ' Myocardial infarction 1/94 (1.06%)', ' Haemorrhoids 1/94 (1.06%)', ' Ileus 1/94 (1.06%)', ' Nausea 1/94 (1.06%)', ' Vomiting 1/94 (1.06%)', ' Asthenia 1/94 (1.06%)', ' Disease progression 0/94 (0.00%)', ' Oedema peripheral 1/94 (1.06%)', 'Adverse Events 2:', ' Total: 9/39 (23.08%)', ' Anaemia 2/39 (5.13%)', ' Lymphadenopathy 0/39 (0.00%)', ' Angina pectoris 0/39 (0.00%)', ' Ischaemic cardiomyopathy 0/39 (0.00%)', ' Myocardial infarction 1/39 (2.56%)', ' Haemorrhoids 1/39 (2.56%)', ' Ileus 1/39 (2.56%)', ' Nausea 1/39 (2.56%)', ' Vomiting 1/39 (2.56%)', ' Asthenia 1/39 (2.56%)', ' Disease progression 0/39 (0.00%)', ' Oedema peripheral 1/39 (2.56%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

1ac9c526-91e6-4e0d-8570-0a78e3ec78db

Single

Adverse Events

NCT00767520

Both cohorts of the primary trial reported the same precentage of patients vomiting during the trial.

Contradiction

{'Clinical Trial ID': 'NCT00767520', 'Intervention': ['INTERVENTION 1: ', ' Exemestane + Dasatinib', ' Oral dose of exemestane 25 mg + dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity', 'INTERVENTION 2: ', ' Exemestane + Placebo', ' Oral dose of exemestane 25 mg + placebo 100 mg, once daily, until disease progression or unacceptable toxicity'], 'Eligibility': ['Inclusion Criteria:', ' Histologically-documented invasive estrogen receptor positive breast cancer , with tumor tissue from prior surgery available for analysis', ' Prior therapy with a non-steroidal aromatase inhibitor', ' Recurrent or progressive advanced breast cancer (locally-advanced or metastatic)', ' Documented breast cancer with tumor 28 days prior to study entry', ' Women who are NOT of childbearing potential', ' Must be able to take oral medication', ' Performance Status 0 or 1', 'Exclusion Criteria:', ' Pleural or pericardial effusion or ascites (of any etiology; Grade 1) within 6 months prior to study entry', ' Any chemotherapy, immunotherapy < 6 months before study entry. Any targeted therapy (eg. lapatinib) < 6 months before study entry, unless given in combination with an NSAI', ' Any antitumor therapy, including radiotherapy or hormonal therapy, within 15 days prior to study entry', ' Prior exposure to exemestane, any Src-family kinase inhibitor including dasatinib, to agents intended to control osteolytic disease other than bisphosphonates, or to any investigational agent for breast cancer', ' Concurrent or previous malignant disease requiring chemotherapy or radiation treatment within the prior 3 years', ' Significant bleeding disorder, or ongoing or recent clinically-significant gastrointestinal bleeding', ' Any serious cardiac condition, including congestive heart failure or myocardial infarction within 6 months, uncontrolled angina, or Class III or IV heart disease as defined by the New York Heart Association, baseline ejection fraction 40%, diagnosed congenital long QT syndrome, clinically-significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes), QTc interval > 450 msec at baseline (Fridericia correction)', ' Hematologic abnormality Grade 2', ' Hypocalcemia of Grade 1', " Any Chemistry abnormality of Grade 2 [except Grade 2 indirect bilirubin permitted if diagnosed Gilbert's disease]", ' Pregnant Women and Women of Childbearing Potential (WOCBP)', ' Extremely lactose intolerant, in the judgment of treating physician (100 mg dasatinib contains 135 mg lactose, posing a problem only if intolerance is severe)', ' Receiving any of the following concomitant medications: Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes including: (Subjects must discontinue drug use at least 7 days prior to starting dasatinib)', ' Potent inhibitors of CYP3A4 isoenzyme', ' Prisoners or subjects who are involuntarily incarcerated; or subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness'], 'Results': ['Outcome Measurement: ', ' Progression Free Survival (PFS) Distribution for Exemestane Plus Dasatinib vs Exemestane Plus Placebo', ' PFS= The time (weeks) from date of randomization to date of progressive disease(PD). PFS for each randomization arm was estimated using the Kaplan-Meier product-limit method. A point estimate and a 95% confidence interval (CI) for the median PFS was computed for each randomization arm using the Brookmeyer & Crowley method. PD=Increase ( 20%) in sum of longest diameters from smallest value during study (including baseline).', ' Time frame: Prior to study therapy, at 8 week intervals until progression occurs (maximum participant PFS of 71 weeks)', 'Results 1: ', ' Arm/Group Title: Exemestane + Dasatinib', ' Arm/Group Description: Oral dose of exemestane 25 mg + dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity', ' Overall Number of Participants Analyzed: 79', ' Median (95% Confidence Interval)', ' Unit of Measure: weeks 18.1 (15.1 to 24.3)', 'Results 2: ', ' Arm/Group Title: Exemestane + Placebo', ' Arm/Group Description: Oral dose of exemestane 25 mg + placebo 100 mg, once daily, until disease progression or unacceptable toxicity', ' Overall Number of Participants Analyzed: 78', ' Median (95% Confidence Interval)', ' Unit of Measure: weeks 16.1 (12.1 to 18.1)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 22/79 (27.85%)', ' Anaemia 0/79 (0.00%)', ' Right ventricular dysfunction 1/79 (1.27%)', ' Diarrhoea 1/79 (1.27%)', ' Vomiting 2/79 (2.53%)', ' Abdominal pain 0/79 (0.00%)', ' Colonic obstruction 0/79 (0.00%)', ' Dysphagia 1/79 (1.27%)', ' Nausea 1/79 (1.27%)', ' Mucosal inflammation 1/79 (1.27%)', ' Performance status decreased 1/79 (1.27%)', ' Sudden death 1/79 (1.27%)', 'Adverse Events 2:', ' Total: 13/76 (17.11%)', ' Anaemia 1/76 (1.32%)', ' Right ventricular dysfunction 0/76 (0.00%)', ' Diarrhoea 0/76 (0.00%)', ' Vomiting 2/76 (2.63%)', ' Abdominal pain 1/76 (1.32%)', ' Colonic obstruction 1/76 (1.32%)', ' Dysphagia 0/76 (0.00%)', ' Nausea 1/76 (1.32%)', ' Mucosal inflammation 0/76 (0.00%)', ' Performance status decreased 0/76 (0.00%)', ' Sudden death 0/76 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

79c07f36-daf9-4844-ad8a-f362fbbaaf81

Single

Results

NCT01381874

The Exemestane group in the primary trial had a better median Tumor Response than the Abiraterone Acetate + Prednisone group, however the patient with the maximum TR was in the Abiraterone Acetate + Prednisone group.

Contradiction

{'Clinical Trial ID': 'NCT01381874', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Participants received exemestane tablet as oral dose of 25 milligram (mg) per day in 28-day treatment cycles until disease progression, unacceptable toxicity, or death (up to 3 years).', 'INTERVENTION 2: ', ' Abiraterone Acetate + Prednisone', ' Participants received abiraterone acetate tablet at a total oral dose of 1000 milligram (mg) along with 5 mg capsule of prednisone/prednisolone per day in 28-day treatment cycles until disease progression, unacceptable toxicity, or death (up to 3 years).'], 'Eligibility': ['Inclusion Criteria:', ' Female patients must be postmenopausal', ' ER+, Human epidermal growth factor receptor 2 (Her2) negative metastatic breast cancer', ' Disease must have been sensitive to anastrozole or letrozole therapy prior to disease progression', ' No more than two prior lines of therapy in the metastatic setting, of which no more than one was chemotherapy', ' Eastern Cooperative Oncology Group (ECOG) performance status score of <=1', ' Patients with disease confined only to bone may be included, but patients with purely sclerotic lesions may not participate in the study', 'Exclusion Criteria:', ' Prior treatment with exemestane, ketoconazole, aminoglutethimide, or a CYP17 inhibitor. Prior treatment with ketoconazole for <= 7 days is permitted and topical formulations of ketoconazole are permitted', ' Potential patients must not have taken anastrozole, letrozole, fulvestrant, or any chemotherapy for at least 2 weeks (bevacizumab for at least 3 weeks) before randomization', ' Anticancer immunotherapy or investigational agent within 4 weeks before randomization, or anticancer radiotherapy (except palliative) or anticancer endocrine therapy within 2 weeks before randomization', ' Serious or uncontrolled nonmalignant disease, including active or uncontrolled infection', ' Clinical or biochemical evidence of hyperaldosteronism or hypopituitarism', ' Any condition that, in the opinion of the investigator, would compromise the well-being of the patient or that could prevent, limit, or confound the protocol-specified assessments'], 'Results': ['Outcome Measurement: ', ' Progression-Free Survival (PFS)', ' Progression-free survival was defined as the time from randomization to first occurrence of disease progression (either radiographic or clinical), or death from any cause. PFS was determined using radiographic progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) on measurable lesions captured by computed tomography (CT) or magnetic resonance imaging (MRI). Clinical disease progression was considered only when disease progression could not be confirmed by CT or MRI, such as when the disease site is skin, bone marrow, or central nervous system.', ' Time frame: Approximately 2 years', 'Results 1: ', ' Arm/Group Title: Exemestane', ' Arm/Group Description: Participants received exemestane tablet as oral dose of 25 milligram (mg) per day in 28-day treatment cycles until disease progression, unacceptable toxicity, or death (up to 3 years).', ' Overall Number of Participants Analyzed: 102', ' Median (95% Confidence Interval)', ' Unit of Measure: Months 3.68 (1.94 to 5.26)', 'Results 2: ', ' Arm/Group Title: Abiraterone Acetate + Prednisone', ' Arm/Group Description: Participants received abiraterone acetate tablet at a total oral dose of 1000 milligram (mg) along with 5 mg capsule of prednisone/prednisolone per day in 28-day treatment cycles until disease progression, unacceptable toxicity, or death (up to 3 years).', ' Overall Number of Participants Analyzed: 89', ' Median (95% Confidence Interval)', ' Unit of Measure: Months 3.65 (2.73 to 5.59)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 12/102 (11.76%)', ' Anaemia * 0/102 (0.00%)', ' Febrile Neutropenia * 0/102 (0.00%)', ' Atrial Fibrillation * 0/102 (0.00%)', ' Cardiac Failure Congestive * 0/102 (0.00%)', ' Vertigo * 1/102 (0.98%)', ' Hypoaldosteronism * 0/102 (0.00%)', ' Abdominal Pain * 0/102 (0.00%)', ' Anorectal Varices * 0/102 (0.00%)', ' Ascites * 0/102 (0.00%)', " Crohn's Disease * 0/102 (0.00%)", 'Adverse Events 2:', ' Total: 18/87 (20.69%)', ' Anaemia * 0/87 (0.00%)', ' Febrile Neutropenia * 0/87 (0.00%)', ' Atrial Fibrillation * 1/87 (1.15%)', ' Cardiac Failure Congestive * 0/87 (0.00%)', ' Vertigo * 0/87 (0.00%)', ' Hypoaldosteronism * 0/87 (0.00%)', ' Abdominal Pain * 0/87 (0.00%)', ' Anorectal Varices * 0/87 (0.00%)', ' Ascites * 0/87 (0.00%)', " Crohn's Disease * 1/87 (1.15%)", ' Faecal Incontinence * 1/87 (1.15%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

bced9c90-5ce0-416c-a168-f9e74359b332

Comparison

Eligibility

NCT00593827

NCT00478257

Patients with HER2 negative BC are eligible for both the primary trial and the secondary trial.

Entailment

{'Clinical Trial ID': 'NCT00593827', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone 16 mg/m^2', ' ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest', 'INTERVENTION 2: ', ' Ixabepilone 40 mg/m^2', ' ixabepilone 40 mg/m^2 every 3 weeks'], 'Eligibility': ['Inclusion Criteria:', ' Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29 (or CA15.3) 50', ' Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer', ' Prior chemotherapy is permitted with no limit on the number of prior regimens', ' Two weeks or more have elapsed since last chemotherapy or radiation treatment', ' Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2', ' Is female, 18 yrs of age', ' Protocol defined appropriate laboratory values', ' Negative pregnancy test within 7 calendar days prior to registration', ' Has signed a patient informed consent', 'Exclusion Criteria:', ' Had prior treatment with ixabepilone or other epothilones', ' Has HER2+ disease', ' Has a known, prior, severe (National Cancer Institute Common Terminology Criteria Adverse Events [NCI CTCAE] Grade 3-4) history of hypersensitivity reaction to a drug formulated in Cremophor ® EL (polyoxyethylated castor oil)', ' Is receiving concurrent immunotherapy, hormonal therapy or radiation therapy', ' Is receiving concurrent investigational therapy or has received such therapy within the past 30 days', ' Has peripheral neuropathy > Grade 1', ' Has evidence of central nervous system (CNS) involvement requiring radiation or steroid treatment. Participants with stable brain metastases who are off steroids at least 2 weeks are eligible', ' Is pregnant or breast feeding'], 'Results': ['Outcome Measurement: ', ' Progression-Free Survival (PFS) at 6 Months (6-month PFS Rate): Proportion of Participants Progression Free at 6 Months', ' PFS at 6 months was defined as proportion of participants who neither progressed nor died before 6 months. Computed using Kaplan-Meier estimates.', ' Time frame: From the date of randomization to 6-months on study', 'Results 1: ', ' Arm/Group Title: Ixabepilone 16 mg/m^2', ' Arm/Group Description: ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest', ' Overall Number of Participants Analyzed: 85', ' Measure Type: Number', ' Unit of Measure: Percentage of Participants 28.6 (18.9 to 38.9)', 'Results 2: ', ' Arm/Group Title: Ixabepilone 40 mg/m^2', ' Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks', ' Overall Number of Participants Analyzed: 91', ' Measure Type: Number', ' Unit of Measure: Percentage of Participants 42.7 (31.5 to 53.5)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 25/82 (30.49%)', ' neutropenia 1/82 (1.22%)', ' anemia 1/82 (1.22%)', ' thrombocytopenia 1/82 (1.22%)', ' febrile neutropenia 0/82 (0.00%)', ' tachycardia 3/82 (3.66%)', ' fibrillation atrial 0/82 (0.00%)', ' supraventricular tachycardia 1/82 (1.22%)', ' ventricular tachycardia 1/82 (1.22%)', ' angina attack 0/82 (0.00%)', ' congestive heart failure 0/82 (0.00%)', ' flutter atrial 0/82 (0.00%)', 'Adverse Events 2:', ' Total: 30/89 (33.71%)', ' neutropenia 5/89 (5.62%)', ' anemia 1/89 (1.12%)', ' thrombocytopenia 1/89 (1.12%)', ' febrile neutropenia 2/89 (2.25%)', ' tachycardia 1/89 (1.12%)', ' fibrillation atrial 1/89 (1.12%)', ' supraventricular tachycardia 0/89 (0.00%)', ' ventricular tachycardia 0/89 (0.00%)', ' angina attack 1/89 (1.12%)', ' congestive heart failure 1/89 (1.12%)', ' flutter atrial 1/89 (1.12%)']}

{'Clinical Trial ID': 'NCT00478257', 'Intervention': ['INTERVENTION 1: ', ' Effect of Bright Light', ' Effect of bright light on fatigue in women with breast cancer', 'INTERVENTION 2: ', ' Effect of Red Light', ' effect of red light on fatigue in women with breast cancer'], 'Eligibility': ['Inclusion Criteria:', ' stage I-III breast cancer', ' adjuvant or neoadjuvant anthracycline-based chemotherapy', 'Exclusion Criteria:', ' under age 18', ' pregnancy', ' metastatic or inoperable (including inflammatory) breast cancer', ' confounding underlying medical illnesses', ' history of mania', ' history of other axis-I psychiatric disorder', ' other physical or psychological impairments -'], 'Results': ['Outcome Measurement: ', ' Fatigue', ' The Short Form of the Multidimensional Fatigue Symptom Inventory (MFSI-sf) was used to measure fatigue. The range of possible score for each subscale is 0 to 24, and the range for total score is -24 to 96, with a higher score indicating more severe fatigue, except for the Vigor subscale, where larger score indicates less fatigue.', ' Time frame: four cycles of chemotherapy', 'Results 1: ', ' Arm/Group Title: Effect of Bright Light', ' Arm/Group Description: Effect of bright light on fatigue in women with breast cancer', ' Overall Number of Participants Analyzed: 23', ' Mean (Standard Error)', ' Unit of Measure: units on a scale 15.25 (5.5)', 'Results 2: ', ' Arm/Group Title: Effect of Red Light', ' Arm/Group Description: effect of red light on fatigue in women with breast cancer', ' Overall Number of Participants Analyzed: 16', ' Mean (Standard Error)', ' Unit of Measure: units on a scale 21.6 (7.2)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/23 (0.00%)', 'Adverse Events 2:', ' Total: 0/16 (0.00%)']}

ce88c763-0062-48dc-b5e1-f81af32f2628

Single

Intervention

NCT00296036

the primary trial administers the Urea/Lactic Acid Cream topically, twice daily, and the placebo is administered orally once a day.

Contradiction

{'Clinical Trial ID': 'NCT00296036', 'Intervention': ['INTERVENTION 1: ', ' Urea/Lactic Acid Cream', ' Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily.', 'INTERVENTION 2: ', ' Placebo Cream', ' Patients receive placebo cream applied to palms and soles twice daily.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed breast and/or other cancer', ' Undergoing first treatment with capecitabine as adjuvant (including neo-adjuvant) therapy OR for metastatic disease', ' Receiving a dose of capecitabine either 2,000 mg/day (1,000 mg twice daily) OR 2,500 mg/day for 14 days with 4 courses of therapy at 3 week (+/- 3 days) intervals', ' Hormone-receptor status not specified', ' PATIENT CHARACTERISTICS:', ' Male or female', ' Menopausal status not specified', ' No history of allergy to urea-containing cream', ' No pre-existing neuropathy grade 2', ' No other dermatologic condition, that, in the opinion of the physician, may affect the hands or feet or may complicate evaluation during study treatment', ' PRIOR CONCURRENT THERAPY:', ' No other concurrent agents that function to prevent palmar-plantar erythrodysesthesia caused by capecitabine or topical agents in the hands or feet for other indications (e.g., dryness)', ' No concurrent vitamin B6 > 50 mg/day', ' No concurrent or planned use of over-the-counter products that contain urea or lactic acid, including any of the following:', ' Aqua Care®', ' Medicated Calamine^® lotion (0.3%)', ' Coppertone^® Waterproof Ultra Protection Sunblock', " Dr. Scholl's^® Smooth Touch deep moisturizing cream", ' Depicure^® So Smooth Cream', ' Dove^® Moisturizing Cream Wash', ' Cetaphil^ ®Moisturizing Cream', ' Vaseline Intensive Care ^ ® lotion'], 'Results': ['Outcome Measurement: ', ' To Determine Whether the Prophylactic Use of a Topical Urea/Lactic Acid Cream Can Decrease the Incidence/Severity of Capecitabine-caused Palmar-plantar Erythrodysesthesia', ' A patient self-reported hand-foot syndrome (HFSD), also known as palmar-plantar erythrodysesthesia, was completed daily while applying the cream. Patients rated skin severity symptoms individually in their hands and in their feet. Definitions of symptoms, which were based on Common Terminology Criteria for Adverse Events (CTCAE) v3.0, were provided to patients. The number of patients reporting moderate to severe symptoms in either hands or feet were tabulated and percentages are reported.', ' Time frame: First 3 weeks of treatment', 'Results 1: ', ' Arm/Group Title: Urea/Lactic Acid Cream', ' Arm/Group Description: Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily.', ' Overall Number of Participants Analyzed: 59', ' Measure Type: Number', ' Unit of Measure: percentage of participants 13.6', 'Results 2: ', ' Arm/Group Title: Placebo Cream', ' Arm/Group Description: Patients receive placebo cream applied to palms and soles twice daily.', ' Overall Number of Participants Analyzed: 49', ' Measure Type: Number', ' Unit of Measure: percentage of participants 10.2'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/67 (0.00%)', 'Adverse Events 2:', ' Total: ']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

982469a3-2fc1-40b4-92a9-d531b6c0ab5d

Comparison

Eligibility

NCT00334802

NCT00167414

There is no age limit for either the secondary trial or the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00334802', 'Intervention': ['INTERVENTION 1: ', ' Dose Level 1', ' Gemcitabine: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxcel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles', 'INTERVENTION 2: ', ' Dose Level 2', ' Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxcel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles'], 'Eligibility': ['Inclusion Criteria:', ' Histologically and/or cytologically confirmed breast cancer', ' Received adjuvant/neo-adjuvant chemotherapy for breast cancer with anthracycline regimen', ' To have at least one measurable region', ' Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1', ' To have adequate organ function (bone marrow, liver and renal function)', 'Exclusion Criteria:', ' To have interstitial pneumonia or pulmonary fibrosis', ' To have inflammatory breast cancer', ' Within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest hormonal/immunotherapy or 7 days after surgery', ' To have brain metastases with symptoms', ' To have severe complication (cardiac infarction, infection, drug hypersensitivity or diabetes)'], 'Results': ['Outcome Measurement: ', ' Tumor Response', ' Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Responders are patients with complete response or partial response.', ' Time frame: baseline to measured progressive disease', 'Results 1: ', ' Arm/Group Title: Dose Level 1', ' Arm/Group Description: Gemcitabine: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxcel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles', ' Overall Number of Participants Analyzed: 6', ' Measure Type: Number', ' Unit of Measure: participants Complete Response: 0', ' Partial Response: 3', ' Stable Disease: 1', ' Progressive Disease: 1', 'Not Evaluable: 1', 'Results 2: ', ' Arm/Group Title: Dose Level 2', ' Arm/Group Description: Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxcel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles', ' Overall Number of Participants Analyzed: 56', ' Measure Type: Number', ' Unit of Measure: participants Complete Response: 0', ' Partial Response: 25', ' Stable Disease: 17', ' Progressive Disease: 11', 'Not Evaluable: 3'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1', ' Pneumonia 0/6 (0.00%)', ' Haemoglobin decreased 1/6 (16.67%)', ' Anorexia 0/6 (0.00%)', ' Panic disorder 0/6 (0.00%)', 'Adverse Events 2:', ' Total: 3', ' Pneumonia 1/56 (1.79%)', ' Haemoglobin decreased 0/56 (0.00%)', ' Anorexia 1/56 (1.79%)', ' Panic disorder 1/56 (1.79%)']}

{'Clinical Trial ID': 'NCT00167414', 'Intervention': ['INTERVENTION 1: ', ' Hypofractionated Stereotactic Body Radiation Therapy', ' Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.', ' Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy', ' Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.'], 'Eligibility': ['Inclusion Criteria:', ' Age: no limit', ' Karnofsky performance status (KPS) 70', ' No more than 5 metastatic sites involving one or more different organs (liver, lung or bone).', ' The size of the lesion must be such that it can be safely treated to sterilizing radiation doses according to the rules in the protocol.', ' Previously treated lesions are not eligible unless the prescribed dose can be safely delivered.', ' Concurrent therapy is allowed and recommended. The chemotherapy protocol type and schedule are at the discretion of the medical oncologist.', ' Informed consent must be obtained.', ' Pregnancy test must be negative for women of child bearing potential', 'Exclusion Criteria:', ' Inability of patient to be followed longitudinally as specified by protocol.', ' Technical inability to achieve required dose based on safe dose constraints required for radiosurgery.', ' Women who are pregnant or nursing.', ' Failure to meet requirements in Inclusion Criteria', ' Contraindications to radiation.'], 'Results': ['Outcome Measurement: ', ' Overall Survival', ' The percent of patients that survived from date of enrollment until 2 year follow-up visit.', ' Time frame: 2 years', 'Results 1: ', ' Arm/Group Title: Hypofractionated Stereotactic Body Radiation Therapy', ' Arm/Group Description: Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.', ' Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy', ' Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.', ' Overall Number of Participants Analyzed: 39', ' Measure Type: Number', ' Unit of Measure: percentage of participants 74'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/39 (0.00%)']}

71d16ba8-2cc9-4cb0-aa14-6b6adf0dd625

Single

Results

NCT00143390

In the primary trial There was less than 3 months difference between the maximum and minimum recorded TTP of the Exemestane group.

Contradiction

{'Clinical Trial ID': 'NCT00143390', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' One tablet each of exemestane 25 mg and anastrozole placebo were orally administered once daily after a meal. The study treatment was continued until the disease progression or other discontinuation criteria were met.', 'INTERVENTION 2: ', ' Anastrozole', ' One tablet each of anastrozole 1 mg and exemestane placebo were orally administered once daily after a meal. The study treatment was continued until the disease progression or other discontinuation criteria were met.'], 'Eligibility': ['Inclusion Criteria:', ' Have histologically or cytologically confirmed breast cancer at original diagnosis. At study entry, the patient must have metastatic progressive or locally recurrent inoperable breast cancer.', 'Exclusion Criteria:', ' Having received any hormonal therapy (e.g., Tamoxifen, LHRH-agonists) ovariectomy or any chemotherapy for advanced/recurrent breast cancer'], 'Results': ['Outcome Measurement: ', ' Time to Progression (TTP) - Expert Evaluation Committee Assessment', ' Time in months from randomization to first documentation of objective tumor progression or death due to breast cancer, whichever comes first. Tumor progression was determined by the expert evaluation committee using RECIST version 1.0 as an at least a 20% increase in the sum of the longest diameters (SLD) of the target lesions compared to the smallest SLD since the study treatment started. For participants with bone metastasis only, at least 25% increase in the measurable lesion according to General Rules for Clinical and Pathological Study of Breast Cancer (The 14th edition).', ' Time frame: Up to 2008 days of the treatment', 'Results 1: ', ' Arm/Group Title: Exemestane', ' Arm/Group Description: One tablet each of exemestane 25 mg and anastrozole placebo were orally administered once daily after a meal. The study treatment was continued until the disease progression or other discontinuation criteria were met.', ' Overall Number of Participants Analyzed: 147', ' Median (95% Confidence Interval)', ' Unit of Measure: months 13.8 (10.8 to 16.5)', 'Results 2: ', ' Arm/Group Title: Anastrozole', ' Arm/Group Description: One tablet each of anastrozole 1 mg and exemestane placebo were orally administered once daily after a meal. The study treatment was continued until the disease progression or other discontinuation criteria were met.', ' Overall Number of Participants Analyzed: 145', ' Median (95% Confidence Interval)', ' Unit of Measure: months 11.1 (10.8 to 16.6)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 19/149 (12.75%)', ' Anaemia 0/149 (0.00%)', ' Acute myocardial infarction 1/149 (0.67%)', ' Pericardial effusion 1/149 (0.67%)', ' Prinzmetal angina 1/149 (0.67%)', " Meniere's disease 0/149 (0.00%)", ' Vertigo 0/149 (0.00%)', ' Cataract 2/149 (1.34%)', ' Colitis ischaemic 1/149 (0.67%)', ' Nausea 0/149 (0.00%)', ' Vomiting 0/149 (0.00%)', ' Chest pain 1/149 (0.67%)', 'Adverse Events 2:', ' Total: 19/149 (12.75%)', ' Anaemia 1/149 (0.67%)', ' Acute myocardial infarction 0/149 (0.00%)', ' Pericardial effusion 0/149 (0.00%)', ' Prinzmetal angina 0/149 (0.00%)', " Meniere's disease 1/149 (0.67%)", ' Vertigo 2/149 (1.34%)', ' Cataract 1/149 (0.67%)', ' Colitis ischaemic 0/149 (0.00%)', ' Nausea 1/149 (0.67%)', ' Vomiting 3/149 (2.01%)', ' Chest pain 0/149 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

e6901a45-4c97-4618-bfcb-6f6dd046ef0c

Single

Results

NCT00004888

Most the primary trial participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8 of the study.

Contradiction

{'Clinical Trial ID': 'NCT00004888', 'Intervention': ['INTERVENTION 1: ', ' Arm I: Doxorubicin and Taxotere', ' Patients received PLD 30 mg/m^2 IV followed by docetaxel 60 mg/m^2 IV, one hour after PLD completion, every 3 weeks for a total of 8 cycles. Dexamthasone 8 mg orally twice a day was administered the day before, the day of, and the day following docetaxel. The maximum allowed cumulative dose of PLD was 240 mg/m^2. Pyridoxine 200 mg PO daily started on Day 1 of Cycle 1 and continued daily while the patient was on PLD.', 'INTERVENTION 2: ', ' Arm II: Doxorubicin, Taxotere, and Herceptin', ' Patients received the weekly antibody therapy with trastuzumab in addition to the induction chemotherapy with PLD and docetaxel every 3 weeks as outlined for Arm I above for a total of 8 cycles. Trastuzumab was administered 4 mg/kg IV on Day 1, then 2 mg/kg IV weekly.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed adenocarcinoma of the breast with manifestations of metastatic progression', ' HER2 expression status in primary breast tissue and/or site(s) of metastasis must be determined by the ECOG Pathology Coordinating Office; (these are the results that will be used at time of registration); NOTE: for this protocol, HER2/neu non-overexpressed status will be defined as 0 and 1+ scores using the DAKO HercepTest; HER2 overexpressed status will be defined as 2+ score (if confirmed amplified by FISH) or 3+ score using the DAKO HercepTest', ' Cytologically positive pleural or peritoneal effusions are considered evaluable disease provided local intra-cavitary treatment is not introduced at the onset of therapy; to be considered as evaluable disease, pleural effusions may not have been previously drained or sclerosed', ' Blastic or mixed blastic/lytic osseous metastases only are evaluable disease provided they are accompanied by an analgesic requirement or a decrease in performance status, and will not require radiation treatment within two cycles from the start of protocol; pure osteolytic disease is evaluable; bone disease must be x-ray proven for the site to be evaluable; patients whose only evidence of metastatic disease is an abnormal bone scan without confirmatory x-rays are not eligible for this study', ' No prior chemotherapy for advanced disease; prior adjuvant chemotherapy (including taxanes) allowed, if completed > 6 months before the diagnosis of metastatic disease; no prior adjuvant anthracycline, nor any prior exposure to other anthracycline- (e.g., epirubicin, any liposomal doxorubicin formulation), nor any anthracenedione- (e.g., mitoxantrone) containing regimen allowed; no prior therapy with Herceptin allowed; NOTE: chemotherapy after ipsilateral breast recurrence following breast conservation surgery would not be considered chemotherapy for advanced disease; however, in post-mastectomy patients chemotherapy for local/regional recurrence is considered treatment for advanced disease', ' No prior radiotherapy other than to the conserved breast, to the post-mastectomy chest wall, or to a limited field involving < 25% of marrow-containing bone; NOTE: previous post-mastectomy radiation therapy involving chest wall ± internal mammary lymph node chain (IMN) is allowed; however, patients who received photon IMN treatment are ineligible; NOTE: radiotherapy must be completed >= 2 weeks prior to registration; it may not be given concurrently with Doxil, Taxotere, or Herceptin', ' Prior hormonal therapy in either a metastatic or adjuvant setting is allowed, but patients must have been off such therapy for >= 2 weeks prior to registration', ' Disease-free of prior non-breast invasive malignancies for >= 5 years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix', ' ECOG performance status of 0, 1, or 2', ' At least two weeks after any major surgery (including mastectomy) and recovered from all toxicity', ' Creatinine =< 1.5 mg/dl', ' Granulocytes >= 1,500/mm³', ' Platelets >= 100,000/mm³', ' SGOT(AST) =< 2.5 x the upper limit of normal', ' Bilirubin within normal limits for institution', ' No history of deep venous thrombosis, pulmonary thromboembolism, or other thromboembolic condition', ' Women must not be pregnant or breastfeeding; the effect of Herceptin to the fetus is unknown; Doxil is known to be harmful to the fetus', ' Women of childbearing potential must be advised to use an accepted and effective method of contraception', ' No patients with untreated brain metastasis or brain metastasis undergoing radiation or for whom brain metastasis represent the sole site of disease; patients with previously treated brain metastasis who have responded to brain radiotherapy and/or surgery and continue in response are eligible, provided the brain is not the only site of disease', ' The left ventricular ejection fraction must be at or above the lower institutional limits of normal (as assessed by MUGA scan or echocardiogram obtained within six weeks prior to registration); patient will not be eligible if baseline LVEF assessment not performed', ' No prior history of myocardial infarction, congestive heart failure, or arrhythmia requiring medication; no history of hypertension or systolic or diastolic dysfunction; no EKG evidence of ventricular hypertrophy, conduction abnormality, or serious arrhythmia; patient will not be eligible if baseline EKG assessment not performed within 4 weeks'], 'Results': ['Outcome Measurement: ', ' Grades of Cardiotoxicity Events in the Subset of Patients Reporting a Cardiotoxicity Event', ' This table summarizes the cardiotoxicity events of different grades. Grade 1 is a decline of left ventricular ejection fraction(LVEF) >=10% but <20% of baseline value. Grade 2 is LVEF below LLN (50%) or decline of LVEF >=20% of baseline value. Grade 3 is congestive heart failure responsive to treatment. Please note that only a subset of patients reported cardiotoxic events so the totals will not add up to the total number of participants.', ' Time frame: Baseline, after cycle 4 (~84 days), after cycle 8 (~168 days), and 30 or more days after last cycle of induction therapy', 'Results 1: ', ' Arm/Group Title: Arm I: Doxorubicin and Taxotere', ' Arm/Group Description: Patients received PLD 30 mg/m^2 IV followed by docetaxel 60 mg/m^2 IV, one hour after PLD completion, every 3 weeks for a total of 8 cycles. Dexamthasone 8 mg orally twice a day was administered the day before, the day of, and the day following docetaxel. The maximum allowed cumulative dose of PLD was 240 mg/m^2. Pyridoxine 200 mg PO daily started on Day 1 of Cycle 1 and continued daily while the patient was on PLD.', ' Overall Number of Participants Analyzed: 16', ' Measure Type: Number', ' Unit of Measure: participants Grade 1 After Cycle 4 (approx. 84 days): 2', ' Grade 1 After Cycle 8 (approx. 168 days): 4', ' Grade 1 After 30 days or more after last cycle: 1', ' Grade 2 After Cycle 4 (approx 84 days): 3', ' Grade 2 After Cycle 8 (approx 168 days): 4', ' Grade 2 After 30 days or more after last cycle: 1', ' Grade 3 After Cycle 4 (approx 84 days): 1', ' Grade 3 After Cycle 8 (approx 168 days): 0', ' Grade 3 After 30 days or more after last cycle: 0', 'Results 2: ', ' Arm/Group Title: Arm II: Doxorubicin, Taxotere, and Herceptin', ' Arm/Group Description: Patients received the weekly antibody therapy with trastuzumab in addition to the induction chemotherapy with PLD and docetaxel every 3 weeks as outlined for Arm I above for a total of 8 cycles. Trastuzumab was administered 4 mg/kg IV on Day 1, then 2 mg/kg IV weekly.', ' Overall Number of Participants Analyzed: 37', ' Measure Type: Number', ' Unit of Measure: participants Grade 1 After Cycle 4 (approx. 84 days): 12', ' Grade 1 After Cycle 8 (approx. 168 days): 8', ' Grade 1 After 30 days or more after last cycle: 10', ' Grade 2 After Cycle 4 (approx 84 days): 0', ' Grade 2 After Cycle 8 (approx 168 days): 2', ' Grade 2 After 30 days or more after last cycle: 5', ' Grade 3 After Cycle 4 (approx 84 days): 0', ' Grade 3 After Cycle 8 (approx 168 days): 0', ' Grade 3 After 30 days or more after last cycle: 0'], 'Adverse Events': ['Adverse Events 1:', ' Total: 41/41 (100.00%)', ' Febrile Neutropenia 5/41 (12.20%)', ' Leukopenia 22/41 (53.66%)', ' Neutropenia 24/41 (58.54%)', ' Thrombocytopenia 2/41 (4.88%)', ' Anemia 5/41 (12.20%)', ' Thrombosis/embolism 4/41 (9.76%)', ' DIC 1/41 (2.44%)', ' AST Increased 1/41 (2.44%)', ' Hypoalbuminemia 1/41 (2.44%)', ' Creatinine Increased 1/41 (2.44%)', ' Hypertension 1/41 (2.44%)', 'Adverse Events 2:', ' Total: 48/48 (100.00%)', ' Febrile Neutropenia 5/48 (10.42%)', ' Leukopenia 28/48 (58.33%)', ' Neutropenia 32/48 (66.67%)', ' Thrombocytopenia 0/48 (0.00%)', ' Anemia 6/48 (12.50%)', ' Thrombosis/embolism 0/48 (0.00%)', ' DIC 0/48 (0.00%)', ' AST Increased 1/48 (2.08%)', ' Hypoalbuminemia 1/48 (2.08%)', ' Creatinine Increased 0/48 (0.00%)', ' Hypertension 1/48 (2.08%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

e94ea1b1-1816-4bac-b1ca-f6d66b95702a

Comparison

Intervention

NCT01216319

NCT03346161

the secondary trial and the primary trial are evaluating surgical interventions for breast reconstruction for patients that have had mastectomies.

Contradiction

{'Clinical Trial ID': 'NCT01216319', 'Intervention': ['INTERVENTION 1: ', ' Nipple Reconstruction Cylinder', ' Nipple reconstruction: Biodesign® Nipple Reconstruction Cylinder'], 'Eligibility': ['Inclusion Criteria:', ' Patient presents with a history of breast cancer, having previously completed either uni- or bi-lateral breast removal and reconstruction.', ' Patient presents with a desire to obtain nipple reconstruction', ' Patient is at least 18 years of age', ' And other inclusion criteria', 'Exclusion Criteria:', ' Patient is not medically fit enough for surgery under local anesthesia', ' Patient is currently smoking, using tobacco products, or nicotine products (i.e. patch, gum, or nasal spray)', ' Patient is pregnant, breastfeeding or planning further pregnancy during the study period', ' Patient has physical allergies or cultural objections to the receipt of porcine products', ' And other exclusion criteria'], 'Results': ['Outcome Measurement: ', ' Percent Nipple Projection at 12 Months Compared to Baseline (1 Week Post-procedure)', ' [Not Specified]', ' Time frame: 12 months', 'Results 1: ', ' Arm/Group Title: Nipple Reconstruction Cylinder', ' Arm/Group Description: Nipple reconstruction: Biodesign Nipple Reconstruction Cylinder', ' Overall Number of Participants Analyzed: 44', ' Overall Number of Units Analyzed', ' Type of Units Analyzed: Nipples Mean (Standard Deviation)Unit of Measure: percentage of projection vs baseline: 37.3 (17.5)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/50 (2.00%)', ' Metastatic breast cancer 1/50 (2.00%)']}

{'Clinical Trial ID': 'NCT03346161', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: BREASTChoice (Decision Tool)', " Investigators recruited patients scheduled for a plastic/reconstruction consult. Investigators identified patients who completed a mastectomy, or were scheduled for one, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home. Patients randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with the decision tool. They were asked to answer a survey. After the appointment, the team collected information consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes.", 'INTERVENTION 2: ', ' Arm 2: Enhanced Usual Care (Surgical Care Booklet)', ' Investigators recruited patients scheduled for plastic/reconstruction consultation. Investigators identified patients who completed or scheduled a mastectomy, and considering reconstruction, but didn\'t have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or to complete the pre-appointment procedures at home. Patients were randomized using computer random assignment. If the patient didn\'t have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with American Society of Plastic Surgeons booklet "Breast Reconstruction." They were asked to answer a survey. After the appointment, the team collected information about consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes.'], 'Eligibility': ['Newly diagnosed or recurrent breast cancer', ' Considering a referral or already referred to a plastic surgeon by their surgical oncologist for possible reconstruction', ' Considering or completing a mastectomy.', ' Does not have known distant metastatic disease (stage IV disease) at the time of recruitment', ' Female.', ' English-speaking.', ' At least 18 years of age.', ' Able to understand and willing to sign an IRB-approved written informed consent document.'], 'Results': ['Outcome Measurement: ', ' Percent Correct on the Knowledge Measure (Objective Knowledge Score)', ' To determine whether the CDT increases knowledge about their choice, the investigators will compare objective knowledge scores between participants using the CDT and those who received usual care', ' Time frame: Through completion of breast consultation appointment (total participant time approximately 30 minutes)', 'Results 1: ', ' Arm/Group Title: Arm 1: BREASTChoice (Decision Tool)', " Arm/Group Description: Investigators recruited patients scheduled for a plastic/reconstruction consult. Investigators identified patients who completed a mastectomy, or were scheduled for one, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home. Patients randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with the decision tool. They were asked to answer a survey. After the appointment, the team collected information consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes.", ' Overall Number of Participants Analyzed: 60', ' Mean (Standard Deviation)', ' Unit of Measure: percentage of answers correct 84.6 (14.2)', 'Results 2: ', ' Arm/Group Title: Arm 2: Enhanced Usual Care (Surgical Care Booklet)', ' Arm/Group Description: Investigators recruited patients scheduled for plastic/reconstruction consultation. Investigators identified patients who completed or scheduled a mastectomy, and considering reconstruction, but didn\'t have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or to complete the pre-appointment procedures at home. Patients were randomized using computer random assignment. If the patient didn\'t have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with American Society of Plastic Surgeons booklet "Breast Reconstruction." They were asked to answer a survey. After the appointment, the team collected information about consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes.', ' Overall Number of Participants Analyzed: 60', ' Mean (Standard Deviation)', ' Unit of Measure: percentage of answers correct 59.7 (18.0)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/60 (0.00%)', 'Adverse Events 2:', ' Total: 0/60 (0.00%)']}

0e3c62f7-a152-4370-9d09-b69a715c0a21

Single

Results

NCT00410813

In the primary trial, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily.

Entailment

{'Clinical Trial ID': 'NCT00410813', 'Intervention': ['INTERVENTION 1: ', ' Dasatinib, 100 mg, Daily', ' Dasatinib, 100 mg PO daily until progression of disease', 'INTERVENTION 2: ', ' Dasatinib, 70 mg, Twice Daily', ' Dasatinib, 70 mg PO twice daily until progression of disease'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Diagnosis of breast carcinoma meeting the following criteria:', ' Stage IV disease', ' Bone metastasis-predominant disease, defined as the presence of 1 bone metastasis with or without nonbone (visceral or soft tissue) disease where the number of bone metastases is at least the number of measurable visceral target lesions', ' Visceral disease that does not cause a reduction in ECOG performance status allowed', ' Must meet 1 of the following criteria:', ' Measurable disease within the past 28 days', ' Nonmeasurable disease with rising serum CA 15-3, CA 27-29, CEA, or CA-125 documented by 2 consecutive measurements taken 14 days apart with the most recent measurement being within the past 42 days', ' These measurements need not be consecutive, and the prior measurement could have been months to years prior to the current measurement if the marker is considered by the investigator to reflect disease progression', " The second serum marker value must be greater than the institution's upper limit of normal and show a 20% increase over the first measurement", ' No symptomatic brain or CNS metastases', ' Prior CNS or brain metastasis allowed provided it was treated with radiotherapy 8 weeks ago', ' No pleural or pericardial effusion', ' Hormone receptor status known', ' Estrogen receptor- and/or progesterone receptor-positive disease must have progressed on 1 hormonal therapy in the metastatic setting', ' PATIENT CHARACTERISTICS:', ' Male or female', ' Menopausal status not specified', ' Zubrod performance status 0-2', ' QTc < 450 msec by EKG', ' Ejection fraction 50% by MUGA or 2-dimensional echocardiogram with no significant abnormalities within the past 12 weeks for patients on trastuzumab', ' No active infection requiring systemic therapy', ' No uncontrolled concurrent condition that would preclude the ability to take oral medication, including the following:', ' Nausea', ' Vomiting', ' Diarrhea', ' Lack of physical integrity of the upper gastrointestinal tract', ' Malabsorption syndrome', ' No clinically significant cardiac disease, including the following:', ' Congestive heart failure', ' Symptomatic coronary artery disease', ' Cardiac arrhythmias not well controlled', ' Myocardial infarction within the past 12 months', ' No concurrent active malignancy', ' Prior malignancies allowed provided the patient is currently disease-free', ' Not pregnant or nursing', ' Fertile patients must use effective contraception during and for 3 months after completion of study therapy', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics', ' No prior RankL inhibitor therapy', ' No more than 1 prior cytotoxic chemotherapy for metastatic disease', ' At least 3 weeks since prior chemotherapy and recovered', ' At least 1 week since prior radiotherapy to non-CNS disease and recovered', ' At least 3 weeks since prior and no concurrent intravenous bisphosphates (e.g., zoledronate)', ' At least 7 days since prior and no concurrent antiplatelet agents, including any of the following*:', ' Anticoagulants (e.g., tirofiban, eptifibatide, ticlopidine)', ' Aspirin or aspirin-containing combinations', ' Dipyridamole', ' Epoprostenol', ' Clopidogrel', ' Cilostazol', ' Abciximab NOTE: *Nonsteroidal anti-inflammatory drugs and medically indicated platelet-inhibiting medication allowed', ' At least 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the following:', ' HIV protease inhibitors (e.g., amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir)', ' Select antibiotics (e.g., ciprofloxacin, clarithromycin, doxycycline, enoxacin, isoniazid, telithromycin)', ' Azole antifungals (e.g., itraconazole, ketoconazole, miconazole, voriconazole)', ' Select anesthetics (e.g., ketamine, propofol)', " Hypericum perforatum (St. John's wort)", ' Nefazodone', ' Nicardipine', ' Diclofenac', ' Quinidine', ' Imatinib mesylate', ' At least 7 days since prior and no concurrent medications that prolong the QTc interval, including any of the following:', ' Antiarrhythmic agents (e.g., quinidine, procainamide, disopyramide phosphate, amiodarone, sotalol hydrochloride, ibutilide, dofetilide)', ' Antipsychotic agents (e.g., chlorpromazine, mesoridazine, thioridazine, pimozide, haloperidol, droperidol)', ' Select antibiotics (e.g., erythromycin, clarithromycin, sparfloxacin, pentamidine)', ' Narcotic analgesics (e.g., levomethadyl, methadone, domperidone)', ' Calcium channel blockers (e.g., bepridil, lidoflazine)', ' Antimalarial agents (e.g., halofantrine, chloroquine)', ' Parasympathomimetic agents (e.g., cisapride)', ' Arsenic trioxide', ' No other concurrent antineoplastic therapy for breast cancer, including any of the following:', ' Radiotherapy', ' Chemotherapy', ' Immunotherapy', ' Biologic therapy', ' Hormonal therapy', ' Gene therapy', ' No concurrent grapefruit juice consumption', ' No concurrent short-acting antacid agents within 2 hours of dasatinib administration', ' Concurrent trastuzumab (Herceptin®) therapy for HER-2 positive patients allowed provided patients have been on continuous trastuzumab for 12 weeks'], 'Results': ['Outcome Measurement: ', ' Progression-free Survival', ' RECIST progression defined as 20% increase in the sum of longest diameters of target measurable lesions over the smallest sum observed, unequivocal progression of non-measurable disease, the appearance of any new lesion/site, death due to disease without prior documentation of progression and without symptomatic deterioration, development of one or more new bone lesions from baseline, or symptomatic deterioration related to disease progression. Time from date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free are censored at last date of contact.', ' Time frame: Up to 2 years', 'Results 1: ', ' Arm/Group Title: Dasatinib, 100 mg, Daily', ' Arm/Group Description: Dasatinib, 100 mg PO daily until progression of disease', ' Overall Number of Participants Analyzed: 41', ' Median (95% Confidence Interval)', ' Unit of Measure: weeks 10.3 (8.4 to 16.7)', 'Results 2: ', ' Arm/Group Title: Dasatinib, 70 mg, Twice Daily', ' Arm/Group Description: Dasatinib, 70 mg PO twice daily until progression of disease', ' Overall Number of Participants Analyzed: 38', ' Median (95% Confidence Interval)', ' Unit of Measure: weeks 15.3 (8.7 to 20.1)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/41 (14.63%)', ' Left ventricular systolic dysfunction 0/41 (0.00%)', ' Constipation 0/41 (0.00%)', ' Death not associated with CTCAE term - Death NOS 0/41 (0.00%)', ' Sudden death 0/41 (0.00%)', ' Inf w/normal ANC or Gr 1-2 neutrophils - Skin 0/41 (0.00%)', ' Inf w/normal ANC or Gr 1-2 neutrophils - UTI 1/41 (2.44%)', ' Rash: dermatitis associated w/Chemoradiation 0/41 (0.00%)', 'Adverse Events 2:', ' Total: 12/38 (31.58%)', ' Left ventricular systolic dysfunction 1/38 (2.63%)', ' Constipation 1/38 (2.63%)', ' Death not associated with CTCAE term - Death NOS 1/38 (2.63%)', ' Sudden death 1/38 (2.63%)', ' Inf w/normal ANC or Gr 1-2 neutrophils - Skin 1/38 (2.63%)', ' Inf w/normal ANC or Gr 1-2 neutrophils - UTI 1/38 (2.63%)', ' Rash: dermatitis associated w/Chemoradiation 1/38 (2.63%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

7191b5e9-4f29-4261-8a64-51653ee151fe

Single

Eligibility

NCT01597193

ECOG > 1 and a life expectancy over 12 weeks are necessary to participate in the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT01597193', 'Intervention': ['INTERVENTION 1: ', ' Dose Escalation: Enzalutamide 80 mg', ' Participants received enzalutamide 80 mg (two 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. Participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first.', 'INTERVENTION 2: ', ' Dose Escalation: Enzalutamide 160 mg', ' Participants received enzalutamide 160 mg (four 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. Participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed breast cancer with accompanying pathology report;', ' Submit unstained representative tumor specimen, either as a paraffin block (preferred) or 10 unstained slides', ' Received at least 2 lines of systemic therapy in the advanced setting (for enzalutamide alone arm only);', ' Eastern Cooperative Oncology Group performance (ECOG) status of 0 or 1;', ' Estimated life expectancy of at least 3 months', 'Exclusion Criteria:', ' Severe concurrent disease, infection, or comorbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment;', ' Pregnant or lactating;', ' Known or suspected brain metastasis or leptomeningeal disease;', ' History of another malignancy within the previous 5 years other than curatively treated in situ carcinomas;', ' For patients who are enrolled to receive enzalutamide plus anastrozole or exemestane or fulvestrant must not have received tamoxifen or any medication known to be a potent CYP3A4 inducer or inhibitor.'], 'Results': ['Outcome Measurement: ', ' Dose-Escalation Phase: Percentage of Participants With Dose-limiting Toxicity (DLTs)', ' DLTs were defined as any of following events related to the study drug: Any adverse event (AE) consistent with a seizure of any grade; Grade greater than equal to (>=) 3 fatigue, diarrhea, nausea, or vomiting that did not improve to Grade 1 within 14 days of initiating standard of care therapy; any Grade >=3 hematologic toxicity with the following modifications: 1) Grade >=3 platelet count associated with bleeding, 2) Grade >=3 absolute neutrophil count that persists for 7 or more days or that was associated with fevers (febrile neutropenia); Grade >=3 any other non-hematological toxicity that was determined to be related to study drug.', ' Time frame: Baseline up to Day 35', 'Results 1: ', ' Arm/Group Title: Dose Escalation: Enzalutamide 80 mg', ' Arm/Group Description: Participants received enzalutamide 80 mg (two 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. Participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first.', ' Overall Number of Participants Analyzed: 6', ' Measure Type: Number', ' Unit of Measure: percentage of participants 16.7', 'Results 2: ', ' Arm/Group Title: Dose Escalation: Enzalutamide 160 mg', ' Arm/Group Description: Participants received enzalutamide 160 mg (four 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. Participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first.', ' Overall Number of Participants Analyzed: 7', ' Measure Type: Number', ' Unit of Measure: percentage of participants 0.0'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/7 (28.57%)', ' Anaemia * 0/7 (0.00%)', ' Iron Deficiency Anaemia * 0/7 (0.00%)', ' Pericardial Effusion * 0/7 (0.00%)', ' Adrenal Insufficiency * 1/7 (14.29%)', ' Abdominal Pain * 0/7 (0.00%)', ' Gastritis Erosive * 0/7 (0.00%)', ' Urosepsis * 0/7 (0.00%)', ' Pneumonia * 0/7 (0.00%)', ' Urinary Tract Infection * 0/7 (0.00%)', ' Enterocolitis infectious * 0/7 (0.00%)', 'Adverse Events 2:', ' Total: 1/8 (12.50%)', ' Anaemia * 1/8 (12.50%)', ' Iron Deficiency Anaemia * 0/8 (0.00%)', ' Pericardial Effusion * 0/8 (0.00%)', ' Adrenal Insufficiency * 0/8 (0.00%)', ' Abdominal Pain * 0/8 (0.00%)', ' Gastritis Erosive * 0/8 (0.00%)', ' Urosepsis * 0/8 (0.00%)', ' Pneumonia * 0/8 (0.00%)', ' Urinary Tract Infection * 0/8 (0.00%)', ' Enterocolitis infectious * 0/8 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

639ccada-370d-4709-bdd7-1b29bbcc8769

Single

Results

NCT02069093

All of the patients in the primary trial had minimal Stomatitis symptoms and a normal diet.

Contradiction

{'Clinical Trial ID': 'NCT02069093', 'Intervention': ['INTERVENTION 1: ', ' Dexamethasone Based Mouthwash', ' Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks. Participants remained without food or drink (NPO) for one hour after administration of the mouthwash. Also, participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations.'], 'Eligibility': ['Inclusion Criteria:', ' Adult women > 18 years of age with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy', ' Histological or cytological confirmation of hormone-receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer', ' Postmenopausal women. Postmenopausal status is defined either by:', ' Age 55 years and one year or more of amenorrhea', ' Age < 55 years and one year or more of amenorrhea, with an estradiol assay < 20 pg/ml', ' Surgical menopause with bilateral oophorectomy', ' Note: Ovarian radiation or treatment with a luteinizing hormone-releasing hormone (LH-RH) agonist (goserelin acetate or leuprolide acetate) is not permitted for induction of ovarian suppression', ' Patient has been assessed by treating physician to be appropriate candidate for everolimus plus exemestane therapy as treatment of advanced or metastatic breast cancer and plans to prescribe everolimus 10mg PO QD in combination with exemestane 25mg PO QD', ' Patient must start everolimus 10mg plus exemestane 25mg treatment on Cycle 1 Day 1 of trial', ' ECOG Performance status 2', ' Adequate renal function: serum creatinine 1.5x ULN;', " Willingness to self-report level of oral pain using Visual Analog Scale (VAS) and the Normalcy Diet Scale (NDS) throughout each stomatitis event, as required in the patient diary. At baseline, patient's self-reported oral pain level, using VAS, must be 0 and the normalcy diet scale score should 60", ' Signed informed consent obtained prior to any screening procedure', 'Exclusion criteria:', ' Patients currently receiving anticancer therapies (except biphosphonate, denosumab);', ' Patients who currently have stomatitis/oral mucositis/mouth ulcers;', ' Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus);', ' Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral Everolimus;', ' Uncontrolled diabetes mellitus as defined by HbA1c >8% despite adequate therapy. Patients with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, however blood glucose and antidiabetic treatment must be monitored closely throughout the trial and adjusted as necessary;', ' Patients who have any severe and/or uncontrolled medical conditions such as:', ' Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction 6 months prior to start of everolimus, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease', ' Symptomatic congestive heart failure of New York heart Association Class III or IV', ' active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease (except for Hep B and Hep C positive patients)', ' Known severely impaired lung function (spirometry and DLCO 50% or less of normal and O2 saturation 88% or less at rest on room air)', ' active, bleeding diathesis;', ' Chronic treatment with corticosteroids or other immunosuppressive agents. Topical or inhaled corticosteroids are allowed;', ' Known history of HIV seropositivity;', ' Patients who have received live attenuated vaccines within 1 week of start of everolimus and during the study. Patient should also avoid close contact with others who have received live attenuated vaccines. Examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella and TY21a typhoid vaccines;', ' Patients who have a history of another primary malignancy, with the exceptions of: non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from which the patient has been disease free for 3 years;', ' Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study or patient diaries;', " Patients who are currently part of any clinical investigation or who has not had resolution of all acute toxic effects or prior anti-cancer therapy to NCI CTCAE version 4.03 Grade 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion)."], 'Results': ['Outcome Measurement: ', ' Number of Participants With Stomatitis Grade 2', ' The incidence of grade 2 stomatitis was reported. Grade 1 = minimal symptoms, normal diet; grade 2 = symptomatic, but able to swallow a modified diet; grade 3 = symptomatic and unable to aliment or hydrate orally; and grade 4 = symptoms associated with life-threatening consequences.', ' Time frame: 56 days', 'Results 1: ', ' Arm/Group Title: Dexamethasone Based Mouthwash', ' Arm/Group Description: Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks. Participants remained without food or drink (NPO) for one hour after administration of the mouthwash. Also, participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations.', ' Overall Number of Participants Analyzed: 86', ' Measure Type: Number', ' Unit of Measure: Participants Stomatitis grade >=2: Yes: 2', ' Stomatitis grade >=2: No: 83', ' Stomatitis grade >=2: Not evaluable: 1'], 'Adverse Events': ['Adverse Events 1:', ' Total: 20/92 (21.74%)', ' Lymphadenopathy 1/92 (1.09%)', ' Cardiac failure 1/92 (1.09%)', ' Pericardial effusion 1/92 (1.09%)', ' Gastric ulcer 1/92 (1.09%)', ' Rectal haemorrhage 1/92 (1.09%)', ' Chest pain 1/92 (1.09%)', ' Generalised oedema 1/92 (1.09%)', ' Mass 1/92 (1.09%)', ' Pyrexia 2/92 (2.17%)', ' Lung infection 1/92 (1.09%)', ' Pneumonia 2/92 (2.17%)', ' Sepsis 1/92 (1.09%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

8c6e6c06-c409-4c42-b195-e9d2a1065b97

Comparison

Adverse Events

NCT00191815

NCT01301729

None of the patients in the primary trial committed suicide, however there was one such case in the secondary trial.

Entailment

{'Clinical Trial ID': 'NCT00191815', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine + Cisplatin', ' Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).', ' Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).'], 'Eligibility': ['Inclusion Criteria:', ' You are female in the age of 18 to 75 years old.', ' You have been diagnosed with the metastatic breast cancer.', ' You have desire and an opportunity to visit your doctor in medical site, both during realization of the active treatment program, and within 24 months of medical follow up.', ' You must sign this informed consent form', 'Exclusion Criteria:', ' You are pregnant or breastfeeding.', ' Your laboratory parameters fall outside the limits, admitted by requirements of the present clinical study.', ' You have been diagnosed with serious concomitant or acute infectious disease.', ' You have used experimental medications within the last month.'], 'Results': ['Outcome Measurement: ', ' Objective Tumor Response', ' Best response recorded from the start of treatment until disease progression/recurrence using World Health Organization (WHO) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.', ' Time frame: baseline to measured progressive disease (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration. Data collected every 4 months.)', 'Results 1: ', ' Arm/Group Title: Gemcitabine + Cisplatin', ' Arm/Group Description: Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).', ' Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).', ' Overall Number of Participants Analyzed: 54', ' Measure Type: Number', ' Unit of Measure: participants Complete Response: 7', ' Partial Response: 19', ' Stable Disease: 19', ' Progressive Disease: 5', 'Not Assessable: 4'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6', ' Atrial fibrillation 1/67 (1.49%)', ' Ventricular fibrillation 1/67 (1.49%)', ' Gastrointestinal perforation 1/67 (1.49%)', ' Periproctitis 1/67 (1.49%)', ' General physical health deterioration 1/67 (1.49%)', ' Escherichia sepsis 1/67 (1.49%)', ' Pneumonia 1/67 (1.49%)', ' Tumour pain 1/67 (1.49%)', ' Renal failure acute 1/67 (1.49%)', ' Pleurisy 1/67 (1.49%)']}

{'Clinical Trial ID': 'NCT01301729', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams per meter square (mg/m^2), every 3 weeks or paclitaxel 90 mg/m^2 once a week until progression of disease, occurrence of intolerable toxicity, the participant discontinues the study or dies.'], 'Eligibility': ['Inclusion Criteria:', ' Female participants , >/= 18 years of age', ' Locally recurrent/metastatic breast cancer (relapse in supra- or infraclavicular lymph nodes is regarded as metastatic disease)', ' HER2-positive primary disease', ' Participants must have received Herceptin in the adjuvant and/or neoadjuvant setting', ' Relapsed breast cancer >/= 6 months after discontinuing last drugs of Herceptin and/or chemotherapy in the adjuvant and/or neoadjuvant setting for HER2-positive breast cancer', ' Measurable disease according to RECIST 1.0', ' Eastern Cooperative Oncology Group (ECOG) performance status 0-2', ' Maximum cumulative dose of doxorubicin </= 360 mg/m2 or of epirubicin </= 720 mg/m2 or no prior anthracyclines', ' At least 3 weeks after prior surgery or radiotherapy', 'Exclusion Criteria:', ' Pregnant or breastfeeding women', ' Previous chemotherapy for metastatic breast cancer (prior endocrine therapy till progressive disease is allowed)', ' Pleural effusions, ascites or bone lesions as only manifestation of disease', ' Brain metastases', ' Invasive malignancy other than metastatic breast cancer', ' Inadequate bone marrow, hepatic or renal function', ' Prior treatment with anti-HER therapies other than (neo)adjuvant Herceptin'], 'Results': ['Outcome Measurement: ', ' Progression-Free Survival (PFS)', ' PFS was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.0 and was defined as the time from the date when the participant signed the informed consent form (ICF) until death or progressive disease (PD). PD was defined as 20% increase in the sum of the longest diameter of target lesions. PFS and associated confidence intervals were calculated using the Kaplan-Meier method.', ' Time frame: From the date of informed consent to the date of death or progressive disease (up to 28 months)', 'Results 1: ', ' Arm/Group Title: Trastuzumab', ' Arm/Group Description: Participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams per meter square (mg/m^2), every 3 weeks or paclitaxel 90 mg/m^2 once a week until progression of disease, occurrence of intolerable toxicity, the participant discontinues the study or dies.', ' Overall Number of Participants Analyzed: 32', ' Median (95% Confidence Interval)', ' Unit of Measure: months 9.9 (6.28 to 13.63)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 5/32 (15.63%)', ' Leukopenia 1/32 (3.13%)', ' Neutropenia 1/32 (3.13%)', ' Cataract 1/32 (3.13%)', ' Infection 1/32 (3.13%)', ' Upper respiratory tract infection 1/32 (3.13%)', ' Completed suicide 1/32 (3.13%)']}

b5183c1c-adb5-4877-b061-50a16d6a5b52

Comparison

Results

NCT01855828

NCT00696072

the secondary trial uses Clinical Benefit (CBR) as outcome measurement, which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial.

Entailment

{'Clinical Trial ID': 'NCT01855828', 'Intervention': ['INTERVENTION 1: ', ' Chemo Plus Pertuzumab,Trastuzumab', ' During weeks 1-12, patients will receive pertuzumab, trastuzumab, and paclitaxel at the same time; during weeks 13-24 patients will receive pertuzumab and trastuzumab at the same time with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC).', ' Pertuzumab: First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)', ' Trastuzumab: For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).', ' For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total).', ' Paclitaxel: Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).', ' 5-fluorouracil: Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).', ' Epirubicin: Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).', ' Cyclophosphamide: Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).'], 'Eligibility': ['Inclusion Criteria:', ' - Patients with histologically confirmed stage I-III, HER2-positive invasive breast cancer for which adjuvant/neoadjuvant chemotherapy is indicated based on physician judgment following NCCN practice guidelines.', ' HER2 overexpression or amplification will be based on local test results and is defined as either:', ' (i) IHC staining of 3+ (uniform, intense membrane staining) in greater than or equal to 10% of invasive tumor cells or, (ii) Fluorescent in situ hybridization (FISH) result of more than six HER2 gene copies per nucleus or, (iii) FISH ratio (HER2 gene signals to chromosome 17 signals) of greater than or equal to 2.0.', ' Patients with synchronous bilateral breast cancers are eligible if at least one of the tumors is HER2-positive.', " Left Ventricular Ejection Fraction (LVEF) greater or equal to 50% at baseline as determined by either ECHO or MUGA, or within the institution's normal limits.", ' Women of childbearing potential must have a negative pregnancy test (serum or urine beta HCG) prior to initiation of chemotherapy. Both female and male breast cancer patients who are sexually active have to agree to practice contraception while participating in the trial and for 3 month after completion of therapy.', ' Adequate bone marrow function as indicated by the following:', ' ANC greater than or equal to 1500/uL', ' Platelets greater than or equal to 100,000/uL', ' Hemoglobin greater than or equal to 10 g/dL', ' Adequate renal function, as indicated by creatinine less than or equal to 1.5 times upper limit of normal (ULN)', ' Adequate liver function, as indicated by bilirubin less than or equal to 1.5 X ULN and AST or ALT less than or equal to 2x ULN.', ' Signed informed consent.', 'Exclusion Criteria:', ' Patients will be excluded from the study based on any of the following criteria:', ' Patients who underwent partial excisional biopsy, lumpectomy, segmental mastectomy, modified radical mastectomy or sentinel node biopsy and, therefore cannot be assessed for pathologic response accurately.', ' Patients who are high risk for developing the following anthracycline, paclitaxel, trastuzumab or pertuzumab related toxicities including:', ' History of congestive heart failure, myocardial infarction or cardiomyopathy, uncontrolled hypertension despite adequate medications Pre-existing peripheral neuropathy > grade 3 Prior anthracycline therapy Known hypersensitivity to any of the study medications Patients older than age 65 due to increased risk of cardiotoxicity', ' Active infection requiring systemic antibiotic therapy.', ' Pregnant or lactating women'], 'Results': ['Outcome Measurement: ', ' Proportion of Participants With a Pathologic Complete Response Rate', ' To estimate the pathologic complete response rate (pCR) when pertuzumab is added to weekly trastuzumab/paclitaxel followed by trastuzumab/5-fluorouracil, epirubicin and cyclophosphamide neoadjuvant chemotherapy in HER2-positive breast cancer. This study will assess pCR rates separately in ER+ and ER- cancers. Pathologic complete response is defined as no evidence of viable invasive tumor cells at the primary tumor site and axillary lymph nodes in the surgical specimen. Residual Disease (RD) is defined as: Any invasive cancer in the breast or axillary lymph nodes in the surgical specimen.', ' Time frame: 20 weeks', 'Results 1: ', ' Arm/Group Title: Chemo Plus Pertuzumab,Trastuzumab', ' Arm/Group Description: During weeks 1-12, patients will receive pertuzumab, trastuzumab, and paclitaxel at the same time; during weeks 13-24 patients will receive pertuzumab and trastuzumab at the same time with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC).', ' Pertuzumab: First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)', ' Trastuzumab: For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).', ' For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total).', ' Paclitaxel: Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).', ' 5-fluorouracil: Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).', ' Epirubicin: Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).', ' Cyclophosphamide: Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).', ' Overall Number of Participants Analyzed: 48', ' Measure Type: Number', ' Unit of Measure: proportion of participants HR Positive: 23 participants', ' .26 (.13 to .46)', ' HR Negative: 25 participants', ' .80 (.60 to .91)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/50 (12.00%)', ' Ventricular tachycardia 1/50 (2.00%)', ' Fever [1]1/50 (2.00%)', ' Flu like symptoms 1/50 (2.00%)', ' Catheter related infection 2/50 (4.00%)', ' Suicidal ideation * [2]1/50 (2.00%)', ' Thromboembolic event 1/50 (2.00%)']}

{'Clinical Trial ID': 'NCT00696072', 'Intervention': ['INTERVENTION 1: ', ' Dasatinib Plus Letrozole', ' Dasatinib + Letrozole: Tablets, Oral, once daily, up to 2 years', ' Dasatinib 100 mg + Letrozole 2.5 mg', ' Patients on letrozole plus dasatinib received both drugs until progressive disease (PD) or intolerable toxicity. If the intolerable toxicity was determined to be related to dasatinib, dasatinib was discontinued and the patient continued on single-agent letrozole. Although drugs were taken daily, cycle length was 28-days', 'INTERVENTION 2: ', ' Letrozole', ' Letrozole: Tablets, Oral, 2.5 mg, once daily, up to 2 years', ' Patients on letrozole who developed progressive disease continued letrozole, and dasatinib was added to their treatment regimen. Although drugs were taken daily, cycle length was 28-days'], 'Eligibility': ['For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.', 'Inclusion Criteria:', ' Has histologic or cytologic diagnosis of breast cancer; evidence of unresectable locally recurrent or metastatic disease', ' Has measurable or evaluable-only disease', ' Is female, 18 yrs of age, post menopausal or surgically sterile', ' HER2 negative, HR+, ER+ and/or PgR+ breast cancer', ' 0-1 prior chemotherapy regimen for metastatic disease.', ' Prior adjuvant or neoadjuvant chemotherapy completed at least 1 month prior', ' Prior tamoxifen therapy is allowed', ' No AI therapy for >1 year without recurrence', 'Exclusion Criteria:', ' Pregnant or breast feeding', ' Prior hormonal therapy for metastatic or locally recurrent disease', ' >1 chemotherapy regimen for metastatic disease', ' Pleural or pericardial effusion', ' Serious cardiac condition'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population', ' CBR=participants with complete response (CR) + participants with partial response (PR) + participants with stable disease (SD) for a length of time greater than, equal to 6 months. CR= Disappearance of all target lesions. No new lesions. PR= At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started. Physical examination,radiological assessment, and bone scans (if applicable) were used to assess outcome.', ' Time frame: First dose of study drug to last dose plus 7 days, up to study completion (approximately 6 years)', 'Results 1: ', ' Arm/Group Title: Dasatinib Plus Letrozole', ' Arm/Group Description: Dasatinib + Letrozole: Tablets, Oral, once daily, up to 2 years', ' Dasatinib 100 mg + Letrozole 2.5 mg', ' Patients on letrozole plus dasatinib received both drugs until progressive disease (PD) or intolerable toxicity. If the intolerable toxicity was determined to be related to dasatinib, dasatinib was discontinued and the patient continued on single-agent letrozole. Although drugs were taken daily, cycle length was 28-days', ' Overall Number of Participants Analyzed: 56', ' Measure Type: Number', ' Unit of Measure: participants CBR (CR+PR+SD): 40', ' CBR, DFI <= 2 Years: 20', 'CBR, DFI > 2 Years: 20', 'Results 2: ', ' Arm/Group Title: Letrozole', ' Arm/Group Description: Letrozole: Tablets, Oral, 2.5 mg, once daily, up to 2 years', ' Patients on letrozole who developed progressive disease continued letrozole, and dasatinib was added to their treatment regimen. Although drugs were taken daily, cycle length was 28-days', ' Overall Number of Participants Analyzed: 61', ' Measure Type: Number', ' Unit of Measure: participants CBR (CR+PR+SD): 40', ' CBR, DFI <= 2 Years: 20', 'CBR, DFI > 2 Years: 20'], 'Adverse Events': ['Adverse Events 1:', ' Total: 14/57 (24.56%)', ' Anemia * 0/57 (0.00%)', ' CVA * 2/57 (3.51%)', ' Cardiac Insufficiency * 0/57 (0.00%)', ' Congestive Heart Failure * 0/57 (0.00%)', ' Coronary Insufficiency * 1/57 (1.75%)', ' Effusion Pericardial * 0/57 (0.00%)', ' Cholelithiasis * 1/57 (1.75%)', ' Colitis * 0/57 (0.00%)', ' Dehydration * 1/57 (1.75%)', ' Diverticulitis * 0/57 (0.00%)', ' Nausea * 2/57 (3.51%)', 'Adverse Events 2:', ' Total: 2/63 (3.17%)', ' Anemia * 1/63 (1.59%)', ' CVA * 0/63 (0.00%)', ' Cardiac Insufficiency * 1/63 (1.59%)', ' Congestive Heart Failure * 1/63 (1.59%)', ' Coronary Insufficiency * 0/63 (0.00%)', ' Effusion Pericardial * 1/63 (1.59%)', ' Cholelithiasis * 0/63 (0.00%)', ' Colitis * 1/63 (1.59%)', ' Dehydration * 1/63 (1.59%)', ' Diverticulitis * 1/63 (1.59%)', ' Nausea * 0/63 (0.00%)']}

69f57cdb-22e9-4a3a-8f19-6095c66c6497

Comparison

Eligibility

NCT01771666

NCT01256567

Japanese participants with an ECOG <=1 are eligible for the secondary trial and the primary trial.

Entailment

{'Clinical Trial ID': 'NCT01771666', 'Intervention': ['INTERVENTION 1: ', ' ISB and IC-Green Dye', ' The dose of Isosulfan blue (ISB) dye is 3 to 5 mL and Indocyanine green solution will be started at 1 mg/mL. If fluorescence is not detected with this dose, then it will be increased by 50%. A gamma probe [Neoprobe 2010] will be used to localize the sentinel lymph nodes in the axilla.'], 'Eligibility': ['Inclusion Criteria:', ' Ability to understand and the willingness to sign a written informed consent document.', ' Signed written informed consent.', ' Women undergoing sentinel lymph node biopsy.', ' Women with breast cancer with known or suspected lymph node involvement.', ' Women undergoing sentinel node identification and completion axillary lymph node dissection.', ' Women of 18 years of age or older.', ' Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status 0,1,2.', ' Complete Blood Count (CBC) and basic Metabolic Panel within 6 months', 'Exclusion Criteria:', ' History of liver or kidney failure will not be eligible.', ' Allergies to iodine containing products will not be eligible.', ' Women who are pregnant will not be eligible.', ' Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.'], 'Results': ['Outcome Measurement: ', ' Agreement of Labeling Between Isosulfan Blue (IS-BLUE) and Indocyanine Green (IC-GREEN)', ' Number of women with agreement of the two dies [ie, isosulfan blue (IS-BLUE) and indocyanine green (IC-GREEN)] on all nodes examined in the lymphatics and arm-draining lymph nodes, during nodal staging procedures for surgery to treat breast cancer with curative intent.', 'Time frame: 1 day', 'Results 1: ', ' Arm/Group Title: ISB and IC-Green Dye', ' Arm/Group Description: The dose of Isosulfan blue (ISB) dye is 3 to 5 mL and Indocyanine green solution will be started at 1 mg/mL. If fluorescence is not detected with this dose, then it will be increased by 50%. A gamma probe [Neoprobe 2010] will be used to localize the sentinel lymph nodes in the axilla.', ' Overall Number of Participants Analyzed: 23', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 8 34.8%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/23 (0.00%)']}

{'Clinical Trial ID': 'NCT01256567', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab and Docetaxel Combination', ' Docetaxel: Docetaxel administered by intravenous infusion at a dose of 75 milligrams per square meter (mg/m^2) every 3 weeks.', ' Ramucirumab: Ramucirumab administered as an intravenous infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' The participant is Japanese', ' The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', ' The participant has a histopathologically or cytologically confirmed diagnosis of breast adenocarcinoma that is now metastatic or locally-recurrent and inoperable with curative intent', ' The participant has measurable and/or non-measurable disease', " The participants' primary and/or metastatic tumor is Human Epidermal Growth Factor Receptor 2 (HER2) negative", ' The participant received neo adjuvant or adjuvant taxane therapy 6 months prior to the study', ' The participant received neo adjuvant or adjuvant biologic therapy 6 weeks prior to the study', ' The participant completed all prior radiotherapy 3 weeks prior to the study registration date', ' The participant received prior hormonal therapy for breast cancer in the neo adjuvant, adjuvant,and/or the metastatic setting 2 weeks prior to the study registration date', " The participant's left ventricular ejection fraction (LVEF) is within normal ranges", ' The participant has adequate hematologic, hepatic, and coagulation function.', ' Eligible participants of reproductive potential agree to use adequate contraceptive methods (hormonal or barrier methods) during the study period and for 12 weeks after the last dose of study medication', 'Exclusion Criteria:', ' The participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non-melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. Participants with previous treatment of malignancy is eligible, provided that she has been disease free for >3 years', ' The participant has a known sensitivity to docetaxel', ' The participant has a known sensitivity to agents of similar biologic composition as ramucirumab', ' The participant has a history of chronic diarrheal disease within 6 months prior to the study registration date', ' The participant has received irradiation to a major bone marrow area within 30 days prior to the study registration date', ' The participant has received any experimental agents within 4 weeks prior to the study registration date', ' The participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders', ' The participant has Grade 3-4 bleeding within 3 months prior to the study registration date', ' The participant has an ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy', ' The participant has uncontrolled hypertension, symptomatic congestive heart failure, psychiatric illness, or any other serious uncontrolled medical disorders', ' The participant has brain metastases', ' The participant has known human immunodeficiency virus infection or acquired immunodeficiency syndrome related illness', ' The participant is pregnant or lactating', ' The participant has not fully recovered from effects of prior chemotherapy', ' The participant has undergone major surgery within 28 days prior to the study registration date'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Adverse Events', ' Number participants with drug related dose-limiting toxicities (DLT) during Cycle 1; ramucirumab related: treatment-emergent adverse events (TEAE), serious adverse events (SAE), Grade 3 or higher TEAE, or TEAE leading to discontinuation or ramucirumab dose modification. DLT=G4 neutropenia >7days; G 3 neutropenia with fever 38.5°C requiring IV antibiotics or bacteriemia or sepsis; G4 thrombocytopenia; G 3 thrombocytopenia with bleeding requiring platelets; G 3 prothrombin time and/or partial thromboplastin time in absence of anticoagulants; G 2 hyperbilirubinemia 5 days; QTc >500 milliseconds (ms) or increase 100 ms or arrhythmia; G 4 or uncontrollable hypertension; G 3 nonhematologic toxicity (excluding G3: hypersensitivity, injection-site reaction, arthralgia/myalgia, asthenia/fatigue, diarrhea without loperamide therapy, nausea/vomiting without antiemetics, transient G3/4 elevation of aminotransferases); treatment delay >2 weeks due to toxicity.', ' Time frame: Baseline up to data cut off (approximately 48.3 weeks)', 'Results 1: ', ' Arm/Group Title: Ramucirumab and Docetaxel Combination', ' Arm/Group Description: Docetaxel: Docetaxel administered by intravenous infusion at a dose of 75 milligrams per square meter (mg/m^2) every 3 weeks.', ' Ramucirumab: Ramucirumab administered as an intravenous infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.', ' Overall Number of Participants Analyzed: 7', ' Measure Type: Number', ' Unit of Measure: participants Dose Limiting Toxicity (DLT) during Cycle 1: 2', ' TEAE related to ramucirumab: 7', ' SAE related to ramucirumab: 4', ' TEAE of Grade 3 related to ramucirumab: 6', ' TEAE resulting in ramucirumab discontinuation: 3', ' TEAE with ramucirumab dose modification/delay: 5'], 'Adverse Events': ['Adverse Events 1:', ' Total: 7/7 (100.00%)', ' Febrile neutropenia 3/7 (42.86%)', ' Cardiac failure 1/7 (14.29%)', ' Neutrophil count decreased 1/7 (14.29%)', ' Muscular weakness 1/7 (14.29%)', ' Epistaxis 1/7 (14.29%)', ' Interstitial lung disease 1/7 (14.29%)', ' Pleural effusion 2/7 (28.57%)']}

ea505463-c509-416e-ad88-11576764b734

Single

Adverse Events

NCT00930930

The overall most frequent adverse event in the primary trial was Dehydration.

Entailment

{'Clinical Trial ID': 'NCT00930930', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin and Paclitaxel + RAD001', ' Cisplatin 25 mg/m2 IV weekly + RAD001 5 mg PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + RAD001 5 mg PO daily for 11 weeks', ' cisplatin: Given IV', ' everolimus: Given orally', ' paclitaxel: Given IV', ' Venous blood draw: Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment', 'INTERVENTION 2: ', ' Cisplatin and Paclitaxel + Placebo', ' Cisplatin 25 mg/m2 IV weekly + placebo PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + placebo PO daily for 11 weeks', ' cisplatin: Given IV', ' paclitaxel: Given IV', ' placebo: Given orally', ' Venous blood draw: Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment'], 'Eligibility': ['Eligibility criteria', ' -Maximum number of patients will include two-thirds of the patients in Arm 1 and one-third of the patients for Arm 2 (total of 145 patients). Estimated time for accrual with ~ 3 patients/month would be ~ 3.5 years.', 'Inclusion criteria:', ' Patients must provide informed written consent.', ' Patient must be 18 years of age.', ' ECOG performance status 0-1.', ' Clinical stage II or stage III triple-negative (ER and/or PR no staining or weak staining in less than or equal to 10% cells by immunohistochemistry [IHC] and HER2-negative by Herceptest [0, 1+] or FISH) invasive mammary carcinoma, confirmed by histological analysis.', ' Patients who have measurable* residual tumor at the primary site', ' *Measurable disease: any mass that can be reproducibly measured by physical examination, mammogram, and/or ultrasound and can be accurately measured in at least one dimension (longest diameter to be recorded) as 10 mm (1 cm), either in the breast or axillary lymph nodes.', ' Available core biopsies from the time of diagnosis. Fresh tissue must be obtainable at baseline or fresh tissue biopsy prior to treatment initiation.', ' Patients who will undergo surgical treatment with either segmental resection or total mastectomy.', ' Patients must have adequate hematologic, hepatic, and renal function. All tests must be obtained less than 4 weeks from study entry. This includes:', ' ANC >/=1500/mm3', ' Platelet count >/=100,000/mm3', ' Creatinine </=1.5X upper limits of normal', ' Bilirubin, SGOT, SGPT </=1.5X upper limits of normal*', ' * for patients with Gilbert"s syndrome, direct bilirubin will be measured instead of total bilirubin.', ' The patient must have not had anyprior chemotherapy for primary breast cancer.', ' Patients with a prior history of contra-lateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer within the last 5 years.', ' Able to swallow and retain oral medication.', ' Four days prior to biopsy procedures patients must be off medications that could increase risk of bleeding (i.e. ASA, NSAIDS, Coumadin, heparin products)', ' Potential subjects must complete all screening assessments as outlined in the protocol.', ' The pre-menopausal patient of childbearing potential must have had a negative pregnancy test and agreed to use birth control methods while participating in the study. Note: Women of childbearing potential and their male counterparts should use a barrier method of contraception during and for 3 months following protocol therapy.', ' Ineligibility Criteria', 'Exclusion Criteria:', ' Locally recurrent breast cancer.', ' Pregnant or lactating women.', ' Evidence of distant metastatic disease (i.e. lung, liver, bone, brain, etc.)', ' Use of CYP3A4 modifiers (Appendix A)', ' Serious medical illness that in the judgment of the treating physician places the patient at high risk of operative mortality.', ' Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.', ' History of other malignancy. Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinomas are eligible.', ' History of hepatitis B or hepatitis C. If patient is judged to be at risk for having had exposure to viral B or C hepatitis (i.e. illicit IV drug use, blood transfusion prior to 1990, body piercing, tattoos, etc.), appropriate testing should be performed (i.e. Hepatitis B surface antigen antibody, and Hepatitis C antibody)', ' Active or uncontrolled infection requiring parenteral antibiotics.', ' Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.', ' Symptomatic neuropathy ( grade 2).', ' Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, or any other biologic therapy) other than the ones specified in the protocol.', ' Concurrent treatment with an investigational agent.', ' Used an investigational drug within 15 days or 5 half-lives, whichever is longer, preceding the first dose of randomized therapy.'], 'Results': ['Outcome Measurement: ', ' Number of Patients With Pathological Complete Response', ' Pathological complete response is defined as no residual tumor on histopathological analysis of both breast and axillary contents.', ' Time frame: at time of surgery, week 15-18', 'Results 1: ', ' Arm/Group Title: Cisplatin and Paclitaxel + RAD001', ' Arm/Group Description: Cisplatin 25 mg/m2 IV weekly + RAD001 5 mg PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + RAD001 5 mg PO daily for 11 weeks', ' cisplatin: Given IV', ' everolimus: Given orally', ' paclitaxel: Given IV', ' Venous blood draw: Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment', ' Overall Number of Participants Analyzed: 88', ' Measure Type: Number', ' Unit of Measure: participants 34', 'Results 2: ', ' Arm/Group Title: Cisplatin and Paclitaxel + Placebo', ' Arm/Group Description: Cisplatin 25 mg/m2 IV weekly + placebo PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + placebo PO daily for 11 weeks', ' cisplatin: Given IV', ' paclitaxel: Given IV', ' placebo: Given orally', ' Venous blood draw: Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment', ' Overall Number of Participants Analyzed: 44', ' Measure Type: Number', ' Unit of Measure: participants 17'], 'Adverse Events': ['Adverse Events 1:', ' Total: 22/96 (22.92%)', ' Anemia 1/96 (1.04%)', ' lymphopenia 1/96 (1.04%)', ' cardiac ischemia/infarction 1/96 (1.04%)', ' sinus tachycardia 2/96 (2.08%)', ' Dehydration 5/96 (5.21%)', ' colitis 1/96 (1.04%)', ' diarrhea 5/96 (5.21%)', ' ileus 1/96 (1.04%)', ' nausea 2/96 (2.08%)', ' vomiting 1/96 (1.04%)', ' distal small bowel obstruction 1/96 (1.04%)', ' edema 1/96 (1.04%)', ' fatigue 2/96 (2.08%)', 'Adverse Events 2:', ' Total: 6/49 (12.24%)', ' Anemia 0/49 (0.00%)', ' lymphopenia 0/49 (0.00%)', ' cardiac ischemia/infarction 0/49 (0.00%)', ' sinus tachycardia 0/49 (0.00%)', ' Dehydration 1/49 (2.04%)', ' colitis 0/49 (0.00%)', ' diarrhea 0/49 (0.00%)', ' ileus 0/49 (0.00%)', ' nausea 1/49 (2.04%)', ' vomiting 1/49 (2.04%)', ' distal small bowel obstruction 0/49 (0.00%)', ' edema 0/49 (0.00%)', ' fatigue 0/49 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

81669281-db01-4493-a797-0d60f448f706

Comparison

Intervention

NCT00382785

NCT00784849

Neither the primary trial or the secondary trial use Low Dose Magnesium Oxide, High Dose Magnesium Oxide or Mometasone in their intervention.

Entailment

{'Clinical Trial ID': 'NCT00382785', 'Intervention': ['INTERVENTION 1: ', ' Moderated Group', ' one 12-week online support group led by a professional healthcare provider', 'INTERVENTION 2: ', ' Non-facilitated (Peer-led)', ' 12-week online support in a peer-led format'], 'Eligibility': ['Inclusion Criteria: Clinical diagnosis of breast cancer', ' Female', ' At least 21 years of age', ' Internet access; Able to read and write English', ' Have completed treatment for breast cancer in the past 36 months or are receiving treatment', ' Do not currently belong to an online or face-to-face cancer support group', ' Internet access', 'Exclusion Criteria:', ' Male', ' not diagnosed with breast cancer', ' under 21 years of age', ' received treatment more than 36 months ago for breast cancer', ' no Internet access', ' unable to read and write English'], 'Results': ['Outcome Measurement: ', ' Scores on the Personal Resource Questionnaire 85.', ' The Personal Resource Questionnaire 85 (PRQ85), Part II measures perceived social support and consists of 25 items in a seven-point Likert format which are rated from seven (7) strongly agree, to one (1) strongly disagree. Scores range from 25 to 175 with higher scores indicative of higher levels of perceived social support. Alpha reliability of the PRQ 85 has been demonstrated at >.90', ' Time frame: 16 weeks', 'Results 1: ', ' Arm/Group Title: Moderated Group', ' Arm/Group Description: one 12-week online support group led by a professional healthcare provider', ' Overall Number of Participants Analyzed: 25', ' Mean (Standard Error)', ' Unit of Measure: Scores on a scale 50.22 (3.23)', 'Results 2: ', ' Arm/Group Title: Non-facilitated (Peer-led)', ' Arm/Group Description: 12-week online support in a peer-led format', ' Overall Number of Participants Analyzed: 26', ' Mean (Standard Error)', ' Unit of Measure: Scores on a scale 53.44 (3.08)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/25 (0.00%)', 'Adverse Events 2:', ' Total: 0/26 (0.00%)']}

{'Clinical Trial ID': 'NCT00784849', 'Intervention': ['INTERVENTION 1: ', ' Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue', ' One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel lymph nodes'], 'Eligibility': ['Inclusion Criteria:', ' Stage 0,I, II breast cancer', ' Clinical node status N0, N1', ' No know allergy to iodine, lymphazurin or methylene blue dyes', 'Exclusion Criteria:', ' Patient cannot be pregnant or nursing', ' Prisoners will not be eligible', ' Women under the age of 18 will not be eligible', ' Patients with a known allergy to iodine or methylene blue or lymphazurin blue dyes'], 'Results': ['Outcome Measurement: ', ' The Number of Participants That Have Sentinel Nodes Which Are Radioactive or Blue, or Radioactive and Blue or Have Efferent Blue Lymphatics Leading up to the Sentinel Node(s)', ' [Not Specified]', ' Time frame: intraoperatively; up to 6 hours', 'Results 1: ', ' Arm/Group Title: Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue', ' Arm/Group Description: One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel lymph nodes', ' Overall Number of Participants Analyzed: 62', ' Measure Type: Number', ' Unit of Measure: participants Radioactive: 58', ' Blue: 55', ' Radioactive and Blue: 55', ' Efferent blue lymphatics leading up to the SLN: 0'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/62 (0.00%)']}

40dbf023-ead5-45fc-bdce-bf40e1955578

Single

Adverse Events

NCT00003782

One of the cohorts in the primary trial had more than 5% of patients experiencing side effects.

Contradiction

{'Clinical Trial ID': 'NCT00003782', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Doxorubicin + Cyclophosphamide, Then Docetaxel', ' Doxorubicin + Cyclophosphamide, then Docetaxel', 'INTERVENTION 2: ', ' Arm 2: Doxorubicin + Docetaxel', ' Doxorubicin + Docetaxel'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed invasive adenocarcinoma of the breast', ' Confined to the breast and ipsilateral axilla on clinical exam', ' Stage I, II, or IIIA (cT1-3, N0-1, M0)', ' At least one axillary lymph node with evidence of tumor on histologic exam', ' Sentinel node biopsy allowed if followed by axillary dissection', ' No suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes, unless proven on biopsy to not be involved with tumor', ' No bilateral malignancy or mass in the opposite breast, unless mass is histologically proven to be benign', ' Must have undergone either a prior total mastectomy and axillary dissection (modified radical mastectomy) OR', ' Prior lumpectomy and axillary dissection', ' Patients must receive radiotherapy after randomization (not before) AND after chemotherapy', ' Margins must be clear', ' No ipsilateral lymph nodes that are fixed to one another or to other structures (N2 disease) and/or any positive nonaxillary lymph nodes (intramammary nodes are considered axillary nodes)', ' No histologically evident invasive tumor or ductal carcinoma in situ', ' No diffuse tumors by mammography that would not be surgically amenable to lumpectomy', ' No other dominant mass in the ipsilateral breast remnant unless one of the following is true:', ' Histologically benign', ' Surgically removed with clear margins if malignant', " No ulceration, erythema, infiltration of the skin or underlying chest wall (complete fixation), peau d'orange, or skin edema of any magnitude", ' Tethering or dimpling of the skin or nipple inversion allowed', ' No metastatic disease', ' Skeletal pain allowed if bone scan negative for metastases', ' Hormone receptor status:', ' Estrogen and progesterone status determined', ' PATIENT CHARACTERISTICS:', ' Age:', ' greater than or equal to 18 years', ' Sex:', ' Female', ' Menopausal status:', ' Not specified', 'Performance status:', ' Not specified', ' Life expectancy:', ' At least 10 years, excluding diagnosis of cancer', ' Hematopoietic:', ' Absolute neutrophil count at least 1,500/mm^3 (may be less, if in the opinion of the investigator, this represents an ethnic or racial variation)', ' Platelet count at least 100,000/mm^3* NOTE: *If platelet count is above the upper limit of normal (ULN), significant underlying hematologic disorders must be excluded', ' Hepatic:', ' Bilirubin no greater than ULN', ' Alkaline phosphatase less than 2.5 times ULN*', ' SGOT less than 1.5 times ULN*', ' No nonmalignant systemic hepatic disease that would preclude study participation NOTE: *Alkaline phosphatase and SGOT cannot both be greater than ULN', ' Renal:', ' Creatinine no greater than normal', ' No nonmalignant systemic renal disease that would preclude study participation', ' Cardiovascular:', ' No nonmalignant systemic cardiovascular disease that would preclude study participation', ' LVEF at least lower limit of normal (LLN) by MUGA or echocardiogram', ' No active cardiac disease that would preclude use of doxorubicin or docetaxel, including the following:', ' Any prior myocardial infarction', ' Angina pectoris requiring anti-anginal medication', ' History of congestive heart failure', ' Cardiac arrhythmia requiring medication', ' Severe conduction abnormality', ' Valvular disease with documented cardiac function compromise', ' Cardiomegaly on chest x-ray or ventricular hypertrophy on EKG, unless LVEF at least LLN', ' Poorly controlled hypertension (diastolic greater than 100 mm/Hg)', ' Hypertension well controlled by medication allowed', ' Other:', ' No grade 2 or greater peripheral neuropathy', ' No other prior malignancy within the past 5 years except:', ' Effectively treated squamous cell or basal cell skin cancer', ' Surgically treated carcinoma in situ of the cervix', ' Segmentally resected lobular carcinoma in situ of the ipsilateral or contralateral breast', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective barrier contraception', ' No nonmalignant systemic disease that would preclude study participation', ' No diabetes with morning fasting blood glucose of 200 mg/dL or greater', ' No psychiatric or addictive disorders that would preclude informed consent', ' No contraindication to corticosteroids that would preclude study participation', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy:', ' No prior immunotherapy for breast cancer', ' Chemotherapy:', ' No prior chemotherapy for breast cancer', ' No prior anthracyclines or taxanes', ' No other concurrent investigational chemotherapy', ' Endocrine therapy:', ' No prior hormonal therapy for breast cancer', ' No concurrent hormonal birth control methods or other hormonal therapy', ' No concurrent raloxifene, including for osteoporosis', ' Concurrent low-dose topical estrogen in the form of conjugated estrogen ring or conjugated estrogen vaginal cream (dose no more than 0.3 mg or 1/8 of an applicator applied vaginally 3 times a week) allowed', ' Radiotherapy:', ' See Disease Characteristics', ' No prior radiotherapy for this malignancy', ' Surgery:', ' See Disease Characteristics', ' No more than 84 days since prior surgery for breast cancer (e.g., lumpectomy, mastectomy, sentinel node biopsy, axillary dissection, or re-excision of lumpectomy margins)', ' Other:', ' No prior systemic therapy for this malignancy', ' No concurrent medications that alter cardiac conduction (e.g., digitalis, beta blockers, or calcium-channel blockers) for cardiac arrhythmia, angina, or congestive heart failure (allowed if administered for other reasons [e.g., hypertension])', ' Concurrent bisphosphonates allowed'], 'Results': ['Outcome Measurement: ', ' Overall Survival', ' [Not Specified]', ' Time frame: 8 years', 'Results 1: ', ' Arm/Group Title: Arm 1: Doxorubicin + Cyclophosphamide, Then Docetaxel', ' Arm/Group Description: Doxorubicin + Cyclophosphamide, then Docetaxel', ' Overall Number of Participants Analyzed: 1753', ' Measure Type: Number', ' Unit of Measure: percentage of patients alive 83', 'Results 2: ', ' Arm/Group Title: Arm 2: Doxorubicin + Docetaxel', ' Arm/Group Description: Doxorubicin + Docetaxel', ' Overall Number of Participants Analyzed: 1753', ' Measure Type: Number', ' Unit of Measure: percentage of patients alive 79'], 'Adverse Events': ['Adverse Events 1:', ' Total: 66/1748 (3.78%)', ' Febrile neutropenia 2/1748 (0.11%)', ' Cardiac disorders - Other, specify 3/1748 (0.17%)', ' Conduction disorder 0/1748 (0.00%)', ' Myocardial infarction 0/1748 (0.00%)', ' Ventricular arrhythmia 1/1748 (0.06%)', ' Left ventricular systolic dysfunction 0/1748 (0.00%)', ' Colitis 1/1748 (0.06%)', ' Diarrhea 0/1748 (0.00%)', ' Duodenal ulcer 0/1748 (0.00%)', 'Adverse Events 2:', ' Total: 43/1748 (2.46%)', ' Febrile neutropenia 1/1748 (0.06%)', ' Cardiac disorders - Other, specify 1/1748 (0.06%)', ' Conduction disorder 0/1748 (0.00%)', ' Myocardial infarction 1/1748 (0.06%)', ' Ventricular arrhythmia 0/1748 (0.00%)', ' Left ventricular systolic dysfunction 1/1748 (0.06%)', ' Colitis 1/1748 (0.06%)', ' Diarrhea 1/1748 (0.06%)', ' Duodenal ulcer 1/1748 (0.06%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

b64ae9c9-956a-421e-a41f-1886408fec2a

Comparison

Intervention

NCT01539317

NCT01323530

the primary trial uses a topical intervention and the secondary trial uses a combination of oral and intravenous treatments.

Entailment

{'Clinical Trial ID': 'NCT01539317', 'Intervention': ['INTERVENTION 1: ', ' Topical Saline', ' Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule', ' Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness', 'INTERVENTION 2: ', ' Topical Liquid Lidocaine', ' Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule', ' Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness'], 'Eligibility': ['Eligibility Criteria', ' Women aged 18 to 70 years old.', ' Has a previous diagnosis of breast cancer (ductal or lobular carcinoma, invasive).', ' 1 year from diagnosis of breast cancer.', ' Stable heterosexual partnership =/>5 years or by investigator discretion.', ' More than 6 months of consistent insertional pain with intercourse (may have stopped having intercourse due to this consistent experience of pain).', ' Menopausal, demonstrated by at least one of the following:', " i. cessation of menses for 1 years ii. Bilateral oophorectomy iii. Follicle Stimulating Hormone (FSH) level >25 in women below age 50 with an ovary and scarred or absent uterus (acceptable FSH levels can be inferred if the woman's oncologist monitors FSH during aromatase inhibitor therapy).", ' Willingness to enter a study comparing a topical placebo liquid to topical liquid lidocaine.', ' Willingness to evaluate the liquids by use of a tampon test as many as 4 times per month, and willingness to attempt intercourse if the tampon test indicates tolerable penetrative pain.', ' 3.2 Exclusion Criteria', ' Diagnosis of benign or malignant phyllodes tumor of the breast.', ' Consistently has pain in the pelvis or low abdomen during or after intercourse (deep dyspareunia).', ' Has developed shrinkage of the vaginal opening or vaginal length to the point of being too small to succeed in having vaginal penetration with the partner (will also be assessed at the clinical exam).', ' Partner has a problem of sexual dysfunction limiting his performance or making it inconsistent.', ' The potential subject or her partner has a serious current medical condition that might interrupt completion of a 6 month study.', ' Potential subject has been diagnosed by a physical therapist with significant pelvic floor muscle dysfunction causing pain (pelvic floor myalgia).', ' Potential subject has used topical or systemic estrogen within the last 4 months.', ' Has continued tenderness of vestibule mucosa immediately after application of both test liquids.', ' Allergy to lidocaine or other numbing agents.'], 'Results': ['Outcome Measurement: ', ' Prevention of Entry Dyspareunia With Non-hormonal Therapy', ' Mean intercourse pain reported by subjects using the Numerical Rating Scale pain ratings (range 0-10, 0 being "no pain" and 10 being "worst possible pain"). Testing was during weeks 0-4 (Phase II) (with blinded randomization for placebo vs active intervention medication) and testing was during weeks 5-12 (Phase III) (with open-label active medication for 8 weeks after completing the blinded 4 weeks). Subjects agreed to try penetration twice per week and score their pain using the Numerical Rating Scale pain ratings.The scores were averaged during each phase.', ' Time frame: During Phase II (0-4 weeks) and during Phase III (5-12 weeks)', 'Results 1: ', ' Arm/Group Title: Topical Saline', ' Arm/Group Description: Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule', ' Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness', ' Overall Number of Participants Analyzed: 21', ' Mean (Inter-Quartile Range)', ' Unit of Measure: Units on a scale Phase II: 5.3 (3 to 7)', ' Phase III: 0.57 (0.07 to 1.80)', 'Results 2: ', ' Arm/Group Title: Topical Liquid Lidocaine', ' Arm/Group Description: Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule', ' Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness', ' Overall Number of Participants Analyzed: 22', ' Mean (Inter-Quartile Range)', ' Unit of Measure: Units on a scale Phase II: 1.04 (0.65 to 1.92)', ' Phase III: 0.45 (0 to 1.14)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/25 (0.00%)', 'Adverse Events 2:', ' Total: 0/25 (0.00%)']}

{'Clinical Trial ID': 'NCT01323530', 'Intervention': ['INTERVENTION 1: ', ' Phase 1b (Schedule 1): Eribulin Mesilate (1.2 mg/m^2)', ' Participants received eribulin mesilate 1.2 mg/m^2, injection, intravenously, once, on Day 1 and capecitabine 1000 mg/m^2, tablets, orally, twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD, undue toxicity, the presence of other medical conditions that prohibit continuation of therapy, pregnancy, a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1).', 'INTERVENTION 2: ', ' Phase 1b (Schedule 1): Eribulin Mesilate (1.6 mg/m^2)', ' Participants received eribulin mesilate 1.6 mg/m^2, injection, intravenously, once, on Day 1 and capecitabine 1000 mg/m^2, tablets, orally, twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD, undue toxicity, the presence of other medical conditions that prohibit continuation of therapy, pregnancy, a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1).'], 'Eligibility': ['Inclusion Criteria', ' Subjects who meet all of the following criteria will be included in the study:', ' Dose-escalation cohorts (Phase 1b):', ' Histologically or cytologically confirmed cancer that is advanced and/or metastatic', ' Resistant/refractory to approved therapies (defined as progressive disease during or within 6 months after the last anti-cancer therapy) or for whom single agent capecitabine at this dose level and schedule would be a reasonable treatment option in the opinion of the investigator', ' For subjects that previously received capecitabine, all capecitabine related toxicities must have completely resolved', ' Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L, hemoglobin greater than or equal to 10.0 g/dL (this may have been corrected by growth factor or transfusion), and platelet count greater than or equal to 100 x 10^9/L', ' Adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the upper limit of normal (ULN) and alkaline phosphatase (AP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 x ULN (in the case of liver metastases less than or equal to 5 x ULN). In case AP is greater than 3 x ULN (in absence of liver metastases) or greater than 5 x ULN (in presence of liver metastases) AND subject also is known to have bone metastases, the liver specific AP must be separated from the total and used to assess the liver function instead of the total AP.', ' Adequate renal function as evidenced by calculated creatinine clearance greater than or equal to 50 mL/min as per the Cockcroft-Gault formula (Appendix 1) or radioisotope measurement.', ' Females of childbearing potential must have a negative urine or serum beta human chorionic gonadotropin (hCG) at Visit 1 (Screening) and prior to starting study drugs on Day 1. Female subjects of childbearing potential must agree to be abstinent or to use highly effective methods of contraception (e.g., condom + spermicide, condom + diaphragm with spermicide, intrauterine device (IUD), or have a vasectomized partner) having starting for at least one menstrual cycle prior to starting study drug(s) and throughout the entire study period and for 30 days (longer if appropriate) after the last dose of study drug. Those women using hormonal contraceptives must also be using an additional approved method of contraception (as described previously). Perimenopausal women must be amenorrheic for at least 12 months to be considered of nonchildbearing potential.', ' Male subjects who are not abstinent or have not undergone a successful vasectomy, who are partners of women of childbearing potential must use, or their partners must use, a highly affective method of contraception (e.g. condom + spermicide, condom + diaphragm with spermicide, IUD) starting for at least one menstrual cycle prior to starting study drug(s) and throughout the entire study period and for 30 days (longer if appropriate) after the last dose of study drug. Those with partners using hormonal contraceptives must also be using an additional approved method of contraception (as described previously)', ' Life expectancy of greater than 3 months', ' Willing and able to comply with all aspects of the protocol', ' Provide written informed consent', ' Eastern Cooperative Oncology Group (ECOG) performance status (PS) less than or equal to 2', ' Males and females, age greater than or equal to18 years', ' Dose-confirmation cohorts (Phase 2):', ' Histologically or cytologically confirmed carcinoma of the breast that is advanced and/or metastatic', ' Received up to three prior chemotherapy regimens in any setting (sequential neoadjuvant/ adjuvant treatment counting as one regimen)', ' Chemotherapy regimens must have included an anthracycline (unless anthracycline containing chemotherapy is inappropriate) and a taxane, either in combination or in separate regimens', ' No prior treatment with capecitabine in any setting', ' At least one lesion of greater than or equal to 1.5cm in longest diameter for non-lymph nodes and greater than or equal to 1.5cm in shortest diameter for lymph nodes which is serially measurable according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 7', ' Adequate bone marrow function as evidenced by ANC greater than or equal to 1.5 x 10^9/L, hemoglobin greater than or equal to 10.0 g/dL (this may have been corrected by growth factor or transfusion), and platelet count greater than or equal to 100 x 10^9/L', ' Adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the upper limits of normal (ULN) and alkaline phosphatase (AP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal 3 x ULN (in the case of liver metastases less than or equal to 5 x ULN). In case AP is greater than 3 x ULN (in absence of liver metastases) or greater than 5 x ULN (in presence of liver metastases) AND subject also is known to have bone metastases, the liver specific AP must be separated from the total and used to assess the liver function instead of the total AP.', ' Adequate renal function as evidenced by calculated creatinine clearance greater than or equal to 50 mL/min as per the Cockcroft-Gault formula (Appendix 1) or radioisotope measurement.', ' Females of childbearing potential must have a negative urine or serum beta hCG at Visit 1 (Screening) and prior to starting study drugs on Day 1. Female subjects of childbearing potential must agree to be abstinent or to use highly effective methods of contraception (e.g., condom + spermicide, condom + diaphragm with spermicide, IUD, or have a vasectomized partner) having starting for at least one menstrual cycle prior to starting study drug(s) and throughout the entire study period and for 30 days (longer if appropriate) after the last dose of study drug. Those women using hormonal contraceptives must also be using an additional approved method of contraception (as described previously). Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential', ' Life expectancy of greater than 3 months', ' Willing and able to comply with all aspects of the protocol', ' ECOG-PS 0 or 1', ' Females, age greater than or equal to 18 years', ' Exclusion Criteria', ' Subjects who meet any of the following criteria will be excluded from participation in the study:', ' Radiotherapy, chemotherapy, biological therapy or investigational agents within 4 weeks prior to the start of study treatment; subjects must have recovered from any previous therapy related toxicity to less than Grade 1 at study entry (except for stable sensory neuropathy less than or equal to Grade 2 and alopecia)', ' Treatment with mitomycin C or nitrosourea within 6 weeks prior to commencing on study treatment', ' Hormonal treatment within 2 weeks prior to start of study treatment (continued use of antiandrogens and/or gonadorelin analogues for treatment of prostate cancer permitted)', ' Prior participation in an eribulin clinical study, even if not assigned to eribulin treatment', ' Subject with hypersensitivity to halochondrin B and /or halochondrin B chemical derivates or capecitabine or any of the excipients', ' Suspected dihydropyrimidine dehydrogenase (DPD) deficiency', ' Previous radiotherapy encompassing greater than 30% of marrow', ' Previous organ allograft requiring immunosuppression', ' Subjects with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication at least 4 weeks before starting study treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before starting study treatment; radiographic stability should be determined by comparing contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) brain scan performed during screening to a prior scan performed at least 4 weeks earlier', ' Meningeal carcinomatosis', ' Significant cardiovascular impairment (history of congestive heart failure greater than New York Heart Association [NYHA] grade II, unstable angina or myocardial infarction within the past 6 months, or serious cardiac arrhythmia)', " Electrocardiogram (ECG) with QT interval corrected for heart rate (QTc) interval greater than 470 msec (as measured either by Bazett's or Fredericia's formula)", ' Pre-existing neuropathy greater than Grade 2', ' Anti-coagulant therapy with warfarin or related compounds, other than for line patency, that cannot be changed to heparin-based therapy for the duration of the study', ' Subjects with known positive serology for Human Immunodeficiency Virus (HIV), or Hepatitis B or C', " Subjects with other significant disease or disorder that, in the Investigator's opinion, would exclude the subject from the study", ' Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study', ' Unable to swallow tablets'], 'Results': ['Outcome Measurement: ', ' Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0)', ' DLTs as per NCI CTCAE v3.0 were defined as:1) Neutropenia Grade 4 that lasted at least 7 days, 2) Neutropenia Grade 3 or 4 complicated by fever and/or infection (absolute neutrophil count [ANC] less than 1.0*10^9/liter [L], fever of at least 38.5 degree celsius [°C]), 3)Thrombocytopenia Grade 4, 4) Thrombocytopenia Grade 3 complicated by bleeding and/or requiring platelet or blood transfusion, 5) Non-hematological toxicity Grade 3 or higher (excluding Grade 3 nausea, and Grade 3 or 4 vomiting or diarrhea in participants who had not received optimal treatment with antiemetic and/or antidiarrheal medication; excluding laboratory abnormalities without clinical symptoms), 6) Delayed recovery from treatment-related toxicity resulting in dose delay greater than 14 days, 7) Failure to administer at least 75 percent (%) of planned study drugs during Cycle 1 as result of Grade 2 or higher treatment-related toxicity that constituted increase of at least 2 grades from baseline.', ' Time frame: Cycle 1 (21 days)', 'Results 1: ', ' Arm/Group Title: Phase 1b (Schedule 1): Eribulin Mesilate (1.2 mg/m^2)', ' Arm/Group Description: Participants received eribulin mesilate 1.2 mg/m^2, injection, intravenously, once, on Day 1 and capecitabine 1000 mg/m^2, tablets, orally, twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD, undue toxicity, the presence of other medical conditions that prohibit continuation of therapy, pregnancy, a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1).', ' Overall Number of Participants Analyzed: 8', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 1 12.5%', 'Results 2: ', ' Arm/Group Title: Phase 1b (Schedule 1): Eribulin Mesilate (1.6 mg/m^2)', ' Arm/Group Description: Participants received eribulin mesilate 1.6 mg/m^2, injection, intravenously, once, on Day 1 and capecitabine 1000 mg/m^2, tablets, orally, twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD, undue toxicity, the presence of other medical conditions that prohibit continuation of therapy, pregnancy, a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1).', ' Overall Number of Participants Analyzed: 6', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 1 16.7%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/8 (25.00%)', ' Febrile neutropenia 1/8 (12.50%)', ' Heparin-induced Thrombocytopenia 0/8 (0.00%)', ' Neutropenia 0/8 (0.00%)', ' Constipation 0/8 (0.00%)', ' Dysphagia 0/8 (0.00%)', ' Nausea 0/8 (0.00%)', ' Vomiting 0/8 (0.00%)', ' Abdominal Pain 0/8 (0.00%)', ' Diarrhoea 0/8 (0.00%)', ' Intestinal Ischaemia 0/8 (0.00%)', ' Small intestine obstruction 0/8 (0.00%)', ' Fatigue 0/8 (0.00%)', 'Adverse Events 2:', ' Total: 4/6 (66.67%)', ' Febrile neutropenia 0/6 (0.00%)', ' Heparin-induced Thrombocytopenia 0/6 (0.00%)', ' Neutropenia 2/6 (33.33%)', ' Constipation 0/6 (0.00%)', ' Dysphagia 1/6 (16.67%)', ' Nausea 0/6 (0.00%)', ' Vomiting 0/6 (0.00%)', ' Abdominal Pain 0/6 (0.00%)', ' Diarrhoea 0/6 (0.00%)', ' Intestinal Ischaemia 0/6 (0.00%)', ' Small intestine obstruction 0/6 (0.00%)', ' Fatigue 0/6 (0.00%)']}

e0980234-0611-44de-9165-54bdd086663d

Single

Adverse Events

NCT00005908

There were 8 cases of pharyngitis in cohort 2 of the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT00005908', 'Intervention': ['INTERVENTION 1: ', ' Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine', ' Docetaxel 75 mg/m^2 intravenous day 1, capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles Once the dose was deemed to be too toxic, subsequent patients were enrolled on dose B.', 'INTERVENTION 2: ', ' Dose B-Cohort 2-Arm 2 Reduced Dose-Docetaxel & Capecitabine', ' Docetaxel 60 mg/m^2 intravenous day 1 capecitabine 937.5 mg/m^2 orally twice daily day 2-15'], 'Eligibility': ['INCLUSION CRITERIA:', ' Stage II or III breast cancer with a tumor size of greater than 2 cm. Patients with a previous biopsy are eligible provided adequate tumor tissue remains for biopsy in this study.', ' At least 18 years of age.', ' Adequate hematopoietic function as defined by absolute neutrophil count greater than 1200/mm^3 and platelet count greater than 100,000/mm^3.', ' Adequate renal function as defined by creatinine less than 1.6 mg/dL.', ' Adequate hepatic function as defined by total (T.) bilirubin less than 1.4 mg/dL and serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvic transaminase (SGPT) less than 1.5 times the upper limit of normal and alkaline phosphatase less than 2.5 times upper limit of normal', ' Zubrod Performance status 0-2.', 'EXCLUSION CRITERIA:', ' Medical or psychiatric condition that, in the opinion of the Principal Investigator, would preclude chemotherapy administration. Patients may be evaluated by psychiatry or medical subspecialties as appropriate.', ' Pregnant or lactating women', ' Known bleeding disorders', ' Hypersensitivity to Tween 80 (Polysorbate)', ' Cardiac ejection fraction below normal limits, myocardial infarction within the past 12 months, or symptomatic arrhythmia requiring medical intervention.', ' Prior chemotherapy or hormonal therapy for breast cancer. Patients treated with hormonal chemoprevention (tamoxifen or raloxifene) will be eligible.', ' Active malignancy diagnosed within the last 5 years. (Cervical cancer or non-melanomatous skin cancer that has been treated with curative intent will be eligible).'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Adverse Events', ' Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.', ' Time frame: 6 years', 'Results 1: ', ' Arm/Group Title: Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine', ' Arm/Group Description: Docetaxel 75 mg/m^2 intravenous day 1, capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles Once the dose was deemed to be too toxic, subsequent patients were enrolled on dose B.', ' Overall Number of Participants Analyzed: 9', ' Measure Type: Number', ' Unit of Measure: Participants 9', 'Results 2: ', ' Arm/Group Title: Dose B-Cohort 2-Arm 2 Reduced Dose-Docetaxel & Capecitabine', ' Arm/Group Description: Docetaxel 60 mg/m^2 intravenous day 1 capecitabine 937.5 mg/m^2 orally twice daily day 2-15', ' Overall Number of Participants Analyzed: 20', ' Measure Type: Number', ' Unit of Measure: Participants 20'], 'Adverse Events': ['Adverse Events 1:', ' Total: 29/30 (96.67%)', ' Febrile neutropenia [1]3/30 (10.00%)', ' Lymphatics 1/30 (3.33%)', ' Diarrhea (without colostomy) 5/30 (16.67%)', ' Abdominal pain or cramping 2/30 (6.67%)', ' Colitis 1/30 (3.33%)', ' Dehydration 1/30 (3.33%)', ' Nausea 1/30 (3.33%)', ' Stomatitis/pharyngitis (oral/pharyngeal/mucositis) 1/30 (3.33%)', ' Vomiting 1/30 (3.33%)', 'Adverse Events 2:', ' ']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

3366c10a-3d41-48ae-bfa8-26b9e655761e

Single

Adverse Events

NCT01572727

Cohort 1 of the primary trial recorded more white blood cell related adversse events than cohort 2.

Entailment

{'Clinical Trial ID': 'NCT01572727', 'Intervention': ['INTERVENTION 1: ', ' BKM120 and Paclitaxel', ' Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel', 'INTERVENTION 2: ', ' Placebo and Paclitaxel', ' Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel'], 'Eligibility': ['Inclusion Criteria:', ' Breast cancer that is locally advanced or metastatic', ' HER2 negative disease, and a known hormone receptor status - ER/PgR (common breast cancer classification tests)', ' A tumor sample must be shipped to a central lab for identification of biomarkers (PI3K activation status) before randomization', ' Adequate bone marrow and organ function', ' Measurable or non-measurable disease', 'Exclusion Criteria:', ' Prior chemotherapy for locally advanced or metastatic disease', ' Previous treatment with PI3K or AKT inhibitors', ' Patient has symptomatic CNS metastases', ' Concurrent malignancy or malignancy within 3 years of study enrollment', ' Hematopoietic colony-stimulating growth factors or radiation within 2-4 weeks prior to starting study drug', ' Increasing or chronic treatment (> 5 days) with corticosteroids or another immunosuppressive agent', ' Active heart (cardiac) disease as defined in the protocol', ' Known hypersensitivity or contraindications to use paclitaxel', ' Pregnant or nursing (lactating) woman', ' Certain scores on an anxiety and depression mood questionaire given at screening', ' Other protocol defined criteria may apply'], 'Results': ['Outcome Measurement: ', " Progression-free Survival (PFS)Assessed by Local Investigator's Assessment (Phase ll)", ' PFS was defined as the time from the date of randomization to the date of the event, defined as the first radiologically documented disease progression or death due to any cause. Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.', ' Time frame: Every 8 weeks from randomization until disease progression up to 10 months after futility was analyzed', 'Results 1: ', ' Arm/Group Title: BKM120 and Paclitaxel', ' Arm/Group Description: Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel', ' Overall Number of Participants Analyzed: 168', ' Median (95% Confidence Interval)', ' Unit of Measure: Months 8.0 (7.2 to 9.2)', 'Results 2: ', ' Arm/Group Title: Placebo and Paclitaxel', ' Arm/Group Description: Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel', ' Overall Number of Participants Analyzed: 170', ' Median (95% Confidence Interval)', ' Unit of Measure: Months 9.2 (7.3 to 11.0)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 61/202 (30.20%)', ' FEBRILE NEUTROPENIA 1/202 (0.50%)', ' LEUKOPENIA 0/202 (0.00%)', ' NEUTROPENIA 2/202 (0.99%)', ' CARDIAC FAILURE CONGESTIVE 0/202 (0.00%)', ' CARDIO-RESPIRATORY ARREST 1/202 (0.50%)', ' PERICARDIAL EFFUSION 1/202 (0.50%)', ' CATARACT 1/202 (0.50%)', ' OPTIC NEUROPATHY 0/202 (0.00%)', ' ABDOMINAL PAIN 0/202 (0.00%)', ' CONSTIPATION 0/202 (0.00%)', ' DIARRHOEA 5/202 (2.48%)', 'Adverse Events 2:', ' Total: 42/201 (20.90%)', ' FEBRILE NEUTROPENIA 0/201 (0.00%)', ' LEUKOPENIA 1/201 (0.50%)', ' NEUTROPENIA 0/201 (0.00%)', ' CARDIAC FAILURE CONGESTIVE 1/201 (0.50%)', ' CARDIO-RESPIRATORY ARREST 0/201 (0.00%)', ' PERICARDIAL EFFUSION 0/201 (0.00%)', ' CATARACT 1/201 (0.50%)', ' OPTIC NEUROPATHY 1/201 (0.50%)', ' ABDOMINAL PAIN 1/201 (0.50%)', ' CONSTIPATION 1/201 (0.50%)', ' DIARRHOEA 3/201 (1.49%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

be29030a-98e8-40ad-9138-90076fdb50d3

Single

Results

NCT01097460

Every patient in the primary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years.

Entailment

{'Clinical Trial ID': 'NCT01097460', 'Intervention': ['INTERVENTION 1: ', ' MM-111 + Herceptin', ' MM-111 will be combined with Herceptin', ' MM-111 and Herceptin: For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have histologically or cytologically confirmed advanced breast cancer that is amplified for HER2, based on archived tumor biopsy (IHC 2+ or greater)', ' Patients must have histologically or cytologically confirmed advanced breast cancer that is heregulin positive based on fresh tumor tissue biopsy', " The patient's cancer must have recurred, progressed or not responded to standard chemotherapy or other standard treatment. Prior therapies may include but are not limited to Herceptin, Tykerb (lapatinib), anthracyclines, and taxanes", ' Patients must be 18 years of age', ' Patients or their legal representatives must be able to understand and sign an informed consent', ' Patients may have measurable (per RECIST 1.1) or non-measurable tumor(s) (for Phase 1)', ' Patients should have ECOG Performance Score (PS) 0, 1 or 2 (for Phase 1).', ' Patients should have a life expectancy of at least 12 weeks', ' Patients must have adequate bone marrow reserves', ' Patients must have adequate hepatic function', ' Patients must have adequate renal function', ' Patients must be recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy.', ' Women of childbearing potential as well as fertile men and their partners must agree to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-111.', 'Exclusion Criteria:', ' Patients who are pregnant or lactating', ' Patients with an active infection or with an unexplained fever > 38.5°C (101.3° F) during screening visits or on the first scheduled day of dosing.', ' Patients with untreated and/or symptomatic metastatic CNS malignancies.', ' Patients with known hypersensitivity to any of the components of MM-111 or who have had hypersensitivity reactions to fully human monoclonal antibodies, including Herceptin.', ' Patients who have received other recent antitumor therapy including:', ' Treatment with Herceptin within the 28 days prior to the first scheduled day of dosing with MM-111', " Investigational therapy administered within the 28 days prior to the first scheduled day of dosing MM-111 (Dosing in less than 28 days' since receiving investigational therapy is acceptable once a time interval equal to at least five half-lives of the investigational agent has passed.)", ' Any standard chemotherapy, Tykerb (lapatinib) or radiation within 14 days (and having passed the time of any actual or anticipated toxicities) prior to the first scheduled dose of MM-111', ' Patients who have previously received MM-111', ' Patients with NYHA Class III or IV congestive heart failure or LVEF < 50%', ' Patients with a history of allogeneic transplant', ' Patients with known HIV, hepatitis B or C (if patients have previously been treated for hepatitis C and have undetectable viral loads, they can be considered eligible for the trial)', " Patients with any other medical or psychological condition deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results"], 'Results': ['Outcome Measurement: ', " Incidence of Treatment-emergent AE's", ' [Not Specified]', ' Time frame: 2 years', 'Results 1: ', ' Arm/Group Title: MM-111 + Herceptin', ' Arm/Group Description: MM-111 will be combined with Herceptin', ' MM-111 and Herceptin: For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV', ' Overall Number of Participants Analyzed: 16', ' Measure Type: Number', ' Unit of Measure: participants 16'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/16 (12.50%)', ' PERICARDIAL EFFUSION * 1/16 (6.25%)', ' TRACHEAL OBSTRUCTION * 1/16 (6.25%)', ' PLEURAL EFFUSION * 1/16 (6.25%)', ' DEEP VEIN THROMBOSIS * 1/16 (6.25%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

a31298d5-20ae-4a3d-a57b-e97288fff6c0

Single

Adverse Events

NCT00003830

The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected less than 1% of patients.

Entailment

{'Clinical Trial ID': 'NCT00003830', 'Intervention': ['INTERVENTION 1: ', ' Arm I:Sentinel Node Resection+Conventional Axillary Dissection', ' Sentinel node resection immediately followed by axillary dissection', ' conventional surgery: Sentinel node resection immediately followed by axillary dissection.', 'INTERVENTION 2: ', ' Arm II: Sentinel Node Resection Followed by Node Examination', ' Sentinel node resection followed by node examination then axillary dissection if positive sentinel node.', ' Sentinel node resection followed by node examination: Sentinel node resection followed by node examination then axillary dissection if positive sentinel node. No axillary dissection for negative sentinel node.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Resectable invasive adenocarcinoma of the breast, confirmed by 1 of the following:', ' Histologically confirmed by core or open biopsy', ' Confirmed by fine needle aspiration cytology AND positive clinical breast examination and ultrasound or mammography', ' Clinically negative lymph nodes', ' No positive ipsilateral axillary lymph nodes', ' No prior removal of ipsilateral axillary lymph nodes', ' No suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes, unless proven nonmalignant by biopsy', " No ulceration, erythema, infiltration of the skin or underlying chest wall (complete fixation), peau d'orange, or skin edema of any magnitude", ' Tethering or dimpling of the skin or nipple inversion allowed', ' No bilateral malignancy or mass in the opposite breast that is suspicious for malignancy, unless proven nonmalignant by biopsy', ' No diffuse tumors or multiple malignant tumors in different quadrants of the breast', ' No other prior breast malignancy except lobular carcinoma in situ', ' No prior or concurrent breast implants', ' Hormone receptor status:', ' Not specified', ' PATIENT CHARACTERISTICS:', ' Age:', ' 18 years and older', ' Sex:', ' Female', ' Menopausal status:', ' Not specified', 'Performance status:', ' Not specified', ' Life expectancy:', ' At least 10 years (excluding diagnosis of cancer)', ' Hematopoietic:', ' Not specified', ' Hepatic:', ' No hepatic systemic disease', ' Renal:', ' No renal systemic disease', ' Cardiovascular:', ' No cardiovascular systemic disease', ' Other:', ' No prior malignancy within past 5 years except:', ' Effectively treated squamous cell or basal cell skin cancer', ' Surgically treated carcinoma in situ of the cervix', ' Surgically treated lobular carcinoma in situ of the ipsilateral or contralateral breast', ' No concurrent psychiatric or addictive disorder', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy:', ' No prior immunotherapy for this cancer', ' Chemotherapy:', ' No prior chemotherapy for this cancer, including neoadjuvant chemotherapy', ' Endocrine therapy:', ' No prior hormonal therapy for this cancer', ' Radiotherapy:', ' No prior radiotherapy for this cancer', ' Surgery:', ' See Disease Characteristics', ' No prior breast reduction surgery', ' Prior excisional biopsy or lumpectomy allowed'], 'Results': ['Outcome Measurement: ', ' Morbidity - Number of Participants With Residual Shoulder Abduction Deficit', ' Morbidity as measured by residual shoulder abduction deficit. Shoulder Abduction Deficit definition: Shoulder range of motion decreased by greater than or equal to 10% as compared with that measured prior to surgery.', ' Time frame: Before and after surgery (within 30 days of randomization)', 'Results 1: ', ' Arm/Group Title: Arm I:Sentinel Node Resection+Conventional Axillary Dissection', ' Arm/Group Description: Sentinel node resection immediately followed by axillary dissection', ' conventional surgery: Sentinel node resection immediately followed by axillary dissection.', ' Overall Number of Participants Analyzed: 1449', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 276 19.0%', 'Results 2: ', ' Arm/Group Title: Arm II: Sentinel Node Resection Followed by Node Examination', ' Arm/Group Description: Sentinel node resection followed by node examination then axillary dissection if positive sentinel node.', ' Sentinel node resection followed by node examination: Sentinel node resection followed by node examination then axillary dissection if positive sentinel node. No axillary dissection for negative sentinel node.', ' Overall Number of Participants Analyzed: 1519', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 200 13.2%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 9/2788 (0.32%)', ' Anaphylaxis 5/2788 (0.18%)', ' Infections and infestations - Other, specify 2/2788 (0.07%)', ' Nervous system disorders - Other, specify 0/2788 (0.00%)', ' Respiratory, thoracic and mediastinal disorders - Other, specify 1/2788 (0.04%)', ' Thromboembolic event 1/2788 (0.04%)', 'Adverse Events 2:', ' Total: 8/2800 (0.29%)', ' Anaphylaxis 5/2800 (0.18%)', ' Infections and infestations - Other, specify 0/2800 (0.00%)', ' Nervous system disorders - Other, specify 1/2800 (0.04%)', ' Respiratory, thoracic and mediastinal disorders - Other, specify 1/2800 (0.04%)', ' Thromboembolic event 2/2800 (0.07%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

54e93334-0f21-4ea2-b0f2-34473385da53

Single

Eligibility

NCT00404066

Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00404066', 'Intervention': ['INTERVENTION 1: ', ' Neoadjuvant Chemotherapy', ' Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles, followed by docetaxel + lapatinib for four 21-day cycles, followed by surgery. Dexamethasone was administered twice-a-day for 3 days, starting 24 hours before the docetaxel infusions. After surgery +/- radiation, participants may receive trastuzumab (Herceptin) for a year.'], 'Eligibility': ['INCLUSION CRITERIA', ' Female', ' Histologically-confirmed Her2neu positive breast cancer, by either Immunohistochemistry (IHC) 3+ or Fluorescence In Situ Hybridization (FISH)+', ' Stage II/III breast cancer including any large primary tumor (> 2 cm), tumors of any size associated with skin or chest wall involvement, tumors of any size with axillary lymph node involvement, (T2-T4, N0-N2) and those with ipsilateral subclavicular or supraclavicular lymph nodes).', ' At least one bi-dimensional, measurable indicator lesion.', ' Between 18 and 70 years of age', ' Eastern Cooperative Oncology Group (ECOG) performance status 2 / Karnofsky 60% at screening and on the first day of treatment.', ' Informed consent must be obtained prior to registration.', ' Cardiac ejection fraction within the institutional range of normal as measured by multigated acquisition (MUGA) or echocardiography (ECHO) scan.', ' Absolute neutrophil count > 1,500/mm³', ' Hemoglobin > 8.0 g/dL', ' Platelet count > 100,000/mm³', ' Creatinine within normal institutional limits', ' Total Bilirubin equal to or less than institutional upper limit of normal (ULN)', ' Aspartate aminotransferase (AST); alanine aminotransferase (ALT); and alkaline phosphatase must be within the range allowing for eligibility. In determining eligibility the more abnormal of the two values (AST or ALT) should be used.', ' Eligibility of patients receiving medications or substances known to affect, or with the potential to affect the activity or pharmacokinetics of GW572016 will be determined following review of their use by the Principal Investigator', ' Antacid use is prohibited 1 hour before and 1 hour after GW572016 dosing.', ' All herbal (alternative) medicines are prohibited.', ' Medications prohibited during the administration of lapatinib .', ' Women of child-bearing potential must have negative pregnancy test and must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation.', ' Peripheral neuropathy: must be < grade 1', ' Able to swallow and retain oral medication', ' EXCLUSION CRITERIA', ' Evidence of disease outside the breast or chest wall, except for ipsilateral axillary , supraclavicular, or infraclavicular lymph nodes.', ' Prior chemotherapy, immunotherapy, or hormonal therapy for breast cancer.', ' More than 3 months between histologic diagnosis and registration on this study.', ' History of other malignancy within the last 5years, except curatively treated basal cell carcinoma of the skin or carcinoma in situ of the cervix.', ' Psychological, familial, sociological or geographical conditions which do not permit weekly medical follow-up and compliance with the study protocol. Those who are medically-unstable, including but not limited to active infection, acute hepatitis, deep vein thrombosis requiring anticoagulant therapy, gastrointestinal bleeding, uncontrolled hypercalcemia, uncontrolled diabetes, dementia, seizures, superior vena cava syndrome, and those whose circumstances do not permit completion of the study or the required follow-up.', ' Congestive heart failure, abnormal left ventricular ejection fraction (LVEF), angina pectoris, uncontrolled cardiac arrhythmias, or other significant heart disease, or who have had a myocardial infarction within the past year.', ' Pregnant or lactating', ' Of childbearing potential and not employing adequate contraception', ' History of allergic reactions attributed to compounds of similar chemical or biologic composition to GW572016.', ' HIV-positive and receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with lapatinib. Appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated.', " GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).", ' History of severe hypersensitivity reaction to taxotere or other drugs formulated with polysorbate 80.', ' Current active hepatic or biliary disease (with exception of patients with Gilberts syndrome, asymptomatic gallstones, or stable chronic liver disease per investigator assessment ).'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Pathologic Complete Response (pCR)', ' Pathologic Complete Response (pCR) rate, assessed as no evidence of invasive disease in excised surgical specimens of breast and/or axilla, in participants who received at least 1 cycle of docetaxel and lapatinib and at least one follow-up evaluation.', ' Time frame: 12 weeks', 'Results 1: ', ' Arm/Group Title: Neoadjuvant Chemotherapy', ' Arm/Group Description: Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles, followed by docetaxel + lapatinib for four 21-day cycles, followed by surgery. Dexamethasone was administered twice-a-day for 3 days, starting 24 hours before the docetaxel infusions. After surgery +/- radiation, participants may receive trastuzumab (Herceptin) for a year.', ' Overall Number of Participants Analyzed: 18', ' Measure Type: Number', ' Unit of Measure: percentage of participants 38.9'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/21 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

fbedd8fc-05e8-4438-b780-d7483aed3b45

Single

Results

NCT01202591

100% of patients in the primary trial suffered life threatening adverse events.

Contradiction

{'Clinical Trial ID': 'NCT01202591', 'Intervention': ['INTERVENTION 1: ', ' AZD4547 80mg bd Cont + Ex 25mg', ' 80 mg AZD4547 BD continuous + 25 mg exemestane', 'INTERVENTION 2: ', ' AZD4547 40mg Cont + Ex 25mg', ' 40 mg AZD4547 BD continuous + 25 mg exemestane'], 'Eligibility': ['Inclusion Criteria:', ' Post-menopausal women (either through bilateral oophorectomy or amenorrhoeic for 24 months)', ' Histological confirmation of Breast Cancer with documented ER+ receptor status', ' Safety run-in: Relapsing during/within 12 months of completion of a single regimen of adjuvant endocrine therapy with non-steroidal AI and/ tamoxifen or progression following 1st line endocrine therapy with non-steroidal AL', ' Rand phase IIa: Received at least 1 prior endocrine therapy in the metastatic setting or have relapsed during/ within 6 months of completion of adjuvant endocrine therapy (either non-steroidal AI or tamoxifen or a combination of both). Chemotherapy administered in the adjuvant setting is permitted.', ' Rand phase IIa: Mandatory provision of tumour sample to confirm FGFR1 polysomy or gene amplification. At least one measurable lesion that can be accurately assessed by CT/MRI/x-ray at baseline and follow up visits', 'Exclusion Criteria:', ' Prior exposure to exemestane (safety run-in) / fulvestrant (randomized phase IIa), or any agent known to inhibit FGFRs.', ' More than 1 prior regimen of chemotherapy for breast cancer', ' ECG recordings that demonstrate significant abnormalities in cardiac rate, rhythm or conduction', ' History of hypersensitivity to active or inactive excipients of AZD4547 or exemestane (safety run-in ) or fulvestrant (Randomized phase), including castor oil, or drugs with a similar chemical structure or class to AZD4547 or exemestane or fulvestrant.', ' Randomized phase IIa: bleeding/blood clotting conditions that would prevent the administration of the fulvestrant injection into the buttocks'], 'Results': ['Outcome Measurement: ', ' Safety and Tolerability in Terms of Number of Patients With Adverse Events (Serious and Non-serious)', ' [Not Specified]', ' Time frame: 3 years, 10 months (Adverse events recorded from patient screening to discontinuation plus 28 days safety follow-up).', 'Results 1: ', ' Arm/Group Title: AZD4547 80mg bd Cont + Ex 25mg', ' Arm/Group Description: 80 mg AZD4547 BD continuous + 25 mg exemestane', ' Overall Number of Participants Analyzed: 5', ' Measure Type: Number', ' Unit of Measure: Participants 5', 'Results 2: ', ' Arm/Group Title: AZD4547 40mg Cont + Ex 25mg', ' Arm/Group Description: 40 mg AZD4547 BD continuous + 25 mg exemestane', ' Overall Number of Participants Analyzed: 5', ' Measure Type: Number', ' Unit of Measure: Participants 5'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/5 (40.00%)', ' ANAEMIA 0/5 (0.00%)', ' DIARRHOEA 0/5 (0.00%)', ' OESOPHAGEAL ACHALASIA 0/5 (0.00%)', ' STOMATITIS 0/5 (0.00%)', ' DEVICE DEPOSIT ISSUE 0/5 (0.00%)', ' INFLAMMATION 0/5 (0.00%)', ' GAIT DISTURBANCE 0/5 (0.00%)', ' LOWER RESPIRATORY TRACT INFECTION VIRAL 0/5 (0.00%)', ' NEUTROPENIC SEPSIS 1/5 (20.00%)', ' PLEURAL INFECTION 1/5 (20.00%)', ' PYELONEPHRITIS 0/5 (0.00%)', 'Adverse Events 2:', ' Total: 2/5 (40.00%)', ' ANAEMIA 1/5 (20.00%)', ' DIARRHOEA 0/5 (0.00%)', ' OESOPHAGEAL ACHALASIA 0/5 (0.00%)', ' STOMATITIS 0/5 (0.00%)', ' DEVICE DEPOSIT ISSUE 0/5 (0.00%)', ' INFLAMMATION 0/5 (0.00%)', ' GAIT DISTURBANCE 0/5 (0.00%)', ' LOWER RESPIRATORY TRACT INFECTION VIRAL 0/5 (0.00%)', ' NEUTROPENIC SEPSIS 0/5 (0.00%)', ' PLEURAL INFECTION 0/5 (0.00%)', ' PYELONEPHRITIS 0/5 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

4bd9f061-6420-443d-8f84-b703733644ac

Single

Intervention

NCT00046891

cohort 1 of the primary trial recieves 120 mg of Ginkgo Biloba twice daily.

Contradiction

{'Clinical Trial ID': 'NCT00046891', 'Intervention': ['INTERVENTION 1: ', ' Ginkgo Biloba', ' Ginkgo Biloba: Patients will take 120 mg per day (60 mg BID)', 'INTERVENTION 2: ', ' Placebo', ' Placebo: Patients will take 1 tablet BID'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Newly diagnosed breast cancer', ' Planned standard doses of adjuvant chemotherapy with or without a taxane', ' PATIENT CHARACTERISTICS:', ' Age', ' 18 and over', ' Sex', ' Female', ' Menopausal status', ' Any status', ' Performance status', ' Eastern Cooperative Oncology Group (ECOG) 0-1', ' Life expectancy', ' At least 6 months', ' Hematopoietic', ' No bleeding diathesis', ' Hepatic', ' serum glutamate oxaloacetate transaminase (SGOT) no greater than 1.5 times upper limit of normal (ULN)', ' Alkaline phosphatase no greater than 1.5 times ULN', ' Renal', ' Creatinine no greater than 1.5 times ULN', ' Cardiovascular', ' No arterial vascular disease', ' Other', ' Able to complete questionnaires alone or with assistance', ' No diabetes', ' No dementia', ' No diagnosis of a psychiatric disorder within the past 5 years that would preclude study compliance', ' No other significant comorbidity', ' No known allergy to ginkgo biloba', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy', ' No concurrent stem cell transplantation', ' Chemotherapy', ' No concurrent high-dose chemotherapy', ' Other', ' More than 6 months since prior EGb761', ' No concurrent antithrombotic therapy (e.g., daily aspirin or anticoagulants)', ' Anticoagulants used for central or peripheral line maintenance (i.e., warfarin 1 mg/day or heparin flushes) allowed', ' No concurrent dose-intensive regimens', ' No concurrent aspirin or aspirin-like medicines (e.g., indomethacin, ibuprofen, or some antihistamines or heparin or warfarin [except as used above])', ' No concurrent regimen expected to cause thrombocytopenia', ' No concurrent trazodone, monoamine oxidase inhibitors, or thiazide diuretics (e.g., chlorothiazide, hydrochlorothiazide, indapamide, or metolazone)'], 'Results': ['Outcome Measurement: ', ' The Level of Cognitive Dysfunction as Measured by the High Sensitivity Cognitive Screen (HSCS) Overall Score.', ' The primary analysis involved compiling each subscale score for the HSCS into area under the curve (AUC) scores for the data points from baseline to the 12 month data point. HSCS instrument contains questions regarding Memory (0-39), Language (0-30), Visual-motor (0-10), Spatial (0-8), Attention and Concentration (0-25), Self-Regulation and Planning (0-6) on a varying scales. Total is calculated by summing afore mentioned subscales, values of Total ranged from 0 to 125. Lower scores are better.', ' Time frame: Baseline, 12 months after starting Chemotherapy.', 'Results 1: ', ' Arm/Group Title: Ginkgo Biloba', ' Arm/Group Description: Ginkgo Biloba: Patients will take 120 mg per day (60 mg BID)', ' Overall Number of Participants Analyzed: 107', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale*months Memory: 12.2 (9.18)', ' Language: 3.9 (6.84)', ' Visual-motor: 1.1 (1.29)', ' Spatial: 1.4 (0.92)', ' Attention/concentration: 2.2 (3.59)', ' Self-regulation: 2.4 (2.14)', ' Total: 20.7 (19.59)', 'Results 2: ', ' Arm/Group Title: Placebo', ' Arm/Group Description: Placebo: Patients will take 1 tablet BID', ' Overall Number of Participants Analyzed: 103', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale*months Memory: 12.6 (9.16)', ' Language: 2.6 (2.72)', ' Visual-motor: 0.7 (0.84)', ' Spatial: 1.3 (0.92)', ' Attention/concentration: 1.8 (2.16)', ' Self-regulation: 2.0 (2.10)', ' Total: 18.0 (12.26)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/104 (3.85%)', ' Febrile neutropenia 0/104 (0.00%)', ' Infection with grade 3 or 4 neutropenia 1/104 (0.96%)', ' Leukocyte count decreased 1/104 (0.96%)', ' Neutrophil count decreased 4/104 (3.85%)', ' Platelet count decreased 1/104 (0.96%)', 'Adverse Events 2:', ' Total: 3/101 (2.97%)', ' Febrile neutropenia 1/101 (0.99%)', ' Infection with grade 3 or 4 neutropenia 0/101 (0.00%)', ' Leukocyte count decreased 2/101 (1.98%)', ' Neutrophil count decreased 2/101 (1.98%)', ' Platelet count decreased 0/101 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

e6d3354b-b36a-42b9-b406-61a9af594686

Single

Eligibility

NCT00896649

prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00896649', 'Intervention': ['INTERVENTION 1: ', ' Single Arm Positron Emission Mammography and Questionnaire', ' questionnaire administration positron emission mammography', ' digital mammography: standard screening mammogram', ' questionnaire administration: Questionnaire regarding patient satisfaction with mammogram experience and with positron emission mammography experience.', ' positron emission mammography: one-time positron emission mammography to compare recall rates with that of standard mammogram'], 'Eligibility': ['Inclusion criteria:', ' DISEASE CHARACTERISTICS:', ' Scheduled to undergo screening mammogram at one of the Boston Medical Center-affiliated primary care clinics and meets 1 of the following criteria:', ' Dense breast tissue', ' At high-risk for breast cancer', ' PATIENT CHARACTERISTICS:', " Has 1 of the following racial or ethnic backgrounds based on the patient's country of birth or the mother and father's country of birth:", ' Hispanic', ' Haitian Creole', ' African American', ' Caucasian', ' PRIOR CONCURRENT THERAPY:', ' None specified', 'Exclusion criteria:', ' No history of breast cancer, palpable breast mass, abnormal nipple discharge, or other focal complaints warranting diagnostic mammogram'], 'Results': ['Outcome Measurement: ', ' Frequency of Breast Imaging Assessment Reporting and Data System (BI-RADS) "0" Call-back in Mammography vs Breast Imaging Assessment Reporting and Data System (BI-RADS) "0" in Positron Emission Mammography', ' Number of participants called back due to Breast Imaging Assessment Reporting and Data System (BI-RADS) "0" Mammogram compared to number of patients with Breast Imaging Assessment Reporting and Data System (BI-RADS) "0" in positron emission mammography', ' Breast Imaging Assessment Reporting and Data System (BI-RADS) Scale:', ' 0 = Inconclusive for malignancy; call-back in mammography', ' = normal', ' = abnormal, with no malignancy', ' = abnormal, likely benign', ' = abnormal, likely malignant', ' = malignant', ' Time frame: immediately at completion of mammogram', 'Results 1: ', ' Arm/Group Title: Single Arm Positron Emission Mammography and Questionnaire', ' Arm/Group Description: questionnaire administration positron emission mammography', ' digital mammography: standard screening mammogram', ' questionnaire administration: Questionnaire regarding patient satisfaction with mammogram experience and with positron emission mammography experience.', ' positron emission mammography: one-time positron emission mammography to compare recall rates with that of standard mammogram', ' Overall Number of Participants Analyzed: 188', ' Measure Type: Number', ' Unit of Measure: participants Number of BI-RAD "0" Mammogram: 28', ' Number of BI-RAD "0" positron emission mammograph: 27'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/188 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

62b3d09e-6b2a-4827-8ceb-96ccafca18d4

Single

Eligibility

NCT00317603

Participants of the primary trial must be older than 18, have histologically confirmed stage 3 or above breast cancer, ECOG<2 and a life expectancy exceeding 6 months.

Contradiction

{'Clinical Trial ID': 'NCT00317603', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', ' Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately 1x10 7 , 4x10 6 ,', ' 1x10 6 , or 1x10 5 depending on the final cell yield.', ' Autologous, Lethally Irradiated Breast Cancer Cells: Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed Stage IV breast cancer', ' Prior banked malignant effusion or significant malignant effusion for tumor harvest or surgically-accessible tumor nodule of at least 2cm in greatest diameter by physical exam, magnetic resonance imaging (MRI) or computed tomography (CT) scan', ' Must have received at least one prior regimen of chemotherapy for metastatic disease', ' Patients with HER2 positive tumors must have received at least one prior trastuzumab-based therapy in the metastatic setting, and may not receive trastuzumab therapy and vaccine treatment concurrently', ' Patients may receive concurrent bisphosphonate therapy and/or erythropoetin therapy at any point while on study', ' ECOG performance status 0 or 1', ' Estimated life expectancy of greater than or equal to 6 months', ' 18 years of age or older', ' Greater than 4 weeks from immunotherapy, or systemic glucocorticoid therapy', ' Adequate recovery from drug-related toxicities from prior systemic therapies', ' Adequate recovery from recent surgery and radiation therapy', ' Greater than 6 months since bone marrow or peripheral blood stem cell transplant', 'Exclusion Criteria:', ' Urgent need for cytotoxic chemotherapy, radiotherapy, or surgery in the next 60 days', ' Uncontrolled active infection or illness', ' Psychiatric illness/social situation that would limit study compliance', ' Pregnant or nursing mothers', ' Evidence of HIV infection', ' Previous participation in an adenovirus-based trial', ' Concurrent invasive malignancy'], 'Results': ['Outcome Measurement: ', ' Minimum Number of Vaccine Doses Created Using Participant Tumor Sample', ' Tumor samples were obtained via malignant effusion or a surgically accessible tumor nodule of 2 cm in greatest diameter. Tumor cells were processed to single cell suspension and transduced with adenoviral vector encoding human Granulocyte-macrophage colony-stimulating factor (GM-CSF). Then, the cells washed extensively and irradiated with 10,000 cGy. Over the next 14 days, sterility cultures were tested for endotoxin and mycoplasma contamination. Individual vaccine cell dose and number varied depending on the final cell yield from vaccine production. The minimal dose was 1 x 10^5 cells and the maximal dose was 1 x 10^7 cells.', ' Time frame: Vaccine doses created and banked soon after registration, up to 8 days.', 'Results 1: ', ' Arm/Group Title: Vaccine', ' Arm/Group Description: Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately 1x10 7 , 4x10 6 ,', ' 1x10 6 , or 1x10 5 depending on the final cell yield.', ' Autologous, Lethally Irradiated Breast Cancer Cells: Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out', ' Overall Number of Participants Analyzed: 12', ' Measure Type: Number', ' Unit of Measure: doses 6'], 'Adverse Events': ['Adverse Events 1:', ' Total: 3/12 (25.00%)', ' Hemoglobin 1/12 (8.33%)', ' Alkaline phosphatase 1/12 (8.33%)', ' Dehydration 1/12 (8.33%)', ' Syncope 2/12 (16.67%)', ' Dyspnea 1/12 (8.33%)', ' Hypotension 1/12 (8.33%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

065a6cfe-3991-4dd5-8a55-22b9b31d1fc3

Comparison

Intervention

NCT00278109

NCT01881230

Gemcitabine is not used in the primary trial, and used in only one of the arms of the secondary trial.

Entailment

{'Clinical Trial ID': 'NCT00278109', 'Intervention': ['INTERVENTION 1: ', ' Experimental', ' cyclophosphamide: chemotherapy', ' doxorubicin hydrochloride: chemotherapy', ' adjuvant therapy: chemotherapy', ' radiation therapy: chemotherapy'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed adenocarcinoma of the breast by routine hematoxylin and eosin (H&E) staining', ' Primary tumor 4 cm and 0-3 positive axillary lymph nodes (pathologic T1-2, pathologic N0-N1, M0)', ' Patients with lymph nodes positive only by cytokeratin staining (i.e., H&E negative) are eligible', ' No squamous cell carcinoma or sarcoma of the breast', ' Patients must have undergone a segmental mastectomy (SM) with a level I and ll axillary dissection or sentinel lymph node biopsy within the past 14 weeks', ' Surgical margins at the time of SM must be negative (> 3 mm) for both invasive carcinoma and for non-invasive ductal carcinoma', ' No active local-regional disease', ' Hormone receptor status not specified', ' PATIENT CHARACTERISTICS:', ' ECOG performance status 0-1', ' Sex: female', ' Menopausal status not specified', ' Not pregnant', ' Negative pregnancy test', ' Fertile patients must use effective non-hormonal contraception', ' No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix', ' No other serious or poorly controlled medical or psychiatric condition that could be exacerbated by, or complicate compliance with study treatment', ' PRIOR CONCURRENT THERAPY:', ' No prior radiation therapy to the breast', ' No prior trastuzumab (Herceptin ®)', ' No other concurrent chemotherapy', ' No concurrent hormonal therapy except the following:', ' Steroids given for adrenal failure', ' Hormones administered for non-disease-related conditions (e.g., insulin for diabetes, synthroid for hypothyroidism)', ' Intermittent dexamethasone as an antiemetic or premedication'], 'Results': ['Outcome Measurement: ', ' Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity', ' Number of participants with Grade 4 toxicity as defined by the following criteria:', ' Acute Skin Toxicity: 0=No change, 1= Follicular, faint, or dull erythema/epilation/dry/desquamation/decreased swelling, 2= Tender or bright erythemal patchy moist desquamation/moderate edema, 3= Confluent moist desquamation other than skin folds, piting edema, 4= Ulceration, hemorrahage, necrosis, Late Skin Toxicity: 0= None, 1= Slight Atrophy, Pigmentation change, some hair loss, 2= Patch atrophy, moderate telangectasias, total hair loss, 3= Marked atrophy, gross telangectasias, 4= Ulceration; Subcutaneous Tissue Toxicity: 0= None, 1= Slight induration (fibrosis) and loss of subcutaneous fat, 2= Moderate fibrosis but asymptomatic; slight field contracture; <10% linear reduction, 3= Severe induration and loss subcutaneous tissue; field contracture >10% linear reduction; 4= Necrosis', ' Time frame: up to 5 years', 'Results 1: ', ' Arm/Group Title: Experimental', ' Arm/Group Description: cyclophosphamide: chemotherapy', ' doxorubicin hydrochloride: chemotherapy', ' adjuvant therapy: chemotherapy', ' radiation therapy: chemotherapy', ' Overall Number of Participants Analyzed: 25', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 0 0.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/25 (4.00%)', ' Neutropenia *1/25 (4.00%)']}

{'Clinical Trial ID': 'NCT01881230', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Nab-Paclitaxel + Gemcitabine', ' Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle. Participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment', 'INTERVENTION 2: ', ' Arm B: Nab-Paclitaxel + Carboplatin', ' Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle. Participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment.'], 'Eligibility': ['Inclusion Criteria: A subject will be eligible for inclusion in this study only if all of the following criteria are met:', ' Female subjects, age 18 years at the time informed consent is signed', ' Pathologically confirmed adenocarcinoma of the breast', ' Pathologically confirmed as triple negative, source documented, defined as both of the following', ' Estrogen Receptor (ER) and Progesterone Receptor (PgR) negative: < 1% of tumor cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PgR (positive intrinsic controls)', ' Human Epidermal Growth Factor Receptor 2 (HER2) negative as per American Society of Clinical Oncology - College of American Pathologists (ASCO/CAP) guidelines i. Immunohistochemistry (IHC) 0 or 1 Fluorescence In Situ Hybridization (FISH) negative (or equivalent negative test). Subjects with IHC 2 must have a negative by Fluorescence In Situ Hybridization (FISH),, (or equivalent negative test).', ' Subjects with prior breast cancer history of different phenotypes (ie, ER/PgR/HER2 positive) must have pathologic confirmation of triple negative disease in at least one of the current sites of metastasis', " Subjects must have received prior adjuvant or neoadjuvant anthracycline therapy; unless (a) anthracycline treatment was not indicated or was not the best treatment option for the subject in the opinion of the treating physician; and (b) anthracycline treatment remains not indicated or, in the opinion of the treating physician, is not the best treatment option for the subject's metastatic disease.", ' a. Newly diagnosed subjects presenting with TNMBC are eligible for the study if anthracycline treatment is not indicated or is not the best treatment option for the subject in the opinion of the treating physician.', ' Subjects with measurable metastatic disease, defined by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) guidelines', ' Life expectancy 16 weeks from randomization', ' No prior cytotoxic chemotherapy for metastatic breast cancer. Prior immunotherapy and/or monoclonal antibody therapy are acceptable. Prior treatments must have been discontinued at least 30 days prior to start of study treatment and all related toxicities must have resolved to Grade 1 or less.', ' Prior neoadjuvant or adjuvant chemotherapy, if given, must have been completed at least 6 months before randomization with all related toxicities resolved, and documented evidence of disease progression per RECIST 1.1 guidelines is required.', ' a. If prior neoadjuvant or adjuvant chemotherapy contained taxane, gemcitabine, or platinum agents, the treatment must have completed at least 12 months before randomization', ' Prior radiotherapy must have completed before randomization, with full recovery from acute radiation side effects. At least one measurable lesion must be completely outside the radiation portal or there must be unequivocal radiologic or clinical exam proof of progressive disease within the radiation portal, in accordance with RECIST 1.1 guidelines', ' At least 30 days from major surgery before randomization, with full recovery', ' Eastern Cooperative Oncology Group (ECOG) performance status 0-1', ' Subject has the following blood counts at screening:', ' Absolute Neutrophil Count (ANC) 1500/mm^2 ;', ' Platelets 100,000/mm^2 ;', ' Hemoglobin (Hgb) 9 g/dL', ' Subject has the following blood chemistry levels at screening:', ' Aspartate aminotransferase (AST) Serum glutamic-oxaloacetic transaminase (SGOT), Alanine Aminotransferase (ALT ) Serum Glutamic Pyruvate Transaminase (SGPT) 2.5 x upper limit of normal range (ULN); if hepatic metastases present 5.0 x ULN', " Total serum bilirubin ULN; or total bilirubin 3.0 × ULN with direct bilirubin within normal range in subjects with documented Gilbert's Syndrome", ' Creatinine clearance > 60 mL/min (by Cockcroft-Gault)', ' Females of child-bearing potential [defined as a sexually mature women who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months)] must:', ' Demonstrate a negative serum pregnancy test result at screening (performed by central lab) confirmed by local negative urine pregnancy dipstick within 72 hours prior to the first dose of IP); pregnancy test with sensitivity of at least 25 mIU/mL; and', ' Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis) or agree to use, and be able to comply with, two physician approved effective contraception methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) without interruption for 28 days or longer as required by local guidelines, prior to starting study drug, during the study therapy (including dose interruptions), and for 28 days after discontinuation of the study or longer as required by local guidelines', ' Females must abstain from breastfeeding starting at randomization, during study participation and for 28 days or longer as required by local guidelines, after IP discontinuation', ' Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted', ' Able to adhere to the study visit schedule and other protocol requirements', 'Exclusion Criteria:', ' A subject will not be eligible for inclusion in this study if any of the following criteria apply:', ' Male subjects', ' Concurrent chemotherapy or any other anti tumor therapy for breast cancer. Prior immunotherapy & monoclonal antibody therapy are acceptable.', ' Subjects who received prior cytotoxic chemotherapy after incomplete resection of locoregional recurrent disease', ' History of, or known current evidence of brain metastasis, including leptomeningeal involvement.', ' Subjects with bone as the only site of metastatic disease', ' Subjects with regional lymph node as the only site of metastatic disease', ' Serious intercurrent medical or psychiatric illness, including serious active infection', ' History of class II-IV congestive heart failure or myocardial infarction within 6 months of randomization', ' History of other primary malignancy in the last 5 years prior to randomization. Subjects with prior breast cancer history are eligible, however, the most recently obtained biopsy must demonstrate triple negative disease (source documented). Subjects with prior history of in situ cancer or basal or localized squamous cell skin cancer are eligible.', ' Subjects with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple uncontrolled or unstable allergies which, in the opinion of the investigator, may lead to serious complications', ' Peripheral neuropathy Grade 2 by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0', ' Subjects who have received an investigational product within the previous 4 weeks prior to randomization', ' Subject is currently enrolled, or will enroll in a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study', ' Pregnant or nursing women', ' Subjects with prior hypersensitivity to nab-paclitaxel, gemcitabine, carboplatin or any other platin, or nucleoside analogue agents', ' Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study', ' Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if she were to participate in the study', ' Any condition that confounds the ability to interpret data from the study', ' History of seropositive human immunodeficiency virus (HIV)', ' Subjects who are receiving immunosuppressive or myelosuppressive medications that would, in the opinion of the investigator, increase the risk of serious neutropenic complications'], 'Results': ['Outcome Measurement: ', ' Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment.', ' PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause on or prior to the data cutoff date for the statistical analysis, whichever occurred earlier. Tumor responses were assessed every 6 weeks using, Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Stable disease is neither sufficient shrinkage to qualify for a PR nor sufficient increase of lesions to qualify for Progressive disease (PD); Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir.', ' Time frame: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C', 'Results 1: ', ' Arm/Group Title: Arm A: Nab-Paclitaxel + Gemcitabine', ' Arm/Group Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle. Participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment', ' Overall Number of Participants Analyzed: 61', ' Median (95% Confidence Interval)', ' Unit of Measure: months 5.5 (4.1 to 7.0)', 'Results 2: ', ' Arm/Group Title: Arm B: Nab-Paclitaxel + Carboplatin', ' Arm/Group Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle. Participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment.', ' Overall Number of Participants Analyzed: 64', ' Median (95% Confidence Interval)', ' Unit of Measure: months 8.3 (5.7 to 10.6)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 22/60 (36.67%)', ' Anaemia 2/60 (3.33%)', ' Febrile neutropenia 1/60 (1.67%)', ' Neutropenia 1/60 (1.67%)', ' Pancytopenia 0/60 (0.00%)', ' Thrombocytopenia 0/60 (0.00%)', ' Acute myocardial infarction 0/60 (0.00%)', ' Atrial fibrillation 1/60 (1.67%)', ' Cardiac failure 1/60 (1.67%)', ' Myocardial infarction 0/60 (0.00%)', ' Palpitations 1/60 (1.67%)', ' Pericardial effusion 0/60 (0.00%)', 'Adverse Events 2:', ' Total: 20/64 (31.25%)', ' Anaemia 2/64 (3.13%)', ' Febrile neutropenia 3/64 (4.69%)', ' Neutropenia 2/64 (3.13%)', ' Pancytopenia 0/64 (0.00%)', ' Thrombocytopenia 0/64 (0.00%)', ' Acute myocardial infarction 0/64 (0.00%)', ' Atrial fibrillation 0/64 (0.00%)', ' Cardiac failure 0/64 (0.00%)', ' Myocardial infarction 1/64 (1.56%)', ' Palpitations 0/64 (0.00%)', ' Pericardial effusion 0/64 (0.00%)']}

85c315e5-7ae4-4764-8b02-87d36f67a159

Single

Adverse Events

NCT01560416

There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of the primary trial.

Entailment

{'Clinical Trial ID': 'NCT01560416', 'Intervention': ['INTERVENTION 1: ', ' ARM A - Fulvestrant', ' Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Eligible participants on Arm A were allowed to crossover to Arm B upon disease progression. Treatment continued for Arm A participants until 2nd disease progression.', 'INTERVENTION 2: ', ' Arm B - Fulvestrant+Ganetespib', ' Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Ganetespib: 200 mg/m2 administered intravenously on days 1, 8 and 15 of each 28 day cycle', ' Arm B participants whose disease was at a minimum stable could elect to discontinue ganetespib after 6 cycles or stay on combination treatment until disease progression. Otherwise, Arm B participants taken off ganetespib for toxicity were to remain on single agent fulvestrant until disease progression.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed invasive breast cancer that is metastatic or unresectable locally advanced', ' Estrogen and/or progesterone receptor positive breast cancer', ' HER2 negative', ' Measurable disease is required (effective 4/30/14: all non-measurable [evaluable] disease slots have been filled)', ' Endocrine resistant breast cancer', ' May have received up to one prior line of chemotherapy for metastatic or unresectable locally advanced breast cancer', ' May have initiated bisphosphonate therapy prior to start of protocol therapy', ' Must be at least 2 weeks from prior chemotherapy or radiotherapy', ' ECOG performance status of 0 or 1', ' Availability of tissue block from initial breast cancer diagnosis and/or metastatic recurrence', ' For subjects with biopsy-accessible disease, must be willing to undergo a required on-treatment research biopsy', ' Adequate IV access', 'Exclusion Criteria:', ' Pregnant or breastfeeding', ' Prior treatment with HSP90 inhibitor', ' Prior treatment with fulvestrant', " Concurrent treatment with commercial agents or other agents with the intent to treat the participant's malignancy", ' Untreated or progressive brain metastases', ' Pending visceral crisis, in the opinion of the treating investigator', ' History of allergic reactions attributed to compounds of similar chemical or biologic composition to fulvestrant or ganetespib', ' Uncontrolled intercurrent illness', ' Other malignancies within 3 years'], 'Results': ['Outcome Measurement: ', ' Progression-Free Survival (PFS)', ' PFS based on Kaplan-Meier is defined as the time from study entry to the earliest documentation of disease progression (PD) or death. Participants alive without evidence of PD are censored at the date of last disease assessment. Participants who receive non-protocol anti-cancer therapy before disease progression are censored at time of last disease assessment.', ' Time frame: Disease was assessed radiographically every 2 cycles for year 1 and every 2-4 cycles longer-term. Participants in this study cohort were followed for survival up to 4 years from treatment end.', 'Results 1: ', ' Arm/Group Title: ARM A - Fulvestrant', ' Arm/Group Description: Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Eligible participants on Arm A were allowed to crossover to Arm B upon disease progression. Treatment continued for Arm A participants until 2nd disease progression.', ' Overall Number of Participants Analyzed: 15', ' Mean (95% Confidence Interval)', ' Unit of Measure: months 3.7 (1.0 to 12.0)', 'Results 2: ', ' Arm/Group Title: Arm B - Fulvestrant+Ganetespib', ' Arm/Group Description: Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Ganetespib: 200 mg/m2 administered intravenously on days 1, 8 and 15 of each 28 day cycle', ' Arm B participants whose disease was at a minimum stable could elect to discontinue ganetespib after 6 cycles or stay on combination treatment until disease progression. Otherwise, Arm B participants taken off ganetespib for toxicity were to remain on single agent fulvestrant until disease progression.', ' Overall Number of Participants Analyzed: 35', ' Mean (95% Confidence Interval)', ' Unit of Measure: months 3.6 (2.0 to 7.5)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/15 (13.33%)', ' Sinus Tachycardia * 0/15 (0.00%)', ' Acute coronary syndrome * 0/15 (0.00%)', ' Obstruction Gastric * 0/15 (0.00%)', ' Vomiting * 0/15 (0.00%)', ' Hemorrhoids * 0/15 (0.00%)', ' Nausea * 0/15 (0.00%)', ' Duodenal ulcer * 0/15 (0.00%)', ' Hepatic pain * 0/15 (0.00%)', ' Infections and infestations-other * [1]0/15 (0.00%)', ' Lipase Increased * 0/15 (0.00%)', 'Adverse Events 2:', ' Total: 11/35 (31.43%)', ' Sinus Tachycardia * 1/35 (2.86%)', ' Acute coronary syndrome * 1/35 (2.86%)', ' Obstruction Gastric * 1/35 (2.86%)', ' Vomiting * 3/35 (8.57%)', ' Hemorrhoids * 1/35 (2.86%)', ' Nausea * 3/35 (8.57%)', ' Duodenal ulcer * 1/35 (2.86%)', ' Hepatic pain * 1/35 (2.86%)', ' Infections and infestations-other * [1]1/35 (2.86%)', ' Lipase Increased * 1/35 (2.86%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

497188e0-9d88-406f-b163-c154516cb12c

Comparison

Eligibility

NCT00438100

NCT00662025

Patients with BUN < 20 mg/dL, Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both the primary trial and the secondary trial.

Entailment

{'Clinical Trial ID': 'NCT00438100', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine Arm', ' Capecitabine (Xeloda): 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.', ' Capecitabine: 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.', 'INTERVENTION 2: ', ' S-1 Arm', ' S-1: 80 mg/m2 orally bid daily for day 1 through day28 followed by 14-day washout; repeat this as a course.', ' S-1: 80 mg/m2 orally bid daily for day 1 through day 28 followed by 14-day washout; repeat this as a course.'], 'Eligibility': ['Inclusion Criteria:', ' Biopsy-diagnosed breast cancer with metastasis in multiple organs', ' Performance Status (World Health Organization :WHO) 0-2', ' Functions below are maintained in major organs:', ' Leukocyte count: 4,000/mm3 to 12,000/mm3', ' Neutrophil count: >2,000/mm3 or more', ' Platelet count: <100,000/mm3 or more', ' Hemoglobin: >9.5 g/dL', ' Total bilirubin: >1.5 mg/dL', ' AST(GOT): within twice a normal upper value in an institution', ' AST(GPT): within twice a normal upper value in an institution', ' BUN: < 25 mg/dL', ' Creatinine: within a normal upper value in the institution', ' 24 hours creatinine clearance: >50 mL/min (using the Cockcroft-Gault formula)', " Women's Ccr = Body weight x (140-Age)/(72 x Serum creatinine) x 0.85", ' Written informed consent will be obtained for patients for entering this study', 'Exclusion Criteria:', ' Patients with synchronous multiple cancers', ' Complicated with infection', ' Fever from suspected infection', ' Metastasis to the central nerve system', ' A history of ischemic cardiac diseases', ' Active gastrointestinal ulcer', ' Severe nerve disorder', ' Women who are potentially pregnant, pregnant, or breast-feeding', ' Severe drug allergy', ' Severe suppression of the bone marrow', ' Severe renal disorder', ' Being treated with other pyrimidine fluoride antineoplastic agents (including any combination therapy)', ' Being treated with flucytosine', ' Complicated with the infection onset which a study doctor assesses to be inappropriate for this study'], 'Results': ['Outcome Measurement: ', ' Progression Free Survival', ' [Not Specified]', ' Time frame: The follow up period will be two years after the last dose has been administered.', 'Results 1: ', ' Arm/Group Title: Capecitabine Arm', ' Arm/Group Description: Capecitabine (Xeloda): 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.', ' Capecitabine: 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.', ' Overall Number of Participants Analyzed: 71', ' Median (95% Confidence Interval)', ' Unit of Measure: years 1.2 (0.76 to 2.04)', 'Results 2: ', ' Arm/Group Title: S-1 Arm', ' Arm/Group Description: S-1: 80 mg/m2 orally bid daily for day 1 through day28 followed by 14-day washout; repeat this as a course.', ' S-1: 80 mg/m2 orally bid daily for day 1 through day 28 followed by 14-day washout; repeat this as a course.', ' Overall Number of Participants Analyzed: 65', ' Median (95% Confidence Interval)', ' Unit of Measure: years 1.3 (0.96 to 2.68)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/71 (0.00%)', 'Adverse Events 2:', ' Total: 0/65 (0.00%)']}

{'Clinical Trial ID': 'NCT00662025', 'Intervention': ['INTERVENTION 1: ', ' SUNITINIB+CAPECITABINE', ' Sunitinib was administered orally from Day 1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles. Capecitabine was administered orally from Days 1 to 14 every 21 days at a starting dose of 2,000 mg/m^2/day. Participants were monitored for toxicity, and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance. Participants with progressive disease (PD) or intolerable toxicity were considered for discontinuation from the study.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically- or cytologically-proven diagnosis of breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent', ' Measurable disease as per RECIST. Measurable lesions that have been previously irradiated will not be considered target lesions unless increase in size has been observed following completion of radiation therapy.', ' Prior treatment with an anthracycline and a taxane in the neoadjuvant, adjuvant or metastatic disease settings.', 'Exclusion Criteria:', ' Histology of inflammatory carcinoma with no other measurable disease. Patients with histology of inflammatory carcinoma are allowed on study if they have measurable disease.', ' Brain metastases, spinal cord compression, or carcinomatous meningitis, or leptomeningeal disease.', " Prior treatment with 5-fluorouracil (5-FU) and 5-FU derivatives such as Furtulon (5'-DFUR), Futraful/ Sunfural (tegafur), UFT/UFT-E (tegafur/uracil), TS-1 (tegafur/gimeracil/oteracil) or Mifurol (carmofur) in metastatic disease setting"], 'Results': ['Outcome Measurement: ', " Number of Participants With Objective Response Based on Data Review Committee's Assessment", ' Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST). CR is defined as disappearance of all target and non-target lesions. PR is defined as 30% decrease in sum of the longest dimensions (LDs) of the target lesions taking as reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat evaluation 4 weeks after initial documentation of response.', ' Time frame: Day 1 of Cycle 2, every 6 weeks after Cycle 2, and at the end of Cycle 8.', 'Results 1: ', ' Arm/Group Title: SUNITINIB+CAPECITABINE', ' Arm/Group Description: Sunitinib was administered orally from Day 1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles. Capecitabine was administered orally from Days 1 to 14 every 21 days at a starting dose of 2,000 mg/m^2/day. Participants were monitored for toxicity, and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance. Participants with progressive disease (PD) or intolerable toxicity were considered for discontinuation from the study.', ' Overall Number of Participants Analyzed: 63', ' Measure Type: Number', ' Unit of Measure: participants Total Number of Participants with CR+PR: 19', ' Complete Response (CR): 0', ' Partial Response (PR): 19'], 'Adverse Events': ['Adverse Events 1:', ' Total: 17/63 (26.98%)', ' Febrile neutropenia 1/63 (1.59%)', ' Leukopenia 1/63 (1.59%)', ' Thrombocytopenia 3/63 (4.76%)', ' Anemia 1/63 (1.59%)', ' Ascites 1/63 (1.59%)', ' Diarrhoea 1/63 (1.59%)', ' Gingival bleeding 1/63 (1.59%)', ' Vomiting 1/63 (1.59%)', ' Gastrointestinal haemorrhage 1/63 (1.59%)', ' Fatigue 2/63 (3.17%)', ' Malaise 2/63 (3.17%)', ' Pyrexia 2/63 (3.17%)']}

abc437e1-9e38-4d68-ab9f-fdbaf37d20f3

Comparison

Adverse Events

NCT01828021

NCT01326481

Patients in the primary trial and the secondary trial did not have any of the same adverse events, except Supraventricular extrasystoles which was the most common event in both trials.

Contradiction

{'Clinical Trial ID': 'NCT01828021', 'Intervention': ['INTERVENTION 1: ', ' Margetuximab', ' Monotherapy of Anti-HER2 monoclonal antibody', ' Margetuximab: Anti-HER2 monoclonal antibody'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically confirmed invasive carcinoma of the breast', ' Treatment with at least two prior systemic therapies for advanced (unresectable locoregional or metastatic) disease', ' Evidence of HER2 oncoprotein expression at the 2+ level by central laboratory. Patients whose tumors exhibit 2+ staining by IHC are eligible for the study.', ' Patients whose tumors score 1+ by conventional IHC, are non-amplified by FISH testing, and whose tumors score > or = 10.5 by HERmark® testing, are eligible for the study.', ' Evidence of lack of HER2 oncogene amplification as determined by FISH testing by central laboratory', ' Performance Status of 0 or 1', ' Life expectancy at least 6 months', ' Measurable disease (by RECIST 1.1)', ' Acceptable laboratory parameters and organ reserve', ' Baseline left ventricular ejection fraction > or = 50%', ' Anti-cancer therapy (including conventional cytotoxic chemotherapy and/or biological therapy) and radiotherapy must be completed and any associated toxicities resolved to </= Grade 1 levels or baseline levels and at least 2 weeks must have elapsed before enrollment. Treatment with monoclonal antibodies must be completed at least 14 days before entry. Must have completed immunosuppressive medications or vaccinations before enrollment.', ' Patients who are estrogen receptor+ and/or progesterone receptor+ and who are receiving anti-hormone therapy for at least three months may continue to receive such therapy during the course of the trial', ' Eighteen (18) years of age or older', 'Exclusion Criteria:', ' Major surgery or trauma within 4 weeks', ' Known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in the margetuximab drug formulation', ' Second primary malignancy that has not been in remission for more than 3 years', ' History of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 14 days', ' History within 3 months of deep vein thrombosis, pulmonary embolism, or stroke', ' Symptomatic or untreated central nervous system (CNS) metastatic disease. Patients with previously treated CNS metastatic disease which has been stable for at least 56 days are eligible', ' Requirement, at time of study entry, for concurrent steroids > 10 mg/day of oral prednisone or the equivalent, except steroid inhaler, nasal spray, or ophthalmic solution', ' Serious medical condition that would impair the ability to receive or tolerate margetuximab; dementia or altered mental status that would preclude provision of informed consent', ' Uncontrolled hypertension, heart disease including history of congestive heart failure, history of myocardial infarction, angina pectoris requiring medication, clinically significant valvular heart disease, high risk arrhythmias, or disease corresponding to New York Heart Association class III or IV.', ' Significant pulmonary compromise', ' Have previously been exposed to MGAH22 in this or any other trial'], 'Results': ['Outcome Measurement: ', ' Best Overall Response', ' Response based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria based on Cycle 2, Day 21 computed tomography (CT) scans. Response is categorized as complete response (CR): disappearance of all target lesions, confirmed at 4 weeks; partial response (PR): 30% decrease in target lesions from baseline, confirmed at 4 weeks; progressive disease (PD): 20% increase over smallest sum observed with an absolute increase of at least 5 mm, or appearance of new lesions; and stable disease (SD): neither PR or PD criteria met.', ' A Simon two-stage design was planned in which an initial cohort of 21 patients was treated. If 2 or more responses (PR or CR) are seen at the first tumor re-evaluation on day 21 of Cycle 2, the study would be expanded to include up to 41 patients (20 additional patients in Cohort 2, the second stage of the study) in order to determine whether further development of the drug is warranted (5 or more responses in 41 evaluable patients).', ' Time frame: Cycle 2, Day 21', 'Results 1: ', ' Arm/Group Title: Margetuximab', ' Arm/Group Description: Monotherapy of Anti-HER2 monoclonal antibody', ' Margetuximab: Anti-HER2 monoclonal antibody', ' Overall Number of Participants Analyzed: 22', ' Measure Type: Number', ' Unit of Measure: participants Complete Response: 0', ' Partial Response: 0', ' Stable Disease: 6', ' Progressive Disease: 12', 'Not Done: 4'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/25 (24.00%)', ' Supraventricular extrasystoles 1/25 (4.00%)', ' Ventricular extrasystoles 1/25 (4.00%)', ' Ascites 2/25 (8.00%)', ' Diarrhea 1/25 (4.00%)', ' Nausea 1/25 (4.00%)', ' Pancreatitis 1/25 (4.00%)', ' Small intestinal obstruction 1/25 (4.00%)', ' Vomiting 1/25 (4.00%)', ' Bile duct obstruction 1/25 (4.00%)', ' Portal hypertension 1/25 (4.00%)']}

{'Clinical Trial ID': 'NCT01326481', 'Intervention': ['INTERVENTION 1: ', ' Carotuximab (TRC105) Plus Capecitabine', ' All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg weekly) Capecitabine: oral (1,000 mg/m2 BID)'], 'Eligibility': ['Inclusion Criteria:', ' Histologically proven advanced solid cancer for which curative therapy is not available (Part 1 only)', ' Histologically proven metastatic Her-2-negative breast cancer (Part 2 only)', ' Measurable disease by RECIST 1.1 criteria (Part 2 only)', ' Willing and able to consent for self to participate in study', ' Progressive or recurrent disease after prior systemic chemotherapy regimen', ' Age 18 years', ' ECOG performance status of 0 or 1', ' Resolution of all acute toxic effects of prior therapy to NCI CTCAE Grade 1 or baseline (except alopecia)', ' Adequate organ function', 'Exclusion Criteria:', ' Prior treatment with more than one systemic chemotherapy regimen for metastatic disease.', ' Prior treatment with TRC105', ' History of hypersensitivity reaction to antimetabolite therapy', ' Receipt of an investigational agent within 28 days of starting study treatment', ' Prior surgery (including open biopsy), radiation therapy or systemic therapy within 28 days of starting study treatment', ' Minor surgical procedures within 14 days prior to first dose of TRC105', ' History of brain metastasis, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease', ' Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG within the past 6 months', ' Uncontrolled chronic hypertension defined as systolic > 140 or diastolic > 90 despite optimal therapy', ' Past medical history of acquired or inherited coagulopathy including patients with known hereditary hemorrhagic telangiectasia', ' Thrombolytic or anticoagulant use (except to maintain i.v. catheters) within 10 days prior to first dose with TRC105', ' Cardiac dysrhythmias of NCI CTCAE Grade 2 within the last month', ' Hemorrhage within 28 days of starting study treatment', ' Unhealed wounds within 28 days of starting study treatment', ' History of peptic ulcer disease or gastritis within the past 6 months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment', ' Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness', ' Known active viral or nonviral hepatitis', ' History of hypersensitivity reaction to human or mouse antibody products', ' Lung cancer with central chest lesions', ' Pregnancy or breastfeeding'], 'Results': ['Outcome Measurement: ', ' Determine Maximum Tolerated Dose of TRC105 in Combination With Capecitabine', ' Assess safety and dose limiting toxicity by dose cohort and coding all terms utilized MedDRA version 14.1.', ' Time frame: 1.5 years', 'Results 1: ', ' Arm/Group Title: Carotuximab (TRC105) Plus Capecitabine', ' Arm/Group Description: All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg weekly) Capecitabine: oral (1,000 mg/m2 BID)', ' Overall Number of Participants Analyzed: 6', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Patients with DLT at 7.5 mg/kg: 0 0.0%', ' Patients without DLT at 7.5 mg/kg: 3 50.0%', ' Patients with DLT at 10 mg/kg: 0 0.0%', ' Patients without DLT at 10 mg/kg: 3 50.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/19 (31.58%)', ' Febrile neutropenia [1]1/19 (5.26%)', ' Fatigue [1]1/19 (5.26%)', ' Pyrexia [1]1/19 (5.26%)', ' Fracture [1]1/19 (5.26%)', ' Hip Fracture [1]1/19 (5.26%)', ' Headache [2]1/19 (5.26%)']}

f26fb90b-a9a5-4614-9680-2e9f6f0ba649

Single

Eligibility

NCT00388726

A 75 year old female patient, with an ECOG of 1 and an estimated life expectancy of more than a year would be eligible for the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00388726', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/kg^2', ' Eribulin Mesylate 1.4 mg/kg^2 on Days 1 and 8', 'INTERVENTION 2: ', " Treatment of Physician's Choice", " Treatment of Physician's Choice"], 'Eligibility': ['Inclusion Criteria:', ' Female patients with histologically or cytologically confirmed carcinoma of the breast.', ' Every effort should be made to make paraffin embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis.', ' Patients with locally recurrent or metastatic disease who have received at least two (and not more than five) prior chemotherapeutic regimens for breast cancer, at least two of which were administered for treatment of locally recurrent and/or metastatic disease.', ' Prior therapy must be documented by the following criteria prior to entry onto study:', ' Regimens must have included an anthracycline (e.g., doxorubicin, epirubicin) and a taxane (e.g., paclitaxel, docetaxel) in any combination or order. Treatment with any of these agents is not required if they are contraindicated for a certain patient.', ' One or two of these regimens may have been administered as adjuvant and/or neoadjuvant therapy, but at least 2 must have been given for relapsed or metastatic disease.', ' Patients must have proved refractory to the most recent chemotherapy, documented by progression on or within six (6) months of therapy.', ' Patients with Human Epidermal Growth Factor 2 (HER2/neu) positive tumors may additionally have been treated with trastuzumab.', ' Patients may have additionally been treated with anti-hormonal therapy.', ' Resolution of all chemotherapy or radiation-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy <= Grade 2 and alopecia.', ' Age >= 18 years.', ' Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.', ' Life expectancy of >= 3 months.', ' Adequate renal function as evidenced by serum creatinine <= 2.0 mg/dL or calculated creatinine clearance >= 40 mL/min per the Cockcroft and Gault formula.', ' Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) >= 1.5 x 10^9/L, hemoglobin >= 10.0 g/dL (a hemoglobin <10.0 g/dL is acceptable if it is corrected by growth factor or transfusion), and platelet count >= 100 x 10^9/L.', ' Adequate liver function as evidenced by bilirubin <= 1.5 times the upper limits of normal (ULN) and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) <= 3 x ULN (in the case of liver metastases <= 5 x ULN), unless there are bone metastases, in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase. In case alkaline phosphatase is >3 x ULN (in absence of liver metastases) or > 5 x ULN (in presence of liver metastases) AND patient is known to have bone metastases, the liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase.', ' Patients willing and able to comply with the study protocol for the duration of the study.', ' Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.', ' EXCLUSION CRITERIA', ' Patients who have received any of the following treatments within the specified period before E7389 or TPC treatment start:', ' chemotherapy, radiation, trastuzumab or hormonal therapy within three weeks.', ' any investigational drug within four weeks.', ' Radiation therapy encompassing > 30% of marrow.', ' Prior treatment with mitomycin C or nitrosourea.', ' Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.', ' Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (e.g., radiologic) and/or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment; radiographic stability should be determined by comparing a contrast-enhanced computed tomography or magnetic resonance imaging brain scan performed during screening to a prior scan performed at least 4 weeks earlier.', ' Patients with meningeal carcinomatosis.', ' Patients who are receiving anti-coagulant therapy with warfarin or related compounds, other than for line patency, and cannot be changed to heparin-based therapy if randomized to E7389 are not eligible. If a patient is to continue on mini-dose warfarin, then the prothrombin time (PT) or international normalized ratio (INR) must be closely monitored.', ' Women who are pregnant or breast-feeding; women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test; women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator. Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.', ' Severe/uncontrolled intercurrent illness/infection.', ' Significant cardiovascular impairment (history of congestive heart failure > New York Heart Association grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia).', ' Patients with organ allografts requiring immunosuppression.', ' Patients with known positive HIV status.', ' Patients who have had a prior malignancy, other than previous breast cancer, carcinoma in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated >= 5 years previously with no subsequent evidence of recurrence.', ' Patients with pre-existing neuropathy > Grade 2.', ' Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative.', ' Patients who participated in a prior E7389 clinical trial whether or not E7389 was received.', " Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study."], 'Results': ['Outcome Measurement: ', ' Overall Survival', ' Defined as the time from the date of randomization until the date of death from any cause.', ' Time frame: From date of randomization until death from any cause', 'Results 1: ', ' Arm/Group Title: Eribulin Mesylate 1.4 mg/kg^2', ' Arm/Group Description: Eribulin Mesylate 1.4 mg/kg^2 on Days 1 and 8', ' Overall Number of Participants Analyzed: 508', ' Median (Full Range)', ' Unit of Measure: Days 399 (360 to 434)', 'Results 2: ', " Arm/Group Title: Treatment of Physician's Choice", " Arm/Group Description: Treatment of Physician's Choice", ' Overall Number of Participants Analyzed: 254', ' Median (Full Range)', ' Unit of Measure: Days 324 (282 to 380)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 130/503 (25.84%)', ' Febrile Neutropenia21/503 (4.17%)', ' Neutropenia9/503 (1.79%)', ' Anaemia1/503 (0.20%)', ' Pancytopenia1/503 (0.20%)', ' Pericardial Effusion2/503 (0.40%)', ' Cardiac Failure1/503 (0.20%)', ' Extrasystoles0/503 (0.00%)', ' Vertigo1/503 (0.20%)', ' Nausea7/503 (1.39%)', ' Vomiting5/503 (0.99%)', ' Diarrhoea1/503 (0.20%)', ' Abdominal Pain1/503 (0.20%)', ' Ascites1/503 (0.20%)', 'Adverse Events 2:', ' Total: 64/247 (25.91%)', ' Febrile Neutropenia3/247 (1.21%)', ' Neutropenia0/247 (0.00%)', ' Anaemia2/247 (0.81%)', ' Pancytopenia0/247 (0.00%)', ' Pericardial Effusion0/247 (0.00%)', ' Cardiac Failure0/247 (0.00%)', ' Extrasystoles1/247 (0.40%)', ' Vertigo0/247 (0.00%)', ' Nausea2/247 (0.81%)', ' Vomiting1/247 (0.40%)', ' Diarrhoea4/247 (1.62%)', ' Abdominal Pain3/247 (1.21%)', ' Ascites2/247 (0.81%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

90dd042b-c16c-4ea7-b360-625bd5e64590

Single

Results

NCT01271725

In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 13% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group.

Entailment

{'Clinical Trial ID': 'NCT01271725', 'Intervention': ['INTERVENTION 1: ', ' Afatinib Monotherapy', ' Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal. Patients could have dose reduced if 40 mg was not tolerated.', 'INTERVENTION 2: ', ' Afatinib and Paclitaxel or Vinorelbine Combination Therapy', ' Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy'], 'Eligibility': ['Inclusion criteria:', ' Female patients >=18 years with proven diagnosis of HER2-overexpressing, histologically confirmed breast cancer', ' Stage IV metastatic disease', ' At least one measurable lesion according to RECIST 1.1 (Response Evaluation Criteria for Solid Tumours version 1.1). Skin, bone and brain lesions are considered non-target lesions', ' Must have failed or progressed on either trastuzumab or lapatinib or trastuzumab and lapatinib treatment in the neoadjuvant and/or adjuvant setting', 'Exclusion criteria:', ' Prior first line therapy for metastatic breast cancer', ' Known pre-existing interstitial lung disease', ' Active brain metastases', ' History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to trial treatment.', ' Cardiac left ventricular function with resting ejection fraction of less than 50%.', ' Prior treatment with Epidermal Growth Factor Receptor (EGFR)/HER2-targeted small molecules or antibodies other than trastuzumab and lapatinib in the neoadjuvant or adjuvant setting', ' Prior treatment with paclitaxel in the past 12 months', ' Must not have received prior vinorelbine treatment - Further exclusion criteria apply'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version (RECIST) 1.1', ' Objective response according to RECIST v1.1. Best overall response of confirmed complete response (CR) or confirmed partial response (PR) recorded since first administration of trial medication and until the earliest of disease progression, death or start of next treatment in each part separately. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by Magnetic resonance imaging (MRI): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR. Percentage of participants with OR along with exact 95% Confidence Interval by Clopper and Pearson is presented.', ' Time frame: From the initial dose of study drug until 28 days after end of the treatment period, up to 1562 days', 'Results 1: ', ' Arm/Group Title: Afatinib Monotherapy', ' Arm/Group Description: Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal. Patients could have dose reduced if 40 mg was not tolerated.', ' Overall Number of Participants Analyzed: 74', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 18 (10 to 28)', 'Results 2: ', ' Arm/Group Title: Afatinib and Paclitaxel or Vinorelbine Combination Therapy', ' Arm/Group Description: Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy', ' Overall Number of Participants Analyzed: 39', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 31 (17 to 48)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 18/74 (24.32%)', ' Anaemia 0/74 (0.00%)', ' Febrile neutropenia 0/74 (0.00%)', ' Cardio-respiratory arrest 1/74 (1.35%)', ' Abdominal pain 2/74 (2.70%)', ' Diarrhoea 3/74 (4.05%)', ' Nausea 0/74 (0.00%)', ' Vomiting 2/74 (2.70%)', ' Asthenia 3/74 (4.05%)', ' Chest pain 1/74 (1.35%)', ' Pain 0/74 (0.00%)', ' Pyrexia 0/74 (0.00%)', ' Hepatic function abnormal 1/74 (1.35%)', 'Adverse Events 2:', ' Total: 5/13 (38.46%)', ' Anaemia 1/13 (7.69%)', ' Febrile neutropenia 1/13 (7.69%)', ' Cardio-respiratory arrest 0/13 (0.00%)', ' Abdominal pain 2/13 (15.38%)', ' Diarrhoea 0/13 (0.00%)', ' Nausea 0/13 (0.00%)', ' Vomiting 1/13 (7.69%)', ' Asthenia 1/13 (7.69%)', ' Chest pain 0/13 (0.00%)', ' Pain 1/13 (7.69%)', ' Pyrexia 2/13 (15.38%)', ' Hepatic function abnormal 0/13 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

9b03c9e7-ca64-4e9f-9c10-f8c2d64ff0b7

Comparison

Eligibility

NCT00915603

NCT02511730

INR equal to or above 1.5 is mandatory for participation in the primary trial, it is not necessary for the secondary trial.

Entailment

{'Clinical Trial ID': 'NCT00915603', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel/Bevacizumab/Everolimus', 'Systemic Therapy', 'INTERVENTION 2: ', ' Paclitaxel/Bevacizumab/Placebo', 'Systemic Therapy'], 'Eligibility': ['Inclusion Criteria:', ' Female or male patients >=18 years of age.', ' Histologically confirmed invasive breast cancer, locally unresectable or metastatic.', ' No prior chemotherapy for MBC. Patients may have received adjuvant or', ' neoadjuvant chemotherapy (including taxanes and/or bevacizumab) as long as', ' treated was completed >12 months prior to relapse. Prior hormonal therapy in the', ' adjuvant or metastatic setting will be permitted.', ' Prior hormonal therapy in the adjuvant or metastatic setting is permitted. Estrogen receptor positive patients should be considered candidates for chemotherapy.', ' HER2-negative breast cancer, defined as follows:', ' FISH-negative (FISH ratio <2.2), or', ' IHC 0-1+, or', ' IHC 2-3+ AND FISH-negative (FISH ratio <2.2).', ' Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.', ' Adequate hematologic function, defined by:', ' · Absolute neutrophil count (ANC) >1500/mm3', ' Platelet count >=100,000/mm3', ' Hemoglobin >9 g/dL', ' Adequate liver function, defined by:', ' · AST and ALT <=2.5 x the upper limit of normal (ULN) or <=5 x ULN in', ' presence of liver metastases', ' Total bilirubin <=1.5 x ULN', ' Adequate renal function, defined by:', ' · Serum creatinine <=1.5 x ULN or calculated creatinine clearance of', ' >=40 ml/min', ' International normalized ratio (INR) <=1.5 or prothrombin time (PT)/partial', ' thromboplastin time (PTT) within normal limits (WNL) of the institution (if patient is not on anti-coagulation therapy). Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin are eligible if the INR is stable and within the therapeutic range prior to study treatment initiation.', ' Adequate lipid profile: total cholesterol <=300 mg/dL OR <=7.75 mmol/L and fasting triglyceride 2.5 x ULN. Note: In case one or both of these thresholds are exceeded,the patient can only be included after initiation of appropriate lipid lowering medication.', ' Patients with proteinuria at screening as demonstrated by either:', ' · Urine protein creatinine (UPC) ration >1.0 at screening', ' or', ' Urine dipstick for proteinuria >=2+ (patients discovered to have', ' >=2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour', ' urine collection and must demonstrate <1 g of protein in 24 hours to be', ' eligible).', ' Measurable disease by RECIST criteria.', ' Life expectancy >=12 weeks.', ' Ability to swallow oral medications.', ' Adequate cardiac function, defined by baseline left ventricular ejection fraction (LVEF) value >= normal per institutional guidelines by MUGA scan or', ' echocardiogram (ECHO).', ' Adequate recovery from recent surgery.', ' Major surgical procedure >28 days from study entry', ' Minor surgical procedure >7 days from study entry (Portacath placement', ' excepted - patients can start treatment <7 days after portacath placement.)', ' Patients with previous history of invasive cancers (including breast cancer) are eligible if definitive treatment was completed more than 5 years prior to initiating current study treatment, and there is no evidence of recurrent disease.', ' Patient must be accessible for treatment and follow-up.', ' All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry.', ' -', 'Exclusion Criteria:', ' Patients with active brain metastases or meningeal metastases. Patients who have had brain metastases resected, or have received brain radiation therapy >4 weeks prior to study entry are eligible, if they meet all of the following criteria: 1) residual symptoms < grade 2, 2) no dexamethasone requirement, and 3) follow-up MRI shows regression of lesions after treatment and no new lesions appearing.', ' Previous treatment with an m-TOR inhibitor (sirolimus, temsirolimus, everolimus) or anti-angiogenesis agent unless:', ' in the adjuvant setting, and', ' >=12 months prior to recurrence.', ' Previous radiotherapy for metastatic disease completed <2 weeks prior to study treatment initiation.', ' Patients who are current receiving systemic cancer therapy or have received', ' previous systemic therapy within 4 weeks of the start of study drug (e.g.', ' chemotherapy, antibody therapy, targeted agents).', ' Women who are pregnant or lactating. All patients with reproductive potential must agree to use effective contraception from time of study entry until at least 3 months after the last administration of study drug.', ' Uncontrolled hypertension defined as systolic blood pressure >150 mmHg or', ' diastolic pressure >100 mmHg, despite optimal medical management.', ' Concurrent use of CYP3A4 inhibitors and inducers from 72 hours prior to initiation of study treatment until the end of treatment with everolimus.', ' Cardiac disease, including: congestive heart failure (CHF) > Class II per New York Heart Association (NYHA) classification; unstable angina (anginal symptoms at rest) or new-onset angina (i.e., began within the last 3 months), or myocardial infarction within the past 6 months; symptomatic CHF, unstable angina pectoris, or cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.', ' History of stroke or transient ischemic attack within 6 months prior to first', ' bevacizumab dose.', ' Patients with any non-healing wound, ulcer, or long-bone fracture.', ' Patients with clinical history of hemoptysis or hematemesis.', ' Patients with any history of a bleeding diathesis or coagulopathy.', ' Patients with a PEG or G tube cannot be enrolled into this trial.', ' History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning bevacizumab.', ' Patients with an impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).', ' Patients who have any severe and/or uncontrolled medical conditions or other', ' conditions that could affect their participation such as:', ' severe impaired lung functions as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air', ' uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN.', ' History of any other disease, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug, or that might affect interpretation of the results of this study, or render the subject at high risk for treatment complications.', ' History of hypersensitivity to Cremophor EL (polyoxyethylated castor oil) or a drug formulated in Cremophor EL, such as paclitaxel.', ' Patients may not receive any other investigational or anti-cancer treatments while participating in this study.', ' Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.', ' Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period.', ' Concurrent severe, uncontrolled infection or intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.', ' Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or its excipients.', ' Patients with a known HIV seropositivity.', '-'], 'Results': ['Outcome Measurement: ', ' Progression-Free Survival (PFS)', ' Progression-free survival will be measured from Day 1 of study drug administration to disease progression defined by Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions', ' Time frame: every 8 weeks until progressive disease, expected average of 18 months', 'Results 1: ', ' Arm/Group Title: Paclitaxel/Bevacizumab/Everolimus', ' Arm/Group Description: Systemic Therapy', ' Overall Number of Participants Analyzed: 56', ' Median (95% Confidence Interval)', ' Unit of Measure: months 9.1 (6.8 to 10.8)', 'Results 2: ', ' Arm/Group Title: Paclitaxel/Bevacizumab/Placebo', ' Arm/Group Description: Systemic Therapy', ' Overall Number of Participants Analyzed: 57', ' Median (95% Confidence Interval)', ' Unit of Measure: months 7.1 (5.6 to 10.8)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 16/55 (29.09%)', ' NEUTROPENIA 1/55 (1.82%)', ' FEBRILE NEUTROPENIA 1/55 (1.82%)', ' PANCYTOPENIA 0/55 (0.00%)', ' LEFT VENTRICULAR DYSFUNCTION 1/55 (1.82%)', ' TACHYCARDIA 0/55 (0.00%)', ' ABDOMINAL PAIN 0/55 (0.00%)', ' PANCREATITIS 1/55 (1.82%)', ' HAEMATEMESIS 0/55 (0.00%)', ' INTESTINAL PERFORATION 0/55 (0.00%)', ' OESOPHAGEAL OBSTRUCTION 0/55 (0.00%)', ' MUCOSAL INFLAMMATION 1/55 (1.82%)', 'Adverse Events 2:', ' Total: 16/56 (28.57%)', ' NEUTROPENIA 2/56 (3.57%)', ' FEBRILE NEUTROPENIA 2/56 (3.57%)', ' PANCYTOPENIA 1/56 (1.79%)', ' LEFT VENTRICULAR DYSFUNCTION 0/56 (0.00%)', ' TACHYCARDIA 1/56 (1.79%)', ' ABDOMINAL PAIN 1/56 (1.79%)', ' PANCREATITIS 0/56 (0.00%)', ' HAEMATEMESIS 1/56 (1.79%)', ' INTESTINAL PERFORATION 1/56 (1.79%)', ' OESOPHAGEAL OBSTRUCTION 1/56 (1.79%)', ' MUCOSAL INFLAMMATION 0/56 (0.00%)']}

{'Clinical Trial ID': 'NCT02511730', 'Intervention': ['INTERVENTION 1: ', ' FFDM Plus DBT', ' Breast Images with FFDM and DBT', ' FFDM Plus DBT: Fujifilm Aspire Cristalle System', 'INTERVENTION 2: ', ' FFDM', ' Breast Images with FFDM alone', ' FFDM: Fujifilm Aspire Cristalle System'], 'Eligibility': ['Inclusion Criteria:', ' Female subjects participating in FMSU004A protocol with known clinical status', 'Exclusion Criteria:', ' Subjects with unknown clinical status not participating in FMSU004A protocol.'], 'Results': ['Outcome Measurement: ', ' Compare Per Subject Area Under Curve (AUC): FFDM Only vs DBT Plus FFDM', " Breast AUC performance metrics to determine if FFDM plus DBT improved cancer detection rate, requiring correct lesion localization. Statistician to estimate AUCs for each reader in each review condition (FFDM read in conjunction with FFDM plus DBT read) based on their Probability of Malignancy (POM) scores. POM scores will require correct lesion localization, such that in a case with cancer if the reader recorded one or more findings in the case but none of them are determined by the truther to match the location(s) of any proven malignancies, a POM score of 0 will be assigned to the case. Statistician to provide graphical representations of each reader's ROC curve for each review condition. For each reader the difference between the AUC for the FFDM read in conjunction with the FFDM plus DBT will be presented. Statistician to perform MRMC comparison of AUC's between FFDM read in conjunction with FFDM plus DBT using the MRMC method of Dorfman, Berbaum & Metz (1992).", ' Time frame: 1 month', 'Results 1: ', ' Arm/Group Title: FFDM Plus DBT', ' Arm/Group Description: Breast Images with FFDM and DBT', ' FFDM Plus DBT: Fujifilm Aspire Cristalle System', ' Overall Number of Participants Analyzed: 100', ' Mean (Standard Error)', ' Unit of Measure: Probability 100 (0.812)', 'Results 2: ', ' Arm/Group Title: FFDM', ' Arm/Group Description: Breast Images with FFDM alone', ' FFDM: Fujifilm Aspire Cristalle System', ' Overall Number of Participants Analyzed: 100', ' Mean (Standard Error)', ' Unit of Measure: Probability 100 (0.780)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/100 (0.00%)', 'Adverse Events 2:', ' Total: 0/100 (0.00%)']}

20cc98f8-a71a-466d-a39c-735899791613

Single

Adverse Events

NCT00391092

In total there were 32 cases of Febrile neutropenia in the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00391092', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Docetaxel', " Trastuzumab 8 mg/kg loading dose administered intravenously on Day 1 of Cycle 1, followed by docetaxel 100 mg/m^2 on Day 2 of Cycle 1. Then a maintenance dose of trastuzumab at 6 mg/kg and docetaxel at 100 mg/m^2 were administered intravenously on Day 1 of each 3-weekly cycle until disease progression, unacceptable toxicity (requiring discontinuation of study treatment), or withdrawal of participant's consent, and for a minimum of 6 cycles, respectively.", 'INTERVENTION 2: ', ' Trastuzumab + Bevacizumab + Docetaxel', " Trastuzumab 8 mg/kg loading dose administered intravenously on Day 1 of Cycle 1, followed by bevacizumab 15 mg/kg and docetaxel 100 mg/m^2 on Day 2 of Cycle 1. Then a maintenance dose of trastuzumab at 6 mg/kg, bevacizumab 15 mg/kg and docetaxel at 100 mg/m^2 were administered intravenously on Day 1 of each 3-weekly cycle until disease progression, unacceptable toxicity (requiring discontinuation of study treatment), or withdrawal of participant's consent."], 'Eligibility': ['Inclusion Criteria:', ' adult patients, >=18 years of age;', ' HER2 positive breast cancer with locally recurrent or metastatic lesions;', ' eligible for chemotherapy;', ' baseline LVEF >=50%.', 'Exclusion Criteria:', ' previous chemotherapy for metastatic or locally recurrent breast cancer;', ' previous radiotherapy for metastatic breast cancer (except for metastatic bone pain relief);', ' other primary tumor within last 5 years, with the exception of basal or squamous skin cancer, or in situ cancer of the cervix;', ' clinically significant cardiovascular disease;', ' chronic daily treatment with aspirin (>325mg/day) or clopidogrel (>75mg/day).'], 'Results': ['Outcome Measurement: ', ' Progression Free Survival (PFS)', " PFS was defined as the time from randomization to time of first documented disease progression (unequivocal progression of existing non-target lesions) or death, whichever occurred first as assessed by Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST v1.0). Progressive disease is defined using RECIST v1.0 as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started. Primary PFS variable was defined based on the investigators' assessments and the statistical conclusions on the primary efficacy endpoint were based on investigator assessed PFS. PFS was estimated using Kaplan-Meier methods.", ' Time frame: Every 9 weeks up to Week 36, thereafter every 12 weeks until disease progression (up to the clinical cutoff of 30 June 2011, up to 4.75 years)', 'Results 1: ', ' Arm/Group Title: Trastuzumab + Docetaxel', " Arm/Group Description: Trastuzumab 8 mg/kg loading dose administered intravenously on Day 1 of Cycle 1, followed by docetaxel 100 mg/m^2 on Day 2 of Cycle 1. Then a maintenance dose of trastuzumab at 6 mg/kg and docetaxel at 100 mg/m^2 were administered intravenously on Day 1 of each 3-weekly cycle until disease progression, unacceptable toxicity (requiring discontinuation of study treatment), or withdrawal of participant's consent, and for a minimum of 6 cycles, respectively.", ' Overall Number of Participants Analyzed: 208', ' Median (95% Confidence Interval)', ' Unit of Measure: months 13.7 (11.4 to 16.3)', 'Results 2: ', ' Arm/Group Title: Trastuzumab + Bevacizumab + Docetaxel', " Arm/Group Description: Trastuzumab 8 mg/kg loading dose administered intravenously on Day 1 of Cycle 1, followed by bevacizumab 15 mg/kg and docetaxel 100 mg/m^2 on Day 2 of Cycle 1. Then a maintenance dose of trastuzumab at 6 mg/kg, bevacizumab 15 mg/kg and docetaxel at 100 mg/m^2 were administered intravenously on Day 1 of each 3-weekly cycle until disease progression, unacceptable toxicity (requiring discontinuation of study treatment), or withdrawal of participant's consent.", ' Overall Number of Participants Analyzed: 216', ' Median (95% Confidence Interval)', ' Unit of Measure: months 16.5 (14.1 to 19.1)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 63/206 (30.58%)', ' Febrile neutropenia * 14/206 (6.80%)', ' Neutropenia * 9/206 (4.37%)', ' Anaemia * 1/206 (0.49%)', ' Leukopenia * 0/206 (0.00%)', ' Thrombocytopenia * 1/206 (0.49%)', ' Cardiac failure * 0/206 (0.00%)', ' Cardiac failure congestive * 1/206 (0.49%)', ' Cardiomyopathy * 0/206 (0.00%)', ' Coronary artery occlusion * 1/206 (0.49%)', ' Coronary artery thrombosis * 0/206 (0.00%)', 'Adverse Events 2:', ' Total: 72/215 (33.49%)', ' Febrile neutropenia * 18/215 (8.37%)', ' Neutropenia * 6/215 (2.79%)', ' Anaemia * 1/215 (0.47%)', ' Leukopenia * 1/215 (0.47%)', ' Thrombocytopenia * 0/215 (0.00%)', ' Cardiac failure * 1/215 (0.47%)', ' Cardiac failure congestive * 0/215 (0.00%)', ' Cardiomyopathy * 1/215 (0.47%)', ' Coronary artery occlusion * 0/215 (0.00%)', ' Coronary artery thrombosis * 1/215 (0.47%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

fa1c6f63-ae37-4c18-918b-7b9ba445fd81

Comparison

Intervention

NCT00194779

NCT04080297

IV is used as route of administration by the interventions in the primary trial and the secondary trial.

Contradiction

{'Clinical Trial ID': 'NCT00194779', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Neoadjuvant Therapy, Adjuvant Therapy)', ' See Detailed Description.', ' doxorubicin hydrochloride: Given IV', ' cyclophosphamide: Given PO', ' paclitaxel: Given IV', ' filgrastim: Given SC', ' capecitabine: Given PO', ' methotrexate: Given IV', ' vinorelbine tartrate: Given IV', ' needle biopsy: Correlative studies', ' therapeutic conventional surgery: Undergo definitive breast surgery', ' immunohistochemistry staining method: Correlative studies', ' trastuzumab: Given IV', ' tamoxifen citrate: Given PO', ' letrozole: Given PO', ' laboratory biomarker analysis: Correlative studies'], 'Eligibility': ['Inclusion Criteria:', ' Have known tumor HER-2/neu expression; if determination is "intermediate" by immunohistochemistry, fluorescent in situ hybridization (FISH) must be performed; protocol therapy is determined by HER-2/neu result', ' Have histologically confirmed, operable breast cancer that is either:', ' Hormone receptor (estrogen receptor [ER] or progesterone receptor [PR]) positive and HER2/neu positive or', ' ER/PR negative', ' Have radiographically measurable breast cancer > 1cm (Operable lesions are T1c-T3 and N0-N2a; histologic confirmation should be by core needle biopsy only)', ' Be chemotherapy naïve', ' Eastern Cooperative Oncology Group (ECOG) performance status of =< 2', ' Absolute neutrophil count (ANC) >= 1,500', ' Platelet count >= 100,000', ' Serum creatinine =< 1.5 x international upper limit of normal (IULN)', ' Bilirubin < 2.0', ' Serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvate transaminase (SGPT) =< 2 x IULN', ' Alkaline phosphatase =< 2 x IULN', ' Have staging studies and tumor assessment prior to registration; staging studies include physical exam with bidimensional tumor measurements and mammography, ultrasound, or magnetic resonance imaging (MRI) to assess tumor volume; sentinel lymph node dissection or axillary needle biopsy must be completed prior to enrollment; MRI and positron emission tomography (PET) (fluorodeoxyglucose [FDG], methoxyisobutylisonitrile [MIBI] and fluoroestradiol [FES]) imaging will be done before enrollment if clinically indicated to assess tumor volume or may be done within the first month of study participation on another institutional protocol', ' Patients with clinically apparent cardiac disease, or history of same, are not eligible; patients who are >= 60 years of age or who have a history of hypertension must have an echocardiogram or multi gated acquisition scan (MUGA) prior to enrollment; patients with breast cancer that is HER-2/neu positive who will receive herceptin (trastuzumab) must have an echocardiogram or MUGA scan; the left ventricular ejection fraction (LVEF) must be within the institutional normal range; if LVEF is > 75%, the investigator should consider having the LVEF reviewed or repeating the MUGA prior to registration', ' Women of childbearing potential must have a negative pregnancy test within seven days prior to registration', ' Be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study specific screening procedures', 'Exclusion Criteria:', ' Primary tumor =< 1 cm, not measurable; inflammatory disease', ' Pregnant or lactating; woman of childbearing potential with either a positive or no pregnancy test at baseline are excluded; postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential; patients must agree to continue contraception for 30 days from the date of the last study drug administration; woman of childbearing potential not using a reliable and appropriate contraceptive method are excluded', ' Evidence of distant metastatic disease', ' Prior chemotherapy or hormonal therapy for breast cancer', ' Except for the following no other malignancy is allowed: synchronous ipsilateral breast cancer of the same subtype (ER/PR, HER-2/neu), adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other stage I or II cancer from which the patient has been disease free for at least 5 years', ' Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil', ' Previous enrollment in an investigational drug study within the past four weeks', ' History of uncontrolled seizures, central nervous system disorders, or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance with oral drug intake', ' Patients with cardiac disease that would preclude the use of Adriamycin, Taxol or Herceptin are not eligible', ' Active cardiac disease:', ' Angina pectoris that requires the use of antianginal medication', ' Cardiac arrhythmia requiring medication', ' Severe conduction abnormality', ' Clinically significant valvular disease', ' Cardiomegaly on chest x-ray', ' Ventricular hypertrophy on electrocardiogram (EKG)', ' Uncontrolled hypertension, (diastolic greater than 100 mm/Hg or systolic > 200 mm/hg)', ' Current use of digitalis or beta blockers for congestive heart failure (CHF)', ' Clinically significant pericardial effusion', ' History of cardiac disease:', ' Myocardial infarction documented as a clinical diagnosis or by EKG or any other test', ' Documented congestive heart failure', ' Documented cardiomyopathy', ' Documented arrhythmia or cardiac valvular disease that requires medication or is medically significant', ' Major surgery within 4 weeks of the start of study treatment without complete recovery', ' Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome', ' Known, existing uncontrolled coagulopathy', ' Unwillingness to give written informed consent', ' Unwillingness to participate or inability to comply with the protocol for the duration of the study'], 'Results': ['Outcome Measurement: ', ' Combined Rate of Microscopic pCR and Macroscopic Pathologic Complete Response (mCR)', ' Microscopic pCR: No evidence of microscopic invasive tumor at the primary site or in the regional lymph nodes at the time of definitive surgical resection. mCR: The examining pathologist cannot identify gross residual tumor mass in the surgical specimen. This differs from a pCR where the specimen must also be negative for invasive tumor by microscopy. For this study, we are using a definition of mCR that will make the trial more translatable to other institutions. For this study, mCR will be defined as no focus of invasive cancer >= 1 cm.', ' Count of participants with either a pCR or mCR.', ' Time frame: Up to 16 weeks', 'Results 1: ', ' Arm/Group Title: Treatment (Neoadjuvant Therapy, Adjuvant Therapy)', ' Arm/Group Description: See Detailed Description.', ' doxorubicin hydrochloride: Given IV', ' cyclophosphamide: Given PO', ' paclitaxel: Given IV', ' filgrastim: Given SC', ' capecitabine: Given PO', ' methotrexate: Given IV', ' vinorelbine tartrate: Given IV', ' needle biopsy: Correlative studies', ' therapeutic conventional surgery: Undergo definitive breast surgery', ' immunohistochemistry staining method: Correlative studies', ' trastuzumab: Given IV', ' tamoxifen citrate: Given PO', ' letrozole: Given PO', ' laboratory biomarker analysis: Correlative studies', ' Overall Number of Participants Analyzed: 42', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 29 69.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 8/50 (16.00%)', ' Febrile Neutropenia1/50 (2.00%)', ' Death1/50 (2.00%)', ' Neutropenia5/50 (10.00%)']}

{'Clinical Trial ID': 'NCT04080297', 'Intervention': ['INTERVENTION 1: ', ' 100 mg Q-122', ' Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days.', 'INTERVENTION 2: ', ' 200 mg Q-122', ' Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.'], 'Eligibility': ['Inclusion Criteria:', ' Be a female of any race between the ages of 30-70 years.', ' History of breast cancer and presently taking an aromatase inhibitor or tamoxifen.', ' Naturally menopausal: 12 months spontaneous amenorrhea or > 6 but < 12 months amenorrhea with a serum follicle stimulating hormone (FSH) level of > 40 mIU/mL (Milli-international Units Per Milliliter).', ' Surgically menopausal with an FSH level > 40 mIU/mL.', ' Have a minimum of 7 moderate to severe hot flushes/day or 50 moderate to severe hot flushes per week, as verified for both weeks during the 14-day Screening Phase, prior to enrollment into the treatment phase of the study.', ' Able to read, understand and complete the required subject diary.', ' Willing and able to complete the daily subject diary, attend all study visits, and participate in all study procedures, including PK blood draws.', 'Exclusion Criteria:', ' Childbearing potential, including pregnancy, or lactation.', ' Undiagnosed abnormal genital bleeding.', ' Significant day-to-day variability in hot flushes.', ' Participation in another clinical trial within 30 days prior to screening or during the study.', ' Legal incapacity or limited legal capacity.', ' Chronic renal (serum creatinine > 2.0 mg/dL) or hepatic disease [SGPT (ALT) or SGOT (AST) > 2X normal limits].', ' Gastrointestinal, liver, kidney or other conditions which could interfere with the absorption, distribution, metabolism or excretion of Q-122.', ' Untreated overt hyperthyroidism.', ' Use of thyroid medication of less than 12 weeks on a stable dose.', ' Any clinically important systemic disease in the judgement of the investigator.', ' Inability to complete all study visits and study assessments for scheduling or other reasons.', " Any other reason which in the investigator's opinion makes the subject unsuitable for a clinical trial.", ' Abnormal laboratory findings including:', ' Hematocrit < 30% or hemoglobin < 9.5 gm/dL', ' Fasting blood sugar > 140 mg/dL', ' Fasting serum triglycerides > 300 mg/dL', ' Fasting SGOT, SGPT, GGT, or bilirubin greater than twice the upper limit of normal (a subject will not be excluded if a second measurement is less than twice the upper limit of normal)', ' Creatinine > 2.0 mg/dL'], 'Results': ['Outcome Measurement: ', ' Adverse Event (AE) Reporting of Q-122', ' Number of participants with indicated AE receiving Q-122', ' Time frame: 4 weeks', 'Results 1: ', ' Arm/Group Title: 100 mg Q-122', ' Arm/Group Description: Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days.', ' Overall Number of Participants Analyzed: 10', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 7 70.0%', 'Results 2: ', ' Arm/Group Title: 200 mg Q-122', ' Arm/Group Description: Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.', ' Overall Number of Participants Analyzed: 11', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 7 63.6%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/10 (0.00%)', ' Breast pain 0/10 (0.00%)', 'Adverse Events 2:', ' Total: 1/11 (9.09%)', ' Breast pain 1/11 (9.09%)']}

6d0b2acc-11f4-479f-9a86-004e2f5f7599

Comparison

Intervention

NCT02352779

NCT00263588

The differences between cohorts in the primary trial is once cohort recieves a placebo and the other Low-dose Omega-3 Fatty Acid, in contrast the difference in the secondary trial is patient characteristics.

Entailment

{'Clinical Trial ID': 'NCT02352779', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Low-dose Omega-3 Fatty Acid)', ' Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks.', 'Omega-3 Fatty Acid: Given PO', ' Placebo: Given PO', ' Questionnaire Administration: Ancillary studies', ' Laboratory Biomarker Analysis: Correlative studies', 'INTERVENTION 2: ', ' Arm II (High-dose Omega-3 Fatty Acid)', ' Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks.', 'Omega-3 Fatty Acid: Given PO', ' Questionnaire Administration: Ancillary studies', ' Laboratory Biomarker Analysis: Correlative studies'], 'Eligibility': ['Inclusion Criteria:', ' Have a confirmed diagnosis of breast cancer; participants can have had more than one primary cancer diagnosis in the past', ' Have undergone some type or combination of standard adjuvant treatment (surgery, chemotherapy, radiation therapy) for breast cancer', ' Have completed all forms of standard adjuvant treatment (surgery, chemotherapy, radiation therapy) for breast cancer between 4 and 36 months prior to enrollment in the study; participants can be currently taking hormones (such as tamoxifen) or monoclonal antibodies (such as Herceptin)', ' Must have cancer-related fatigue, as indicated by a response of 4 or greater when asked to rate their level of fatigue at its worst in the past week on an 11-point scale anchored by "0" = no fatigue and "10" = as bad as you can imagine', ' Be able to read English', ' Able to swallow medication', ' Give written informed consent', 'Exclusion Criteria:', ' Have used marine omega-3 supplements at any time within previous 3 months (this includes prescription omega-3 drugs such as Lovaza®)', ' Be taking anticoagulant medication (does not include aspirin)', ' Have sensitivity or allergy to fish and/or shellfish', ' Have sensitivity or allergy to soy and/or soybeans', ' Have confirmed diagnosis of chronic fatigue syndrome or other diagnosis known to cause severe fatigue'], 'Results': ['Outcome Measurement: ', ' Mean Change (6 Weeks - Baseline) and Standard Deviation in Cancer-related Fatigue, Using the Brief Fatigue Inventory-Short Form (BFI-SF) and Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF). 81 Subjects Had Both a Baseline and 6 Week Value', ' BFI-SF is a 4 item questionnaire to assess the severity of fatigue, ranging from 0 (No Fatigue) to 10 (As bad as you can imagine).', ' MFSI-SF is a 30 item questionnaire to assess the level of fatigue in terms of general fatigue, physical fatigue, emotional fatigue, mental fatigue, and vigor). First four subscales (general, physical, emotional, and mental) are summed and the vigor scale is subtracted to create fatigue total score with a range of -32 (low fatigue) to 96 (high fatigue).', ' Time frame: Baseline to 6 weeks', 'Results 1: ', ' Arm/Group Title: Arm I (Low-dose Omega-3 Fatty Acid)', ' Arm/Group Description: Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks.', 'Omega-3 Fatty Acid: Given PO', ' Placebo: Given PO', ' Questionnaire Administration: Ancillary studies', ' Laboratory Biomarker Analysis: Correlative studies', ' Overall Number of Participants Analyzed: 24', ' Least Squares Mean (95% Confidence Interval)', ' Unit of Measure: units on a scale BFI-SF Mean Post - Pre: -3.66 (-4.37 to -2.96)', ' MFSI-SF Mean Post - Pre: -11.03 (-16.55 to -5.50)', 'Results 2: ', ' Arm/Group Title: Arm II (High-dose Omega-3 Fatty Acid)', ' Arm/Group Description: Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks.', 'Omega-3 Fatty Acid: Given PO', ' Questionnaire Administration: Ancillary studies', ' Laboratory Biomarker Analysis: Correlative studies', ' Overall Number of Participants Analyzed: 30', ' Least Squares Mean (95% Confidence Interval)', ' Unit of Measure: units on a scale BFI-SF Mean Post - Pre: -3.68 (-4.31 to -3.05)', ' MFSI-SF Mean Post - Pre: -13.93 (-18.82 to -9.05)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/29 (0.00%)', 'Adverse Events 2:', ' Total: ']}

{'Clinical Trial ID': 'NCT00263588', 'Intervention': ['INTERVENTION 1: ', ' Cohort A', ' 750mg lapatinib administered orally twice daily. Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens, in total, for treatment of breast cancer in adjuvant and/or metastatic settings', 'INTERVENTION 2: ', ' Cohort B', ' 750mg lapatinib administered orally twice daily. Cohort B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of breast cancer in the adjuvant and/or metastatic settings.'], 'Eligibility': ['Inclusion criteria:', ' Signed Informed Consent', ' ErbB2(HER2)overexpressing breast cancer.', ' Brain lesion(s) which are progressing.', ' Prior treatment of brain metastases with Whole Brain Radiotherapy (WBR)and/or Stereotactic Radiosurgery (SRS).', ' Prior treatment with trastuzumab (Herceptin), either alone or in combination with chemotherapy.', ' Cardiac ejection fraction(LVEF)within the institutional range of normal as measured by Echocardiogram.', ' Able to swallow an oral medication.', ' Adequate kidney and liver function.', ' Adequate bone marrow function.', 'Exclusion criteria:', ' Pregnant or lactating females.', ' Conditions that would effect the absorption of an oral drug.', ' History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents.', ' Pre-existing severe cerebral vascular disease, such as stroke involving a major vessel.', " Serious medical or psychiatric disorder that would interfere with the patient's safety or informed consent."], 'Results': ['Outcome Measurement: ', ' The Number of Participants With Central Nervous System (CNS) Best Overall Response', ' Summary of CNS Objective Response (Lapatinib Monotherapy - MITT Population)', ' Response to lapatinib in patients with progressive brain metastases from ErbB2-overexpressing breast cancer.', ' The primary indicator of drug efficacy was CNS objective response rate. A CNS objective response was defined as either a Complete response (CR) or Partial response (PR), as assessed by volumetric analysis of brain Magnetic resonance imaging (MRI), provided there was no progression of systemic disease outside of the CNS, increasing steroid requirements, or worsening of Neurological signs and symptoms (NSS)', ' A CNS objective response rate was defined as a 50% volumetric reduction in sum of CNS target lesions, with no new or progressive CNS or non-CNS lesions, no increases in tumor-related steroid requirements and no worsening of neurological signs or symptoms', ' Time frame: time from baseline to data cutoff (25 Sept 2007); approximately 2 years', 'Results 1: ', ' Arm/Group Title: Cohort A', ' Arm/Group Description: 750mg lapatinib administered orally twice daily. Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens, in total, for treatment of breast cancer in adjuvant and/or metastatic settings', ' Overall Number of Participants Analyzed: 94', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Complete response (CR): 0 0.0%', ' Partial response (PR): 6 6.4%', ' Stable disease (SD): 40 42.6%', ' Progressive disease (PD): 40 42.6%', 'Unknown: 8 8.5%', 'Results 2: ', ' Arm/Group Title: Cohort B', ' Arm/Group Description: 750mg lapatinib administered orally twice daily. Cohort B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of breast cancer in the adjuvant and/or metastatic settings.', ' Overall Number of Participants Analyzed: 143', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Complete response (CR): 0 0.0%', ' Partial response (PR): 9 6.3%', ' Stable disease (SD): 46 32.2%', ' Progressive disease (PD): 70 49.0%', ' Unknown: 18 12.6%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 36/95 (37.89%)', ' Atrial fibrillation 0/95 (0.00%)', ' Cardio-respiratory arrest 1/95 (1.05%)', ' Left ventricular dysfunction 0/95 (0.00%)', ' Pericardial effusion 0/95 (0.00%)', ' Vertigo 0/95 (0.00%)', ' Constipation 1/95 (1.05%)', ' Diarrhoea 6/95 (6.32%)', ' Duodenal ulcer 0/95 (0.00%)', ' Duodenal ulcer haemorrhage 0/95 (0.00%)', ' Gastrointestinal haemorrhage 0/95 (0.00%)', 'Adverse Events 2:', ' Total: 52/147 (35.37%)', ' Atrial fibrillation 1/147 (0.68%)', ' Cardio-respiratory arrest 0/147 (0.00%)', ' Left ventricular dysfunction 1/147 (0.68%)', ' Pericardial effusion 1/147 (0.68%)', ' Vertigo 1/147 (0.68%)', ' Constipation 0/147 (0.00%)', ' Diarrhoea 4/147 (2.72%)', ' Duodenal ulcer 1/147 (0.68%)', ' Duodenal ulcer haemorrhage 1/147 (0.68%)', ' Gastrointestinal haemorrhage 2/147 (1.36%)']}

7e9c3980-9f12-40c7-920e-76594db26fd1

Comparison

Eligibility

NCT00499083

NCT03045653

In order to be eligible for both the secondary trial and the primary trial, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 negative breast cancer.

Entailment

{'Clinical Trial ID': 'NCT00499083', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', ' Patients with HER-2/neu negative tumors received therapeutic autologous dendritic cells: injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.', ' Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor.', ' Patients received 4 cycles of paclitaxel: 175 mg/m2 (IV), followed by 4 cycles of cyclophosphamide: 600 mg/m2 IV and doxorubicin hydrochloride: 60 mg/m2 IV in a bi-weekly dose dense fashion', ' All patients had pre-treatment biopsy and second tumor biopsy after 4 cycles of paclitaxel to evaluate responses to the dendritic cell injections.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed invasive breast cancer meeting the following criteria:', ' Primary tumor 3 cm by mammography, ultrasound, or palpation AND/OR palpable axillary lymph nodes > 1 cm', ' Survivin- and/or carcinoembryonic antigen-positive by IHC', ' Tumor must be localized by exam or ultrasound to allow tumor injection', ' No stage IV or metastatic disease', ' HER2/neu-negative tumor by IHC', ' If 2+ or in the indeterminate range, further testing of HER2/neu overexpression by fluorescent in situ hybridization (FISH) is required', ' Hormone receptor status known', ' PATIENT CHARACTERISTICS:', ' Female', ' Pre-, peri-, or postmenopausal', ' ECOG performance status 0-1', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception during and for up to 6 months following completion of study therapy', ' ANC 1,500/mm³', ' Platelet count 100,000/mm³', ' Alkaline phosphatase 1.5 times upper limit of normal (ULN)', ' Total bilirubin 1.5 times ULN', ' AST and ALT 1.5 times ULN', ' Creatinine < 1.5 times ULN', ' No active serious infections', ' No prior malignancy except adequately treated basal cell or squamous cell skin cancer, noninvasive carcinoma, or other cancer from which the patient has been disease free for 5 years', ' No comorbidity or condition that would interfere with study assessments and procedures or preclude study participation', ' PRIOR CONCURRENT THERAPY:', ' No prior chemotherapy or radiotherapy'], 'Results': ['Outcome Measurement: ', ' Number of Patients With Pathological Complete Response', ' Assessed by the institutional pathologist.', ' Grade 1: disappearance of all tumor on microscopic assessment in the breast and LNs', ' Grade 2: presence of in situ carcinoma only in the breast, no invasive tumor, and no tumor found in the LNs', ' Grade 3: presence of invasive carcinoma with stromal alteration, such as sclerosis or fibrosis', ' Grade 4: no or few modifications of the tumor appearance', ' Time frame: At definitive surgery.', 'Results 1: ', ' Arm/Group Title: Vaccine', ' Arm/Group Description: Patients with HER-2/neu negative tumors received therapeutic autologous dendritic cells: injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.', ' Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor.', ' Patients received 4 cycles of paclitaxel: 175 mg/m2 (IV), followed by 4 cycles of cyclophosphamide: 600 mg/m2 IV and doxorubicin hydrochloride: 60 mg/m2 IV in a bi-weekly dose dense fashion', ' All patients had pre-treatment biopsy and second tumor biopsy after 4 cycles of paclitaxel to evaluate responses to the dendritic cell injections.', ' Overall Number of Participants Analyzed: 14', ' Measure Type: Number', ' Unit of Measure: participants 2'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/3 (33.33%)', ' Febrile neutropenia 1/3 (33.33%)']}

{'Clinical Trial ID': 'NCT03045653', 'Intervention': ['INTERVENTION 1: ', ' Treatment Arm', ' receiving a treatment of tamoxifen 100 mg/d'], 'Eligibility': ['Inclusion Criteria:', ' - Female 18 years, 70 years. ECOG 0-1 with no deterioration over previous 2 weeks Minimum life expectancy 3 months Histological confirmation of hormone receptor-high expressed breast cancer(IHC:ER 60% and PR 60%) on primary tumour at diagnosis/on biopsy of metastasis Histological confirmation of HER2 negative breast cancer on primary tumour at diagnosis/on biopsy of a metastasis The disease-free time of relapsed patients is more than 12 months Once received standard hormone treatment and progressed Clinical or histological confirmation of metastatic or locally advanced disease not amenable to curative surgical resection At least one evaluative focus according to RECIST creterion or non-measurable disease but only bone metastasis Adequate bone marrow and organ function Progressive disease whilst receiving endocrine therapy for locally advanced or metastatic BC or relapsed with metastatic disease whilst receiving endocrine therapy Radiological or objective clinical evidence of recurrence or progression on or after last systemic therapy prior to enrolment', ' 4 prior lines of endocrine therapy for ABC', ' 3 line of cytotoxic chemotherapy for ABC Suitable for further endocrine therapy Availability of archival tumour sample or fresh biopsy Informed consent Normal organ function', 'Exclusion Criteria:', ' Last dose chemotherapy, immunotherapy targeted therapy, biological therapy or tumour embolisation <21 days prior to study treatment Last dose of palliative radiotherapy <7 days prior to study treatment Rapidly progressive visceral disease not suitable for further endocrine therapy Spinal cord compression or brain/meningeal metastases unless asymptomatic, treated and stable and not requiring steroids for 4 weeks study treatment Creatinine clearance <30 ml/min. Patients with creatinine clearance <50 mL/min will start at a permanently reduced vandetanib dose of 200 mg.', ' Major surgery (excluding placement of vascular access) within 4 weeks before study treatment Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and HIV With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment Elevated ALP in absence of bone metastasis Evidence of dementia, altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent Participation in another study with investigational product during last 30 days Inability or unwillingness to comply with study procedures, including inability to take regular oral medication'], 'Results': ['Outcome Measurement: ', ' Progression-free Survival (PFS)', ' [Not Specified]', ' Time frame: 36months', 'Results 1: ', ' Arm/Group Title: Treatment Arm', ' Arm/Group Description: receiving a treatment of tamoxifen 100 mg/d', ' Overall Number of Participants Analyzed: 30', ' Median (95% Confidence Interval)', ' Unit of Measure: months 5 (2.6 to 7.3)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/30 (0.00%)']}

c83e003d-d12d-4f72-ab1f-c39f3a13326b

Single

Adverse Events

NCT00244933

the primary trial monitors the occurrence of anemia in its adverse events.

Contradiction

{'Clinical Trial ID': 'NCT00244933', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine & Genistein', ' Gemcitabine, genistein (Novasoy), Tumor biopsy Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days: Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically or cytologically confirmed breast cancer', ' Stage IV disease', ' Clinical and/or radiological evidence of metastatic disease', ' Measurable disease', ' Prior radiotherapy allowed provided there is 1 measurable disease site outside the radiation field', ' No active CNS metastases', ' Previously treated CNS metastases allowed provided disease is stable for 3 months without steroids or antiseizure medications', ' Hormone receptor status:', ' Not specified', ' PATIENT CHARACTERISTICS:', ' Sex', ' Female', ' Menopausal status', ' Not specified', ' Performance status', ' SWOG 0-2', ' Life expectancy', ' Not specified', ' Hematopoietic', ' Absolute neutrophil count 1,500/mm^3', ' Platelet count 100,000/mm^3', ' Hemoglobin 10 g/dL', ' Hepatic', ' Bilirubin 3.0 mg/dL', ' AST and ALT 2.5 times upper limit of normal', ' Renal', ' Creatinine 1.5 mg/dL', ' Other', ' Not pregnant or nursing', ' Fertile patients must use effective contraception', ' No serious systemic disorder that would preclude study compliance', ' No history of another malignancy except curatively treated carcinoma of the cervix or basal cell or squamous cell skin cancer in complete remission', ' No unresolved bacterial infection requiring antibiotic treatment', ' No known HIV-1 positivity', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy', ' At least 3 weeks since prior biologic therapy', ' Chemotherapy', ' Prior adjuvant chemotherapy allowed', ' Prior adjuvant or neoadjuvant taxane-based therapy or taxane therapy for metastatic disease allowed', ' Patient must have failed therapy within 2 years after completion of treatment', ' At least 3 weeks since prior chemotherapy', ' No more than 2 prior cytotoxic chemotherapy regimens for metastatic disease', ' No prior gemcitabine hydrochloride', ' No other concurrent chemotherapy', ' Endocrine therapy', ' See Disease Characteristics', ' At least 2 weeks since prior and no concurrent hormonal therapy', ' Must have documented disease progression during prior hormonal therapy', ' Radiotherapy', ' See Disease Characteristics', ' At least 4 weeks since prior radiotherapy and recovered', ' No concurrent radiotherapy', ' Surgery', ' At least 3 weeks since prior surgery', ' Other', ' At least 3 weeks since prior investigational therapy', ' At least 1 week since prior soy supplements (e.g., soy-based pills, liquids, or concentrates)', ' Dietary soy as part of a meal (e.g., tofu) allowed once a week', ' No concurrent nutritional supplements, herbal agents, or high doses of antioxidants (e.g., vitamins C, D, or E) that may interact with, antagonize, alter, or imitate the potential effects of gemcitabine hydrochloride or genistein', ' A single daily multivitamin is allowed', ' No other concurrent immunotherapy', ' No other concurrent experimental medication', ' Concurrent anticoagulants, appetite stimulants, and replacement steroids allowed'], 'Results': ['Outcome Measurement: ', ' Objective Response Rate by RECIST Criteria Following', ' Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', ' Time frame: every 2 courses until disease progression or death, up to 24 weeks', 'Results 1: ', ' Arm/Group Title: Gemcitabine & Genistein', ' Arm/Group Description: Gemcitabine, genistein (Novasoy), Tumor biopsy Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days: Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.', ' Overall Number of Participants Analyzed: 17', ' Measure Type: Number', ' Unit of Measure: participants 0'], 'Adverse Events': ['Adverse Events 1:', ' Total: 5/19 (26.32%)', ' Pain 3/19 (15.79%)', ' White blood cells (WBC) 5/19 (26.32%)', ' Hemoglobin (Hgb) 1/19 (5.26%)', ' Absolute neutrophil count (ANC) 5/19 (26.32%)', ' Platelets 3/19 (15.79%)', ' Elevated Aspartate Aminotransferase (AST) 1/19 (5.26%)', ' Elevated Alanine Aminotransferase (ALT) 1/19 (5.26%)', ' Dyspnea 3/19 (15.79%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

cae58656-76e7-447a-940e-dfcc78159173

Single

Adverse Events

NCT02481050

There are no adverse events in the primary trial that occurred more than once.

Contradiction

{'Clinical Trial ID': 'NCT02481050', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/m^2', ' Participants with histologically confirmed HER2-negative MBC who were previously treated with 2 to 5 chemotherapy regimens received eribulin mesylate 1.4 mg/m^2, intravenous infusion over 2 to 5 minutes on Day 1 and Day 15 of each 28-days treatment cycle until intercurrent illness, unacceptable toxicity, disease progression occurred, or until the participant withdrew consent (up to 16 cycles).'], 'Eligibility': ['Inclusion Criteria:', ' Histological or cytological adenocarcinoma of the breast.', ' Females, aged greater than or equal to 18 years at time of informed consent.', ' HER2-negative as determined by fluorescence in situ hybridization (FISH); or 0 or 1+ by immunohistochemistry (IHC) staining .', ' Participants with metastatic breast cancer who have received at least 2 and not more than 5 prior chemotherapy regimens.', ' Participants with at least one measurable lesion greater than or equal to 10 mm in the longest diameter for a non-lymph node or greater than or equal to 15 mm in the short-axis diameter for a lymph node as determined by investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).', ' Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2.', ' Life expectancy of greater than or equal to 3 months.', ' Any neuropathy must recover to Grade less than or equal to 2 prior to enrollment.', ' Adequate renal function as evidenced by serum creatinine less than or equal to 1.5 mg/dL or calculated creatinine clearance greater than or equal to 50 mL/minute according to the Cockcroft and Gault formula.', ' Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) greater than or equal to 1.5 X 10^9/L, hemoglobin greater than or equal to 10.0 g/dL (can be corrected by growth factor or transfusion), and platelet count greater than or equal to 100 X 10^9/L.', ' Adequate liver function as evidenced by total bilirubin less than or equal to 1.5 X upper limit of normal (ULN), alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 X ULN (less than or equal to 5 X ULN in the case of liver metastases), unless there are bone metastases, in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase.', ' Are willing and able to comply with all aspects of the treatment protocol.', ' Provide written informed consent.', 'Exclusion Criteria:', ' Previous treatment with eribulin.', ' Hypersensitivity to eribulin/excipients or halichondrin B or known intolerance of eribulin.', ' Current enrollment in another clinical study or used of any investigational drug or device within the past 28 days preceding informed consent.', ' Previous treatment with chemotherapy, radiation, biological, or targeted therapy within the last 2 weeks or 5 X half-life, whichever is longer, preceding informed consent.', ' Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin ([B-hCG] test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.', ' All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).', ' Females of childbearing potential who had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period or for 28 days after study drug discontinuation.', ' Females who are currently abstinent and do not agree to use a double barrier method as described above or to refrain from sexual activity during the study period or for 28 days after study drug discontinuation.', ' Females who are using hormonal contraceptives but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study or for 28 days after study drug discontinuation.', ' Known central nervous system (CNS) disease, except for those participants with treated brain metastasis who are stable for at least 1 month with no evidence of progression or hemorrhage after treatment and no ongoing requirement for corticosteroids.', ' Known human immunodeficiency virus (HIV) positive.', ' Existing anticancer, therapy-related toxicities of Grades greater than or equal to 2, with the exception of alopecia.', ' A prior malignancy other than carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated greater than 5 years previously with no subsequent evidence of recurrence.', ' Clinically significant cardiovascular impairment (congestive heart failure of New York Heart Association [NYHA] Classification greater than II, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia).', ' Clinically significant ECG abnormality, including a marked Baseline prolonged QT/QTc interval (ie, a repeated demonstration of a QTc interval greater than 500 milliseconds).', ' Pulmonary lymphangitic involvement that resulted in pulmonary dysfunction requiring active treatment, including the use of oxygen.', " History of concomitant medical condition(s) that, in the opinion of the investigator, would compromise the participant's ability to safely complete the study.", " The investigator's belief that the participant is medically unfit to receive eribulin or unsuitable for any other reason."], 'Results': ['Outcome Measurement: ', ' Objective Response Rate (ORR) by Investigator Assessment', ' ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) measured by response evaluation criteria in solid tumors (RECIST) 1.1. CR defined as disappearance of all target lesions (a short diameter is less than [<] 10 millimeter [mm] if it exists in a lymph node). PR defined as at least 30 percent (%) decrease in the sum of the long diameter (LD) of all target lesions, as compared with Baseline summed LD.', ' Time frame: From first dose of study drug until intercurrent illness, unacceptable toxicity, disease progression, or until the participant withdrew consent (approximately up to 2.3 years)', 'Results 1: ', ' Arm/Group Title: Eribulin Mesylate 1.4 mg/m^2', ' Arm/Group Description: Participants with histologically confirmed HER2-negative MBC who were previously treated with 2 to 5 chemotherapy regimens received eribulin mesylate 1.4 mg/m^2, intravenous infusion over 2 to 5 minutes on Day 1 and Day 15 of each 28-days treatment cycle until intercurrent illness, unacceptable toxicity, disease progression occurred, or until the participant withdrew consent (up to 16 cycles).', ' Overall Number of Participants Analyzed: 57', ' Measure Type: Number', ' Unit of Measure: percentage of participants 12.3 (5.08 to 23.68)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 14/58 (24.14%)', ' Constipation 1/58 (1.72%)', ' Vomiting 1/58 (1.72%)', ' Upper gastrointestinal haemorrhage 1/58 (1.72%)', ' Asthenia 1/58 (1.72%)', ' Chest pain 1/58 (1.72%)', ' Pain 1/58 (1.72%)', ' Sepsis 2/58 (3.45%)', ' Fall 1/58 (1.72%)', ' Spinal compression fracture 1/58 (1.72%)', ' Neutrophil count decreased 1/58 (1.72%)', ' Dehydration 1/58 (1.72%)', ' Hypovolaemia 1/58 (1.72%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

94c4c3fc-7bcb-407b-86b5-6699305d3dbd

Single

Adverse Events

NCT00022516

At most 3 patients in the primary trial suffered from Neutropenia.

Contradiction

{'Clinical Trial ID': 'NCT00022516', 'Intervention': ['INTERVENTION 1: ', ' No-CM', ' No further chemotherapy following standard adjuvant chemotherapy.', 'INTERVENTION 2: ', ' CM-Maintenance', ' 12-month CM-maintenance regimen (C, cyclophosphamide 50 mg/day orally continuously and M, methotrexate 2.5 mg twice/day orally days 1 and 2 of every week for 1 year)', ' Cyclophosphamide: 50 mg/day orally continuously for 1 year', ' Methotrexate: 2.5 mg twice/day orally days 1 and 2 of every week for 1 year'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed stage I, II, or III breast cancer', ' T1-3, N0-2, M0', ' Patients with sentinel node biopsy positive disease must have undergone axillary dissection', ' Tumor must be confined to the breast without detected metastases elsewhere', ' T4 disease with minimal dermal invasion allowed', " No T4 disease with ulceration of skin, infiltration of skin (except pathologically minimal dermal involvement), peau d'orange, or inflammatory breast cancer", ' No bilateral breast cancer (except in situ carcinoma) or suspicious mass in opposite breast that has not been proven benign', ' No distant metastases', ' No skeletal pain of unknown cause, elevated alkaline phosphatase, or bone scan showing hot spots that cannot be ruled out as metastases by x-ray, MRI, and/or CT', ' Must have undergone prior total mastectomy OR breast-conserving procedure (e.g., lumpectomy, quadrantectomy, or partial mastectomy with negative margins) with radiotherapy planned', ' Patients must begin or have begun an approved induction chemotherapy regimen within 8 weeks after definitive surgery', ' Negative surgical margins', ' Axillary clearance with at least 6 lymph nodes examined OR negative sentinel node biopsy', ' Known HER2 status by immunohistochemistry or fluorescence in situ hybridization', ' Hormone receptor status:', ' Estrogen and progesterone receptor negative', ' Less than 10% positive tumor cells by immunohistochemistry', ' PATIENT CHARACTERISTICS:', ' Age:', 'Not specified', ' Sex:', ' Not specified', ' Menopausal status:', ' Premenopausal, defined as less than 6 months since last menstrual period (LMP) AND no prior bilateral ovariectomy AND not on estrogen replacement (OR under age 50) OR', ' Postmenopausal, defined as prior bilateral ovariectomy OR more than 12 months since LMP without prior hysterectomy (OR age 50 and over)', 'Performance status:', ' Not specified', ' Life expectancy:', ' Not specified', ' Hematopoietic:', ' WBC greater than 3,000/mm3', ' Platelet count greater than 100,000/mm3', ' Hepatic:', ' See Disease Characteristics', ' Bilirubin less than 2.0 mg/dL', ' ALT less than 1.5 times upper limit of normal OR AST less than 60 IU/L', ' Renal:', ' Creatinine less than 1.2 mg/dL', ' Other:', ' Not pregnant or lactating within the past 6 months', ' Fertile patients must use effective barrier contraception', ' No other prior or concurrent malignancy except adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or contralateral or ipsilateral in situ breast carcinoma', ' No psychiatric or addictive disorders that would preclude study', ' No non-malignant systemic disease that would preclude study', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy:', ' Prior trastuzumab (Herceptin) allowed', ' Chemotherapy:', ' See Disease Characteristics', ' No prior adjuvant or neoadjuvant chemotherapy for breast cancer', ' Endocrine therapy:', ' No prior endocrine therapy for breast cancer or prevention', ' No prior tamoxifen or raloxifene for breast cancer', ' Radiotherapy:', ' No prior radiotherapy for breast cancer except primary irradiation', ' Surgery:', ' See Disease Characteristics', ' Other:', ' No prior preventative therapy for breast cancer'], 'Results': ['Outcome Measurement: ', ' Disease-free Survival', ' Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to the first appearance of one of the following: invasive breast cancer recurrence at local, regional, or distant site, invasive contralateral breast cancer, second (non-breast) invasive cancer, or death without cancer event; or censored at date of last follow-up.', ' Time frame: 5-year estimates, reported at a median follow-up of 6.9 years', 'Results 1: ', ' Arm/Group Title: No-CM', ' Arm/Group Description: No further chemotherapy following standard adjuvant chemotherapy.', ' Overall Number of Participants Analyzed: 539', ' Measure Type: Number', ' Unit of Measure: percentage of participants 74.7 (70.6 to 78.3)', 'Results 2: ', ' Arm/Group Title: CM-Maintenance', ' Arm/Group Description: 12-month CM-maintenance regimen (C, cyclophosphamide 50 mg/day orally continuously and M, methotrexate 2.5 mg twice/day orally days 1 and 2 of every week for 1 year)', ' Cyclophosphamide: 50 mg/day orally continuously for 1 year', ' Methotrexate: 2.5 mg twice/day orally days 1 and 2 of every week for 1 year', ' Overall Number of Participants Analyzed: 542', ' Measure Type: Number', ' Unit of Measure: percentage of participants 78.1 (74.2 to 81.6)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/0', ' Leukopenia 0/0', ' Neutropenia 0/0', ' Ocular-other 0/0', ' Elevated SGPT 0/0', ' Arthralgia 0/0', ' CNS hemorrhage 0/0', ' Neurologic-other 0/0', ' Radiation dermatitis 0/0', 'Adverse Events 2:', ' Total: 11/473 (2.33%)', ' Leukopenia 2/473 (0.42%)', ' Neutropenia 5/473 (1.06%)', ' Ocular-other 1/473 (0.21%)', ' Elevated SGPT 1/473 (0.21%)', ' Arthralgia 1/473 (0.21%)', ' CNS hemorrhage 1/473 (0.21%)', ' Neurologic-other 1/473 (0.21%)', ' Radiation dermatitis 1/473 (0.21%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

103fbaa8-1852-402a-9368-36bbf6c747b2

Single

Eligibility

NCT00581256

Patients with left-sided breast cancer and an ECOG of 3 are excluded from the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00581256', 'Intervention': ['INTERVENTION 1: ', ' IMRT', ' Best Delivery-optimized radiotherapy technique (IMRT)', ' IMRT: All patients treated with the optimized plan will be treated to the entire target volume to 52.2 Gy in 1.74 Gy fractions, which is biologically equivalent to 50 Gy in 2 Gy fractions. This fractionation scheme will allow the boost of 10 Gy to be incorporated into the planning directive and to be delivered simultaneously with the treatment to the remaining target volume.', 'INTERVENTION 2: ', ' 3DRT', ' Best 3-dimensional standard PWTF technique', ' 3D: All patients treated using the best standard technique will receive 50 Gy in 2 Gy fractions or 50.4 Gy in 1.8 Gy fractions to the entire target volume delivering one treatment per day, five fractions per week (excluding holidays). A boost of 10 Gy to the tumor bed of an intact breast will be delivered. Patients treated to the chest wall will receive a 10Gy scar boost if mastectomy margins are positive in a patient with Stage II disease or if the patient was originally diagnosed with T3 or T4 (Stage III) disease'], 'Eligibility': ['Inclusion Criteria:', ' Eligibility Criteria', ' Breast cancer diagnosis: Patients must have histologically confirmed adenocarcinoma of the breast requiring comprehensive loco-regional irradiation that includes treatment to the intact breast/chest wall, supraclavicular (SCV), infraclavicular nodes (ICV), and internal mammary nodes (IMN).', ' Patients must have pathologic T 1, 2, 3 or 4, N 1, 2, or 3 Stage II or III disease as defined by the AJCC Staging System, 6th edition. Patients who do not undergo axillary staging but are at risk for nodal involvement may also be treated.', ' All patients must have left-sided breast cancer.', ' Both men and women are eligible.', ' Patients must be adults (18 years of age or older)', ' For women of child-bearing age, effective contraception must be used. A written statement must be obtained that the patient is not pregnant. If there is any question of pregnancy at time of therapeutic RT or at time of each SPECT-CT scan, a pregnancy test will be done to confirm the patient is not pregnant.', ' Performance status should be 0-2 by ECOG criteria.', ' Patients that have received prior RT may be enrolled on the present study if the new breast lesion can be treated with no overlap of RT fields.', ' Patients must be aware of the neoplastic nature of her/his disease.', ' Patients must be informed of the investigational nature of this study and must sign an informed consent in accordance with the Institutional Review Board (IRB) of the University of Michigan and federal guidelines.', " Patients' blood tests should indicate they are able to tolerate radiotherapy. Tests must be done within 28 days of registration:", ' CBC with differential and platelet count (Hemoglobin > 8.0 g/dl; wbc > 2000/mm3; absolute neutrophil count > 1000/mm3; platelet count > 75,000/mm3.', 'Exclusion Criteria:', ' Patients who are pregnant or are nursing are excluded.', ' Pathologically node negative breast cancer unless treated with neo-adjuvant chemotherapy.', ' Performance status > 2 by ECOG criteria', ' Patients who are unable to lie on their back and raise their arm above their head in the treatment planning position for radiotherapy', ' Patients with a clinically unstable medical condition', ' Patients with a life-threatening disease state', ' History or suspicion of serious life-threatening allergic reaction to Tc-99m imaging agents.', ' Patients that have had breast-conservation surgery with positive margins or any patient with negative margins with a tumor positive for an extensive intraductal component.', ' Patients that are not able to use the ABC device.'], 'Results': ['Outcome Measurement: ', ' The Number of Participants With a Significant Increase in Perfusion Defects (PD)', " To compare the extent of new myocardial perfusion defects following breast cancer radiotherapy using the best standard 3-D radiotherapy technique, partially wide tangent fields, versus the best optimized technique. Perfusion defects (PD) were assessed by comparing normalized perfusion distributions against our institution's normal polar map databases for the left anterior descending artery (LAD) using thresholds of 2.5-SD (standard deviation) and 1.5-SD below the normal mean. On the basis of interest variability, a PD increase greater than 5% or 10% was considered significant for 2.5- and 1.5-SD thresholds, respectively.", 'Time frame: 1 Year', 'Results 1: ', ' Arm/Group Title: IMRT', ' Arm/Group Description: Best Delivery-optimized radiotherapy technique (IMRT)', ' IMRT: All patients treated with the optimized plan will be treated to the entire target volume to 52.2 Gy in 1.74 Gy fractions, which is biologically equivalent to 50 Gy in 2 Gy fractions. This fractionation scheme will allow the boost of 10 Gy to be incorporated into the planning directive and to be delivered simultaneously with the treatment to the remaining target volume.', ' Overall Number of Participants Analyzed: 28', ' Measure Type: Number', ' Unit of Measure: participants 2.5 SD and PD increase >5%: 1', ' 1.5 SD and PD increase >10%: 3', 'Results 2: ', ' Arm/Group Title: 3DRT', ' Arm/Group Description: Best 3-dimensional standard PWTF technique', ' 3D: All patients treated using the best standard technique will receive 50 Gy in 2 Gy fractions or 50.4 Gy in 1.8 Gy fractions to the entire target volume delivering one treatment per day, five fractions per week (excluding holidays). A boost of 10 Gy to the tumor bed of an intact breast will be delivered. Patients treated to the chest wall will receive a 10Gy scar boost if mastectomy margins are positive in a patient with Stage II disease or if the patient was originally diagnosed with T3 or T4 (Stage III) disease', ' Overall Number of Participants Analyzed: 26', ' Measure Type: Number', ' Unit of Measure: participants 2.5 SD and PD increase >5%: 2', ' 1.5 SD and PD increase >10%: 5'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/28 (3.57%)', ' Infection with normal ANC or Grade 1 or 2 neutrophils [1]1/28 (3.57%)', 'Adverse Events 2:', ' Total: 0/26 (0.00%)', ' Infection with normal ANC or Grade 1 or 2 neutrophils [1]0/26 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

731dc36f-983d-4d4c-97ac-6e3eeee23a40

Single

Intervention

NCT00429299

Only one cohort in the primary trial is administered trastuzumab at 4 milligrams per kilogram.

Entailment

{'Clinical Trial ID': 'NCT00429299', 'Intervention': ['INTERVENTION 1: ', ' CT Plus Trastuzumab', ' Participants received chemotherapy (CT), which included paclitaxel 80 milligrams per meters squared (mg/m^2) weekly for 12 weeks, followed by intravenous (IV) fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses. Trastuzumab was administered throughout the course of the CT and for two weeks after the last CT administration. The first dose of trastuzumab was administered at 4 milligrams per kilogram (mg/kg) IV for 60 minutes on the day of the first paclitaxel course. Subsequent administrations were given weekly at 2 mg/kg IV for 30 minutes. Treatments were administered for 26 weeks prior to surgery.', 'INTERVENTION 2: ', ' CT Plus Lapatinib 1500 mg', ' Participants received CT, which included paclitaxel 80 mg/m^2 weekly for 12 weeks, followed by IV fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses. Participants received lapatinib 1500 mg/day orally on an empty stomach throughout the course of the CT and for three weeks after the last CT administration. Treatments were administered for 26 weeks prior to surgery.', ' Following Independent Data Monitoring Committee (IDMC) recommendations, lapatinib doses were reduced to 1250 mg/day orally on an empty stomach.'], 'Eligibility': ['Inclusion criteria:', ' Histologically confirmed infiltrating primary breast cancer of > 2.0 cm in largest clinical diameter', ' HER2 positive tumor (either IHC 3+ or FISH+)', ' Availability of tumor tissue suitable for biological and molecular examination before starting primary treatment', ' Age >18, < 65 years', ' ECOG PS 0-1', ' Normal organ and marrow function as defined below:', ' leukocytes ³ 3000/microL', ' absolute neutrophil count ³ 1,500/microL', ' platelets ³ 100,000/microL', " total bilirubin <= 1.5x ULN. In case of Gilbert's syndrome, <2 x ULN is allowed", ' AST (SGOT)/ALT(SGPT)<= 2.5 X institutional upper limit of normal', ' Alkaline phosphatase <= 2.5 x ULN', ' Creatinine within normal institutional limits', ' Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram or MUGA scan', ' Eligibility of patients receiving medications or substances known to affect, or with the potential to affect the activity or pharmacokinetics of lapatinib will be determined following review of their use by the Principal Investigator. A list of medications and substances known or with the potential to interact with CYP450 isoenzymes is provided', ' The effects of lapatinib on the developing human fetus at the recommended therapeutic dose are unknown; women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately, the patient should be apprised of the potential hazard to the fetus and potential risk for loss of the pregnancy', ' Ability to understand and the willingness to sign a written informed consent document', ' Ability to swallow and retain oral medication', 'Exclusion criteria:', ' Stage IIIB, IIIC, and inflammatory breast cancer', ' Stage IV breast cancer', ' Contraindication to the treatment with anthracycline, paclitaxel and/or trastuzumab', ' Prior treatment with chemotherapy, endocrine therapy or radiotherapy. Prior treatment with EGFR targeting therapies', ' Treatment with any other investigational agents, or with all herbal (alternative) medicines', ' History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib', ' Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements', ' Pregnancy or breastfeeding; (breast feeding should be discontinued to be enrolled in the study)', ' Women of childbearing potential that refusal to adopt adequate contraceptive measures', ' HIV-positive patients receiving combination anti-retroviral therapy', " GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis)", ' Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Pathological Complete Response (pCR) in the Breast and in the Lymph Nodes', ' Pathological Complete Response (pCR) is defined by the complete absence of infiltrating tumor cells in the breast and in the lymph nodes. The pathological response in the breast was evaluated according to the criteria of Miller and Payne as follows: Grade 1, no change or some alteration to individual malignant cells, but no reduction in overall cellularity; Grade 2, a minor loss in tumor cells (up to 30%); Grade 3, between an estimated 30% and 90% reduction in tumor cells; Grade 4, marked disappearance of tumor cells, with only a small cluster or a dispersed cell remaining (more than 90% loss); Grade 5, no identifiable malignant cells. Ductal carcinoma in situ (DCIS) may be present. Grades were interpreted as follows: Grade 1-2=no response; Grade 3-4=partial response; Grade 5=complete response. pCR was defined by comparing specimens obtained at Baseline (biopsy) to those obtained upon surgery.', ' Time frame: At Baseline and surgery (within 5 weeks after the last chemotherapy administration) (assessed up to Study Week 29)', 'Results 1: ', ' Arm/Group Title: CT Plus Trastuzumab', ' Arm/Group Description: Participants received chemotherapy (CT), which included paclitaxel 80 milligrams per meters squared (mg/m^2) weekly for 12 weeks, followed by intravenous (IV) fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses. Trastuzumab was administered throughout the course of the CT and for two weeks after the last CT administration. The first dose of trastuzumab was administered at 4 milligrams per kilogram (mg/kg) IV for 60 minutes on the day of the first paclitaxel course. Subsequent administrations were given weekly at 2 mg/kg IV for 30 minutes. Treatments were administered for 26 weeks prior to surgery.', ' Overall Number of Participants Analyzed: 36', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 25', 'Results 2: ', ' Arm/Group Title: CT Plus Lapatinib 1500 mg', ' Arm/Group Description: Participants received CT, which included paclitaxel 80 mg/m^2 weekly for 12 weeks, followed by IV fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses. Participants received lapatinib 1500 mg/day orally on an empty stomach throughout the course of the CT and for three weeks after the last CT administration. Treatments were administered for 26 weeks prior to surgery.', ' Following Independent Data Monitoring Committee (IDMC) recommendations, lapatinib doses were reduced to 1250 mg/day orally on an empty stomach.', ' Overall Number of Participants Analyzed: 38', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 26.3'], 'Adverse Events': ['Adverse Events 1:', ' Total: 14/36 (38.89%)', ' Neutropenia 10/36 (27.78%)', ' Febrile neutropenia 1/36 (2.78%)', ' Diarrhoea 0/36 (0.00%)', ' Vomiting 1/36 (2.78%)', ' Abdominal pain 0/36 (0.00%)', ' Rectal haemorrhage 1/36 (2.78%)', ' Stomatitis 1/36 (2.78%)', ' Pyrexia 1/36 (2.78%)', ' Hyperpyrexia 0/36 (0.00%)', ' Drug hypersensitivity 0/36 (0.00%)', ' Device related infection 0/36 (0.00%)', 'Adverse Events 2:', ' Total: 13/39 (33.33%)', ' Neutropenia 7/39 (17.95%)', ' Febrile neutropenia 2/39 (5.13%)', ' Diarrhoea 3/39 (7.69%)', ' Vomiting 3/39 (7.69%)', ' Abdominal pain 1/39 (2.56%)', ' Rectal haemorrhage 0/39 (0.00%)', ' Stomatitis 0/39 (0.00%)', ' Pyrexia 1/39 (2.56%)', ' Hyperpyrexia 1/39 (2.56%)', ' Drug hypersensitivity 0/39 (0.00%)', ' Device related infection 0/39 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

b2883781-f4e9-405e-9231-7a07e46c35b0

Comparison

Intervention

NCT00791037

NCT00606931

the primary trial and the secondary trial both use vaccine based interventions, however this is done in different intervals and for a different duration of time.

Contradiction

{'Clinical Trial ID': 'NCT00791037', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Vaccine Therapy+ex Vivo-expanded T Cells)', ' Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2 weeks later, patients undergo leukapheresis to isolate and collect peripheral blood mononuclear cells for T-cell expansion.', ' Patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10 days for up to three immunizations. Patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion, followed by 2 additional booster vaccines at 2-month intervals.', ' HER-2/neu peptide vaccine: Given ID', ' leukapheresis: Undergo leukapheresis', ' ex vivo-expanded HER2-specific T cells: Given IV', ' cyclophosphamide: Given IV', ' sargramostim: Given ID', ' laboratory biomarker analysis: Correlative study'], 'Eligibility': ['Inclusion Criteria:', ' Patients with HER2+ Stage IV breast cancer that have been maximally treated and not achieved a complete remission', ' Patients must have stable or slowly progressive disease state, measurable disease as:', ' Extraskeletal disease that can be accurately measured >= 10 mm by standard imaging techniques that can include but not limited to computed tomography (CT), positron emission tomography (PET), PET/CT, magnetic resonance imaging (MRI);', ' Skeletal or bone-only disease which is measurable by fludeoxyglucose (FDG) PET or PET/CT imaging will also be allowed', ' Patients can be currently receiving trastuzumab and/or lapatinib and/or hormonal therapy and/or bisphosphonate therapy', ' HER2 overexpression in the primary tumor or metastasis by immunohistochemistry (IHC) of 2+ or 3+, or documented gene amplification by fluorescence in situ hybridization (FISH) analysis; if overexpression is 2+ by IHC, then patients must have HER2 gene amplification documented by FISH', ' Subjects must have a Performance Status Score (Southwest Oncology Group [SWOG]/Zubrod Scale) = 0, 1 or 2', ' Patients must be off all immunosuppressive treatments such as chemotherapy or systemic steroid therapy a minimum of 14 days prior to initiation of study (i.e. first vaccination)', ' Patients on trastuzumab and/or lapatinib must have a baseline left ventricular ejection fraction (LVEF) measured by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) equal to or greater than the lower limit of normal for the facility within 90 days of eligibility determination', ' Men and women of reproductive ability must agree to contraceptive use during the entire study period', ' Patients must have an expected survival of 6 months', ' White blood cell (WBC) >= 3000/mm^3', ' Absolute neutrophil count (ANC) >= 1000/mm^3', ' Hemoglobin (Hgb) >= 10 mg/dl', ' Platelets >= 75,000/mm^3', ' Serum creatinine =< 2.0 mg/dl or creatinine clearance > 60 ml/min', ' Total bilirubin =< 2.5 mg/dl', ' Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) =< 3 times upper limit of normal (ULN)', ' Patients must be >= 18 years old', 'Exclusion Criteria:', ' Patients with any of the following cardiac conditions:', ' Symptomatic restrictive cardiomyopathy;', ' Unstable angina within 4 months prior to enrollment;', ' New York Heart Association functional class III-IV heart failure on active treatment', ' Patients with any contraindication to receiving rhuGM-CSF based products', ' Patients with any clinically significant autoimmune disease uncontrolled with treatment', ' Patients with a history of brain metastases must have a stable head imaging study within 30 days of eligibility determination; specifically, patients with active brain metastases will not be eligible for study', ' Patients who are simultaneously enrolled in any other treatment study', ' Pregnant or breast-feeding women'], 'Results': ['Outcome Measurement: ', ' Evaluate Toxicity of Infusing HER2-specific T Cells as Assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0', ' Patients are monitored for the development of end organ damage by assessing adverse events with serum chemistries, liver function studies, complete blood counts, urine analysis and physical exams. All adverse events for all systems are graded on a scale of 1-5 and attribution is assigned. There are DLT criteria. DLT is defined as any incidence of Grade 3 hematologic and non-hematologic toxicity (excluding: fever, hypoxia, and urticaria) Thus, if a subject develops a Grade 3 toxicity (excluding those listed in Table 4) will be considered excessive toxicity and no further dose escalations will occur.', ' Time frame: Up to 4 months after first booster vaccine', 'Results 1: ', ' Arm/Group Title: Treatment (Vaccine Therapy+ex Vivo-expanded T Cells)', ' Arm/Group Description: Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2 weeks later, patients undergo leukapheresis to isolate and collect peripheral blood mononuclear cells for T-cell expansion.', ' Patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10 days for up to three immunizations. Patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion, followed by 2 additional booster vaccines at 2-month intervals.', ' HER-2/neu peptide vaccine: Given ID', ' leukapheresis: Undergo leukapheresis', ' ex vivo-expanded HER2-specific T cells: Given IV', ' cyclophosphamide: Given IV', ' sargramostim: Given ID', ' laboratory biomarker analysis: Correlative study', ' Overall Number of Participants Analyzed: 19', ' Measure Type: Number', ' Unit of Measure: participants 0'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/23 (4.35%)', ' Unrelated Pulmonary Embolus 1/23 (4.35%)']}

{'Clinical Trial ID': 'NCT00606931', 'Intervention': ['INTERVENTION 1: ', ' PET Guided Biopsy', ' No comparison group. All enrolled participants were expected to undergo PET guided biopsy.'], 'Eligibility': ['Inclusion Criteria:', ' Individuals aged 25 years or older', ' Individuals who have at least one breast imaging finding requiring biopsy, specifically:', ' Individuals who have a breast abnormality(ies) moderately suspicious for or highly suggestive of malignancy on imaging with mammography, ultrasound, or MRI (as per ACR BIRADS™ 4C or 5) and requiring biopsy confirmation OR o Individuals with known breast cancer who have additional imaging abnormality(ies) suspicious for malignancy detected on a high-resolution FDG PET scan', ' Individuals who had recent conventional imaging work-up including x-ray mammography of the breast containing the abnormality of interest.', ' Individuals with suspected tumor size measuring one cm or less on mammography and/or ultrasound and/or MRI if the lesion is visible on any of these modalities, except that each site may enroll up to three patients each where the lesion of interest as measured on mammography (or ultrasound and/or MRI if not detectable on mammography) is more than 1 cm. (Note: The study will target patient enrollment such that at least 50% of the lesions to undergo biopsy across all sites will be less than 1 cm in diameter as measured on mammography, or as measured by other modalities, such as ultrasound, CT, or MRI, if the lesion is not detectable or measurable on mammography.)', ' Individuals who have agreed to participate in the study and who have signed study-specific informed consent', 'Exclusion Criteria:', ' Women who are or may be pregnant', ' Women who are currently lactating or discontinued breastfeeding < 2 months prior to the study', ' Age less than 25 years', ' Individuals with breast implant(s) in the breast containing the lesion of interest', ' Individuals who are scheduled for a sentinel node procedure using radioactive Tc-99m within 24 hours of PET-guided biopsy', ' Patients with contraindications for core biopsy and other invasive procedures such as blood coagulation disorders, infection, or who are unwilling to discontinue use of anticoagulant medication prior to the procedure', ' Individuals with Type I or poorly controlled Type II diabetes mellitus', ' Individuals with a blood glucose level that is above 140 mg/dl at the time of PEM imaging', ' Inability to provide informed consent', ' Individuals who have had surgery on the study breast(s) within the past 12 months'], 'Results': ['Outcome Measurement: ', ' Number of Lesions That Were Successfully Biopsied Using the PET-guided Biopsy Method.', ' Success in completion of the PET guided biopsy of a suspicious lesion was determined by', ' Alteration in lesion morphology (no change in vs change in lesion morphology) after sampling AND/OR', ' Visualization of regions with high radioactive uptake within the biopsy specimen consistent with target lesion (focal uptake present vs absent).', ' Time frame: within two days of obtaining histopathology of the lesion biopsied', 'Results 1: ', ' Arm/Group Title: PET Guided Biopsy', ' Arm/Group Description: No comparison group. All enrolled participants were expected to undergo PET guided biopsy.', ' Overall Number of Participants Analyzed: 19', ' Measure Type: Number', ' Unit of Measure: Number of lesions 24'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0']}

932c2135-381a-4675-a782-e683eca8d935

Comparison

Results

NCT01648322

NCT00436566

the primary trial has a shorter time frame than the secondary trial.

Entailment

{'Clinical Trial ID': 'NCT01648322', 'Intervention': ['INTERVENTION 1: ', ' 80 µg/kg/Dose of F-627(TC)', ' This dose of F-627 given only to subjects that are to have TC chemotherapy.', ' F-627: subcutaneous injection given 1 per chemotherapy.', 'INTERVENTION 2: ', ' 240 µg/kg/Dose of F-627 (TC)', ' This dose of F-627 given to subjects receiving TC or TAC chemotherapy.', ' F-627: subcutaneous injection given 1 per chemotherapy.'], 'Eligibility': ['Inclusion Criteria:', ' Show evidence of a signed (personally or by a legally acceptable representative) and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial.', ' Females 18 years of age.', ' Diagnosed with Stage I-IV breast cancer.', ' Subject is scheduled to undergo 4 cycles of TC or TAC chemotherapy (Taxotere®, doxorubicin and cyclophosphamide, 75, 50 and 600 mg/m2, respectively).', ' ECOG Performance status of 2.', ' White Blood Cell count (WBC) 4.0 × 109/L, hemoglobin 11.5 g/dL and a platelet count 150 × 109/L.', ' Demonstrate adequate renal, hepatic function (Liver function tests (ALT, AST, alkaline phosphatase and total bilirubin)) should be less than 2.5x upper limits of normal (ULN). Serum creatinine should be less than 1.7x ULN.', ' All subjects must agree to use at least one of the following types of contraception: intrauterine device, implantable progesterone device, progesterone intramuscular injection, or oral contraceptive, which has been started at least one month prior to visit one and will continue for the duration of the trial. The contraceptive patch or condom use with spermicide are also acceptable forms of contraception as long as they will be used continually throughout the duration of the trial.', 'Exclusion Criteria:', ' Subject is <18 or 75 years of age.', ' Disease progression has occurred while receiving a taxane regimen.', ' Subject has undergone radiation therapy within 4 weeks of enrollment.', ' Subject has undergone bone marrow or stem-cell transplantation.', ' Subject has a history of prior malignancy other than breast cancer.', ' Subjects that have used G-CSF within 6 weeks of the screening period are also excluded', ' Subject has had chemotherapy within 365 days of screening', ' Subject has documented congestive heart failure, cardiomyopathy or myocardial infarction by clinical diagnosis, ECG test, or any other relevant test.', ' History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure.', ' Unwillingness to participate in the study.', " Any underlying medical condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or that would obscure the interpretation of adverse events.", ' Receiving other investigational drugs or biologics within 1 month or five half lives of enrollment.', ' Any condition, which can cause splenomegaly.', ' Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease.', ' ALT, AST, alkaline phosphatase > 2.5 upper limit of normal.', ' Patients with active infection, or known to be infected with chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative), or having any history of Hepatitis C.', ' Women who are pregnant or breast-feeding.', ' Patients known to be seropositive for HIV, or who have had an AIDS defining illness or a known immunodeficiency disorder.', ' Patients with a history of tuberculosis or exposure to tuberculosis. Patients that have received a prior chest X-ray for suspicion of tuberculosis are also excluded unless they have been confirmed to be PPD negative or they had latent tuberculosis that has been previously treated.', ' Subjects with Sickle Cell disease', " Subjects with known hypersensitivity to E.coli derived proteins' pegfilgrastim' filgrastim, or any other component of the study drug."], 'Results': ['Outcome Measurement: ', ' Duration of Moderate Neurtopenia Post First Chemotherapy Administration', ' Number of days In which the patient has had an absolute neutrophil count (ANC) Level < 2.0 x 10^9/L after first cycle of chemotherapy', ' Time frame: The first of 4, 21 Day Chemotherapy Cycles', 'Results 1: ', ' Arm/Group Title: 80 g/kg/Dose of F-627(TC)', ' Arm/Group Description: This dose of F-627 given only to subjects that are to have TC chemotherapy.', ' F-627: subcutaneous injection given 1 per chemotherapy.', ' Overall Number of Participants Analyzed: 35', ' Mean (Standard Deviation)', ' Unit of Measure: days 0.6 (1.26)', 'Results 2: ', ' Arm/Group Title: 240 g/kg/Dose of F-627 (TC)', ' Arm/Group Description: This dose of F-627 given to subjects receiving TC or TAC chemotherapy.', ' F-627: subcutaneous injection given 1 per chemotherapy.', ' Overall Number of Participants Analyzed: 37', ' Mean (Standard Deviation)', ' Unit of Measure: days 0.6 (1.01)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/35 (0.00%)', ' Febrile neutropenia * 0/35 (0.00%)', ' Pancreatitis * 0/35 (0.00%)', ' Hepatitis Toxic * 0/35 (0.00%)', ' Cholecystitis acute * 0/35 (0.00%)', ' Pneumonia * 0/35 (0.00%)', ' Gastroenteritis * 0/35 (0.00%)', ' Hypersensitivity vasculitis * 0/35 (0.00%)', 'Adverse Events 2:', ' Total: 1/67 (1.49%)', ' Febrile neutropenia * 0/67 (0.00%)', ' Pancreatitis * 0/67 (0.00%)', ' Hepatitis Toxic * 0/67 (0.00%)', ' Cholecystitis acute * 0/67 (0.00%)', ' Pneumonia * 1/67 (1.49%)', ' Gastroenteritis * 0/67 (0.00%)', ' Hypersensitivity vasculitis * 0/67 (0.00%)']}

{'Clinical Trial ID': 'NCT00436566', 'Intervention': ['INTERVENTION 1: ', ' AC/PTL', ' Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed diagnosis of early-stage breast cancer', ' HER2 positive by immunohistochemistry (IHC) (3+) or fluorescent in situ hybridization (FISH)', ' Ductal carcinoma in situ (DCIS) components should not be counted in the determination of degree of IHC staining or FISH amplification', ' No locally advanced tumors (i.e., T4) at diagnosis, including the following:', ' Tumors fixed to chest wall', " Peau d'orange", ' Skin ulcerations or nodules', ' Clinical inflammatory changes (e.g., diffuse brawny cutaneous induration with an erysipeloid edge)', ' Has undergone mastectomy or lumpectomy with axillary node or sentinel node dissection within the past 84 days', ' Patients who have undergone a mastectomy must meet the following criteria:', ' No evidence of gross or microscopic tumor (i.e., invasive DCIS) at the surgical resection margins noted in final surgery or pathology reports', ' Patients with close margins are eligible', ' Radiation therapy is required for 4 or more positive lymph nodes and must be started after completion of chemotherapy', ' Patients who have undergone a lumpectomy with axillary node or sentinel node dissection must meet the following criteria:', ' No evidence of invasive cancer or DCIS at the surgical resection margins', ' No gross residual adenopathy', ' Planning to undergo radiation therapy to the breast with or without regional lymphatics after completion of chemotherapy', ' No active hepatic or biliary disease', " Patients with liver metastases, stable chronic liver disease, Gilbert's syndrome, or asymptomatic gallstones are eligible", ' Hormone receptor status:', ' Estrogen receptor and progesterone receptor status known', ' PATIENT CHARACTERISTICS:', ' Male or female', ' Menopausal status not specified', ' ECOG performance status 0-2', ' Absolute neutrophil count 1,500/mm³', ' Platelet count 100,000/mm³', ' Hemoglobin 10.0 g/dL', ' Bilirubin 1.5 times upper limit of normal (ULN)', ' AST and ALT 2.5 times ULN', ' Alkaline phosphatase 2.5 times ULN', ' Creatinine normal OR creatinine clearance 60 mL/min', ' LVEF 50% by MUGA scan or echocardiogram', ' Able to complete questionnaire(s) by themselves or with assistance', ' Able and willing to provide blood and tissue samples', ' No known sensitivity to benzyl alcohol', ' No sensory neuropathy grade 2', ' No active cardiac disease, including any of the following:', ' Myocardial infarction within the past 6 months', ' Prior or concurrent congestive heart failure', ' Prior or concurrent arrhythmia or cardiac valvular disease requiring medications or that is clinically significant', ' Uncontrolled hypertension, defined as diastolic blood pressure (BP) >100 mm Hg or systolic BP > 200 mm Hg on 2 separate occasions 14 days apart', ' Clinically significant pericardial effusion', ' Prior or concurrent uncontrolled or symptomatic angina', ' Other cardiac condition that, in the opinion of the treating physician, would put the patient at hazardous risk', ' No history of allergic reactions attributed to compounds of similar chemical or biologic composition as lapatinib ditosylate', ' No uncontrolled intercurrent illness including, but not limited to, the following:', ' Ongoing or active infection', ' Psychiatric illness or social situations that would preclude study compliance', ' Able to swallow and retain oral medication', ' No history of gastrointestinal (GI) disease resulting in an inability to take oral medication, including any of the following:', ' Malabsorption syndrome', ' Requirement for IV alimentation', ' Prior surgical procedures affecting absorption', " Uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)", ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception during and for 6 months after completion of study treatment', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics', ' No prior chemotherapy, radiation therapy, immunotherapy, or biotherapy for breast cancer', ' No primary breast radiation therapy as part of breast-conserving treatment', ' No prior anthracycline or taxane therapy for any malignancy', ' No prior epidermal growth factor receptor-targeting therapies (e.g., gefitinib, cetuximab, erlotinib hydrochloride, rituximab, trastuzumab [Herceptin®], lapatinib ditosylate, panitumumab, or nimotuzumab)', ' At least 14 days since prior and no concurrent CYP3A4 inducers, including the following:', ' Rifamycin-class antibiotics (e.g., rifampin, rifabutin, or rifapentine)', ' Anticonvulsants (e.g., phenytoin, carbamazepine, or barbiturates [e.g., phenobarbital])', ' Antiretrovirals (e.g., efavirenz or nevirapine)', ' Glucocorticoids (e.g., oral cortisone, hydrocortisone, prednisone, methylprednisolone, or dexamethasone)', ' Daily oral dexamethasone 1.5 mg (or equivalent) allowed', ' Modafinil', " Hypericum perforatum (St. John's wort)", ' At least 7 days since prior and no concurrent CYP3A4 inhibitors, including the following:', ' Antibiotics (e.g., clarithromycin, erythromycin, or troleandomycin)', ' Antifungals (e.g., itraconazole, ketoconazole, fluconazole [> 150 mg daily], or voriconazole)', ' Antiretrovirals and protease inhibitors (e.g., delaviridine, nelfinavir, amprenavir, ritonavir, indinavir, saquinavir, or lopinavir)', ' Calcium channel blockers (e.g., verapamil or diltiazem)', ' Antidepressants (e.g., nefazodone or fluvoxamine)', ' Gastrointestinal agents (e.g., cimetidine or aprepitant)', ' Grapefruit and grapefruit juice', ' At least 6 months since prior and no concurrent amiodarone', ' No herbal or alternative medicines or supplements 14 days before, during, and for 30 days after completion of study treatment', ' No concurrent hormonal agents (e.g., birth control pills, ovarian hormonal replacement therapy, or raloxifene)', ' Adjuvant hormonal agents (e.g., tamoxifen, aromatase inhibitors) allowed after completion of chemotherapy as part of treatment for breast cancer', ' No concurrent antiretroviral therapy for HIV-positive patients', ' No concurrent digitalis or beta-blockers for congestive heart failure', ' No concurrent arrhythmia or angina pectoris medication', ' No other concurrent investigational agents or anticancer therapies, including cytotoxic agents or immunotherapy'], 'Results': ['Outcome Measurement: ', ' Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment', ' [Not Specified]', ' Time frame: 6 months', 'Results 1: ', ' Arm/Group Title: AC/PTL', ' Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months.', ' Overall Number of Participants Analyzed: 109', ' Measure Type: Number', ' Unit of Measure: participants 0'], 'Adverse Events': ['Adverse Events 1:', ' Total: 17/108 (15.74%)', ' Febrile neutropenia 1/108 (0.93%)', ' Left ventricular failure 1/108 (0.93%)', ' Diarrhea 6/108 (5.56%)', ' Fatigue 1/108 (0.93%)', ' Pneumonia 1/108 (0.93%)', ' Skin infection 1/108 (0.93%)', ' Urinary tract infection 1/108 (0.93%)', ' Alanine aminotransferase increased 1/108 (0.93%)', ' Aspartate aminotransferase increased 1/108 (0.93%)', ' Leukopenia 2/108 (1.85%)']}

6461007d-fc18-43e2-a797-11cb0a4512ce

Comparison

Eligibility

NCT00630032

NCT00428922

Patients with radiologically confirmed metatases in the CNS are excluded from both the secondary trial and the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00630032', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel', ' 3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of D (100 mg/m² every 3 weeks)', ' Cyclophosphamide: 500 mg/m² every 3 weeks Docetaxel: 100 mg/m² every 3 weeks Epirubicin hydrochloride: 100 mg/m² every 3 weeks Fluorouracil: 500 mg/m² every 3 weeks', 'INTERVENTION 2: ', ' Ixabepilone', ' 3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of Ixabepilone (40 mg/m² every 3 weeks);', ' Cyclophosphamide: 500 mg/m² every 3 weeks Epirubicin hydrochloride: 100 mg/m² every 3 weeks Fluorouracil: 500 mg/m² every 3 weeks Ixabepilone: 40 mg/m² every 3 weeks'], 'Eligibility': ['DISEASE CHARACTERISTICS:', 'Inclusion criteria:', ' Histologically proven invasive unilateral breast cancer (regardless of the type)', ' Initial clinical condition compatible with complete initial resection', ' No residual macro or microscopic tumor after surgical excision', ' Node-positive disease (i.e., positive sentinel node or positive axillary clearance) (N+) or node-negative disease (-) meeting the following criteria :', ' Stage II or III disease', ' pT >20 mm (T1-4)', ' Patients must meet 1 of the following hormone-receptor criteria:', ' Node-positive patients: triple-negative* tumor (HER2 negative, estrogen-receptor [ER] negative, and progesterone receptor [PR] negative) OR double-negative (HER2 negative, PR negative, and ER+)', ' Node-negative patients: triple-negative* tumor only', ' NOTE: *Hormone-receptor negativity is defined as ER <10% and PR <10% by IHC and HER2 negativity is defined as IHC 0-1+ OR IHC 2+ and FISH or CISH negative', ' Must be able to begin chemotherapy no later than day 49 after the initial surgery', 'Exclusion criteria:', ' Clinically or radiologically detectable metastases (M0)', ' Bilateral breast cancer or contralateral ductal carcinoma in situ', ' Any metastatic impairment, including homolateral subclavicular node involvement, regardless of its type', ' Any tumor T4a (cutaneous invasion, deep adherence, inflammatory breast cancer)', ' HER 2 overexpression defined as IHC 3+ OR IHC 2+ and FISH or CISH positive', ' Any clinically or radiologically suspect and non-explored damage to the contralateral breast', ' PATIENT CHARACTERISTICS:', 'Inclusion criteria:', ' Female', ' Pre- or postmenopausal', ' ECOG performance status 0-1', ' Peripheral neuropathy grade 1', ' Neutrophil count 2,000/mm³', ' Platelet count 100,000/mm³', ' Hemoglobin >9 g/dL', ' AST and ALT 1.5 times upper limit of normal (ULN)', ' Alkaline phosphatase 2.5 times ULN', ' Total bilirubin 1.0 times ULN', ' Serum creatinine 1.5 times ULN', ' LVEF 50% by MUGA scan or echocardiography', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception during and for up to 8 weeks after completion of study treatment', 'Exclusion criteria:', ' Previous cancer (except cutaneous baso-cellular epithelioma or uterine peripheral epithelioma) in the preceding 5 years, including invasive contralateral breast cancer', ' Patients with any other concurrent severe and/or uncontrolled medical disease or infection that could compromise participation in the study', ' Clinically significant cardiovascular disease within the past 6 months including any of the following:', ' Unstable angina', ' Congestive heart failure', ' Uncontrolled hypertension (i.e., blood pressure >150/90 mm Hg)', ' Myocardial infarction', ' Cerebral vascular accidents', ' Known prior severe hypersensitivity reactions to agents containing Cremophor EL', ' Patients with any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule', ' Patients deprived of liberty or placed under the authority of a tutor', ' PRIOR CONCURRENT THERAPY:', ' At least 2 weeks since prior minor surgery (excluding breast biopsy) and adequately recovered', ' At least 3 weeks since prior major surgery and adequately recovered', ' No prior chemotherapy, hormonal therapy, or radiotherapy', ' More than 72 hours since prior and no concurrent treatment with any of the following strong inhibitors of CYP3A4:', ' Amiodarone', ' Clarithromycin', ' Amprenavir', ' Delavirdine', ' Voriconazole', ' Erythromycin', ' Fluconazole', ' Itraconazole', ' Ketoconazole', ' Indinavir', ' Nelfinavir', ' Ritonavir', ' Saquinavir', ' No concurrent participation in another therapeutic trial involving an experimental drug'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Disease-free Survival (DFS)', ' DFS is defined as the interval between the date of randomization and the date of breast cancer relapse (local, regional or distant) or the date of invasive contralateral breast cancer or death from any cause, whichever occurs first', ' Time frame: At 5 years', 'Results 1: ', ' Arm/Group Title: Docetaxel', ' Arm/Group Description: 3 cycles of FEC100 (F and C, each at 500 mg/m , E 100 mg/m , every 3 weeks) followed by 3 cycles of D (100 mg/m every 3 weeks)', ' Cyclophosphamide: 500 mg/m every 3 weeks Docetaxel: 100 mg/m every 3 weeks Epirubicin hydrochloride: 100 mg/m every 3 weeks Fluorouracil: 500 mg/m every 3 weeks', ' Overall Number of Participants Analyzed: 398', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 78.97 (74.53 to 82.73)', 'Results 2: ', ' Arm/Group Title: Ixabepilone', ' Arm/Group Description: 3 cycles of FEC100 (F and C, each at 500 mg/m , E 100 mg/m , every 3 weeks) followed by 3 cycles of Ixabepilone (40 mg/m every 3 weeks);', ' Cyclophosphamide: 500 mg/m every 3 weeks Epirubicin hydrochloride: 100 mg/m every 3 weeks Fluorouracil: 500 mg/m every 3 weeks Ixabepilone: 40 mg/m every 3 weeks', ' Overall Number of Participants Analyzed: 364', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 83.37 (79.06 to 86.87)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 207/398 (52.01%)', ' Anemia 1/398 (0.25%)', ' Aplasia bone marrow 1/398 (0.25%)', ' Febrile aplasia 1/398 (0.25%)', ' Febrile neutropenia 56/398 (14.07%)', ' Lymphocele 0/398 (0.00%)', ' Neutropenia 141/398 (35.43%)', ' Auricular fibrillation 1/398 (0.25%)', ' Non ST segment elevation acute coronary syndrome 0/398 (0.00%)', ' Tachycardia 1/398 (0.25%)', ' Ear disorder 0/398 (0.00%)', 'Adverse Events 2:', ' Total: 158/364 (43.41%)', ' Anemia 2/364 (0.55%)', ' Aplasia bone marrow 1/364 (0.27%)', ' Febrile aplasia 4/364 (1.10%)', ' Febrile neutropenia 27/364 (7.42%)', ' Lymphocele 1/364 (0.27%)', ' Neutropenia 95/364 (26.10%)', ' Auricular fibrillation 0/364 (0.00%)', ' Non ST segment elevation acute coronary syndrome 1/364 (0.27%)', ' Tachycardia 1/364 (0.27%)', ' Ear disorder 1/364 (0.27%)']}

{'Clinical Trial ID': 'NCT00428922', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab, Bevacizumab, and Docetaxel', ' Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M²]'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed breast cancer with evidence of metastatic disease', ' HER2 3+ or FISH (fluorescent in situ hybridization)+', ' Age 18 years', ' No prior trastuzumab, except as given in the adjuvant or neoadjuvant setting.', ' No prior chemotherapy in the metastatic setting.', 'Exclusion Criteria:', ' CNS (central nervous system) metastases', ' Prior radiation therapy within the last 4 weeks', ' Pregnant (positive pregnancy test) or lactating women', ' Major surgical procedure, open biopsy, non-healing wounds, or significant traumatic injury within 28 days prior to starting study or anticipation of need for major surgical procedure during the study', ' Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to start of study.'], 'Results': ['Outcome Measurement: ', ' Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen.', ' The trial was designed as a single-stage phase II rather then usual two-stage design because of the progression free survival (PFS) primary endpoint, as it is impractical to wait to assess PFS for patients in the first stage. We will consider a PFS of 50% at twelve months (median PFS of 12 months) or less uninteresting and a PFS of 70% at twelve months (median PFS of twenty months) worthy of pursuing the regimen in a future trials. The single-stage design is as follows: p0=0.50, p1=0.70, α=0.10, β= 0.10. This leads to a total sample size of 39 patients, 24 or higher of who are progression-free at 12 months.', ' Time frame: up to 3 years', 'Results 1: ', ' Arm/Group Title: Trastuzumab, Bevacizumab, and Docetaxel', ' Arm/Group Description: Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M ]', ' Overall Number of Participants Analyzed: 26', ' Median (95% Confidence Interval)', ' Unit of Measure: months 14.3 (9.3 to 35)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/26 (0.00%)']}

819e85b0-2d4e-4535-b920-4e18868da883

Single

Results

NCT03098550

There results from cohort 3 of the primary trial were inconclusive.

Contradiction

{'Clinical Trial ID': 'NCT03098550', 'Intervention': ['INTERVENTION 1: ', ' Nivolumab + Daratumumab (TNBC)', ' Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)', 'INTERVENTION 2: ', ' Nivolumab + Daratumumab (NSCLC)', ' Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)'], 'Eligibility': ['Inclusion Criteria:', ' For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com', ' Patients with metastatic or advanced solid tumors', ' Women with histologically or cytologically confirmed triple negative breast carcinoma', ' Participants with histologically or cytologically confirmed pancreatic adenocarcinoma', ' Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC)', 'Exclusion Criteria:', ' Active brain metastases or leptomeningeal metastases.', ' Any serious or uncontrolled medical disorder', ' Prior malignancy active within the previous 3 years', ' Other protocol defined inclusion/exclusion criteria could apply'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Adverse Events (AEs)', ' Number of participants with any grade of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab', ' Time frame: From first dose to 30 days post last dose (up to 34 months)', 'Results 1: ', ' Arm/Group Title: Nivolumab + Daratumumab (TNBC)', ' Arm/Group Description: Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)', ' Overall Number of Participants Analyzed: 41', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 41 100.0%', 'Results 2: ', ' Arm/Group Title: Nivolumab + Daratumumab (NSCLC)', ' Arm/Group Description: Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)', ' Overall Number of Participants Analyzed: 21', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 21 100.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 36/41 (87.80%)', ' Anaemia 0/41 (0.00%)', ' Febrile bone marrow aplasia 1/41 (2.44%)', ' Acute coronary syndrome 0/41 (0.00%)', ' Atrial fibrillation 0/41 (0.00%)', ' Cardiac tamponade 1/41 (2.44%)', ' Cardio-respiratory arrest 0/41 (0.00%)', ' Pericardial effusion 0/41 (0.00%)', ' Abdominal pain 0/41 (0.00%)', ' Colitis 0/41 (0.00%)', ' Diarrhoea 0/41 (0.00%)', 'Adverse Events 2:', ' Total: 17/21 (80.95%)', ' Anaemia 0/21 (0.00%)', ' Febrile bone marrow aplasia 0/21 (0.00%)', ' Acute coronary syndrome 1/21 (4.76%)', ' Atrial fibrillation 0/21 (0.00%)', ' Cardiac tamponade 0/21 (0.00%)', ' Cardio-respiratory arrest 0/21 (0.00%)', ' Pericardial effusion 1/21 (4.76%)', ' Abdominal pain 0/21 (0.00%)', ' Colitis 1/21 (4.76%)', ' Diarrhoea 1/21 (4.76%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

cc0d6fe8-69c4-49d3-b321-00e47c155db6

Single

Adverse Events

NCT00454532

Less than half of patients in cohorts 1 and 2 in the primary trial experienced adverse events.

Entailment

{'Clinical Trial ID': 'NCT00454532', 'Intervention': ['INTERVENTION 1: ', ' Level 1', '10g/day', 'INTERVENTION 2: ', ' Level 2', '20g/day'], 'Eligibility': ['Key Inclusion Criteria:', ' Women 18 years or older', ' Histologically confirmed breast cancer', ' Clinical evidence of metastatic (stage IV) metastasis (other than bone metastasis)', ' Availability of estrogen and progesterone receptor status', ' At least one measurable disease site defined by RECIST criteria, 30 days prior to study therapy', ' For the phase 1, no more that 3 prior cytotoxic regimens for metastatic breast cancer. For the phase 2, no more than 2 prior cytotoxic regimens for metastatic breast cancer', ' Life expectancy 12 weeks', ' Eastern Cooperative Oncology Group performance status 2', ' Women of child bearing potential must agree to 2 forms of contraception during the course of the trial.', ' Key Exclusion Criteria:', ' Inability to understand/unwillingness to sign a written informed consent', ' Any significant side effects related to prior chemo, radiation, biology or hormonal therapy that did not resolve in the judgment of the investigator', ' Currently using an investigational agent', ' Clinically significant gastrointestinal abnormalities', ' Currently using coumadin at therapeutic doses or within 2 weeks of taking study medication', ' Concurrent palliative radiation or anti-cancer treatment', ' Women who report pregnancy, are breast-feeding or have a positive pregnancy test'], 'Results': ['Outcome Measurement: ', ' Toxicity Based Upon Adverse Events Classifed by the NCI Common Terminology Criteria Version 3 (Phase 1)', ' Dose-Limiting Toxicities graded according to Common Terminology Criteria for Adverse Events, version 3.0', ' Time frame: Monthly', 'Results 1: ', ' Arm/Group Title: Level 1', ' Arm/Group Description: 10g/day', ' Overall Number of Participants Analyzed: 11', ' Measure Type: Number', ' Unit of Measure: participants Elevated AST: 1', ' Diarrhea: 0', ' Fatigue: 0', 'Pain-rib cage: 0', 'Results 2: ', ' Arm/Group Title: Level 2', ' Arm/Group Description: 20g/day', ' Overall Number of Participants Analyzed: 6', ' Measure Type: Number', ' Unit of Measure: participants Elevated AST: 0', ' Diarrhea: 1', ' Fatigue: 1', 'Pain-rib cage: 0'], 'Adverse Events': ['Adverse Events 1:', ' Total: 5/11 (45.45%)', ' Hemorrhage, GI-abdomen NOS 21/11 (9.09%)', ' Pain-liver 21/11 (9.09%)', ' Infection-ulcer 20/11 (0.00%)', ' Hemoglobin 20/11 (0.00%)', ' Hypoglycemia 20/11 (0.00%)', ' Pain-rib cage due to vomiting 20/11 (0.00%)', ' Obstruction-gu ureter 1/11 (9.09%)', ' Hemorrhage gu-bladder 21/11 (9.09%)', ' Pain-breast 21/11 (9.09%)', ' Pleural effusion 22/11 (18.18%)', 'Adverse Events 2:', ' Total: 0/6 (0.00%)', ' Hemorrhage, GI-abdomen NOS 20/6 (0.00%)', ' Pain-liver 20/6 (0.00%)', ' Infection-ulcer 20/6 (0.00%)', ' Hemoglobin 20/6 (0.00%)', ' Hypoglycemia 20/6 (0.00%)', ' Pain-rib cage due to vomiting 20/6 (0.00%)', ' Obstruction-gu ureter 0/6 (0.00%)', ' Hemorrhage gu-bladder 20/6 (0.00%)', ' Pain-breast 20/6 (0.00%)', ' Pleural effusion 20/6 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

0fbb4fb4-620b-4ee9-aaa8-956992026cef

Single

Results

NCT02679755

Every patient in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events.

Entailment

{'Clinical Trial ID': 'NCT02679755', 'Intervention': ['INTERVENTION 1: ', ' Palbociclib+Letrozole India Cohort', ' Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment ofr each 28-day cycle. Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information', 'INTERVENTION 2: ', ' Palbociclib+Letrozole Australia Cohort', ' Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle. Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information'], 'Eligibility': ['Inclusion Criteria:', ' Post-menopausal women (>=18 years of age) with proven diagnosis of advanced carcinoma of the breast (ER(+) and/or PgR(+) and HER2(-)) who are appropriate for letrozole therapy (in the first-line advanced/metastatic disease setting).', ' Eastern Cooperative Oncology Group (ECOG) performance status 0-2.', ' Adequate bone marrow, liver, and renal function.', 'Exclusion Criteria:', ' Prior treatment with any CDK inhibitor .', ' QTc >480 msec; history of QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes.', ' High cardiovascular risk, including, but not limited to myocardial infarction, severe/unstable angina, severe cardiac dysrhythmias, and symptomatic pulmonary embolism in the past 6 months of enrollment.'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Treatment-Emergent Adverse Events (All Causalities)', ' An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as treatment emergent adverse events (TEAEs). AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.', ' Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months', 'Results 1: ', ' Arm/Group Title: Palbociclib+Letrozole India Cohort', ' Arm/Group Description: Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment ofr each 28-day cycle. Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information', ' Overall Number of Participants Analyzed: 100', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Participants with adverse events: 92 92.0%', ' Participants with serious adverse events: 18 18.0%', ' Participants with grade 3 or 4 adverse events: 69 69.0%', ' Participants with grade 5 adverse events: 3 3.0%', ' Participants discontinued due to adverse events: 2 2.0%', 'Results 2: ', ' Arm/Group Title: Palbociclib+Letrozole Australia Cohort', ' Arm/Group Description: Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle. Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information', ' Overall Number of Participants Analyzed: 152', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Participants with adverse events: 152 100.0%', ' Participants with serious adverse events: 45 29.6%', ' Participants with grade 3 or 4 adverse events: 124 81.6%', ' Participants with grade 5 adverse events: 7 4.6%', ' Participants discontinued due to adverse events: 9 5.9%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 18/100 (18.00%)', ' Anaemia * 4/100 (4.00%)', ' Febrile neutropenia * 3/100 (3.00%)', ' Neutropenia * 1/100 (1.00%)', ' Pancytopenia * 0/100 (0.00%)', ' Thrombocytopenia * 1/100 (1.00%)', ' Acute coronary syndrome * 1/100 (1.00%)', ' Stress cardiomyopathy * 0/100 (0.00%)', ' Abdominal pain * 0/100 (0.00%)', ' Abdominal pain upper * 0/100 (0.00%)', ' Ascites * 1/100 (1.00%)', 'Adverse Events 2:', ' Total: 45/152 (29.61%)', ' Anaemia * 0/152 (0.00%)', ' Febrile neutropenia * 3/152 (1.97%)', ' Neutropenia * 1/152 (0.66%)', ' Pancytopenia * 1/152 (0.66%)', ' Thrombocytopenia * 0/152 (0.00%)', ' Acute coronary syndrome * 0/152 (0.00%)', ' Stress cardiomyopathy * 1/152 (0.66%)', ' Abdominal pain * 2/152 (1.32%)', ' Abdominal pain upper * 2/152 (1.32%)', ' Ascites * 0/152 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

69b12ff4-6bb4-4207-b400-67795709c3c8

Single

Eligibility

NCT00829166

Female patients with Peripheral neuropathy grade 3 or 4 are excluded from the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00829166', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine', ' Participants received trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.', 'INTERVENTION 2: ', ' Lapatinib + Capecitabine', ' Participants received lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Participants of this group were allowed to cross over to receive trastuzumab emtansine based on statistically significant OS benefit in favor of trastuzumab emtansine demonstrated in second interim analysis.'], 'Eligibility': ['Inclusion Criteria:', ' HER2 status must be prospectively, centrally tested and be HER2-positive based on central laboratory assay results', ' Histologically or cytologically confirmed invasive breast cancer', ' Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both a taxane, alone or in combination with another agent, and trastuzumab, alone or in combination with another agent', ' Documented progression (which occur during or after most recent treatment or within 6 months after completing of adjuvant therapy) of incurable, unresectable, locally advanced or metastatic breast cancer, defined by the investigator', ' Measurable and/or nonmeasurable disease; participants with central nervous system-only disease are excluded', ' Cardiac ejection fraction greater than or equal to (>/=) 50 percent (%) by either echocardiogram or multi-gated acquisition scan', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', ' For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception; contraception use should continue for the duration of the study treatment and for at least 6 months after the last dose of study treatment', 'Exclusion Criteria:', ' History of treatment with trastuzumab emtansine', ' Prior treatment with lapatinib or capecitabine', ' Peripheral neuropathy of Grade >/= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0', ' History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer, or cancers with a similar curative outcome as those mentioned above', ' History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to randomization except hormone therapy, which could be given up to 7 days prior to randomization; recovery of treatment-related toxicity consistent with other eligibility criteria', ' History of radiation therapy within 14 days of randomization', ' Brain metastases that are untreated, symptomatic, or require therapy to control symptoms, as well as any history of radiation, surgery, or other therapy, including steroids, to control symptoms from brain metastases within 2 months (60 days) of randomization', ' History of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment', ' History of myocardial infarction or unstable angina within 6 months of randomization', ' Current dyspnea at rest due to complications of advanced malignancy or current requirement for continuous oxygen therapy', ' Current severe, uncontrolled systemic disease (for example, clinically significant cardiovascular, pulmonary, or metabolic disease)', ' Pregnancy or lactation', ' Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus', ' Presence of conditions that could affect gastrointestinal absorption: Malabsorption syndrome, resection of the small bowel or stomach, and ulcerative colitis', ' History of intolerance (such as Grade 3-4 infusion reaction) to trastuzumab', ' Known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase deficiency', ' Current treatment with sorivudine or its chemically related analogs, such as brivudine'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)', ' PD was assessed by an IRC using modified Response Evaluation Criteria in Solid Tumors (RECIST). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as target lesions (TLs) and recorded at baseline. TLs should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements either by imaging or clinically. A sum of the longest diameter for all TLs was calculated as baseline sum longest diameter (SLD). All other lesions (or sites of disease) should be identified as non-TLs and recorded at baseline. PD for TLs was defined as greater than or equal to (>/=) 20 percent (%) increase in SLD, taking as reference smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of Participants with PD by IRC or death from any cause was reported.', ' Time frame: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)', 'Results 1: ', ' Arm/Group Title: Trastuzumab Emtansine', ' Arm/Group Description: Participants received trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.', ' Overall Number of Participants Analyzed: 495', ' Measure Type: Number', ' Unit of Measure: percentage of participants 53.5', 'Results 2: ', ' Arm/Group Title: Lapatinib + Capecitabine', ' Arm/Group Description: Participants received lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Participants of this group were allowed to cross over to receive trastuzumab emtansine based on statistically significant OS benefit in favor of trastuzumab emtansine demonstrated in second interim analysis.', ' Overall Number of Participants Analyzed: 496', ' Measure Type: Number', ' Unit of Measure: percentage of participants 61.3'], 'Adverse Events': ['Adverse Events 1:', ' Total: 92/490 (18.78%)', ' Anaemia * 1/490 (0.20%)', ' Anaemia of malignant disease * 0/490 (0.00%)', ' Febrile neutropenia * 0/490 (0.00%)', ' Neutropenia * 0/490 (0.00%)', ' Thrombocytopenia * 4/490 (0.82%)', ' Angina pectoris * 0/490 (0.00%)', ' Atrial fibrillation * 1/490 (0.20%)', ' Cardiomyopathy * 1/490 (0.20%)', ' Coronary artery disease * 0/490 (0.00%)', ' Pericardial effusion * 0/490 (0.00%)', 'Adverse Events 2:', ' Total: 99/488 (20.29%)', ' Anaemia * 1/488 (0.20%)', ' Anaemia of malignant disease * 1/488 (0.20%)', ' Febrile neutropenia * 2/488 (0.41%)', ' Neutropenia * 1/488 (0.20%)', ' Thrombocytopenia * 1/488 (0.20%)', ' Angina pectoris * 1/488 (0.20%)', ' Atrial fibrillation * 0/488 (0.00%)', ' Cardiomyopathy * 0/488 (0.00%)', ' Coronary artery disease * 1/488 (0.20%)', ' Pericardial effusion * 2/488 (0.41%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

9c0b258d-1e66-4eaa-b4e7-a9098eaed1d7

Single

Eligibility

NCT00464646

Anna is a 57 year old female with an ECOG of 0, diagnosed with an invasive adenocarcinoma of the breast, IHC results were 1+. She is eligible for the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT00464646', 'Intervention': ['INTERVENTION 1: ', ' Cohort A', ' Cohort A: Women with unresected locally advanced breast cancer (clinical Stage IIIA, IIIB, and IIIC)', 'INTERVENTION 2: ', ' Cohort B', ' Cohort B: Women with resected pN2 or pN3 (pathologic Stage III) breast cancer'], 'Eligibility': ['Inclusion Criteria:', ' Conditions for eligibility for patients with LABC (Cohort A):', ' The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy or limited incisional biopsy.', ' Patients must have clinical Stage IIIA, IIIB, or IIIC disease with a mass in the breast or axilla that is greater than or equal to 2.0 cm measured by clinical exam, unless the patient has inflammatory breast carcinoma, in which case measurable disease is not required.', ' Conditions for eligibility for patients with resected Stage III breast cancer (Cohort B)', ' Patients must have undergone either a total mastectomy or a lumpectomy.', ' Patients must have completed one of the following procedures for evaluation of pathologic nodal status.', ' Sentinel lymphadenectomy followed by removal of additional non-sentinel lymph nodes, or', ' Axillary lymphadenectomy without SN isolation procedure.', ' The interval between the last surgery (for breast cancer treatment or staging) and study entry must be no more than 84 days.', ' By pathologic evaluation, ipsilateral nodes must be pN2 or pN3.', ' For patients who undergo lumpectomy, the margins of the resected specimen must be histologically free of invasive tumor and DCIS as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional operative procedures may be performed to obtain clear margins. If tumor is still present at the resected margin after re-excision(s), the patient must undergo total mastectomy to be eligible. (Patients with margins positive for LCIS are eligible without additional resection.)', ' For patients who undergo mastectomy, margins must be free of gross residual tumor. Patients with microscopic positive margins are eligible.', ' Conditions for patient eligibility (ALL patients)', ' The patient must have consented to participate and must have signed and dated an IRB-approved consent form that conforms to federal and institutional guidelines.', ' Patients must be female.', ' The patient must be greater than or equal to 18 years old.', " The patient's ECOG performance status must be 0 or 1.", ' The tumor must be invasive adenocarcinoma of the breast on histologic examination.', ' The breast cancer must be determined to be HER2-positive prior to study entry. Assays performed using FISH require gene amplification. Assays using IHC require a strongly positive (3+) staining score.', ' At the time of study entry, blood counts must meet the following criteria:', ' Absolute neutrophil count (ANC) must be greater than/equal to 1200/mm3.', ' Platelet count must be greater than/equal to 100,000/mm3.', ' Hemoglobin must be greater than/equal to 10 g/dL.', ' The following criteria for evidence of adequate hepatic function must be met:', " total bilirubin must be less than/equal to ULN for the lab unless the patient has a grade 1 bilirubin elevation (greater than ULN to 1.5 x ULN) due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and", ' alkaline phosphatase must be less than 2.5 x ULN for the lab; and', ' AST must be less than/equal to 1.5 x ULN for the lab.', ' Alkaline phosphatase and AST may not both be greater than the ULN. For example, if the alkaline phosphatase is greater than the ULN but less than/equal to 2.5 x ULN, then the AST must be less than/equal to the ULN. If the AST is greater than the ULN but less than/equal to 1.5 x ULN, then the alkaline phosphatase must be less than/equal to ULN.', ' Patients with AST or alkaline phosphatase greater than ULN are eligible for inclusion in the study if liver imaging (CT, MRI, or PET scan) does not demonstrate metastatic disease, and has adequate hepatic function.', ' Patients with either skeletal pain or alkaline phosphatase that is greater than ULN but less than/equal to 2.5 x ULN are eligible for inclusion in the study if a bone scan or PET scan does not demonstrate metastatic disease. Patients with suspicious findings on bone scan or PET scan are eligible if suspicious findings are confirmed as benign by x-ray, MRI, or biopsy.', ' Serum creatinine less than/equal to ULN for the lab.', ' Urine protein/creatinine (UPC) ratio must be less than 1.0.', " All patients must have their LVEF assessed by 2-D echocardiogram within 3 months prior to study entry. (MUGA scan may be substituted for 2-D echocardiogram based on institutional preferences.) The LVEF must be greater than/equal to 55% regardless of the institution's LLN.", " Note: Since the pre-entry LVEF serves as the baseline for comparing subsequent LVEF assessments to determine if trastuzumab and bevacizumab therapy can be administered, it is critical that this baseline study be an accurate assessment of the patient's LVEF. If the baseline LVEF is greater than 65%, the investigator is encouraged to have the accuracy of the initial LVEF result confirmed and to consider repeating the study if the accuracy is uncertain.", 'Exclusion Criteria:', ' Conditions for patient ineligibility (Cohort A)', ' FNA alone to diagnose the primary tumor.', ' Surgical axillary staging procedure prior to study entry. (Procedures that are permitted include: 1) FNA or core biopsy of an axillary node for any patient, and 2) although not recommended, a pre-neoadjuvant therapy SN biopsy for patients with clinically negative axillary nodes.', ' Condition for patient ineligibility (Cohort B)', ' Breast reconstruction using tissue expanders or implants at the time of mastectomy.', ' Conditions for patient ineligibility (ALL patients)', ' Definitive clinical or radiologic evidence of metastatic disease.', ' Synchronous bilateral invasive breast cancer.', ' History of ipsilateral or contralateral invasive breast cancer regardless of treatment or ipsilateral DCIS treated with RT.', ' History of non-breast malignancies within the 5 years prior to study entry. Patients with the following cancers are eligible if diagnosed and treated within the previous 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.', ' Prior therapy with anthracyclines, taxanes, trastuzumab, or bevacizumab for any malignancy.', ' Treatment including RT, chemotherapy, and/or targeted therapy, administered for the currently diagnosed breast cancer prior to study entry.', ' Continued therapy with any hormonal agent such as raloxifene, tamoxifen, or other SERM. (Patients are eligible if these medications are discontinued prior to study entry.)', ' Any sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy, etc. These patients are eligible if this therapy is discontinued prior to study entry. (Women of reproductive potential must agree to use an effective non-hormonal method of contraception during study therapy and for at least 6 months after completion of targeted therapy.)', ' Cardiac disease that would preclude the use of the drugs included in the FB-5 treatment regimen. This includes but is not confined to:', ' Active cardiac disease: angina pectoris that requires the use of anti-anginal medication; ventricular arrhythmias except for benign premature ventricular contractions controlled by medication; supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; conduction abnormality requiring a pacemaker; and clinically significant valvular disease.', ' History of cardiac disease: myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LV function; documented CHF; or documented cardiomyopathy.', ' Uncontrolled hypertension defined as systolic BP greater than 150 mmHg or diastolic BP greater han 90 mmHg, with or without anti-hypertensive medication. Patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria.', ' History of hypertensive crisis or hypertensive encephalopathy.', ' History of TIA or CVA.', ' History of other arterial thrombotic event within 12 months before study entry.', ' Symptomatic peripheral vascular disease.', ' Any significant bleeding within 6 months before study entry, exclusive of menorrhagia in premenopausal women.', ' Serious or non-healing wound, skin ulcers, or bone fracture.', ' Gastroduodenal ulcer(s) determined by endoscopy to be active.', ' History of GI perforation, abdominal fistulae, or intra-abdominal abscess.', ' Anticipation of need for major surgical procedures (other than the breast surgery required for patients in Cohort A) during study therapy and for at least 3 months following completion of bevacizumab.', ' Known bleeding diathesis, coagulopathy, or requirement for therapeutic doses of coumadin.', ' Other nonmalignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up.', " Sensory/motor neuropathy greater than/equal to grade 2, as defined by the NCI's CTCAE v3.0.", ' Conditions that would prohibit administration of corticosteroids.', ' History of hypersensitivity reaction to drugs formulated with polysorbate 80.', ' Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing should be performed according to institutional standards for women of child-bearing potential.)', ' Use of any investigational agent within 4 weeks prior to enrollment in the study.', ' Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.'], 'Results': ['Outcome Measurement: ', ' Number of Patients With Pathological Complete Response (pCR) in the Breast and Nodes for Patients With HER2-positive LABC Following Neoadjuvant Treatment (Cohort A)', ' The determination of pCR is performed by the local pathologist following examination of tissue (breast and nodes)removed at the time of surgery. The outcome measure is the number of participants with no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or SNs identified after neoadjuvant chemotherapy.', ' Time frame: Assessed at time of surgery on average at 8 months', 'Results 1: ', ' Arm/Group Title: Cohort A', ' Arm/Group Description: Cohort A: Women with unresected locally advanced breast cancer (clinical Stage IIIA, IIIB, and IIIC)', ' Overall Number of Participants Analyzed: 73', ' Measure Type: Number', ' Unit of Measure: participants 34', 'Results 2: ', ' Arm/Group Title: Cohort B', ' Arm/Group Description: Cohort B: Women with resected pN2 or pN3 (pathologic Stage III) breast cancer', ' Overall Number of Participants Analyzed: 0', ' Measure Type: Number', ' Unit of Measure: participants '], 'Adverse Events': ['Adverse Events 1:', ' Total: 16/76 (21.05%)', ' Hemoglobin 0/76 (0.00%)', ' Left ventricular systolic function 1/76 (1.32%)', ' Hypertension 0/76 (0.00%)', ' Dehydration 1/76 (1.32%)', ' Diarrhea 1/76 (1.32%)', ' Hemorrhage, GI - stomach 0/76 (0.00%)', ' Perforation, GI - colon 1/76 (1.32%)', ' Ulcer, GI - stomach 0/76 (0.00%)', ' Pain- head/headache 3/76 (3.95%)', ' Pain- back 2/76 (2.63%)', 'Adverse Events 2:', ' Total: 5/29 (17.24%)', ' Hemoglobin 1/29 (3.45%)', ' Left ventricular systolic function 0/29 (0.00%)', ' Hypertension 1/29 (3.45%)', ' Dehydration 1/29 (3.45%)', ' Diarrhea 0/29 (0.00%)', ' Hemorrhage, GI - stomach 1/29 (3.45%)', ' Perforation, GI - colon 0/29 (0.00%)', ' Ulcer, GI - stomach 1/29 (3.45%)', ' Pain- head/headache 0/29 (0.00%)', ' Pain- back 0/29 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

9872cf9f-6f43-44d3-97ce-e205e0e5fc6c

Comparison

Adverse Events

NCT00623233

NCT01525589

the primary trial recorded 1 patient with a deficiency of platelets in the blood, whereas a total of 6 patients with a platelet deficiency where found in the secondary trial.

Entailment

{'Clinical Trial ID': 'NCT00623233', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg', ' Gemcitabine 2500 milligrams per square meter (mg/m^2) intravenous (IV) over 30 minutes given on Day 1 every 14 days (q 14 days) until disease progression (PD) or unacceptable toxicity.', ' Bevacizumab 10 milligrams per kilogram (mg/kg) initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Must be female and greater than or equal to 18 yrs of age', ' Participants must have confirmed cancer with measurable or evaluable, locally recurrent or metastatic disease.', ' Participants must have received a taxane as neo-adjuvant and/or adjuvant therapy', ' Participants may have received prior hormone therapy for locally recurrent or metastatic disease', 'Exclusion Criteria:', ' Participants with breast cancer overexpressing Human Epidermal growth factor Receptor 2 (HER2) gene amplification', ' Prior chemotherapy or targeted therapy for metastatic breast cancer', ' Prior treatment with gemcitabine, trastuzumab, lapatinib or bevacizumab in any setting', ' History of, or active brain mets', ' Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to treatment, or anticipation of need for major surgical procedure during course of study', ' Prior history of high blood pressure crisis', ' Have a serious, nonhealing wound, ulcer, or bone fracture'], 'Results': ['Outcome Measurement: ', ' Progression Free Survival (PFS) Time', " PFS was measured from date of first dose to first date of progressive disease (PD) or death from any cause. For each participant who was not known to have died or to have had PD as of the data inclusion cut-off date for a particular analysis, PFS duration was censored for that analysis at the date of the participant's last progression-free tumor assessment before that cut-off date.", ' Time frame: Baseline to measured PD or death from any cause. Tumor assessments were performed every 8 weeks during therapy and every 2 months during post-therapy until documented PD (up to 34 months).', 'Results 1: ', ' Arm/Group Title: Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg', ' Arm/Group Description: Gemcitabine 2500 milligrams per square meter (mg/m^2) intravenous (IV) over 30 minutes given on Day 1 every 14 days (q 14 days) until disease progression (PD) or unacceptable toxicity.', ' Bevacizumab 10 milligrams per kilogram (mg/kg) initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity.', ' Overall Number of Participants Analyzed: 52', ' Median (95% Confidence Interval)', ' Unit of Measure: months 4.80 (3.42 to 7.56)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 18/52 (34.62%)', ' Anaemia 2/52 (3.85%)', ' Febrile Neutropenia 1/52 (1.92%)', ' Haemolytic Uraemic Syndrome 1/52 (1.92%)', ' Leukopenia 1/52 (1.92%)', ' Neutropenia 1/52 (1.92%)', ' Thrombocytopenia 1/52 (1.92%)', ' Cardiac Failure Congestive 1/52 (1.92%)', ' Cardio-Respiratory Arrest 1/52 (1.92%)', ' Abdominal Pain 1/52 (1.92%)', ' Constipation 1/52 (1.92%)', ' Diarrhoea 1/52 (1.92%)']}

{'Clinical Trial ID': 'NCT01525589', 'Intervention': ['INTERVENTION 1: ', ' Cohort A (BRCA+)', ' Patients with known deleterious BRCA1/2 mutation status at study entry', 'INTERVENTION 2: ', ' Cohort A1 (BRCA+/PARPi)', ' Patients with known deleterious BRCA1/2 mutation status and prior treatment with PARPi.'], 'Eligibility': ['Inclusion Criteria:', ' Women 18 and 75 years of age.', ' Voluntary signed informed consent form (ICF).', ' Proven diagnosis of metastatic breast cancer (MBC).', ' At least one, but no more than three, prior chemotherapy regimens for MBC.', ' Patients with known HER-2 overexpressing MBC must have failed at least one prior trastuzumab-containing regimen for metastatic disease.', ' Disease evaluable for response by specific appropriate criteria.', ' No or minimal disease-related symptoms not affecting patient daily activities.', ' Adequate major organ function (normal or minimal alteration in liver, kidney, hematological, metabolic and cardiac function)', ' Wash out periods prior to Day 1 of Cycle 1:', ' At least three weeks since the last chemotherapy (six weeks in some particular cases) and At least four weeks since the last radiotherapy (RT) > 30 Gy) and At least one week since the last hormonal therapy and At least two weeks since the last biological/investigational therapy', ' Minimal or no ongoing toxicity from immediately prior therapy according to specific appropriate criteria. Mild ongoing toxicity is allowed in case of alopecia, skin toxicity, fatigue and/or finger numbness or tumbling.', ' Patients of child-bearing potential must agree to use a medically approved contraception method until at least six weeks after the last study drug administration.', ' Known deleterious germline mutation of BRCA1/2 (Patients in Cohorts A and A1)', ' Prior treatment with PARP inhibitors (Patients in Cohort A1)', 'Exclusion Criteria:', ' Prior treatment with PM01183 or trabectedin.', ' Extensive prior RT.', ' Prior or concurrent malignant disease unless cured for more than five years.', ' Exceptions are breast cancer in the other breast.', ' Uncommon or rare subtypes of breast cancer.', ' Symptomatic or progressive brain metastases.', ' Bone-limited and exclusively metastases.', " Relevant diseases or clinical situations which may increase patient's risk:", ' History of cardiac disease. Moderate breathing difficulties or oxygen requirement Active uncontrolled infection. Unhealed wound or presence of any external drainage. Chronically active viral hepatitis. Immunocompromised patients, including those known to be infected by human immunodeficiency virus (HIV).', ' Known muscular disease or functional alteration', ' Pregnant or breastfeeding women.', ' Impending need for immediate RT for symptomatic relief.', " Limitation of the patient's ability to comply with the treatment or to follow-up the protocol."], 'Results': ['Outcome Measurement: ', ' Overall Response Rate (ORR)', ' The overall response rate is defined as the percentage of patients with a confirmed response, either complete response (CR) or partial response (PR), according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions and assessed by MRI: CR, Disappearance of all target lesions; PR >=30% decrease in the sum of the longest diameter of target lesions.', ' Time frame: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment', 'Results 1: ', ' Arm/Group Title: Cohort A (BRCA+)', ' Arm/Group Description: Patients with known deleterious BRCA1/2 mutation status at study entry', ' Overall Number of Participants Analyzed: 54', ' Measure Type: Number', ' Unit of Measure: percentage 40.7 (27.6 to 55.0)', 'Results 2: ', ' Arm/Group Title: Cohort A1 (BRCA+/PARPi)', ' Arm/Group Description: Patients with known deleterious BRCA1/2 mutation status and prior treatment with PARPi.', ' Overall Number of Participants Analyzed: 20', ' Measure Type: Number', ' Unit of Measure: percentage 5.0 (0.1 to 24.9)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 14/54 (25.93%)', ' anaemia 2/54 (3.70%)', ' Febrile neutropenia 7/54 (12.96%)', ' Neutropenia 2/54 (3.70%)', ' Thrombocytopenia 6/54 (11.11%)', ' Atrial fibrillation 1/54 (1.85%)', ' Cardiac failure congestive 1/54 (1.85%)', ' Pericardial effusion 1/54 (1.85%)', ' Nausea 2/54 (3.70%)', ' Vomiting 3/54 (5.56%)', ' Catheter site erythema 1/54 (1.85%)', ' Chest discomfort 1/54 (1.85%)', 'Adverse Events 2:', ' Total: 5/20 (25.00%)', ' anaemia 0/20 (0.00%)', ' Febrile neutropenia 2/20 (10.00%)', ' Neutropenia 0/20 (0.00%)', ' Thrombocytopenia 0/20 (0.00%)', ' Atrial fibrillation 0/20 (0.00%)', ' Cardiac failure congestive 0/20 (0.00%)', ' Pericardial effusion 0/20 (0.00%)', ' Nausea 0/20 (0.00%)', ' Vomiting 0/20 (0.00%)', ' Catheter site erythema 0/20 (0.00%)', ' Chest discomfort 0/20 (0.00%)']}

efc15257-5e19-4b7e-8b51-da94840784d8

Comparison

Adverse Events

NCT01310231

NCT00093808

19.57% of patients in the secondary trial developed an eating disorder, there were no cases of this happening in the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT01310231', 'Intervention': ['INTERVENTION 1: ', ' Metformin', ' Metformin plus standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).', ' Metformin: metformin 850 mg bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).', ' Number of cycles: Until progression or unacceptable toxicity develops.', 'INTERVENTION 2: ', ' Placebo', ' Placebo and standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).', ' Placebo: Placebo bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).', ' Number of cycles: until progression or unacceptable toxicity develops.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically proven invasive breast cancer with metastatic spread outside of breast, ipsilateral axillary and supraclavicular nodal areas (Histological confirmation of metastases is not required) OR, Locally advanced breast cancer that is refractory to initial anticancer treatment.', ' A decision has been made to administer single or multiple agent first or second line chemotherapy that includes one of the following agents: anthracycline, taxane, platinum, capecitabine.', ' Age: 18 to 75 years at the time of registration', ' Invasive breast cancer, any ER or PgR status', ' ECOG performance status 0-2', ' Life expectancy of at least 6 months', " Adequate hepatic and renal function (SGOT and ALT < 1.8 X upper limit of normal for the institution, alkaline phosphatase 2X upper limit of normal for the institution, bilirubin within normal limits for the institution (expect in patients with Gilbert's syndrome who will be eligible regardless of bilirubin) and creatinine 130 umol/L)", ' Blood counts: Neutrophils must be at least 1,000/mm3 and Platelets 75,000/mm3.', ' Ability to understand and to provide written informed consent for the study', ' Absence of any psychological, familial, sociological, or other patient related factors that might preclude compliance with the study protocol', ' Measurable or non measurable (but evaluable) tumour must be present - radiologic or clinical evaluation must have been performed within 4 weeks prior to registration.', 'Exclusion Criteria:', ' More than one previous line(s) of chemotherapy for metastatic disease - if prior chemotherapy has been administered, the last date of treatment must have been given at least 3 weeks prior to registration [any adjuvant systemic treatment is acceptable]', ' If prior hormone therapy (as adjuvant or metastatic therapy) has been administered, it must have been stopped at least 3 weeks prior to registration', ' Radiotherapy to a target or non target lesion within 4 weeks of registration', ' Known CNS metastases', ' History of cardiac failure', ' Known hypersensitivity or allergy to metformin', ' History of or known diabetes or baseline fasting glucose 7.0 mmol/L', ' History of lactic or other metabolic acidosis', ' Use of metformin within 3 months of registration', ' Current or planned pregnancy or lactation in women of child-bearing potential. Patients of childbearing potential must have a negative serum pregnancy test.', ' Fertile patients must agree to use an effective method of contraception while on study treatment; which could include IUD, condoms or other barrier methods of birth control', ' Habitual alcohol intake of more than three drinks daily', ' Concurrent use of any biguanide medication (other than metformin as a study medication)', ' Patients with grade 2 diarrhea at baseline, malabsorption syndrome or unable to swallow oral medication', ' Previous or concurrent malignancies, except non-melanoma skin cancers, unless curatively treated and with no evidence of recurrence for 5 years.', ' Use of any investigational agent within 28 days prior to registration.'], 'Results': ['Outcome Measurement: ', ' Progression Free Survival.', ' Scans will be repeated every 9 weeks. Local follow up for survival will continue until all patients have died or for a maximum total follow up of 3 years, which ever occurs first. The two study arms will be compared in an intent to treat fashion using Cox proportional hazard analysis, with the stratification variables included in the model. Treatment discontinuation for toxicity or other reasons will be considered an event.', ' Time frame: From date of randomization to first documented progression or death, which ever occurs first, assessed up to 3 years.', 'Results 1: ', ' Arm/Group Title: Metformin', ' Arm/Group Description: Metformin plus standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).', ' Metformin: metformin 850 mg bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).', ' Number of cycles: Until progression or unacceptable toxicity develops.', ' Overall Number of Participants Analyzed: 22', ' Mean (Standard Deviation)', ' Unit of Measure: months 5.4 (1.04)', 'Results 2: ', ' Arm/Group Title: Placebo', ' Arm/Group Description: Placebo and standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).', ' Placebo: Placebo bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).', ' Number of cycles: until progression or unacceptable toxicity develops.', ' Overall Number of Participants Analyzed: 18', ' Mean (Standard Deviation)', ' Unit of Measure: months 6.3 (1.68)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 3/22 (13.64%)', ' ascites with hyponatraemia 0/22 (0.00%)', ' febrile neutropenia with respiratory infection 1/22 (4.55%)', ' urosepsis 1/22 (4.55%)', ' febrile neutropenia with urinary tract infection 0/22 (0.00%)', ' dyspnoea 1/22 (4.55%)', ' hypoxia 0/22 (0.00%)', ' thromboembolism 0/22 (0.00%)', 'Adverse Events 2:', ' Total: 4/17 (23.53%)', ' ascites with hyponatraemia 1/17 (5.88%)', ' febrile neutropenia with respiratory infection 0/17 (0.00%)', ' urosepsis 0/17 (0.00%)', ' febrile neutropenia with urinary tract infection 1/17 (5.88%)', ' dyspnoea 0/17 (0.00%)', ' hypoxia 1/17 (5.88%)', ' thromboembolism 1/17 (5.88%)']}

{'Clinical Trial ID': 'NCT00093808', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine + Vinorelbine + Trastuzumab', ' Treatment followed a 21-day cycle. Capecitabine was administered orally twice daily at a dose of 825 mg/m^2 on days 1 to 14, vinorelbine was administered intravenously (IV) at a dose of 25 mg/m^2 on days 1 and 8 every 3 weeks, and trastuzumab was administered IV at a dose of 6 mg/kg on day 1 of every 3-week cycle (except cycle 1, when patients were given a loading dose of 8 mg/kg).'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically or cytologically confirmed invasive breast cancer', ' Metastatic disease', ' HER2/neu-positive by immunohistochemistry (3+ by HercepTest^™ or equivalent) OR positive for amplification by fluorescent in situ hybridization', ' Testing may be performed in the primary tumor or the metastatic site', ' Received prior anthracycline or taxane as adjuvant therapy or for metastatic disease', ' Measurable disease', ' At least one measurable lesion 2.0 cm by CT scan or MRI OR 1.0 cm by spiral CT scan', ' The following are considered non-measurable disease:', ' Bone lesions', ' Leptomeningeal disease', ' Ascites', ' Pleural/pericardial effusion', ' Inflammatory breast disease', ' Lymphangitis cutis/pulmonis', ' Abdominal masses that are not confirmed and followed by imaging techniques', ' Cystic lesions', ' No bone metastases as the only evidence of metastasis', ' Previously treated CNS metastases allowed provided disease has been stable for the past 3 months', ' Hormone receptor status:', ' Not specified', ' PATIENT CHARACTERISTICS:', ' Age', ' 18 and over', ' Sex', ' Female or male', ' Performance status', ' ECOG 0-2', ' Life expectancy', ' At least 12 weeks', ' Hematopoietic', ' Absolute neutrophil count 1,500/mm^3', ' Hemoglobin 8.0 g/dL', ' Platelet count 100,000/mm^3', ' No known uncontrolled coagulopathy', ' Hepatic', ' Bilirubin 3.0 times the upper limit of normal (ULN)', ' One of the following must be true:', ' AST or ALT 5 times ULN AND alkaline phosphatase normal', ' Alkaline phosphatase 5 times ULN AND AST or ALT normal', ' Alkaline phosphatase 2.5 times ULN AND AST or ALT 1.5 times ULN', ' INR 1.5 times ULN', ' Renal', ' Calcium 11.5 mg/dL', ' Creatinine 1.5 times ULN', ' Creatinine clearance 30 mL/min', ' Cardiovascular', ' LVEF 50% by MUGA or echocardiogram', ' No clinically significant (i.e., active) cardiac disease', ' No congestive heart failure', ' No symptomatic coronary artery disease', ' No myocardial infarction within the past 12 months', ' No cardiac arrhythmia not controlled with medication', ' Gastrointestinal', ' Able to take oral medication', ' No lack of physical integrity of the upper gastrointestinal tract', ' No clinically significant malabsorption syndrome', ' Other', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception during and for 30 days after study participation', ' No history of allergy or hypersensitivity to study drugs, drug product excipients, including polysorbate 80, or chemically similar agents', ' No prior unanticipated severe reaction to fluoropyrimidine therapy', ' No know hypersensitivity to fluorouracil', ' No known dihydropyrimidine dehydrogenase deficiency', ' No history of uncontrolled seizures or CNS disorders', ' No clinically significant psychiatric disability that would preclude giving informed consent or study compliance', ' No other serious uncontrolled infection or disease', ' No other malignancy within the past 5 years except cured basal cell skin cancer, carcinoma in situ of the cervix, or contralateral breast cancer', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy', ' Prior adjuvant trastuzumab (Herceptin^®) allowed as adjuvant or first-line therapy for metastatic disease', ' No concurrent immunotherapy', ' Chemotherapy', ' See Disease Characteristics', ' No more than 1 prior chemotherapy regimen in the advanced or metastatic (non-adjuvant) setting', ' No prior continuous ( 24 hours) fluorouracil infusion', ' No prior capecitabine', ' No prior oral fluoropyrimidines (e.g., eniluracil and fluorouracil, uracil and tegafur, S1, or emitefur)', ' Endocrine therapy', ' At least 1 day since prior hormonal therapy', ' No concurrent hormonal therapy', ' Radiotherapy', ' More than 4 weeks since prior radiotherapy to the axial skeleton (i.e., skull, spinal column, sternum, or ribs)', ' No concurrent radiotherapy', ' Surgery', ' More than 4 weeks since prior major surgery', ' No prior organ allografts requiring immunosuppressive therapy', ' Other', ' More than 4 weeks since prior investigational drugs', ' No concurrent sorivudine or its chemically related analogues (e.g., brivudine)', ' No concurrent allopurinol, metronidazole, or cimetidine', ' No other concurrent cytotoxic agents', ' No other concurrent investigational drugs', ' No other concurrent anticancer therapy'], 'Results': ['Outcome Measurement: ', ' Confirmed Response Rate', ' A confirmed tumor response is defined to be either a Complete Response (CR) or Partial Response (PR) noted as the objective status on 2 consecutive evaluations at least 6 weeks apart. All patients meeting the eligibility criteria who have signed a consent form and initiated study medication will be evaluable for response. The proportion of confirmed tumor responses will be estimated by the number of tumor regressions that meet the RECIST criteria for a confirmed CR or PR divided by the total number of evaluable patients. A 95% confidence interval for the true confirmed response rate will be calculated using the properties of the binomial distribution. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', ' Time frame: Up to 5 years', 'Results 1: ', ' Arm/Group Title: Capecitabine + Vinorelbine + Trastuzumab', ' Arm/Group Description: Treatment followed a 21-day cycle. Capecitabine was administered orally twice daily at a dose of 825 mg/m^2 on days 1 to 14, vinorelbine was administered intravenously (IV) at a dose of 25 mg/m^2 on days 1 and 8 every 3 weeks, and trastuzumab was administered IV at a dose of 6 mg/kg on day 1 of every 3-week cycle (except cycle 1, when patients were given a loading dose of 8 mg/kg).', ' Overall Number of Participants Analyzed: 45', ' Measure Type: Number', ' Unit of Measure: proportion of patients 0.67 (0.51 to 0.80)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 9/46 (19.57%)', ' Febrile neutropenia 1/46 (2.17%)', ' Cardiac disorder 1/46 (2.17%)', ' Diarrhea 1/46 (2.17%)', ' Upper gastrointestinal hemorrhage 1/46 (2.17%)', ' Chest pain 1/46 (2.17%)', ' Fatigue 1/46 (2.17%)', ' Neutrophil count decreased 2/46 (4.35%)', ' Platelet count decreased 1/46 (2.17%)', ' Anorexia 1/46 (2.17%)', ' Dehydration 1/46 (2.17%)', ' Serum potassium increased 1/46 (2.17%)']}

0d4ea69b-5e78-48c2-ba3e-d51dc5336ee1

Single

Adverse Events

NCT02129556

Cohort 1 of the primary trial had a much higher number of deaths than cohort 2.

Contradiction

{'Clinical Trial ID': 'NCT02129556', 'Intervention': ['INTERVENTION 1: ', ' Phase Ib 2 mg/kg', ' HER2-positive, PD-L1 expressing, unresectable loco-regional or metastatic breast carcinoma that progressed on prior trastuzumab-based therapy', 'INTERVENTION 2: ', ' Phase Ib 10 mg/kg', ' HER2-positive, PD-L1 expressing, unresectable loco-regional or metastatic breast carcinoma that progressed on prior trastuzumab-based therapy'], 'Eligibility': ['Inclusion criteria for screening:', ' Female gender', ' Age 18 years', ' Histologically confirmed breast adenocarcinoma that is unresectable loco-regional, or metastatic.', ' Locally confirmed HER2-positivity (immunohistochemistry score 3+) or ERBB2-amplification (Ratio ERBB2/centromeres 2.0 or mean gene copy number 6) of primary tumor or of biopsy from metastatic or unresectable loco-regional lesion.', ' Trastuzumab resistant disease, defined by:', ' progression of disease while on-treatment with trastuzumab', ' recurrence while on adjuvant trastuzumab or within 12 months of completing adjuvant trastuzumab', ' Any number of prior lines of anti-HER2 therapy acceptable. Patients for whom the treatment with the current first-line combination of trastuzumab, pertuzumab and taxanes is not an option can be considered for enrollment', ' If a patient has received a subsequent anti-HER2 therapy, she must also have progressed on the subsequent therapy.', ' Presence of at least one measurable lesion (RECIST 1.1)', ' LVEF 50%', ' Patient agrees to submit an FFPE tumor biopsy for central confirmation of HER2 positivity and central assessment of PD-L1 status.', ' Written Informed Consent (IC) for screening procedures and trial participation must be signed and dated by the patient and the Investigator prior to screening.', ' Written consent to biological material submission, indicating the patient has been informed of and agrees to tissue and blood material use, transfer and handling, must be signed and dated by the patient and the investigator prior to any procedures specific for this trial, including consent to translational research on FFPE and fresh frozen tumor biopsies in case the patient is enrolled into the trial.', ' The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.', ' Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1', ' Life expectancy >3 months.', ' Hematopoietic status:', ' Absolute neutrophil count 1.5 × 109/L,', ' Platelet count 100 × 109/L,', ' Hemoglobin 9 g/dL', ' Hepatic status:', " Serum total bilirubin 1.5 × upper limit of normal (ULN). In the case of known Gilbert's syndrome, a higher serum total bilirubin (< 2 × ULN) is allowed.", ' AST and ALT 2.5 × ULN; if the patient has liver metastases, ALT and AST must be 5 × ULN.', ' Renal status:', ' Creatinine 1.5 ×ULN or creatinine clearance > 60 ml/min', ' Proteinuria <1 g/day', ' International Normalized Ratio (INR) or Prothrombin Time (PT) 1.5 × ULN unless patient is receiving anticoagulant therapy as long as PT or PTT (partial thromboplastin time) is within therapeutic range of intended use of anticoagulant.', ' Inclusion criteria for enrollment:', ' All inclusion criteria for screening, plus:', ' Central lab confirmation on a metastatic biopsy (or biopsy from unresectable loco-regional disease) of:', ' HER2-positivity (immunohistochemistry score 3+) or ERBB2- amplification (Ratio ERBB2/centromeres 2.0 or mean gene copy number 6),', ' Presence of PD-L1 expression assessed by IHC (during the phase II portion of the trial a parallel, secondary cohort of 15 patients with PD-L1 negative disease will be enrolled)', ' Patient agrees to submit tumor tissue for translational research:', ' tissue biopsy from unresectable loco-regional or metastatic disease obtained 1 year prior to enrollment or new tissue material from a recently obtained surgical or diagnostic biopsy. For patients who have presented with stage 4 disease de novo, a biopsy taken from the presumed primary breast lesion is acceptable (provided this was taken 1 year prior to enrollment).', ' if available: FFPE tumor block from primary surgery or diagnostic biopsy.', ' if available: pre-treatment fresh frozen tumor biopsy.', ' if feasible: FFPE tumor block from post-treatment biopsy will be taken at time of disease progression or end of all treatment if ended prior to progression. This re-biopsy is strongly advised.', ' if feasible: fresh frozen tumor biopsy from post-treatment biopsy will be taken at time of disease progression or end of all treatment if ended prior to progression.', ' Patient agrees to submit baseline (pre-treatment) blood and serial plasma for translational research', ' For patient of childbearing potential, negative serum pregnancy test. Pregnancy test has to be repeated within 72h before treatment start.', ' All anti-cancer treatment including endocrine therapy, with the exception of trastuzumab, must stop 3 weeks prior to first dose of trial treatment.', ' Exclusion criteria for screening:', ' Prior therapy with other anti-PD-1, anti- PD-L1, L2 or anti-CTLA4 therapy.', ' No FFPE material to centrally assess HER2-positivity and PD-L1 expression.', ' Known Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), or positive for Hepatitis B (HBsAg reactive) or Hepatitis C (HCV RNA [qualitative]).', ' Interstitial lung disease', ' History of or active pneumonitis requiring treatment with steroids', ' Active central nervous system metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (patients with history of CNS metastases or spinal cord compression are eligible if they are clinically and radiologically stable for at least 4 weeks before first dose of investigational product and have not required high-dose steroid treatment in the last 4 weeks).', ' Leptomeningeal disease', ' History of clinically significant or uncontrolled cardiac disease, including congestive heart failure (New York Heart Association functional classification 3), angina, myocardial infarction or ventricular arrhythmia.', ' Previous severe hypersensitivity reaction to treatment with another monoclonal antibody.', ' Active infection requiring systemic therapy.', ' Chronic systemic therapy with immunosuppressive agents including cortico¬steroids.', " Concurrent disease or condition that would make the patient inappropriate for trial participation or any serious medical disorder that would interfere with the patient's safety.", ' Known history of uncontrolled hypertension ( 180/110), unstable diabetes mellitus, dyspnea at rest, or chronic therapy with oxygen.', ' Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of Informed Consent.', ' Treatment with an investigational agent in the 4 weeks before enrollment.', " Active autoimmune disease or a documented history of autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Patients that require intermittent use of bronchodilators or local steroid injections would not be excluded from the trial. Patients with hypothyroidism stable on hormone replacement or Sjögren's syndrome will not be excluded from the trial.", ' Chemotherapy, radioactive therapy, and/or biological cancer therapy within 3 weeks prior to the first trial dose and has not recovered to CTCAE v.4 grade 1 or better from adverse events.', ' Pregnant or lactating women; lactation has to stop before enrollment.', ' The patient of childbearing potential who is unwilling to use highly effective contraception during treatment and up to 7 months after stop of trial treatment. Acceptable methods are intrauterine devices (without hormones), bilateral tubal occlusion, vasectomized partner or total abstinence. Oral, injectable, or implant hormonal contraceptives are not allowed.', ' Unresolved or unstable, serious adverse events from prior administration of another investigational drug.', ' Active or uncontrolled infection CTCAE v.4 grade 2 or higher.', ' Live vaccines within 30 days prior to the first dose of trial therapy and during trial treatment.', ' Exclusion criteria for enrollment:', ' All exclusion criteria for screening apply for enrollment as well. Excluded are especially patients who have received any of the treatments below:', ' Live vaccines within 30 days prior to the first dose of trial therapy and during trial treatment.', ' History of CNS metastases or spinal cord compression if they have not been clinically stable for at least 4 weeks before first dose of investigational product and require high-dose steroid treatment.', ' Treatment with an investigational agent in the 4 weeks before enrollment.', ' Patient has not recovered to CTCAE v.4 grade 1 or better from adverse events of prior therapy, except alopecia grade 2.', ' Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), or positive for Hepatitis B or Hepatitis C.'], 'Results': ['Outcome Measurement: ', ' Dose-Limiting Toxicity (DLT) of MK-3475 in Combination With Trastuzumab', ' Determination of dose-limiting toxicity (DLT) which is defined as an adverse event or abnormal laboratory value assessed as suspected to be trial treatment related (possible, probable or definite) and unrelated to disease or disease progression. Toxicities and lab values will be graded according to the NCI CTCAE (v4.0).', ' Any grade-3 or greater non-hematological adverse event lasting at least one week;', ' Any grade-4 hematological toxicity; or,', ' Any adverse event resulting in a delay starting cycle 2 of more than 14 days.', ' Time frame: Within the first 21 days', 'Results 1: ', ' Arm/Group Title: Phase Ib 2 mg/kg', ' Arm/Group Description: HER2-positive, PD-L1 expressing, unresectable loco-regional or metastatic breast carcinoma that progressed on prior trastuzumab-based therapy', ' Overall Number of Participants Analyzed: 3', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 0 0.0%', 'Results 2: ', ' Arm/Group Title: Phase Ib 10 mg/kg', ' Arm/Group Description: HER2-positive, PD-L1 expressing, unresectable loco-regional or metastatic breast carcinoma that progressed on prior trastuzumab-based therapy', ' Overall Number of Participants Analyzed: 3', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 0 0.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/6 (66.67%)', ' Anemia 0/6 (0.00%)', ' Takotsubo cardiomyopathy 1/6 (16.67%)', ' Pericardial effusion 0/6 (0.00%)', ' Vertigo 1/6 (16.67%)', ' Retinal vein occlusion 0/6 (0.00%)', ' Gastroenteritis 1/6 (16.67%)', ' Vomiting 1/6 (16.67%)', ' Diarrhea 0/6 (0.00%)', ' Death 2/6 (33.33%)', ' Bile duct dilatation 0/6 (0.00%)', ' Hepatic hemorrhage 0/6 (0.00%)', 'Adverse Events 2:', ' Total: 25/52 (48.08%)', ' Anemia 1/52 (1.92%)', ' Takotsubo cardiomyopathy 0/52 (0.00%)', ' Pericardial effusion 2/52 (3.85%)', ' Vertigo 0/52 (0.00%)', ' Retinal vein occlusion 1/52 (1.92%)', ' Gastroenteritis 0/52 (0.00%)', ' Vomiting 0/52 (0.00%)', ' Diarrhea 1/52 (1.92%)', ' Death 9/52 (17.31%)', ' Bile duct dilatation 1/52 (1.92%)', ' Hepatic hemorrhage 1/52 (1.92%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

7990b9bf-ac76-4f21-b9a1-5e0b4d91b9a9

Single

Intervention

NCT01819233

All the primary trial participants must reduce the number of calories in their diets by a quarter throughout the duration of the study.

Entailment

{'Clinical Trial ID': 'NCT01819233', 'Intervention': ['INTERVENTION 1: ', ' Behavioral Dietary Intervention', ' Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet. Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy). Patients undergo radiation therapy QD 5 days a week for 6 weeks.', ' Behavioral dietary intervention: Receive caloric restricted dietary intervention', ' Therapeutic conventional surgery: Undergo definitive lumpectomy', ' Radiation therapy: Undergo radiation therapy', ' Counseling intervention: Receive dietary counseling', ' Quality-of-life assessment: Ancillary studies'], 'Eligibility': ['Inclusion Criteria:', ' Pathologically proven diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer', ' Ability to have breast conservation as determined by the judgment of the radiation oncologist, for which the radiation oncologist has determined that he or she will only treat the whole breast and not regional lymph nodes', ' The patient must be female', ' Age >= 18', ' If multifocal breast cancer, then it must be able to be resected through a single lumpectomy incision', ' Appropriate stage for protocol entry, including no clinical evidence for distant metastases, based upon the following minimum diagnostic workup:', ' History/physical examination, including breast exam and documentation of weight and Karnofsky performance status of 80-100% for at least 60 days prior to study entry', ' Ipsilateral mammogram within 6 months prior to study entry', ' Women of childbearing potential must have a negative serum pregnancy test within 14 days of study entry', ' Women of childbearing potential must be non-pregnant and non-lactating and willing to use medically acceptable form of contraception during radiation therapy', ' Patient must capable of and provide study specific informed consent prior to study entry', ' Body mass index (BMI) >= 21', ' Weight >= 100 lbs', ' No prior history of non-breast malignancies in the past 2 years unless it was a non-melanomatous skin lesion or carcinoma in situ of the cervix', ' Patient must not have any of the following severe, active co-morbidity, defined as follows:', ' Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months', ' Transmural myocardial infarction within the last 6 months', ' Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration', ' Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration', ' Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol', ' Acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV) positive based upon current Centers for Disease and Control (CDC) definition; note, however, that HIV testing is not required for entry into this protocol; the need to exclude patients with AIDS or HIV from this protocol is necessary because anti-retrovirals may alter patient metabolism', ' Patient must not have active systemic lupus, erythematosus, or any history of scleroderma, dermatomyositis with active rash', ' No prior radiotherapy to the ipsilateral breast or prior radiation to the region of the breast that would result in overlap of radiation therapy fields', ' Patient may not have any active gastrointestinal/malabsorption disorder at the discretion of the Principal Investigator', ' Inflammatory bowel disease', ' Celiac disease', ' Chronic pancreatitis', ' Chronic diarrhea or vomiting', ' Active eating disorder', ' Creatinine < 1.7', ' Not currently taking steroids', ' No currently active pituitary secreting tumors up to physician discretion', ' No history of or current active drug/alcohol dependence', ' No patients being decisionally impaired', 'Exclusion Criteria:', ' Patient is not a candidate for breast conservation', ' Patient is male', ' Age < 18 years', ' Patient requires regional lymph node irradiation therapy', ' Patient has evidence of distant metastases', ' Karnofsky performance status less than 80% within 60 days prior to study', ' Ipsilateral mammogram done greater than 6 months prior to study', ' Women of childbearing potential with a positive serum beta human chorionic gonadotropin (hCG)', ' Patient has a history of dementia, psychosis or other disorder affecting their mental status to the point where they cannot consent or comply with study guidelines', ' BMI < 21', ' Weight < 100 lbs', ' Weight loss >= 10% in the last 3 months (mos)', ' Prior invasive non-breast malignancy (except non-melanomatous skin cancer, carcinoma in situ of the cervix) unless disease free for a minimum of 2 years prior to registration', ' Two or more breast cancers not resectable through a single lumpectomy incision', ' Non-epithelial breast malignancies such as sarcoma or lymphoma', ' Prior radiotherapy to the ipsilateral breast or prior radiation to the region of the breast that would result in overlap of radiation therapy fields', ' Severe, active co-morbidity, defined as follows:', ' Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months', ' Transmural myocardial infarction within the last 6 months', ' Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration', ' Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration', ' Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol', ' Acquired immune deficiency syndrome (AIDS) or HIV positive based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol; the need to exclude patients with AIDS or HIV from this protocol is necessary because anti-retrovirals may alter patient metabolism', ' Active systemic lupus, erythematosus, or any history of scleroderma, dermatomyositis with active rash', ' Active gastrointestinal/malabsorption disorder at the discretion of the Principal Investigator', ' Inflammatory bowel disease', ' Celiac disease', ' Chronic pancreatitis', ' Chronic diarrhea or vomiting', ' Active eating disorder', ' Creatinine >= 1.7', ' Current use of steroids', ' Pituitary secreting tumors up to physician discretion', ' Active drug/alcohol dependence or abuse history', ' Decisionally impaired patients'], 'Results': ['Outcome Measurement: ', ' Number of Participants Who Are Adherent to the Diet Restriction', ' Computed along with a 95% exact confidence interval. Exact binomial test (with a one-sided alpha of 0.05) will be used to test whether adherence is greater than 60%.', ' Time frame: Up to week 12', 'Results 1: ', ' Arm/Group Title: Behavioral Dietary Intervention', ' Arm/Group Description: Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet. Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy). Patients undergo radiation therapy QD 5 days a week for 6 weeks.', ' Behavioral dietary intervention: Receive caloric restricted dietary intervention', ' Therapeutic conventional surgery: Undergo definitive lumpectomy', ' Radiation therapy: Undergo radiation therapy', ' Counseling intervention: Receive dietary counseling', ' Quality-of-life assessment: Ancillary studies', ' Overall Number of Participants Analyzed: 32', ' Measure Type: Number', ' Unit of Measure: participants 28 [1] (NA to 74.5)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/38 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

e4961c1a-83e2-40ed-93ac-64d5cef1f84a

Comparison

Eligibility

NCT01663727

NCT00072293

There is no maximum or minimum age defined for participation in the primary trial or the secondary trial.

Entailment

{'Clinical Trial ID': 'NCT01663727', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel+Placebo', ' Participants received paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.', 'INTERVENTION 2: ', ' Paclitaxel+ Bevacizumab', ' Participants received paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically confirmed, HER2-negative adenocarcinoma of the breast, with measurable or non-measurable locally recurrent or metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent.', ' ECOG performance status of 0 or 1', ' For women of childbearing potential, use of an acceptable and effective method of non-hormonal contraception', ' For patients who have received recent radiotherapy, recovery prior to randomization from any significant acute toxicity, and radiation treatments have to be completed more than 3 weeks from randomization', 'Exclusion Criteria:', ' Disease-Specific Exclusions:', ' HER2-positive status', ' Prior chemotherapy for locally recurrent or metastatic disease', ' Prior hormonal therapy < 2 weeks prior to randomization', ' Prior adjuvant or neo-adjuvant chemotherapy is allowed, provided its conclusion has been for at least 12 months prior to randomization', ' Investigational therapy within 28 days of randomization', ' General Medical Exclusions:', ' Life expectancy of < 12 weeks', ' Inadequate organ function', ' Uncontrolled serious medical or psychiatric illness', ' Active infection requiring intravenous (IV) antibiotics at screening', ' Pregnancy or lactation', ' History of other malignancies within 5 years prior to screening, except for tumors with a negligible risk for metastasis or death'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Progression or Death in Intent-to-Treat (ITT) Population', ' Tumor assessment was performed as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by investigator. Disease progression was defined as at least 20 percent (%) increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 millimeter (mm), unequivocal progression of existing non-target lesions, or presence of new lesions.', ' Time frame: Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 117.7 weeks)', 'Results 1: ', ' Arm/Group Title: Paclitaxel+Placebo', ' Arm/Group Description: Participants received paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.', ' Overall Number of Participants Analyzed: 242', ' Measure Type: Number', ' Unit of Measure: percentage of participants 69.4', 'Results 2: ', ' Arm/Group Title: Paclitaxel+ Bevacizumab', ' Arm/Group Description: Participants received paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.', ' Overall Number of Participants Analyzed: 239', ' Measure Type: Number', ' Unit of Measure: percentage of participants 63.6'], 'Adverse Events': ['Adverse Events 1:', ' Total: 45/233 (19.31%)', ' Anaemia * 2/233 (0.86%)', ' Febrile neutropenia * 0/233 (0.00%)', ' Leukopenia * 1/233 (0.43%)', ' Neutropenia * 1/233 (0.43%)', ' Atrial fibrillation * 1/233 (0.43%)', ' Left ventricular dysfunction * 0/233 (0.00%)', ' ACUTE CORONARY SYNDROME * 0/233 (0.00%)', ' CARDIAC FAILURE CONGESTIVE * 1/233 (0.43%)', ' Optic nerve disorder * 1/233 (0.43%)', 'Adverse Events 2:', ' Total: 66/238 (27.73%)', ' Anaemia * 1/238 (0.42%)', ' Febrile neutropenia * 4/238 (1.68%)', ' Leukopenia * 1/238 (0.42%)', ' Neutropenia * 0/238 (0.00%)', ' Atrial fibrillation * 0/238 (0.00%)', ' Left ventricular dysfunction * 1/238 (0.42%)', ' ACUTE CORONARY SYNDROME * 1/238 (0.42%)', ' CARDIAC FAILURE CONGESTIVE * 0/238 (0.00%)', ' Optic nerve disorder * 0/238 (0.00%)']}

{'Clinical Trial ID': 'NCT00072293', 'Intervention': ['INTERVENTION 1: ', ' Axillary Dissection', ' Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.', ' Axillary lymph node dissection: Axillary lymph node dissection', 'INTERVENTION 2: ', ' No Axillary Dissection', ' Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.', ' No axillary lymph node dissection: Therapeutic conventional surgery'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Clinical, mammographic, ultrasonographic, or pathologic diagnosis of unicentric and unifocal breast carcinoma', ' Largest tumor lesion 5 cm', ' Palpable or nonpalpable breast lesion', ' Preoperative radioactive occult lesion localization, hook wire, or other method of localization required for nonpalpable lesions', ' Prior (preoperative) or planned (intraoperative) sentinel node biopsy required', ' At least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with no extracapsular extension', ' No clinical evidence of distant metastases', ' No suspicious manifestation of metastases that cannot be ruled out by x-ray, MRI, or CT scan, including the following:', ' Skeletal pain of unknown cause', ' Elevated alkaline phosphatase', ' Bone scan showing hot spots', ' No palpable axillary lymph node(s)', " No Paget's disease without invasive cancer", ' Hormone receptor status:', ' Estrogen receptor and progesterone receptor known', ' PATIENT CHARACTERISTICS:', ' Age', ' Any age', ' Sex', ' Female', ' Menopausal status', ' Any status', ' Performance status', ' Not specified', ' Life expectancy', ' Not specified', ' Hematopoietic', ' Not specified', ' Hepatic', ' See Disease Characteristics', ' Renal', ' Not specified', ' Other', ' Not pregnant or nursing', ' No other prior or concurrent malignancy except the following:', ' Adequately treated basal cell or squamous cell skin cancer', ' Adequately treated carcinoma in situ of the cervix', ' Adequately treated in situ melanoma', ' Contralateral or ipsilateral carcinoma in situ of the breast', ' No psychiatric, addictive, or other disorder that may compromise ability to give informed consent', ' Geographically accessible for follow-up', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy', ' Not specified', ' Chemotherapy', ' Not specified', ' Endocrine therapy', ' Not specified', ' Radiotherapy', ' Not specified', ' Surgery', ' See Disease Characteristics', ' Other', ' No prior systemic therapy for breast cancer', ' More than 1 year since prior chemopreventive agent'], 'Results': ['Outcome Measurement: ', ' 5-year Disease-Free Survival', ' Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to first evidence of invasive relapse at any site, second primary tumor (contralateral or non-breast) or death.', ' Time frame: 5-year estimate reported after a median follow-up of 60 months', 'Results 1: ', ' Arm/Group Title: Axillary Dissection', ' Arm/Group Description: Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.', ' Axillary lymph node dissection: Axillary lymph node dissection', ' Overall Number of Participants Analyzed: 464', ' Measure Type: Number', ' Unit of Measure: percentage of participants 84.4', 'Results 2: ', ' Arm/Group Title: No Axillary Dissection', ' Arm/Group Description: Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.', ' No axillary lymph node dissection: Therapeutic conventional surgery', ' Overall Number of Participants Analyzed: 467', ' Measure Type: Number', ' Unit of Measure: percentage of participants 87.8'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/447 (0.22%)', ' Post-operative infection (L.axilla) 1/447 (0.22%)', 'Adverse Events 2:', ' Total: 0/453 (0.00%)', ' Post-operative infection (L.axilla) 0/453 (0.00%)']}

9cb1c975-0d49-4437-af56-1a4f97e30aef

Single

Eligibility

NCT02732119

Mark suffered Refractory ventricular fibrillation twice in the last month he is therefore excluded from the primary trial.

Entailment

{'Clinical Trial ID': 'NCT02732119', 'Intervention': ['INTERVENTION 1: ', ' Cohort A', ' Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days. If no DLTs occurred, progressed to Cohort B', 'INTERVENTION 2: ', ' Cohort B', ' Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally'], 'Eligibility': ['Inclusion Criteria:', ' Adult men and women', ' Patient has a confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer by local laboratory and has HER2-negative breast cancer', ' Patient must have either measurable disease by RECIST 1.1 or bone lesions in absence of measurable disease.', ' ECOG Performance Status 0 - 1', ' Disease refractory to either, AI, tamoxifen or fulvestrant', ' Previously treated on any CDK 4/6 inhibitor.', ' Patient has adequate bone marrow and organ function.', 'Exclusion Criteria:', " Patient with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy per the investigator's best judgment.", ' Patient has received more than one line of chemotherapy for advanced disease.', ' Previous treatment with mTOR inhibitors, or exemestane for advanced disease.', ' Progressed on more than one CDK 4/6 inhibitor', ' Patient with CNS involvement unless they are at least 4 weeks from prior therapy completion.', ' Clinically significant, uncontrolled heart disease and/or recent cardiac events.'], 'Results': ['Outcome Measurement: ', ' Participants With Dose Limiting Toxicities by Preferred Term in Cycle 1 (28 Days) - in Phase I', ' A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a reasonably possible relationship to the study medication(s) and is unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first 28 days of treatment (cycle 1) and meets any of the criteria defined in the protocol. National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) version 4.03 will be used for all grading.', ' Time frame: Baseline up to 28 days', 'Results 1: ', ' Arm/Group Title: Cohort A', ' Arm/Group Description: Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days. If no DLTs occurred, progressed to Cohort B', ' Overall Number of Participants Analyzed: 8', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Febrile neutropenia Grade 3: 1 12.5%', ' Neutropenia Grade 4: 0 0.0%', ' Thrombocytopenia Grade 4: 0 0.0%', ' Cardiac tamponade Grade 4: 1 12.5%', ' Diarrhea Grade 3: 1 12.5%', ' Hyperglycemia Grade 4: 0 0.0%', 'Results 2: ', ' Arm/Group Title: Cohort B', ' Arm/Group Description: Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally', ' Overall Number of Participants Analyzed: 10', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Febrile neutropenia Grade 3: 1 10.0%', ' Neutropenia Grade 4: 1 10.0%', ' Thrombocytopenia Grade 4: 1 10.0%', ' Cardiac tamponade Grade 4: 0 0.0%', ' Diarrhea Grade 3: 0 0.0%', ' Hyperglycemia Grade 4: 0 0.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 3/8 (37.50%)', ' Anaemia 0/8 (0.00%)', ' Febrile neutropenia 1/8 (12.50%)', ' Neutropenia 2/8 (25.00%)', ' Acute coronary syndrome 0/8 (0.00%)', ' Atrial fibrillation 0/8 (0.00%)', ' Cardiac failure 0/8 (0.00%)', ' Cardiac tamponade 1/8 (12.50%)', ' Abdominal pain 1/8 (12.50%)', ' Diarrhoea 1/8 (12.50%)', ' Intestinal obstruction 0/8 (0.00%)', ' Nausea 0/8 (0.00%)', 'Adverse Events 2:', ' Total: 3/10 (30.00%)', ' Anaemia 0/10 (0.00%)', ' Febrile neutropenia 0/10 (0.00%)', ' Neutropenia 0/10 (0.00%)', ' Acute coronary syndrome 0/10 (0.00%)', ' Atrial fibrillation 0/10 (0.00%)', ' Cardiac failure 0/10 (0.00%)', ' Cardiac tamponade 0/10 (0.00%)', ' Abdominal pain 0/10 (0.00%)', ' Diarrhoea 0/10 (0.00%)', ' Intestinal obstruction 1/10 (10.00%)', ' Nausea 0/10 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

51699ae8-d297-4635-95c1-4ed38c8706c3

Single

Eligibility

NCT02756364

In order to meet the inclusion criteria for the primary trial patients must have had ineffective aromatase inhibitor (AI) therapy before study entry,

Entailment

{'Clinical Trial ID': 'NCT02756364', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Fulvestrant 500 mg', ' Fulvestrant 500 mg, intramuscularly (IM), once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 16.0 weeks).', 'INTERVENTION 2: ', ' Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD', ' Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with the sapanisertib 4 mg, capsules, orally, once daily in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 20.1 and 20.3 weeks for fulvestrant and sapanisertib respectively).'], 'Eligibility': ['Inclusion Criteria:', ' Female participants aged 18 years or older who are postmenopausal.', ' Histologically proven diagnosis of breast cancer with evidence of metastatic disease or locoregional recurrence.', ' Histological confirmation and documentation of estrogen receptor (ER)-positive status ( 1% positive stained cells).', ' Histological or cytological confirmation and documentation of human epidermal growth factor receptor-2 (HER2)-negative status by local laboratory testing using criteria in the American Society of Oncology (ASCO)/College of American Pathologists (CAP) Clinical Practice Guideline update.', ' Measurable disease defined as either of the following:', ' At least 1 extra-osseous lesion that could be accurately measured in at least 1 dimension.', ' The lesion must have measured 20 mm with conventional imaging techniques or 10 mm with spiral CT or MRI. Lymph nodes must be 1.5 cm in the short axis to be considered measurable.', ' Bone lesions (lytic or mixed [lytic plus sclerotic]) in the absence of measurable disease as defined above. Note: Participants with sclerotic/osteoblastic bone lesions only, in the absence of measurable disease, were not eligible.', ' Progressive Disease (PD) during prior aromatase inhibitor (AI) therapy.', ' Have a history of brain metastasis provided that all of the following criteria are met:', ' Brain metastases have been treated.', ' No evidence of PD for 3 months before the first dose of study drug.', ' No hemorrhage after treatment.', ' Off dexamethasone treatment for 4 weeks before the first dose of study drug.', ' No ongoing requirement for dexamethasone or anti-epileptic drugs.', ' Eastern cooperative oncology group (ECOG) performance status of 0 or 1.', ' Clinical laboratory values as specified below within 4 weeks before the first dose of study drug:', ' Bone marrow reserve consistent with absolute neutrophil count (ANC) 1.5*10^9/L; platelet count 100*10^9/L; hemoglobin (Hgb) 9 g/dL.', ' Total bilirubin 1.5*the upper limit of the normal range (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 2.5*ULN ( 5*ULN if liver metastases are present).', ' Creatinine clearance 40 mL/min based on Cockcroft-Gault estimate or based on a 12- or 24-hour urine collection.', ' Fasting serum glucose 130 mg/dL and fasting triglycerides 300 mg/dL.', 'Exclusion Criteria:', ' Prior therapy with mechanistic target of rapamycin (mTOR), phosphoinositide-3-kinase (PI3K), or dual PI3K-mTOR inhibitors, serine/threonine-specific protein kinase (AKT) inhibitors, or fulvestrant.', ' Prior treatment with >1 line of chemotherapy for metastatic breast cancer or for locoregional recurrence that was not amenable to resection or radiation therapy with curative intent.', ' Experienced PD on >2 endocrine therapies for metastatic breast cancer or for locoregional recurrence that was not amenable to resection or radiation therapy with curative intent.', ' Life-threatening metastatic visceral disease (defined as extensive hepatic involvement or symptomatic pulmonary lymphangitic spread).', ' Poorly controlled diabetes mellitus defined as hemoglobin A1c (glycosylated hemoglobin; HbA1c) >7%; participants with a history of transient glucose intolerance due to corticosteroid administration may be eligible if all other inclusion/exclusion criteria are met.'], 'Results': ['Outcome Measurement: ', ' Progression Free Survival (PFS)', ' PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.', ' Time frame: Up to 40 months', 'Results 1: ', ' Arm/Group Title: Arm A: Fulvestrant 500 mg', ' Arm/Group Description: Fulvestrant 500 mg, intramuscularly (IM), once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 16.0 weeks).', ' Overall Number of Participants Analyzed: 46', ' Median (95% Confidence Interval)', ' Unit of Measure: months 3.5 (1.9 to 5.6)', 'Results 2: ', ' Arm/Group Title: Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD', ' Arm/Group Description: Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with the sapanisertib 4 mg, capsules, orally, once daily in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 20.1 and 20.3 weeks for fulvestrant and sapanisertib respectively).', ' Overall Number of Participants Analyzed: 47', ' Median (95% Confidence Interval)', ' Unit of Measure: months 7.2 (3.9 to 10.6)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 8/46 (17.39%)', ' Angina pectoris 0/46 (0.00%)', ' Hypercalcaemia of malignancy 0/46 (0.00%)', ' Vomiting 0/46 (0.00%)', ' Diarrhoea 0/46 (0.00%)', ' Nausea 0/46 (0.00%)', ' Stomatitis 0/46 (0.00%)', ' Pyrexia 0/46 (0.00%)', ' Cholelithiasis 0/46 (0.00%)', ' Hepatic failure 1/46 (2.17%)', ' Pyelonephritis acute 0/46 (0.00%)', ' Appendicitis 0/46 (0.00%)', ' Cellulitis 0/46 (0.00%)', 'Adverse Events 2:', ' Total: 13/47 (27.66%)', ' Angina pectoris 0/47 (0.00%)', ' Hypercalcaemia of malignancy 0/47 (0.00%)', ' Vomiting 2/47 (4.26%)', ' Diarrhoea 2/47 (4.26%)', ' Nausea 0/47 (0.00%)', ' Stomatitis 1/47 (2.13%)', ' Pyrexia 2/47 (4.26%)', ' Cholelithiasis 0/47 (0.00%)', ' Hepatic failure 0/47 (0.00%)', ' Pyelonephritis acute 0/47 (0.00%)', ' Appendicitis 0/47 (0.00%)', ' Cellulitis 0/47 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

c2c73b99-f89c-4dd3-8362-295f9a7965f3

Single

Adverse Events

NCT02129556

Cohort 1 of the primary trial had a much higher mortality rate than cohort 2.

Entailment

{'Clinical Trial ID': 'NCT02129556', 'Intervention': ['INTERVENTION 1: ', ' Phase Ib 2 mg/kg', ' HER2-positive, PD-L1 expressing, unresectable loco-regional or metastatic breast carcinoma that progressed on prior trastuzumab-based therapy', 'INTERVENTION 2: ', ' Phase Ib 10 mg/kg', ' HER2-positive, PD-L1 expressing, unresectable loco-regional or metastatic breast carcinoma that progressed on prior trastuzumab-based therapy'], 'Eligibility': ['Inclusion criteria for screening:', ' Female gender', ' Age 18 years', ' Histologically confirmed breast adenocarcinoma that is unresectable loco-regional, or metastatic.', ' Locally confirmed HER2-positivity (immunohistochemistry score 3+) or ERBB2-amplification (Ratio ERBB2/centromeres 2.0 or mean gene copy number 6) of primary tumor or of biopsy from metastatic or unresectable loco-regional lesion.', ' Trastuzumab resistant disease, defined by:', ' progression of disease while on-treatment with trastuzumab', ' recurrence while on adjuvant trastuzumab or within 12 months of completing adjuvant trastuzumab', ' Any number of prior lines of anti-HER2 therapy acceptable. Patients for whom the treatment with the current first-line combination of trastuzumab, pertuzumab and taxanes is not an option can be considered for enrollment', ' If a patient has received a subsequent anti-HER2 therapy, she must also have progressed on the subsequent therapy.', ' Presence of at least one measurable lesion (RECIST 1.1)', ' LVEF 50%', ' Patient agrees to submit an FFPE tumor biopsy for central confirmation of HER2 positivity and central assessment of PD-L1 status.', ' Written Informed Consent (IC) for screening procedures and trial participation must be signed and dated by the patient and the Investigator prior to screening.', ' Written consent to biological material submission, indicating the patient has been informed of and agrees to tissue and blood material use, transfer and handling, must be signed and dated by the patient and the investigator prior to any procedures specific for this trial, including consent to translational research on FFPE and fresh frozen tumor biopsies in case the patient is enrolled into the trial.', ' The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.', ' Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1', ' Life expectancy >3 months.', ' Hematopoietic status:', ' Absolute neutrophil count 1.5 × 109/L,', ' Platelet count 100 × 109/L,', ' Hemoglobin 9 g/dL', ' Hepatic status:', " Serum total bilirubin 1.5 × upper limit of normal (ULN). In the case of known Gilbert's syndrome, a higher serum total bilirubin (< 2 × ULN) is allowed.", ' AST and ALT 2.5 × ULN; if the patient has liver metastases, ALT and AST must be 5 × ULN.', ' Renal status:', ' Creatinine 1.5 ×ULN or creatinine clearance > 60 ml/min', ' Proteinuria <1 g/day', ' International Normalized Ratio (INR) or Prothrombin Time (PT) 1.5 × ULN unless patient is receiving anticoagulant therapy as long as PT or PTT (partial thromboplastin time) is within therapeutic range of intended use of anticoagulant.', ' Inclusion criteria for enrollment:', ' All inclusion criteria for screening, plus:', ' Central lab confirmation on a metastatic biopsy (or biopsy from unresectable loco-regional disease) of:', ' HER2-positivity (immunohistochemistry score 3+) or ERBB2- amplification (Ratio ERBB2/centromeres 2.0 or mean gene copy number 6),', ' Presence of PD-L1 expression assessed by IHC (during the phase II portion of the trial a parallel, secondary cohort of 15 patients with PD-L1 negative disease will be enrolled)', ' Patient agrees to submit tumor tissue for translational research:', ' tissue biopsy from unresectable loco-regional or metastatic disease obtained 1 year prior to enrollment or new tissue material from a recently obtained surgical or diagnostic biopsy. For patients who have presented with stage 4 disease de novo, a biopsy taken from the presumed primary breast lesion is acceptable (provided this was taken 1 year prior to enrollment).', ' if available: FFPE tumor block from primary surgery or diagnostic biopsy.', ' if available: pre-treatment fresh frozen tumor biopsy.', ' if feasible: FFPE tumor block from post-treatment biopsy will be taken at time of disease progression or end of all treatment if ended prior to progression. This re-biopsy is strongly advised.', ' if feasible: fresh frozen tumor biopsy from post-treatment biopsy will be taken at time of disease progression or end of all treatment if ended prior to progression.', ' Patient agrees to submit baseline (pre-treatment) blood and serial plasma for translational research', ' For patient of childbearing potential, negative serum pregnancy test. Pregnancy test has to be repeated within 72h before treatment start.', ' All anti-cancer treatment including endocrine therapy, with the exception of trastuzumab, must stop 3 weeks prior to first dose of trial treatment.', ' Exclusion criteria for screening:', ' Prior therapy with other anti-PD-1, anti- PD-L1, L2 or anti-CTLA4 therapy.', ' No FFPE material to centrally assess HER2-positivity and PD-L1 expression.', ' Known Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), or positive for Hepatitis B (HBsAg reactive) or Hepatitis C (HCV RNA [qualitative]).', ' Interstitial lung disease', ' History of or active pneumonitis requiring treatment with steroids', ' Active central nervous system metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (patients with history of CNS metastases or spinal cord compression are eligible if they are clinically and radiologically stable for at least 4 weeks before first dose of investigational product and have not required high-dose steroid treatment in the last 4 weeks).', ' Leptomeningeal disease', ' History of clinically significant or uncontrolled cardiac disease, including congestive heart failure (New York Heart Association functional classification 3), angina, myocardial infarction or ventricular arrhythmia.', ' Previous severe hypersensitivity reaction to treatment with another monoclonal antibody.', ' Active infection requiring systemic therapy.', ' Chronic systemic therapy with immunosuppressive agents including cortico¬steroids.', " Concurrent disease or condition that would make the patient inappropriate for trial participation or any serious medical disorder that would interfere with the patient's safety.", ' Known history of uncontrolled hypertension ( 180/110), unstable diabetes mellitus, dyspnea at rest, or chronic therapy with oxygen.', ' Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of Informed Consent.', ' Treatment with an investigational agent in the 4 weeks before enrollment.', " Active autoimmune disease or a documented history of autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Patients that require intermittent use of bronchodilators or local steroid injections would not be excluded from the trial. Patients with hypothyroidism stable on hormone replacement or Sjögren's syndrome will not be excluded from the trial.", ' Chemotherapy, radioactive therapy, and/or biological cancer therapy within 3 weeks prior to the first trial dose and has not recovered to CTCAE v.4 grade 1 or better from adverse events.', ' Pregnant or lactating women; lactation has to stop before enrollment.', ' The patient of childbearing potential who is unwilling to use highly effective contraception during treatment and up to 7 months after stop of trial treatment. Acceptable methods are intrauterine devices (without hormones), bilateral tubal occlusion, vasectomized partner or total abstinence. Oral, injectable, or implant hormonal contraceptives are not allowed.', ' Unresolved or unstable, serious adverse events from prior administration of another investigational drug.', ' Active or uncontrolled infection CTCAE v.4 grade 2 or higher.', ' Live vaccines within 30 days prior to the first dose of trial therapy and during trial treatment.', ' Exclusion criteria for enrollment:', ' All exclusion criteria for screening apply for enrollment as well. Excluded are especially patients who have received any of the treatments below:', ' Live vaccines within 30 days prior to the first dose of trial therapy and during trial treatment.', ' History of CNS metastases or spinal cord compression if they have not been clinically stable for at least 4 weeks before first dose of investigational product and require high-dose steroid treatment.', ' Treatment with an investigational agent in the 4 weeks before enrollment.', ' Patient has not recovered to CTCAE v.4 grade 1 or better from adverse events of prior therapy, except alopecia grade 2.', ' Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), or positive for Hepatitis B or Hepatitis C.'], 'Results': ['Outcome Measurement: ', ' Dose-Limiting Toxicity (DLT) of MK-3475 in Combination With Trastuzumab', ' Determination of dose-limiting toxicity (DLT) which is defined as an adverse event or abnormal laboratory value assessed as suspected to be trial treatment related (possible, probable or definite) and unrelated to disease or disease progression. Toxicities and lab values will be graded according to the NCI CTCAE (v4.0).', ' Any grade-3 or greater non-hematological adverse event lasting at least one week;', ' Any grade-4 hematological toxicity; or,', ' Any adverse event resulting in a delay starting cycle 2 of more than 14 days.', ' Time frame: Within the first 21 days', 'Results 1: ', ' Arm/Group Title: Phase Ib 2 mg/kg', ' Arm/Group Description: HER2-positive, PD-L1 expressing, unresectable loco-regional or metastatic breast carcinoma that progressed on prior trastuzumab-based therapy', ' Overall Number of Participants Analyzed: 3', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 0 0.0%', 'Results 2: ', ' Arm/Group Title: Phase Ib 10 mg/kg', ' Arm/Group Description: HER2-positive, PD-L1 expressing, unresectable loco-regional or metastatic breast carcinoma that progressed on prior trastuzumab-based therapy', ' Overall Number of Participants Analyzed: 3', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 0 0.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/6 (66.67%)', ' Anemia 0/6 (0.00%)', ' Takotsubo cardiomyopathy 1/6 (16.67%)', ' Pericardial effusion 0/6 (0.00%)', ' Vertigo 1/6 (16.67%)', ' Retinal vein occlusion 0/6 (0.00%)', ' Gastroenteritis 1/6 (16.67%)', ' Vomiting 1/6 (16.67%)', ' Diarrhea 0/6 (0.00%)', ' Death 2/6 (33.33%)', ' Bile duct dilatation 0/6 (0.00%)', ' Hepatic hemorrhage 0/6 (0.00%)', 'Adverse Events 2:', ' Total: 25/52 (48.08%)', ' Anemia 1/52 (1.92%)', ' Takotsubo cardiomyopathy 0/52 (0.00%)', ' Pericardial effusion 2/52 (3.85%)', ' Vertigo 0/52 (0.00%)', ' Retinal vein occlusion 1/52 (1.92%)', ' Gastroenteritis 0/52 (0.00%)', ' Vomiting 0/52 (0.00%)', ' Diarrhea 1/52 (1.92%)', ' Death 9/52 (17.31%)', ' Bile duct dilatation 1/52 (1.92%)', ' Hepatic hemorrhage 1/52 (1.92%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

180d7b66-9ee9-40fb-b4c7-a6060e6f67b7

Comparison

Adverse Events

NCT00394082

NCT01033032

the primary trial recorded cases of Anaphylaxis and Spinal compression fracture, neither of these were observed in the secondary trial.

Entailment

{'Clinical Trial ID': 'NCT00394082', 'Intervention': ['INTERVENTION 1: ', ' ABI-007 Plus Bevacizumab', ' ABI-007 is administered on days 1, 8 and 15 at 125 mg/m^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If a patient develops intolerable toxicity to only one of the drugs, the other drug may be continued as single agent therapy in the absence of progression, as long as the treating physician feels this is in the best interests of the patient.'], 'Eligibility': ['Inclusion Criteria:', ' Pathologically confirmed adenocarcinoma of the breast.', ' Stage IV disease.', ' Measurable disease (defined as the presence of at least one lesion that can be accurately measured in at least one dimension with longest diameter greater or = 1.0 cm with spiral computed tomography (CT) scan).', ' Patients must not be a candidate for Herceptin therapy (i.e., patients with HER-2 positive disease (gene amplification by fluorescence in situ hybridization (FISH) or 3 + overexpression by ICH) and patients with unknown HER-2 status are ineligible unless the treating physicians has determined that Herceptin-based therapy would be inappropriate or not indicated).', " For subjects with prior anthracycline exposure, normal cardiac function including a baseline left ventricle ejection fraction >50% or above institution's lower limit of normal and a normal electrocardiogram (ECG) (as assessed by the investigator).", ' At least 2 weeks since radiotherapy, with full recovery. The measurable disease must be completely outside the radiation portal or there must be pathologic proof of progressive disease within the radiation portal.', ' International Normalized Ratio (INR) < 1.5 and activated partial thromboplastin time within normal limits (APTT WNL).', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.', ' Female > 18 years of age.', ' Patients have the following blood counts at Baseline: absolute neutrophil count (ANC) greater or equal to 1.5 x 10^9 cells/L; platelets greater or equal 100 x 10^9 cells/L; hemoglobin (Hgb) greater or equal to 9g/dL.', ' Patients have the following blood chemistry levels at Baseline: aspartate aminotransferase (AST or SGOT), alanine aminotransferase (ALT or SGPT) less than or equal 2.5x upper limit of normal (ULN) range (less than or equal 5x ULN if patient has known liver metastases); total bilirubin greater than or equal to ULN; creatinine greater or equal to 1.5mg/dL.', ' if female of childbearing potential, pregnancy test is negative within 72 hours of first dose of study drug.', ' if fertile, the patient agrees to use an effective method to avoid pregnancy for the duration of the study.', ' Informed consent has been obtained.', 'Exclusion Criteria:', ' No prior chemotherapy for metastatic or locally recurrent disease is allowed.', ' Prio neo-adjuvant chemotherapy is allowed, and patients must have recovered from the acute toxicity of such therapies.', ' if a taxane was part of the adjuvant regimen, at least 12 months must have elapsed between the last dose of the taxane and the date of diagnosis of metastatic disease.', ' if a non-taxane-based adjuvant therapy was administered, at least six months must have elapsed between the last dose of the non- taxane-containing chemotherapy and the date of diagnosis of metastatic disease.', ' Concurrent immunotherapy or hormonal therapy.', ' Parenchymal brain metastases, including leptomeningeal involvement.', ' Uncontrolled hypertension (defined as blood pressure of > 150/100 mmHg)', ' NYHA Grade 2 or greater congestive heart failure', ' History of coagulopathy, bleeding diathesis, therapeutic anticoagulation other than low dose or chronic ASA greater than or equal to 325 mg per day. Low dose coumadin for anticoagulation of venous access device or low dose molecular weight heparin (LMWH)for deep vein thrombosis prophylaxis or low dose (325 mg or less) ASA prophylaxis are allowed, but are best avoided if the treating physician feels it is safe to do so.', ' Urine protein:creatinine ratio less than or equal to 1.0 at screening.', ' No history of cerebrovascular accident within six months of study entry.', ' Active symptomatic peripheral vascular disease (e.g. aortic aneurysm, claudication) within six months of study entry.', ' Uncontrolled or severe cardiovascular disease including myocardial infarction or unstable angina within six months of study entry.', ' No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal process within six months of study entry.', ' No serious non-healing wound, ulcer, or bone fracture', ' Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to first dose, or anticipation of need for major surgical procedure during the course of the study. No minor surgical procedure within seven days of study entry. Serious intercurrent medical or psychiatric illness, including serious active infection.', ' History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer.', ' Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study.', ' Pregnant or nursing women.', ' Patients with current sensory neuropathy of > Grade 1 will be excluded.'], 'Results': ['Outcome Measurement: ', ' Participants With At Least One Treatment-Emergent Adverse Event (TEAE)', ' Count of study participants who had at least one treatment-emergent adverse event (TEAE) defined as any adverse event that began or worsened in grade after the start of study drug through 30 days after the last dose of study drug.', ' Time frame: up to 25 months', 'Results 1: ', ' Arm/Group Title: ABI-007 Plus Bevacizumab', ' Arm/Group Description: ABI-007 is administered on days 1, 8 and 15 at 125 mg/m^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If a patient develops intolerable toxicity to only one of the drugs, the other drug may be continued as single agent therapy in the absence of progression, as long as the treating physician feels this is in the best interests of the patient.', ' Overall Number of Participants Analyzed: 50', ' Measure Type: Number', ' Unit of Measure: participants 50'], 'Adverse Events': ['Adverse Events 1:', ' Total: 13/50 (26.00%)', ' Febrile neutropenia 3/50 (6.00%)', ' Neutropenia 1/50 (2.00%)', ' Pancreatitis 1/50 (2.00%)', ' Cholangitis 1/50 (2.00%)', ' Cholelithiasis 1/50 (2.00%)', ' Anaphylactic reaction [1]1/50 (2.00%)', ' Pneumonia 1/50 (2.00%)', ' Pneumonitis chemical 1/50 (2.00%)', ' Spinal compression fracture 1/50 (2.00%)', ' Dehydration 1/50 (2.00%)', ' Electrolyte imbalance 1/50 (2.00%)']}

{'Clinical Trial ID': 'NCT01033032', 'Intervention': ['INTERVENTION 1: ', ' Amrubicin', ' Systemic therapy with amrubicin'], 'Eligibility': ['Inclusion Criteria:', ' Females >=18 years of age.', ' Histologic diagnosis of HER2-negative breast cancer. HER-2 negativity must be confirmed by one of the following:', ' FISH-negative (FISH ratio <2.2), or', ' IHC 0-1+, or', ' IHC 2-3+ AND FISH-negative (FISH ratio <2.2)', ' Evidence of metastatic or locally advanced, inoperable breast cancer.', ' Minimum of 1 and maximum of 2 prior metastatic breast cancer chemotherapy regimens.', ' Patients with prior anthracycline therapy are eligible, provided their previous anthracycline was 6 months prior to study entry.', ' Measurable disease per RECIST criteria version 1.1', ' Left ventricular ejection fraction (LVEF) ³50% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA).', ' Patients must have QTc interval of <=450 msec.', ' No intercurrent significant medical conditions or cardiac illness.', ' Patients must be >=3 weeks since last chemotherapy, and recovered from all acute toxicities, with the exception of alopecia.', ' Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2.', ' Adequate organ function including the following:', ' ANC >=1500 cells/mL', ' Platelet count >=100,000 cells/mL', ' Hemoglobin >=9 g/dL', ' Total bilirubin <=1.5 x ULN; AST/ALT <=2.5 x ULN, (except if due to hepatic metastases, then <=5 x ULN)', ' Serum creatinine <1.5 x ULN', ' Women of childbearing potential must have a negative serum or urine pregnancy test performed <=7 days prior to start of treatment. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately.', ' Patients must be accessible for treatment and follow-up.', ' Patients must be able to understand the investigational nature of this study and give written informed consent prior to study entry.', " Patients who are on anticoagulation are acceptable if the therapeutic anticoagulation is stable. Additionally, the patient's INR must be adequate if the patient is receiving treatment with coumadin.", " Prior hormonal therapy for metastatic breast cancer is permitted; however, the therapy must be discontinued prior to the patient's enrollment in this study.", 'Exclusion Criteria:', ' Any concurrent therapy with other investigational, chemotherapeutic, or hormonal therapy.', " Prior treatment with >=3 regimens of cytotoxic therapy in the advanced disease setting. (Any number of previous hormonal therapies are acceptable, as long as the therapy is discontinued prior to the patient's enrollment into this study).", ' Major surgery or systemic therapy <=3 weeks of study treatment.', ' Prior high-dose chemotherapy requiring hematopoietic stem cell support.', ' Prior radiation therapy to >25% of the bone marrow.', ' Uncontrolled brain metastases. Patients with treated brain metastases (resection or radiotherapy) are eligible if brain metastases have responded to treatment as documented by CT or MRI scan obtained at >=2 weeks after completion of radiation therapy, neurologic symptoms are absent, and steroids have been discontinued.', ' Suspected, diffuse idiopathic interstitial lung disease or pulmonary fibrosis.', ' Diagnosis of second malignancy within the last 3 years (with the exception of carcinoma in situ of the cervix, squamous or basal cell skin cancer, thyroid cancer, ductal carcinoma in situ [DCIS], or lobular carcinoma in situ [LCIS]).', ' Any of the following <=12 months prior to starting study treatment:', ' myocardial infarction;', ' severe unstable angina;', ' congestive heart failure;', ' ongoing cardiac dysrhythmia.', ' Family history of idiopathic cardiomyopathy or uncontrolled heart arrhythmia.', ' Patients with previous allergy or hypersensitivity to anthracyclines.', ' Patients who have had a 10% drop in LVEF on previous anthracycline therapy.', ' Palliative radiotherapy to areas of metastatic breast cancer must have been completed >7 days prior to the first dose of study treatment. The exception is radiotherapy for brain metastases, which must be completed >=21 days prior to study treatment. (Note: Any measurable lesion that has been previously irradiated will not be considered as a target lesion).', ' Concurrent severe, intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.', ' History of seropositive HIV, or patients who are receiving immunosuppressive medications that increase the risk of neutropenic complications.', ' Mental condition that would prevent patient comprehension of the nature of, and risk associated with, the study.', ' Use of any non-approved or investigational agent <=30 days of administration of the first dose of study drug. Patients may not receive any other investigational or anti-cancer treatments while participating in this study.'], 'Results': ['Outcome Measurement: ', ' Progression-Free Survival (PFS) of MTD/Phase II Patients', ' Progression-free survival is measured from Day 1 of study drug administration to disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death on the study. Progression is defined in RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, a measurable increase in a non-target lesion, or the appearance of new lesions. This outcome measure is reported for all patients treated at the same dose level and is not separated into Phase I and Phase II. The phase I and phase II results are not separated as the timing of enrollment (early in phase 1 or later phase II) is not relevant to the outcome measure.', ' Time frame: every 6 weeks until progressive disease', 'Results 1: ', ' Arm/Group Title: Amrubicin', ' Arm/Group Description: Systemic therapy with amrubicin', ' Overall Number of Participants Analyzed: 66', ' Median (95% Confidence Interval)', ' Unit of Measure: months 4.0 (2.5 to 5.8)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/3 (33.33%)', ' FEBRILE NEUTROPENIA 0/3 (0.00%)', ' LYMPH NODE PAIN 0/3 (0.00%)', ' NEUTROPHIL COUNT DECREASED 0/3 (0.00%)', ' THROMBOCYTOPENIA 0/3 (0.00%)', ' CHEST PAIN 0/3 (0.00%)', ' DEHYDRATION 0/3 (0.00%)', ' PLEURAL EFFUSION 1/3 (33.33%)', ' PNEUMONITIS 0/3 (0.00%)', ' PULMONARY INFILTERATES 0/3 (0.00%)', ' ALOPECIA 0/3 (0.00%)']}

949ac54b-a871-4134-a507-c98a4de55720

Single

Eligibility

NCT00167414

Patients must have Human epidermal growth factor receptor 2 (HER2) overexpressive tumors to participate in the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT00167414', 'Intervention': ['INTERVENTION 1: ', ' Hypofractionated Stereotactic Body Radiation Therapy', ' Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.', ' Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy', ' Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.'], 'Eligibility': ['Inclusion Criteria:', ' Age: no limit', ' Karnofsky performance status (KPS) 70', ' No more than 5 metastatic sites involving one or more different organs (liver, lung or bone).', ' The size of the lesion must be such that it can be safely treated to sterilizing radiation doses according to the rules in the protocol.', ' Previously treated lesions are not eligible unless the prescribed dose can be safely delivered.', ' Concurrent therapy is allowed and recommended. The chemotherapy protocol type and schedule are at the discretion of the medical oncologist.', ' Informed consent must be obtained.', ' Pregnancy test must be negative for women of child bearing potential', 'Exclusion Criteria:', ' Inability of patient to be followed longitudinally as specified by protocol.', ' Technical inability to achieve required dose based on safe dose constraints required for radiosurgery.', ' Women who are pregnant or nursing.', ' Failure to meet requirements in Inclusion Criteria', ' Contraindications to radiation.'], 'Results': ['Outcome Measurement: ', ' Overall Survival', ' The percent of patients that survived from date of enrollment until 2 year follow-up visit.', ' Time frame: 2 years', 'Results 1: ', ' Arm/Group Title: Hypofractionated Stereotactic Body Radiation Therapy', ' Arm/Group Description: Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.', ' Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy', ' Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.', ' Overall Number of Participants Analyzed: 39', ' Measure Type: Number', ' Unit of Measure: percentage of participants 74'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/39 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

02407f87-235d-4240-98fe-498b352cce75

Single

Eligibility

NCT00030823

Patients with stage I, II, III or IV triple negative breast cancer are not eliglbe for the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT00030823', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', ' Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine with QS21 adjuvant subcutaneously weekly on weeks 1, 2, 3, 7, and 19.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Diagnosis of breast cancer at high risk for recurrence, defined by one of the following:', ' Stage IV that is free of all known disease after eradication by surgery, radiotherapy, or chemotherapy', ' May or may not have elevated CA 15-3 or CEA levels', ' Stage I, II, or III previously treated with adjuvant chemotherapy and clinically free of identifiable disease, but have rising CA 15-3 or CEA levels', ' Rising CA 15-3 and CEA defined as a prior normal level increased on 2 consecutive occasions at least 2 weeks apart', ' For patients with a significant history of smoking who have a chronically elevated CEA (less than 15), CEA must be increased at least 1.5 times the uppermost chronic value on 2 consecutive occasions at least 2 weeks apart', ' Stage III and completed adjuvant therapy no more than 24 months ago', ' Recurrence in the ipsilateral axilla after lumpectomy and/or axillary dissection or modified radical mastectomy', ' Recurrence in the ipsilateral breast after lumpectomy and/or axillary dissection', ' Stage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months ago', ' Stage IV that is stable on hormonal therapy', ' Hormone receptor status:', ' Not specified', ' PATIENT CHARACTERISTICS:', ' Age:', ' 18 and over', ' Sex:', ' Male or female', ' Menopausal status:', ' Not specified', 'Performance status:', ' Karnofsky 80-100%', ' Life expectancy:', ' Not specified', ' Hematopoietic:', ' Lymphocyte count at least 500/mm^3', ' WBC at least 3,000/mm^3', ' Hepatic:', ' AST no greater than 1.5 times upper limit of normal (ULN)', ' Alkaline phosphatase no greater than 1.5 times ULN', ' Renal:', ' Creatinine no greater than 1.5 times ULN', ' Cardiovascular:', ' No clinically significant New York Heart Association class III or IV cardiac disease', ' Other:', ' Not pregnant', ' Negative pregnancy test', ' Fertile patients must use effective contraception', ' No prior seafood allergy', ' No known prior immunodeficiency or autoimmune disease', ' No other active cancer except basal cell or squamous cell skin cancer', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy:', ' At least 6 weeks since prior immunotherapy', ' No prior vaccine with any of the antigens in this study', ' Chemotherapy:', ' See Disease Characteristics', ' At least 4 weeks since prior chemotherapy', ' No concurrent chemotherapy', ' Endocrine therapy:', ' See Disease Characteristics', ' Radiotherapy:', ' See Disease Characteristics', ' At least 4 weeks since prior radiotherapy', ' No concurrent radiotherapy', ' Surgery:', ' See Disease Characteristics', ' At least 4 weeks since prior surgery', ' Concurrent surgery for local recurrence allowed if patient remains disease free'], 'Results': ['Outcome Measurement: ', ' Safety', ' By assessing the toxicity and will be graded following immunization with polyvalent vaccine in accordance with the NCI Common Toxicity Criteria 2.0.', ' Time frame: 2 years', 'Results 1: ', ' Arm/Group Title: Vaccine', ' Arm/Group Description: Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine with QS21 adjuvant subcutaneously weekly on weeks 1, 2, 3, 7, and 19.', ' Overall Number of Participants Analyzed: 13', ' Measure Type: Number', ' Unit of Measure: participants 13'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/13 (7.69%)', ' SGPT (ALT) 1/13 (7.69%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

61a524d4-1697-4a10-b36a-a0c6cda79526

Single

Eligibility

NCT01597193

ECOG < 2 and a life expectancy over 12 weeks are necessary to participate in the primary trial.

Entailment

{'Clinical Trial ID': 'NCT01597193', 'Intervention': ['INTERVENTION 1: ', ' Dose Escalation: Enzalutamide 80 mg', ' Participants received enzalutamide 80 mg (two 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. Participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first.', 'INTERVENTION 2: ', ' Dose Escalation: Enzalutamide 160 mg', ' Participants received enzalutamide 160 mg (four 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. Participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed breast cancer with accompanying pathology report;', ' Submit unstained representative tumor specimen, either as a paraffin block (preferred) or 10 unstained slides', ' Received at least 2 lines of systemic therapy in the advanced setting (for enzalutamide alone arm only);', ' Eastern Cooperative Oncology Group performance (ECOG) status of 0 or 1;', ' Estimated life expectancy of at least 3 months', 'Exclusion Criteria:', ' Severe concurrent disease, infection, or comorbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment;', ' Pregnant or lactating;', ' Known or suspected brain metastasis or leptomeningeal disease;', ' History of another malignancy within the previous 5 years other than curatively treated in situ carcinomas;', ' For patients who are enrolled to receive enzalutamide plus anastrozole or exemestane or fulvestrant must not have received tamoxifen or any medication known to be a potent CYP3A4 inducer or inhibitor.'], 'Results': ['Outcome Measurement: ', ' Dose-Escalation Phase: Percentage of Participants With Dose-limiting Toxicity (DLTs)', ' DLTs were defined as any of following events related to the study drug: Any adverse event (AE) consistent with a seizure of any grade; Grade greater than equal to (>=) 3 fatigue, diarrhea, nausea, or vomiting that did not improve to Grade 1 within 14 days of initiating standard of care therapy; any Grade >=3 hematologic toxicity with the following modifications: 1) Grade >=3 platelet count associated with bleeding, 2) Grade >=3 absolute neutrophil count that persists for 7 or more days or that was associated with fevers (febrile neutropenia); Grade >=3 any other non-hematological toxicity that was determined to be related to study drug.', ' Time frame: Baseline up to Day 35', 'Results 1: ', ' Arm/Group Title: Dose Escalation: Enzalutamide 80 mg', ' Arm/Group Description: Participants received enzalutamide 80 mg (two 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. Participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first.', ' Overall Number of Participants Analyzed: 6', ' Measure Type: Number', ' Unit of Measure: percentage of participants 16.7', 'Results 2: ', ' Arm/Group Title: Dose Escalation: Enzalutamide 160 mg', ' Arm/Group Description: Participants received enzalutamide 160 mg (four 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. Participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first.', ' Overall Number of Participants Analyzed: 7', ' Measure Type: Number', ' Unit of Measure: percentage of participants 0.0'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/7 (28.57%)', ' Anaemia * 0/7 (0.00%)', ' Iron Deficiency Anaemia * 0/7 (0.00%)', ' Pericardial Effusion * 0/7 (0.00%)', ' Adrenal Insufficiency * 1/7 (14.29%)', ' Abdominal Pain * 0/7 (0.00%)', ' Gastritis Erosive * 0/7 (0.00%)', ' Urosepsis * 0/7 (0.00%)', ' Pneumonia * 0/7 (0.00%)', ' Urinary Tract Infection * 0/7 (0.00%)', ' Enterocolitis infectious * 0/7 (0.00%)', 'Adverse Events 2:', ' Total: 1/8 (12.50%)', ' Anaemia * 1/8 (12.50%)', ' Iron Deficiency Anaemia * 0/8 (0.00%)', ' Pericardial Effusion * 0/8 (0.00%)', ' Adrenal Insufficiency * 0/8 (0.00%)', ' Abdominal Pain * 0/8 (0.00%)', ' Gastritis Erosive * 0/8 (0.00%)', ' Urosepsis * 0/8 (0.00%)', ' Pneumonia * 0/8 (0.00%)', ' Urinary Tract Infection * 0/8 (0.00%)', ' Enterocolitis infectious * 0/8 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

304977b6-9742-4c3b-84fd-e5ef1737a143

Single

Eligibility

NCT01790932

patients with Phosphoinositide 3-kinase inhibitor based treatments are ineligible for the primary trial

Entailment

{'Clinical Trial ID': 'NCT01790932', 'Intervention': ['INTERVENTION 1: ', ' BKM120', ' BKM120: 100 mg capsule once daily each day of a 28 day cycle .', ' Treatment with BKM120 will continue until disease progression, unacceptable toxicity or withdrawal for other reasons.'], 'Eligibility': ['Inclusion Criteria:', ' Pathologically and radiologically confirmed metastatic triple negative breast cancer', ' Up to two prior lines of chemotherapy for metastatic breast cancer', ' Availability of a representative tumor specimen', ' At least one measurable lesion', 'Exclusion Criteria:', ' Have received previous treatment with PI3K inhibitors', ' Symptomatic central nervous system (CNS) metastases (controlled and asymptomatic CNS metastases are acceptable)', ' Concurrent malignancy or has a malignancy within 3 years of study enrollment', ' Any of the following mood disorders: active major depressive episode, bipolar disorder, obsessive-compulsive disorder, schizophrenia, history of suicidal attempt or ideation, homicidal ideation, greater than or equal to Common Toxicity Criteria for Adverse Events (CTCAE) grade 3 anxiety', ' Concurrently using other approved or investigational antineoplastic agent and/or chemotherapy within 21 days prior to enrollment in this study', ' Has received radiation therapy within 28 days prior to enrollment in this study or has not recovered from side effects of such therapy', ' Major surgery within 28 days of starting therapy or has not recovered from major side effects of a previous surgery', ' Poorly controlled diabetes mellitus', ' History of cardiac dysfunction', ' Currently receiving treatment with QT prolonging medication and the treatment cannot be discontinued or switched to a different medication', ' Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120', ' Receiving chronic treatment with steroids or another immunosuppressive agent', ' Other concurrent severe and/or uncontrolled medical condition that would contraindicate participation in this study', ' History of non-compliance to a medical regimen', ' Currently being treated with drugs known to be moderate or strong inhibitors or inducers of isoenzyme Cytochrome P450, family 3, subfamily A (CYP3A)', ' Known history of human immunodeficiency virus (HIV)', ' Pregnant or breastfeeding', ' Unwilling to observe total abstinence or to use double barrier method for birth control throughout trial'], 'Results': ['Outcome Measurement: ', ' Clinical Benefit Rate', ' Clinical benefit rate (CBR) was defined as the proportion of participants achieving complete response (CR), partial response (PR), or stable disease (SD) for 4 months or longer based on RECIST 1.1 criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PD is at least a 20% increase in sum LD of target lesions (smallest sum LD reference), new lesions, and/or unequivocal progression of existing non-target lesions. Stable disease (SD) is defined as any condition not meeting the above criteria.', ' Time frame: Disease was evaluated radiologically at baseline and every 2 cycles on treatment then every 3 months up to 2 years. Participants in this study cohort were followed for response on average approximately 2 months.', 'Results 1: ', ' Arm/Group Title: BKM120', ' Arm/Group Description: BKM120: 100 mg capsule once daily each day of a 28 day cycle .', ' Treatment with BKM120 will continue until disease progression, unacceptable toxicity or withdrawal for other reasons.', ' Overall Number of Participants Analyzed: 50', ' Measure Type: Number', ' Unit of Measure: proportion of participants 0.12 (0.056 to 0.238)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 17/50 (34.00%)', ' Fatigue 4/50 (8.00%)', ' Papulopustular rash 1/50 (2.00%)', ' Alanine aminotransferase increased 5/50 (10.00%)', ' Aspartate aminotransferase increased 4/50 (8.00%)', ' Alkalosis 1/50 (2.00%)', ' Anorexia 1/50 (2.00%)', ' Hyperglycemia 2/50 (4.00%)', ' Nervous system disorders - Other 1/50 (2.00%)', ' Dry skin 1/50 (2.00%)', ' Rash acneiform 1/50 (2.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

87c65217-85d9-4f05-87aa-f4dfacd9f25a

Comparison

Intervention

NCT01385137

NCT00593346

Placebo treatment is used in the secondary trial, but there is only a test group in the primary trial.

Entailment

{'Clinical Trial ID': 'NCT01385137', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Omega-3-fatty Acid)', ' Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity', 'INTERVENTION 2: ', ' Arm II (Placebo)', ' Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed primary invasive adenocarcinoma of the breast', ' Stage I, II, or IIIA disease', ' No metastatic disease', ' Must have undergone modified radical mastectomy or breast-sparing surgery and recovered', ' Estrogen-receptor positive (ER+) and/or progesterone-receptor positive (PR+)', ' Currently taking a third-generation aromatase inhibitor (AI) [e.g., anastrozole (Arimidex®), letrozole (Femara®), or exemestane (Aromasin®)] for 90 days prior to registration with plans to continue for 180 days after registration', ' Must have completed the S092 Brief Pain Inventory (BPI)-Short Form within the past 14 days, and must have a worst pain/stiffness of 5 on the BPI (item #2) that has started or increased with AI therapy', ' PATIENT CHARACTERISTICS:', ' Postmenopausal', ' Zubrod performance status 0-2', ' Willing to submit blood for serum-free estradiol, total estradiol, serum inflammatory markers (IL6, TNF-α, CRP), DHA and EPA, lipid profile (LDL, HDL, triglycerides), and DNA analysis (CYP19A1)', ' Able to complete study questionnaires in English', ' At least 5 years since other malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, ductal carcinoma in situ of the breast or adequately treated stage I or II cancer from which the patient is currently in complete remission', ' Patients must not have a known allergy to soy, given that the placebo is suspended in soybean oil', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics', ' At least 3 months since prior omega-3 fatty acid supplements and must agree to refrain from omega-3-fatty acid supplements from sources outside of this study', ' More than 28 days since prior investigational agents', ' No other medical therapy, alternative therapy, or physical therapy for joint pain/stiffness within the past 30 days', ' Patients must not be on anticoagulation medication (i.e., heparin/warfarin) because of increased risk of bleeding within 28 days prior to registration', ' Patients must not have a history of bone fracture or surgery of the afflicted knees and/or hands within 6 months prior to registration', ' Patients must not be on narcotics within 14 days of registration', ' Patients may have received corticosteroid treatment; however, the following criteria apply:', ' Patients must not have received oral or intramuscular corticosteroids within the 28 days prior to registration', ' Patients must not have received intra-articular steroids to the study, or any other, joint within 28 days prior to registration', ' Patients must not have received topical analgesics (e.g., capsaicin preparations) to the study joint or any other analgesics (e.g., opiates, tramadol; with the exception of nonsteroidal antiinflammatory drugs (NSAIDs) and acetaminophen) within 14 days prior to registration'], 'Results': ['Outcome Measurement: ', ' Week 12 Brief Pain Inventory (BPI) Worst Pain/Stiffness Score', ' Linear regression model-adjusted week 12 mean score by treatment group.', ' Purpose: To assess the severity of pain Population: Patients with pain from chronic diseases or conditions such as cancer, osteoarthritis and low back pain, or with pain from acute conditions such as postoperative pain Responsiveness: Responds to both behavioral and pharmacological pain interventions Method: Self-report or interview Scoring: Higher scores indicate more pain Range: 0-10', ' Time frame: 12 weeks post-registration', 'Results 1: ', ' Arm/Group Title: Arm I (Omega-3-fatty Acid)', ' Arm/Group Description: Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity', ' Overall Number of Participants Analyzed: 102', ' Mean (95% Confidence Interval)', ' Unit of Measure: BPI score 5.3 (4.68 to 5.91)', 'Results 2: ', ' Arm/Group Title: Arm II (Placebo)', ' Arm/Group Description: Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity', ' Overall Number of Participants Analyzed: 107', ' Mean (95% Confidence Interval)', ' Unit of Measure: BPI score 5.47 (4.86 to 6.09)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/117 (0.00%)', 'Adverse Events 2:', ' Total: 0/124 (0.00%)']}

{'Clinical Trial ID': 'NCT00593346', 'Intervention': ['INTERVENTION 1: ', ' Accelerated Partial Breast Brachytherapy', ' Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.', ' Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.'], 'Eligibility': ['Inclusion Criteria:', ' AJCC stage 0, I, or II (TisN0, T1N0, T2N0 = 3 cm) histologically confirmed carcinoma of the breast, treated with tylectomy. Axillary sampling is required only for cases of invasive cancers. Tumor size is determined by the pathologist. Clinical size may be used if the pathologic size is indeterminate.', ' Signed study-specific informed consent for participation in the study.', ' Negative, or close but negative, inked histologic margins of tylectomy or reexcision specimen to be confirmed prior to placing the brachytherapy catheters. Margins generally are positive if there is invasive or noninvasive tumor at the inked resection margin, close but negative if the tumor is within 2 mm of the inked margin and negative if the tumor is at least 2 mm away from the inked edge.', ' Negative post-tylectomy or post-reexcision mammography if cancer presented with malignancy-associated microcalcifications; no remaining suspicious microcalcifications in the breast before brachytherapy.', ' For patients with invasive cancer, no positive axillary lymph nodes with at least 6 axillary lymph nodes sampled or a negative sentinel node.', ' Invasive ductal, lobular, medullary, papillary, colloid (mucinous),or tubular histologies. Noninvasive ductal carcinoma in situ.', " Chemotherapy or hormonal therapy planned for = 2 weeks after removal of brachytherapy catheters is permitted. Hormonal therapy is allowed during brachytherapy at treating radiation oncologist's decision.", ' Negative pregnancy test for premenopausal patients with an intact uterus', 'Exclusion Criteria:', ' Patients with distant metastases.', ' Patients with in-situ lobular carcinoma or nonepithelial breast malignancies such as sarcoma or lymphoma.', ' Patients with proven multicentric carcinoma (tumors in different quadrants of the breast, or tumors separated by at least 4 cm) with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy.', ' Patients who are pregnant or lactating.', ' Patients with histologically confirmed positive axillary nodes in the ipsilateral axilla. Palpable or radiographically suspicious contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes, unless there is histologic confirmation that these nodes are negative for tumor.', ' Prior non-hormonal therapy for the present breast cancer, including radiation therapy or chemotherapy.', ' Patients with systemic lupus erythematosis, scleroderma, or dermatomyositis with a CPK level above normal or with an active skin rash.', ' Patients with coexisting medical conditions in whom life expectancy is < 2 years.', ' Patients with psychiatric or addictive disorders that would preclude obtaining informed consent or completing the full series of high dose rate brachytherapy treatments on an outpatient basis.', " Patients with Paget's disease of the nipple.", ' Patients with skin involvement, regardless of tumor size.', ' Patients with a breast unsatisfactory for brachytherapy. For example, if there is little breast tissue remaining between the skin and pectoralis muscle after surgery, placement of catheters is technically problematic.', ' Patients with tylectomies so extensive that the cosmetic result is fair or poor prior to brachytherapy.', ' Surgical margins which cannot be microscopically assessed or are positive at pathological evaluation.', ' Any previously treated contralateral breast carcinoma or synchronous bilateral breast carcinoma.', ' Other malignancy, except non-melanoma skin cancer, 5 years prior to participation in this study; the disease free interval from any prior carcinoma must be continuous.', ' Time between final definitive breast procedure to radioactive source loading of the brachytherapy catheters is greater than 8 weeks.', ' Patients with diffuse (> 1 quadrant or >5 cm in diameter) suspicious microcalcifications.', ' Patients with suspicious microcalcifications remaining on the post-tylectomy mammogram'], 'Results': ['Outcome Measurement: ', ' Local Control Using Ipsilateral Breast Tumor Recurrence Rates', ' [Not Specified]', ' Time frame: 2 years after treatment completion', 'Results 1: ', ' Arm/Group Title: Accelerated Partial Breast Brachytherapy', ' Arm/Group Description: Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.', ' Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.', ' Overall Number of Participants Analyzed: 151', ' Measure Type: Number', ' Unit of Measure: percentage of participants .7'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/151 (0.00%)']}

19e89ebc-a417-47a8-bfa7-1778baead178

Comparison

Adverse Events

NCT00950300

NCT00615901

the primary trial recorded a patient with chest pain, whereas the secondary trial observed a patient with abdominal pain.

Entailment

{'Clinical Trial ID': 'NCT00950300', 'Intervention': ['INTERVENTION 1: ', ' Herceptin IV + Chemotherapy', ' Participants received eight cycles of Herceptin IV plus chemotherapy prior to surgery and ten cycles of Herceptin IV after surgery. Chemotherapy consisted of docetaxel 75 mg/m^2 every 21 days for four cycles followed by FEC every 21 days for four cycles. Herceptin was administered as 8 mg/kg on Day 1 and then as 6 mg/kg on Day 22 and every 21 days thereafter. The first eight cycles prior to surgery comprised the Neoadjuvant Treatment Period, and the ten cycles of Herceptin IV after surgery comprised the Adjuvant Treatment Period. Thereafter, participants entered the TFFU Period. Participants who were withdrawn from the Neoadjuvant Treatment Period for any reason, or who experienced disease recurrence during either the Adjuvant Treatment Period or TFFU Period, could be entered into the SFU Period.', 'INTERVENTION 2: ', ' Herceptin SC + Chemotherapy', ' Participants received eight cycles of Herceptin SC plus chemotherapy prior to surgery and ten cycles of Herceptin SC after surgery. Chemotherapy consisted of docetaxel 75 mg/m^2 every 21 days for four cycles followed by FEC every 21 days for four cycles. Herceptin was administered as a 600-mg fixed dose given every 21 days. The first eight cycles prior to surgery comprised the Neoadjuvant Treatment Period, and the ten cycles of Herceptin IV after surgery comprised the Adjuvant Treatment Period. Thereafter, participants entered the TFFU Period. Participants who were withdrawn from the Neoadjuvant Treatment Period for any reason, or who experienced disease recurrence during either the Adjuvant Treatment Period or TFFU Period, could be entered into the SFU Period.'], 'Eligibility': ['Inclusion Criteria:', ' Adult women greater than or equal to ( ) 18 years of age', ' Non-metastatic primary invasive adenocarcinoma of the breast clinical stage I to IIIC, including inflammatory and multicentric/multifocal breast cancer, with tumor size 1 centimeter (cm) by ultrasound or 2 cm by palpation, centrally confirmed HER2-positive (immunohistochemical score [IHC] 3+ or in situ hybridization [ISH]-positive)', ' At least 1 measurable lesion in breast or lymph nodes ( 1 cm by ultrasound or 2 cm by palpation), except for inflammatory carcinoma (T4d)', ' Baseline left ventricular ejection fraction (LVEF) 55%', ' Eastern Cooperative Oncology Group (ECOG) status of 0 or 1', ' Adequate organ function at Baseline', 'Exclusion Criteria:', ' History of any prior (ipsilateral and/or contralateral) invasive breast carcinoma', ' Past or current history of malignant neoplasms, except for curatively treated basal and squamous cell carcinoma of the skin and in situ carcinoma of the cervix', ' Metastatic disease', ' Any prior therapy with anthracyclines', ' Prior anti-HER2 therapy or biologic or immunotherapy', ' Serious cardiac illness', ' Pregnant or lactating women'], 'Results': ['Outcome Measurement: ', ' Observed Serum Trough Concentration (Ctrough) of Trastuzumab Prior to Surgery', ' Pre-dose samples were obtained prior to surgery (Cycle 8). The observed Ctrough was recorded, averaged among all participants, and expressed in micrograms per milliliter (μg/mL).', ' Time frame: Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)', 'Results 1: ', ' Arm/Group Title: Herceptin IV + Chemotherapy', ' Arm/Group Description: Participants received eight cycles of Herceptin IV plus chemotherapy prior to surgery and ten cycles of Herceptin IV after surgery. Chemotherapy consisted of docetaxel 75 mg/m^2 every 21 days for four cycles followed by FEC every 21 days for four cycles. Herceptin was administered as 8 mg/kg on Day 1 and then as 6 mg/kg on Day 22 and every 21 days thereafter. The first eight cycles prior to surgery comprised the Neoadjuvant Treatment Period, and the ten cycles of Herceptin IV after surgery comprised the Adjuvant Treatment Period. Thereafter, participants entered the TFFU Period. Participants who were withdrawn from the Neoadjuvant Treatment Period for any reason, or who experienced disease recurrence during either the Adjuvant Treatment Period or TFFU Period, could be entered into the SFU Period.', ' Overall Number of Participants Analyzed: 235', ' Mean (Standard Deviation)', ' Unit of Measure: μg/mL 57.8 (30.3)', 'Results 2: ', ' Arm/Group Title: Herceptin SC + Chemotherapy', ' Arm/Group Description: Participants received eight cycles of Herceptin SC plus chemotherapy prior to surgery and ten cycles of Herceptin SC after surgery. Chemotherapy consisted of docetaxel 75 mg/m^2 every 21 days for four cycles followed by FEC every 21 days for four cycles. Herceptin was administered as a 600-mg fixed dose given every 21 days. The first eight cycles prior to surgery comprised the Neoadjuvant Treatment Period, and the ten cycles of Herceptin IV after surgery comprised the Adjuvant Treatment Period. Thereafter, participants entered the TFFU Period. Participants who were withdrawn from the Neoadjuvant Treatment Period for any reason, or who experienced disease recurrence during either the Adjuvant Treatment Period or TFFU Period, could be entered into the SFU Period.', ' Overall Number of Participants Analyzed: 234', ' Mean (Standard Deviation)', ' Unit of Measure: μg/mL 78.7 (43.9)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 45/298 (15.10%)', ' Febrile neutropenia * 10/298 (3.36%)', ' Neutropenia * 9/298 (3.02%)', ' Leukopenia * 0/298 (0.00%)', ' Thrombocytopenia * 0/298 (0.00%)', ' Lymphadenopathy * 1/298 (0.34%)', ' Cardiac failure congestive * 0/298 (0.00%)', ' Arrhythmia * 0/298 (0.00%)', ' Myocardial infarction * 1/298 (0.34%)', ' Angina pectoris * 1/298 (0.34%)', ' Atrial fibrillation * 0/298 (0.00%)', 'Adverse Events 2:', ' Total: 65/297 (21.89%)', ' Febrile neutropenia * 13/297 (4.38%)', ' Neutropenia * 7/297 (2.36%)', ' Leukopenia * 1/297 (0.34%)', ' Thrombocytopenia * 1/297 (0.34%)', ' Lymphadenopathy * 0/297 (0.00%)', ' Cardiac failure congestive * 2/297 (0.67%)', ' Arrhythmia * 1/297 (0.34%)', ' Myocardial infarction * 1/297 (0.34%)', ' Angina pectoris * 0/297 (0.00%)', ' Atrial fibrillation * 1/297 (0.34%)']}

{'Clinical Trial ID': 'NCT00615901', 'Intervention': ['INTERVENTION 1: ', ' Cohort A (CMF at 14 Day Intervals)', ' This is a pilot study using 8 cycles of CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2), at 14 day intervals supported by PEG-filgrastim for a cohort of 38 patients. A safety analysis will then be performed.', ' cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim: C (cyclophosphamide) 600 mg/m2 M (methotrexate) 40 mg/m2 F (fluorouracil) 600 mg/m2 P (PEG-filgrastim ) 6 mg. Eight doses of CMF q 14 days with PEG-filgrastim administered approximately 24 hours after chemotherapy. Day 14, is also considered day 1 of the next cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have histologically confirmed adenocarcinoma of the breast confirmed at MSKCC within 3 months of enrollment. Patients with inflammatory breast cancer are not eligible for the study. Pathology will be assessed in the standard fashion. Results of HER-2/neu, estrogen receptor, and progesterone receptor are required for study entry.', ' The patient cannot be Her-2/neu over-expressing either by immunohistochemistry or FISH as per hospital laboratory standard whether institutional or outside laboratory.', ' Patients must be > than or equal to 18 years of age', ' Patients must have a Karnofsky score of > than or equal to 80', ' Patients may have received hormonal therapy for the purpose of chemoprevention but must be willing to discontinue at least 24 hours prior to enrollment and while participating in this trial.', ' Patients will have completed their definitive breast surgery (mastectomy or breast conserving surgery)', ' Patients must be ready to begin therapy within 84 days from the final surgical procedure required to treat their primary tumor', ' Patients must be stage I-II', ' Absolute neutrophil count (ANC) > than or equal to 1500/µL and platelet count > than or equal to 100,000/µL', ' Total bilirubin must be < than or equal to 1.1 mg/dL or within normal institutional limits if outside MSKCC. Transaminases (SGOT/AST and/or SGPT/ALT) may be up to < than or equal to 92.5 U/L or < than or equal to 2.5 x institutional upper limit of normal (ULN) if alkaline phosphatase is < than or equal to ULN, or alkaline phosphatase may be up to 4 x ULN if transaminases are < than or equal to ULN.', ' Serum creatinine must be within 0.6-1.3 mg/dL or within normal institutional limits if outside MSKCC.', ' Patients must be willing to discontinue sex hormonal therapy e.g., birth control pills, ovarian hormonal replacement therapy, etc., prior to enrollment. Women of childbearing potential must be willing to consent to using effective contraception while on treatment and for a reasonable period thereafter.', ' Patients must give written, informed consent indicating their understanding and willingness to participate in the study.', ' Brachytherapy after lumpectomy is permitted.', 'Exclusion Criteria:', ' Stage III-IV breast cancer', ' Prior chemotherapy or radiation therapy is excluded except for brachytherapy.Radiation for patients on this protocol will be given, if indicated, after the completion of chemotherapy.', ' Pregnant or lactating patients', ' Patients with a concurrently active second malignancy, other than adequately treated non-melanoma skin cancers or in situ cervical cancer. Patients with other non-mammary malignancies must have been disease-free for at least five years.', ' Patients with unstable angina, congestive heart failure, current use of digitalis, betablockers, or calcium blockers for therapy of congestive heart failure, arrhythmia requiring medical therapy, or with a history of a myocardial infarction within 12 months.', ' Patients with a psychiatric illness that would prevent them from understanding the nature of the investigational therapy and complying with protocol requirements.', ' Patients with concurrent medical conditions, which, in the judgment of the investigator, would make them inappropriate candidates for study enrollment', ' Patients with active, unresolved infections', ' Patients that have known sensitivity to E. coli derived proteins, PEG-filgrastim, filgrastim, or any component products.', ' Patients must be Her 2/neu non-over-expressing.'], 'Results': ['Outcome Measurement: ', ' The Number of Patients Who Completed 8 Cycles.', ' the study regimen is deemed feasible and tolerable for patients with ANC > 1.5 on day 1 of treatment for all 8 cycles and absence of grade 3 or higher non-hematologic toxicity, excluding alopecia, nausea/vomiting and bone pain We will also evaluate the total number of days needed to complete all 8 cycles.', ' Time frame: 2 years', 'Results 1: ', ' Arm/Group Title: Cohort A (CMF at 14 Day Intervals)', ' Arm/Group Description: This is a pilot study using 8 cycles of CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2), at 14 day intervals supported by PEG-filgrastim for a cohort of 38 patients. A safety analysis will then be performed.', ' cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim: C (cyclophosphamide) 600 mg/m2 M (methotrexate) 40 mg/m2 F (fluorouracil) 600 mg/m2 P (PEG-filgrastim ) 6 mg. Eight doses of CMF q 14 days with PEG-filgrastim administered approximately 24 hours after chemotherapy. Day 14, is also considered day 1 of the next cycle.', ' Overall Number of Participants Analyzed: 29', ' Measure Type: Number', ' Unit of Measure: participants 29'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/38 (5.26%)', ' Febrile neutropenia 0/38 (0.00%)', ' Abdominal pain 1/38 (2.63%)', ' Skin infection 0/38 (0.00%)', ' Seizure 1/38 (2.63%)']}

561a0631-1eb3-48d1-baa2-81eb3fa79b98

Single

Adverse Events

NCT01671319

1/42 patients in cohort 1 of the primary trial fainted.

Entailment

{'Clinical Trial ID': 'NCT01671319', 'Intervention': ['INTERVENTION 1: ', ' Dose Dense TC + Pegfilgrastim', ' Docetaxel + Cyclophosphamide chemotherapy given every 2 weeks x 4 cycles plus pegfilgrastim given 24-48 hours post day 1 of each cycle', ' docetaxel + cyclophosphamide + pegfilgrastim: docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle'], 'Eligibility': ['Inclusion Criteria:', ' histologically confirmed invasive carcinoma of the female breast, status post definitive surgery (lumpectomy or mastectomy plus nodal evaluation if feasible). Patients must initiate therapy with ddTC within 84 days of the last breast or axillary surgery performed for curative intent', ' candidate for chemotherapy by the treating oncologist', ' Patients with pN2 or pN3 disease are NOT explicitly excluded. However, patients with N2 or N3 disease MUST be reviewed with the PI or study chair before being enrolled on the study as TC would not normally be considered adequate therapy for such patients.', ' Patients with bilateral, synchronous invasive breast cancer are eligible as long as both primary tumors meet the eligibility criteria.', ' Patients with estrogen-receptor (ER) and/or progesterone receptor (PR) negative, positive, or unknown tumors are eligible.', ' Patients with HER2 positive, negative or unknown disease are eligible for this trial. Patients whose tumors are HER2 positive by either immunohistochemistry (IHC) 3+ staining or demonstrate gene amplification by FISH should receive trastuzumab, following completion of adjuvant cytotoxic therapy with 4 cycles of ddTC.', ' There must be negative surgical margins for invasive cancer and DCIS. LCIS is acceptable at the margin.', ' Patients with multi-centric breast cancer are eligible as long as all known disease is resected from the breast with negative margins.', ' Age >18 years.', ' ECOG performance status 1', ' Women of childbearing potential should have a negative urine or blood beta-HCG, and must agree to contraception if engaging in sexual activity. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Women must not be pregnant or nursing as the chemotherapy drugs used in this study may cause harm to a fetus or newborn.', ' Ability to understand and the willingness to sign a written informed consent document.', ' Platelets >/=100,000/μl within 4 weeks of registration.', ' Absolute neutrophil count (ANC) >/= 1,500/μl within 4 weeks of registration.', ' Total bilirubin within normal institutional limits within 4 weeks of registration.', ' Alkaline phosphatase (alk phos) 2.5 X institutional Upper Limit of Normal (ULN) within 4 weeks of registration.', ' AST (SGOT)/ALT(SGPT) 1.5X ULN', ' Creatinine within normal institutional limits OR Creatinine clearance>/= 60 mL/min/1.73 m2 for patients with creatinine levels above normal', ' If patient has received tamoxifen or another selective estrogen receptor modulator (SERM) for prevention or for other indications (not for treatment of this cancer), they have been discontinued prior to enrollment.', 'Exclusion Criteria:', ' Patient has received previous trastuzumab, chemotherapy, hormonal therapy, or other anti-cancer agents (including investigational agents) for this malignancy.', ' Patient will be receiving GNRH agonists such as goserelin (Zoladex) or leuprolide acetate (Lupron) concomitantly with chemotherapy for the purpose of preventing breast cancer recurrence.', ' Patient has inflammatory breast cancer (pT4d) or metastatic breast cancer.', ' Patient has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements.', ' Patient has pre-existing persistent neuropathy.', ' The patient has received prior chemotherapy or radiotherapy or any malignancy within the past 2 years.', ' Patient has received prior docetaxel or cyclophosphamide within the past 5 years.', ' Patient has known contraindication or hypersensitivity to docetaxel, cyclophosphamide or pegfilgrastim.'], 'Results': ['Outcome Measurement: ', ' Feasibility for Dose-dense TC Therapy: Number of Participants Receiving at Least 90% of Total Dose of Therapy', ' Evaluate feasibility of delivering 4 cycles (1 cycle = 2 weeks) of docetaxel and cyclophosphamide (TC) on a dose-dense (q2week) schedule with pegfilgrastim support. This regimen will be referred to as dose-dense (dd)TC. Feasibility defined by at least 60% of patients receiving 90% of the total dose of therapy within 10 weeks.', ' Time frame: 4 cycles each 2 weeks in length for a total of 8 weeks, up to 10 weeks', 'Results 1: ', ' Arm/Group Title: Dose Dense TC + Pegfilgrastim', ' Arm/Group Description: Docetaxel + Cyclophosphamide chemotherapy given every 2 weeks x 4 cycles plus pegfilgrastim given 24-48 hours post day 1 of each cycle', ' docetaxel + cyclophosphamide + pegfilgrastim: docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle', ' Overall Number of Participants Analyzed: 41', ' Measure Type: Number', ' Unit of Measure: participants 37'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/42 (9.52%)', ' Perforation, GI 1/42 (2.38%)', ' Febrile neutropenia 1/42 (2.38%)', ' Syncope 1/42 (2.38%)', ' Rash/desquamation 1/42 (2.38%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

bc617e84-a0c1-400b-9ad5-88b56d1805e8

Single

Eligibility

NCT01097642

Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T3 N1 M0) are eligible for the primary trial.

Entailment

{'Clinical Trial ID': 'NCT01097642', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone', ' Brand name is Ixempra ®; it is an epothilone B analog used in combination with other chemotherapeutics against cancer.', ' Ixabepilone: Ixabepilone will be given at 40mg/m^2 IV over 180 minutes on day 1 of each of four 21 day cycles.', 'INTERVENTION 2: ', ' Ixabepilone Plus Cetuximab', ' Cetuximab, brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor and monoclonal antibody used with Ixabepilone against cancer.', ' Cetuximab: Cetuximab will be given at 400mg/m^2 IV over 120 minutes for its initial loading dose on day 1 of the first of four 21 day cycles. It will then be administered on a weekly basis at 250 mg/m^2 IV over 60 minutes.', ' Ixabepilone: Ixabepilone will be given at 40mg/m^2 IV over 180 minutes on day 1 of each of four 21 day cycles.'], 'Eligibility': ['Inclusion Criteria:', ' Patients with histologic confirmation of invasive breast carcinoma.', ' Patients must have intact primary tumor.', ' Patients greater than or equal to 18 years.', ' Patients should have T1N1-3M0 or T2-4 N0-3M0.', ' Patients with bilateral breast cancer are eligible.', ' Patients with second primary breast cancers are eligible.', ' Patients should have a Karnofsky performance scale of greater than or equal to 70%.', ' Patients must have clinically measurable disease to be treated in the neoadjuvant setting.', ' Patients should have adequate bone marrow function, as defined by peripheral granulocyte count of greater than or equal to 1500/mm^3, and platelet count greater than or equal to 100000mm^3.', ' Patients must have adequate liver function with a bilirubin within normal laboratory values. Alkaline phosphatase and transaminases (ALT and AST) may be up to 1.5 x upper limit of normal (ULN) of the institution.', ' Patients should have adequate renal function with creatinine levels within normal range.', ' Patients should have a normal left ventricular ejection fraction (LVEF) of greater than or equal to 50%.', ' Negative serum or urine pregnancy test for a woman of childbearing potential (WOCBP).', ' WOCBP must use a reliable and appropriate contraceptive method during the study and six months after chemotherapy is completed. WOCBP are women who are not menopausal for 12 months or had no previous surgical sterilization.', ' Patients must agree to have study biopsies.', ' Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.', 'Exclusion Criteria:', ' Patients with a history of other invasive malignancies diagnosed and treated within the previous 5 years, except non-melanoma skin cancer and non-invasive cervical cancer.', ' Her2Neu, ER and PR positive patients should be excluded.', ' Patients with Inflammatory breast cancer (IBC) are excluded.', ' Patients with an organ allograft or other history of immune compromise.', ' Prior treatment with any investigational drug within the preceding 4 weeks.', ' Chronic treatment with systemic steroids or another immunosuppressive agent.', ' A Known history of HIV seropositivity.', ' Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumarin defined as 1 mg a day).', ' Other concurrent and/or uncontrolled medical disease which could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, unstable angina, or congestive heart failure - New York Heart Association Class III or IV, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within six months, chronic liver or renal disease, active upper GI tract ulceration).', ' Patients with a pre-existing peripheral neuropathy.'], 'Results': ['Outcome Measurement: ', ' Complete Response Rate', " The study's primary objective is to determine the pathologic complete response rate (pCR) (breast and axilla) of Ixabepilone versus Ixabepilone when combined with cetuximab in patients with invasive breast adenocarcinoma T1N1-N3M0 or T2-4 N0-3M0 disease who are triple negative and who are candidates for preoperative chemotherapy.", ' The criteria used: "Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.", or similar definition that is accurate and appropriate.', ' Time frame: one year after treatment', 'Results 1: ', ' Arm/Group Title: Ixabepilone', ' Arm/Group Description: Brand name is Ixempra ; it is an epothilone B analog used in combination with other chemotherapeutics against cancer.', ' Ixabepilone: Ixabepilone will be given at 40mg/m^2 IV over 180 minutes on day 1 of each of four 21 day cycles.', ' Overall Number of Participants Analyzed: 15', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 2 13.3%', 'Results 2: ', ' Arm/Group Title: Ixabepilone Plus Cetuximab', ' Arm/Group Description: Cetuximab, brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor and monoclonal antibody used with Ixabepilone against cancer.', ' Cetuximab: Cetuximab will be given at 400mg/m^2 IV over 120 minutes for its initial loading dose on day 1 of the first of four 21 day cycles. It will then be administered on a weekly basis at 250 mg/m^2 IV over 60 minutes.', ' Ixabepilone: Ixabepilone will be given at 40mg/m^2 IV over 180 minutes on day 1 of each of four 21 day cycles.', ' Overall Number of Participants Analyzed: 25', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 8 32.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/15 (13.33%)', ' Neutropenia 0/15 (0.00%)', ' GI Events 0/15 (0.00%)', ' Peripheral neuropathy 2/15 (13.33%)', ' Rash 0/15 (0.00%)', 'Adverse Events 2:', ' Total: 6/25 (24.00%)', ' Neutropenia 2/25 (8.00%)', ' GI Events 1/25 (4.00%)', ' Peripheral neuropathy 2/25 (8.00%)', ' Rash 1/25 (4.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

8a8b7b19-9328-4cb3-b01c-8f4c358f4ac5

Single

Intervention

NCT00354640

Patients taking Intervention 1 of the primary trial receive higher doses of anastrozole than of simvastatin.

Contradiction

{'Clinical Trial ID': 'NCT00354640', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole and Simvastatin', ' adjuvant therapy : laboratory analysis', ' pharmacological study : laboratory analysis', ' simvastatin : 40 milligram tablet PO QD for 14 days', ' anastrozole : 1 milligram tablet PO QD for 14 days'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Meets any of the following criteria:', ' History of invasive breast cancer', ' History of ductal carcinoma in situ', ' At high risk for breast cancer, defined as being on anastrozole for chemoprevention of breast cancer', ' Receiving anastrozole for 30 days as adjuvant breast cancer treatment or for prevention of breast cancer', ' No active breast cancer with known metastatic involvement', ' Hormone receptor status not specified', ' PATIENT CHARACTERISTICS:', ' Female', ' Postmenopausal', ' ECOG performance status 0-2', ' AST and ALT 3 times upper limit of normal', ' Creatinine clearance 30 mL/min', ' No active liver disease', ' No prior hypersensitivity to any HMG-CoA reductase inhibitor or any of its components', ' No daily alcohol use of > 3 standard drinks/day', ' A standard drink is defined as 10 g of alcohol, which is equivalent to 285 mL of beer, 530 mL of light beer, 100 mL of wine, or 30 mL of liquor', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics', ' No cholesterol-lowering drug, including a statin, within the past 3 months', ' No selective estrogen receptor modulator (SERM) within the past 3 months', ' No other hormone therapy within the past 3 months', ' No prior estrogen and/or progesterone hormone replacement therapy that lasted for 5 years', ' Vaginal estrogen preparations allowed', ' No other concurrent statin or cholesterol-lowering drug', ' No other concurrent SERM', ' No other concurrent hormone therapy', ' No other concurrent investigational drugs', ' No concurrent CYP3A4 inhibitors, including itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, or cyclosporine', ' No concurrent chemotherapy or biological agents', ' No concurrent daily grapefruit juice > 8 oz/day', ' No other concurrent anticancer agents or therapies'], 'Results': ['Outcome Measurement: ', ' Change in Blood Concentrations', ' The change in blood concentrations of anastrozole at baseline and 14 days was measured.', ' Time frame: Baseline and 14 days', 'Results 1: ', ' Arm/Group Title: Anastrozole and Simvastatin', ' Arm/Group Description: adjuvant therapy : laboratory analysis', ' pharmacological study : laboratory analysis', ' simvastatin : 40 milligram tablet PO QD for 14 days', ' anastrozole : 1 milligram tablet PO QD for 14 days', ' Overall Number of Participants Analyzed: 9', ' Median (Full Range)', ' Unit of Measure: ng/ml Anastrozole concentration: 4.2 (-6.2 to 22.1)', ' Hydroxyanastrozole concentration: -0.03 (-0.14 to 0.08)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/11 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

bb4f69b0-0e2e-44e6-a3b6-049f4a8505fe

Single

Adverse Events

NCT00148668

Cohort 1 and 2 of the primary trial recorded the same number of patients with Febrile Neutropenia.

Contradiction

{'Clinical Trial ID': 'NCT00148668', 'Intervention': ['INTERVENTION 1: ', ' Arm 1', ' Herceptin/navelbine', 'INTERVENTION 2: ', ' Arm 2', ' Taxotere/carboplatin/herceptin'], 'Eligibility': ['Inclusion Criteria:', ' Patients with stage II or III breast cancer', ' HER-2 positive tumors', ' Older than 18 years of age', ' Eastern Cooperative Oncology Group (ECOG) Performance Status of greater or equal to 1.', ' ANC > 1,500/mm3', ' Hemoglobin > 9gm/dl', ' Platelets > 100,000mm3', ' Creatinine < 2mg/dl', ' Glucose < 200mg/dl', ' Bilirubin < 1.5 x ULN', 'Exclusion Criteria:', ' Previous treatment with herceptin, taxanes, doxorubicin or other anthracycline-type therapy, navelbine, or platinum-based therapy.', ' Pregnant or breast-feeding women', ' Serious illness, or medical or psychiatric condition', ' Uncontrolled infections', ' Active or severe cardiovascular or pulmonary disease', ' Patients with left ventricular ejection fraction < 50%', ' Peripheral neuropathy of any etiology that exceeds grade 1', ' Prior history of malignancy', ' Uncontrolled diabetes'], 'Results': ['Outcome Measurement: ', ' Pathological Complete Response After Preoperative Therapy With Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in Patients With HER-2 Positive Early Breast Cancer', ' Pathological Complete Response is defined as the complete disappearance of invasive tumor in the breast at the time of surgery', ' Time frame: 12 weeks', 'Results 1: ', ' Arm/Group Title: Arm 1', ' Arm/Group Description: Herceptin/navelbine', ' Overall Number of Participants Analyzed: 41', ' Measure Type: Number', ' Unit of Measure: percentage of participants 17', 'Results 2: ', ' Arm/Group Title: Arm 2', ' Arm/Group Description: Taxotere/carboplatin/herceptin', ' Overall Number of Participants Analyzed: 39', ' Measure Type: Number', ' Unit of Measure: percentage of participants 31'], 'Adverse Events': ['Adverse Events 1:', ' Total: 5/41 (12.20%)', ' Neutropenia 4/41 (9.76%)', ' Febrile Neutropenia 0/41 (0.00%)', ' SGPT (ALT) 1/41 (2.44%)', 'Adverse Events 2:', ' Total: 5/40 (12.50%)', ' Neutropenia 4/40 (10.00%)', ' Febrile Neutropenia 1/40 (2.50%)', ' SGPT (ALT) 0/40 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

b059e44b-9830-4c45-858e-ebd007fbaf69

Single

Eligibility

NCT00436917

Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from the primary trial, as these would interfere with the necessary CT and MRI scans for the study.

Contradiction

{'Clinical Trial ID': 'NCT00436917', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid', ' 4 mg intravenously over 15 minutes every 6 months (until disease progression or for 5 years)'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Diagnosis of localized breast cancer', ' Stage I-IIIA disease', ' Adequately treated breast cancer', ' No clinical or radiological evidence of recurrent or metastatic disease', ' Baseline total lumbar spine or femoral neck bone mineral density T-score < -2.0 standard deviation (e.g., a patient with a T score of -2.1 is eligible)', ' Hormone-receptor status:', ' Estrogen receptor and/or progesterone receptor-positive breast cancer', ' PATIENT CHARACTERISTICS:', ' Female', ' Postmenopausal, defined by 1 of the following criteria:', ' Age > 55 years with cessation of menses', ' Age 55 years with spontaneous cessation of menses for > 1 year', ' Age 55 years with spontaneous cessation of menses for 1 year, but amenorrheic (e.g., spontaneous or secondary to hysterectomy), AND has postmenopausal estradiol levels', ' Bilateral oophorectomy', ' ECOG performance status 0-2', ' Life expectancy 5 years', ' WBC 3,000/mm³ OR granulocyte count 1,500/mm³', ' Platelet count 100,000/mm³', ' Alkaline phosphatase 3 times upper limit of normal (ULN)', ' AST 3 times ULN', ' Creatinine < 2.0 mg/dL', ' Creatinine clearance 45 mL/min', ' No hypercalcemia (i.e., calcium level > 1 mg/dL above ULN) OR hypocalcemia (i.e., calcium level > 0.5 mg/dL below lower limit of normal) within the past 6 months', ' No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix', ' No other nonmalignant systemic diseases, including any of the following:', ' Uncontrolled infection', ' Uncontrolled diabetes mellitus', ' Uncontrolled thyroid dysfunction', " Disease affecting bone metabolism (hyperparathyroidism, hypercortisolism, Paget's disease, osteogenesis imperfecta)", ' Malabsorption syndrome', ' No uncontrolled seizure disorders associated with falls', ' No known hypersensitivity to zoledronate or other bisphosphonates, letrozole, calcium, or vitamin D', ' No concurrent active dental problems, including any of the following:', ' Infection of the teeth or jawbone (maxillary or mandibular)', ' Dental or fixture trauma', ' Prior or current diagnosis of osteonecrosis of the jaw', ' Exposed bone in the mouth', ' Slow healing after dental procedures', ' No contraindication to spine dual energy x-ray absorptiometry (DXA) as defined by any of the following:', ' History of surgery at the lumbosacral spine, with or without implantable devices', ' Scoliosis with a Cobb angle > 15 degrees at the lumbar spine', ' Immobility, hyperostosis, or sclerotic changes at the lumbar spine, or evidence of sclerotic abdominal aorta sufficient to interfere with DXA scan', ' Disease of the spine that would preclude the proper acquisition of a lumbar spine DXA', ' No condition that would preclude study follow-up or compliance', ' No psychiatric illness that would preclude giving informed consent', ' PRIOR CONCURRENT THERAPY:', ' More than 3 weeks since prior and no other concurrent oral bisphosphonates', ' No prior intravenous bisphosphonates', ' No prior aromatase inhibitor therapy', ' More than 6 months since prior anabolic steroids or growth hormone', ' More than 2 weeks since prior and no concurrent inhibitor of osteoclastic bone resorption (e.g., calcitonin, mithramycin, or gallium nitrate)', ' More than 30 days since prior systemic investigational drug and/or device', ' More than 7 days since prior topical investigational drug', ' More than 6 weeks since prior and no concurrent dental or jaw surgery (e.g., extraction, implants)', ' Concurrent short-term corticosteroid therapy allowed', ' No concurrent sodium fluoride, parathyroid hormone, or tibolone', ' No other concurrent investigational drug or device'], 'Results': ['Outcome Measurement: ', ' Average Intra-patient Change in Total Lumbar Spine (L1 to L4) Bone Mineral Density (BMD)', ' Change: BMD values at twelve months post study entry minus BMD values at baseline, expressed as a percentage of the baseline value.', ' Time frame: Baseline and 1 year', 'Results 1: ', ' Arm/Group Title: Zoledronic Acid', ' Arm/Group Description: 4 mg intravenously over 15 minutes every 6 months (until disease progression or for 5 years)', ' Overall Number of Participants Analyzed: 30', ' Mean (95% Confidence Interval)', ' Unit of Measure: Percentage of the baseline value 2.66 (1.27 to 4.62)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/52 (1.92%)', ' Musculoskeletal disorder 1/52 (1.92%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

fec065ca-fbde-476d-ab0d-7e7054e29858

Comparison

Intervention

NCT01153672

NCT01432145

Patients in the primary trial receive vorinostat at the same frequency, dosage and through the same route of administration as the secondary trial receive 6-Mercaptopurine.

Contradiction

{'Clinical Trial ID': 'NCT01153672', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Enzyme Inhibitor Therapy, AI Sensitization Therapy)', ' Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD, letrozole PO QD, OR exemestane PO QD for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.', ' vorinostat: Given PO', ' laboratory biomarker analysis: Correlative studies', ' biopsy: Optional correlative studies', ' F-18 16 alpha-fluoroestradiol: Correlative studies', ' positron emission tomography: Correlative studies', ' anastrozole: Given PO', ' letrozole: Given PO', ' exemestane: Given PO', ' gene expression analysis: Correlative studies'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically proven diagnosis of breast cancer', ' Stage IV disease', ' Patient has previously derived clinical benefit from endocrine therapy, but is no longer deriving benefit to endocrine therapy in the opinion of the treating investigator; patients need to stop AI for at least one week prior to starting vorinostat treatment on this protocol', ' At least one site of measurable disease, as defined by the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria', ' Eastern Cooperative Oncology Group (ECOG) performance status 0-2', ' Female patient is post menopausal as defined by one of the following; free from menses for > 2 years, surgically sterilized ,FSH and Estradiol in post-menopausal range AND surgical absence of uterus OR chemotherapy induced amenorrhea lasting > 1 year OR currently on ovarian suppression', ' Female patient of childbearing potential has a negative urine or serum (beta-human chorionic gonadotropin [hCG]) pregnancy test within 14 days prior to receiving the first dose of vorinostat', ' Male patient agrees to use two barrier methods of contraception or abstain from intercourse for the duration of the study', ' Absolute neutrophil count (ANC) >= 1,500/mcL', ' Platelets >= 100,000/mcL', ' Hemoglobin >= 9 g/dL', ' Prothrombin Time or international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN) unless receiving therapeutic anticoagulation', ' Partial thromboplastin time (PTT) =< 1.2 times the ULN unless the patient is receiving therapeutic anticoagulation', ' Potassium and magnesium levels within normal limits', ' Calculated creatinine clearance >= 30 mL/min', ' Serum total bilirubin =< 1.5 X ULN', ' Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN', ' Alkaline Phosphatase =< 2.5 X ULN', " Patient, or the patient's legal representative, has voluntarily agreed to participate by giving written informed consent", ' Patient has a life expectancy of at least 12 weeks in the opinion of the treating investigator', ' Patient is willing to continue on same AI therapy', ' Patient agrees to participate in imaging Protocol 7184 and is separately consented', 'Exclusion Criteria:', ' Patient has not derived clinical benefit from prior endocrine therapy', ' Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of initial dosing with study drug(s) other than the imaging protocol 7184', ' Patient has received an ER blocking therapy (selective estrogen receptor modulating [SERM] or downregulating [SERD] i.e. tamoxifen or fulvestrant) within the past 6 weeks', ' Patient had prior treatment with an histone deacetylase (HDAC) inhibitor (e.g., romidespin [Depsipeptide], NSC-630176, MS 275, LAQ-824, belinostat [PXD-101], LBH589, MGCD0103, CRA024781, etc); patients who have received compounds with HDAC inhibitor-like activity, such as valproic acid, as anti-tumor therapy should not enroll in this study; patients who have received such compounds for other indications, e.g. valproic acid for epilepsy, may enroll after a 30-day washout period', ' Patient is on any systemic steroids that have not been stabilized to the equivalent of =<10 mg/day prednisone during the 30 days prior to the start of the study drugs', ' Patient has known hypersensitivity to the components of study drug or its analogs', ' Patients with uncontrolled brain metastases', ' New York Heart Association (NYHA) Class III or IV congestive heart failure, myocardial infarction within the previous 6 months, corrected QT interval (QTc) > 0.47 seconds, or uncontrolled arrhythmia.', ' Type I Diabetes Mellitus; patients with Type II Diabetes Mellitus will be included as long as their glucose can be controlled to under 200 mg/dL', ' Patient is pregnant or breast feeding, or expecting to conceive or father children within the projected duration of the study', ' Patient with a "currently active" second malignancy, other than non-melanoma skin cancer and carcinoma in situ of the cervix, should not be enrolled; patients are not considered to have a "currently active" malignancy if they have completed therapy for a prior malignancy, are disease free from prior malignancies for > 5 years or are considered by their physician to be at less than 30% risk of relapse', ' Patients with known active viral hepatitis', " Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study or is not in the best interest of the patient to participate"], 'Results': ['Outcome Measurement: ', ' Rate of Clinical Benefit According to RECIST', ' Conventional imaging (CT, bone scan) was performed at baseline and at week 8 and tumor response assessed by RECIST criteria', ' Time frame: Up to approximately 5 years', 'Results 1: ', ' Arm/Group Title: Treatment (Enzyme Inhibitor Therapy, AI Sensitization Therapy)', ' Arm/Group Description: Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD, letrozole PO QD, OR exemestane PO QD for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.', ' vorinostat: Given PO', ' laboratory biomarker analysis: Correlative studies', ' biopsy: Optional correlative studies', ' F-18 16 alpha-fluoroestradiol: Correlative studies', ' positron emission tomography: Correlative studies', ' anastrozole: Given PO', ' letrozole: Given PO', ' exemestane: Given PO', ' gene expression analysis: Correlative studies', ' Overall Number of Participants Analyzed: 8', ' Measure Type: Number', ' Unit of Measure: percentage of evaluable participants 15 (12 to 65)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/8 (25.00%)', ' pancreatitis [1]1/8 (12.50%)', ' Flu-like symptoms [1]1/8 (12.50%)']}

{'Clinical Trial ID': 'NCT01432145', 'Intervention': ['INTERVENTION 1: ', ' 6-Mercaptopurine and Methotrexate (6MP/MTX)', ' 6-Mercaptopurine: 6MP 75mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.', ' Methotrexate: Methotrexate 20mg/m2 will be taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.', ' Update: These original doses were reduced following an Urgent Safety Measure in August 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression.', ' The reduced doses were 55mg/m2 of 6MP orally once a day, and 15mg/m2 of Methotrexate orally once a week.'], 'Eligibility': ['Inclusion Criteria:', ' Patients with proven BRCA1 or BRCA2 mutations and after appropriate exposure to standard treatment, as defined by:', ' Breast Cancer', ' Patients with initially histologically or cytologically proven locally advanced or metastatic breast cancer who may have received up to 3 previous lines of chemotherapy in the locally advanced or metastatic breast cancer setting.', ' Patients must have previously had a taxane and an anthracycline in either the adjuvant or metastatic setting, provided that these were not contraindicated.', ' Patients with hormone responsive disease should have had at least 1 line of hormone therapy for metastatic disease.', ' Prior treatment with a poly-Adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor is permissible.', ' OR Ovarian Cancer', ' Patients with initially histologically or cytologically proven ovarian cancer.', ' Patients must have disease that is platinum resistant or in whom further platinum based therapy is inappropriate.', ' Prior treatment with a PARP inhibitor is permissible.', ' Patients must have measurable disease on computerized tomography (CT) or Magnetic resonance imaging (MRI) scan as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria.', ' Age 18 years.', ' Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.', ' Life expectancy >12 weeks.', ' Written informed consent.', ' Patient willing and able to comply with all protocol requirements.', ' No prior anti-cancer treatment in previous 4 weeks, other than palliative radiotherapy (RT).', ' Haematological and biochemical indices within the ranges shown below.', ' Laboratory Test Value required', ' Haemoglobin (Hb) > 10g/dL', ' White Blood Count (WBC) > 3x109/L', ' Platelet count > 100,000/μL', ' Absolute Neutrophil count > 1.5x109/L;', ' Serum bilirubin 2 x Upper limit normal (ULN)', ' Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase (SGOT)) and alanine aminotransferase (ALT) or ALT 5 x ULN (liver metastasis)', ' or 3 x ULN (no liver metastasis)', ' Alkaline phosphatase 5 x ULN', ' Serum creatinine 1.5 x ULN', ' Ascites and pleural effusions must be drained prior to therapy.', 'Exclusion Criteria:', ' Patients with any of the following contra-indications to thiopurines (6MP or 6TG) or methotrexate:', ' family history of severe liver failure;', ' alcoholism;', ' porphyria;', ' diffuse infiltrative pulmonary or pericardial disease;', ' known hypersensitivity to either trial agent.', ' Patients found to have a Low/Low genotype on thiopurine methyltransferase (TPMT) testing will be excluded.', ' Pregnant or breast-feeding women or women of childbearing potential unless highly effective methods of contraception are used.', ' Other active malignancy, with the exception of adequately treated in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.', ' Patients known or tested to be serologically positive for Hepatitis B, Hepatitis C or human immunodeficiency virus (HIV).', ' Patients with active central nervous system (CNS) lesions are excluded (i.e., those with radiographically unstable, symptomatic lesions). However, patients treated with stereotactic therapy or surgery and/or whole brain radiotherapy are eligible if the patient remains without evidence of disease progression in brain 3 months prior to registration date . They must also be off corticosteroid therapy for 3 weeks prior to registration date.', ' Patients who have received anticancer agent(s) or an investigational agent within 28 days prior to study drug administration.', ' Subjects who have not recovered to within one grade level (not to exceed grade 2) of their baseline following a significant adverse event or toxicity attributed to previous anticancer treatment are excluded.'], 'Results': ['Outcome Measurement: ', ' Objective Response Rate to 6-mercaptopurine and Methotrexate (6MP/MTX) in This Patient Population.', ' 1st stage: If less than 3/30 evaluable patients respond at 8 weeks the trial will be stopped for futility. If 3 or more out of 30 evaluable patients respond then a further 35 patients will be recruited (2nd stage) - this was met.', ' The proportion of patients responding to treatment (complete response, partial response or stable disease) at the second stage will be presented per Response Evaluation Criteria In Solid Tumours (RECIST) criteria version 1.1 measured radiologically with computerised tomography (CT) and/or magnetic resonance imaging (MRI); the same method is used at baseline and at follow-up: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Patients who yield progressive disease (PD) are classed as non-responders.', ' Time frame: 8 weeks after start of treatment', 'Results 1: ', ' Arm/Group Title: 6-Mercaptopurine and Methotrexate (6MP/MTX)', ' Arm/Group Description: 6-Mercaptopurine: 6MP 75mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.', ' Methotrexate: Methotrexate 20mg/m2 will be taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.', ' Update: These original doses were reduced following an Urgent Safety Measure in August 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression.', ' The reduced doses were 55mg/m2 of 6MP orally once a day, and 15mg/m2 of Methotrexate orally once a week.', ' Overall Number of Participants Analyzed: 67', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 22 32.8%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 33/67 (49.25%)', ' Pancytopenia 1/67 (1.49%)', ' Febrile neutropenia 1/67 (1.49%)', ' Palpitations 1/67 (1.49%)', ' Abdominal pain 5/67 (7.46%)', ' Ascites 1/67 (1.49%)', ' Colonic obstruction 1/67 (1.49%)', ' Constipation 1/67 (1.49%)', ' Nausea 1/67 (1.49%)', ' Pancreatitis 1/67 (1.49%)', ' Small intestinal obstruction 1/67 (1.49%)', ' Vomiting 2/67 (2.99%)', ' Fever 2/67 (2.99%)']}

ea3bd229-001c-487f-9cda-edf2e699dbb2

Comparison

Eligibility

NCT00297596

NCT00580333

Patients have received prior radiation treatment, to treat the current breast cancer, in the last two 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial.

Contradiction

{'Clinical Trial ID': 'NCT00297596', 'Intervention': ['INTERVENTION 1: ', ' Oxaliplatin/Trastuzumab', ' Patients with HER2 positive breast cancer received treatment with oxaliplatin 130 mg/m2 IV day 1 and trastuzumab 6 mg/kg (following 8 mg/kg loading dose during cycle 1). Cycles were repeated every 21 days. Oxaliplatin : Oxaliplatin will be administered at a dose of 130 mg/ m2 over 120 minutes on day 1 of each cycle, following standard antiemetic premedications. 21 day cycles. For the first cycle, trastuzumab will be administered before oxaliplatin; however for subsequent cycles, oxaliplatin will be infused prior to trastuzumab Trastuzumab : Trastuzumab will be administered as an 8 mg/kg loading dose by intravenous (IV) infusion over 90 minutes on day 1 of cycle 1. Subsequent doses will be administered as a 6 mg/kg IV dose over 30 minutes.'], 'Eligibility': ['Inclusion Criteria:', ' Females 18 years of age', ' Histologically confirmed breast cancer that is HER2/neu positive (3+ by IHC or FISH +) and evidence of metastatic disease. Tumor may be of any estrogen and progesterone receptor type', ' Measurable disease by RECIST and an ECOG 2', ' Patients with known evidence of brain metastases are eligible if they are asymptomatic and have completed all therapy (surgery, radiotherapy, and/or steroids)', ' Baseline LVEF value within the institutional normal range', ' Any number of prior hormonal therapy treatments in the adjuvant setting or for metastatic disease. A subject must have progressed on hormonal therapy and all hormonal therapy (including birth control pills) must be discontinued at study entry.', ' Prior chemotherapy in the adjuvant setting and up to one prior chemotherapy regimen for metastatic disease is allowed.', ' Patients may have received one prior trastuzumab/chemotherapy containing regimen or prior single agent trastuzumab.', ' Prior radiation therapy in the adjuvant setting or for metastatic disease, provided it was not to the only site of evaluable disease.', ' All prior chemotherapy, trastuzumab and radiation therapy should be completed > 2 weeks before enrollment.', ' Patients receiving bisphosphonate therapy are eligible. However, if bisphosphonate were started within < 2 months prior to enrollment, the bone lesions will not be evaluated for response and the patient must have another site of metastatic disease that is either measurable or evaluable for response.', ' Patients must have recovered from toxicities due to prior therapy.', ' Lab values in accordance with the protocol', ' Patients must be nonpregnant and nonlactating. Patients of childbearing potential must implement an effective method of contraception during the study (birth control pills are not allowed).', 'Exclusion Criteria:', ' Bone only disease are ineligible', ' Patients who received more than 1 prior chemotherapy regimen for metastatic disease are ineligible.', ' Patients with a history of other cancers except curatively-treated carcinoma of the cervix in situ or non-melanomatous skin cancer.', ' Active serious infection or other underlying medical condition that would impair their ability to receive protocol treatment.', ' Uncontrolled nervous system metastases', ' Dementia or significantly altered mental status that would interfere with proper consenting.', ' Receiving other investigational therapy.'], 'Results': ['Outcome Measurement: ', ' Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment', ' Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', ' Time frame: 18 months', 'Results 1: ', ' Arm/Group Title: Oxaliplatin/Trastuzumab', ' Arm/Group Description: Patients with HER2 positive breast cancer received treatment with oxaliplatin 130 mg/m2 IV day 1 and trastuzumab 6 mg/kg (following 8 mg/kg loading dose during cycle 1). Cycles were repeated every 21 days. Oxaliplatin : Oxaliplatin will be administered at a dose of 130 mg/ m2 over 120 minutes on day 1 of each cycle, following standard antiemetic premedications. 21 day cycles. For the first cycle, trastuzumab will be administered before oxaliplatin; however for subsequent cycles, oxaliplatin will be infused prior to trastuzumab Trastuzumab : Trastuzumab will be administered as an 8 mg/kg loading dose by intravenous (IV) infusion over 90 minutes on day 1 of cycle 1. Subsequent doses will be administered as a 6 mg/kg IV dose over 30 minutes.', ' Overall Number of Participants Analyzed: 25', ' Measure Type: Number', ' Unit of Measure: percentage of participants 20 (4.3 to 35.7)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 7/25 (28.00%)', ' Perforated appendix 1/25 (4.00%)', ' Allergic reaction 1/25 (4.00%)', ' Pathologic fracture of let proximal humeral diaphysis 1/25 (4.00%)', ' Pathologic fracture of right proximal humeral diaphysis 1/25 (4.00%)', ' Respiratory failure secondary to metastatic disease 1/25 (4.00%)', ' Breast cancer 1/25 (4.00%)', ' Progressive disease 1/25 (4.00%)']}

{'Clinical Trial ID': 'NCT00580333', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin/Avastin', ' Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide , adjuvant (optional) paclitaxel, adjuvant (optional)', ' cisplatin: Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 wks) for four cycles', ' bevacizumab: Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three wks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel', ' doxorubicin: Postoperative: Given intravenously for four 2-week cycles', ' cyclophosphamide: Postoperative: Given intravenously for four two-week cycles', ' paclitaxel: Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two week'], 'Eligibility': ['Inclusion Criteria:', ' All tumors must be ER-, PR- and HER2-negative', ' Clinical stage T2 or T3, N0-3, M0. Subjects with inflammatory breast cancer are not eligible', " For subjects with clinically negative axilla, a sentinel lymph node biopsy will be performed either up front or after preoperative therapy at the discretion of the subject's physicians; for subjects with a clinically positive axilla, a needle aspiration or core biopsy will be performed to confirm the presence of metastatic disease in the lymph nodes.", ' 18 years of age or older', ' Performance status (PS) of 0 or 1', ' Use of an effective means of contraception in subjects of child-bearing potential', ' Normal organ function as described in the protocol', 'Exclusion Criteria:', ' Any prior cytotoxic chemotherapy or radiation for the current breast cancer', ' HER2-negative ipsilateral breast recurrence, unless prior treatment consisted of excision alone for ductal carcinoma in situ (DCIS)or breast-conserving treatment and hormonal therapy for DCIS or invasive cancer', ' Life expectancy of less than 12 weeks', ' Current, recent, or planned participation in an experimental durg study other than a Genentech-sponsored bevacizumab cancer study', ' Renal dysfunction for which exposure to cisplatin would require dose modifications', ' Steroid dependent asthma', ' Peripheral neuropathy of any etiology that exceeds grade 1', ' Uncontrolled diabetes', ' History of malignancy treated without curative intent', ' Any other pre-existing medical condition that would represent toxicity in excess of grade 1', ' Inadequately controlled hypertension', ' Any prior history of hypertensive crisis or hypertensive encephalopathy', ' New York Heart Association (NYHA) Grade II or greater congestive hear failure', ' History of myocardial infarction or unstable angina within 12 months prior to study enrollment', ' Any history of stroke or transient ischemic attack at any time', ' Known central nervous system (CNS) disease', ' Significant vascular disease', ' Symptomatic peripheral vascular disease', ' Evidence of bleeding diathesis or coagulopathy', ' Major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to study enrollment', ' History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to study enrollment', ' Serious, non-healing wound, ulcer or bone fracture', ' Proteinuria at screening', ' Known hypersensitivity to any component of bevacizumab', ' Pregnant or lactating'], 'Results': ['Outcome Measurement: ', ' Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early Breast Cancer.', ' The goal of this measure was to determine the pathologic complete response rate (Miller-Payne (MP) score 5) after preoperative therapy with cisplatin and bevacizumab in ER-, PR-, HER2-negative early breast cancer.', ' Time frame: 2 years', 'Results 1: ', ' Arm/Group Title: Cisplatin/Avastin', ' Arm/Group Description: Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide , adjuvant (optional) paclitaxel, adjuvant (optional)', ' cisplatin: Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 wks) for four cycles', ' bevacizumab: Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three wks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel', ' doxorubicin: Postoperative: Given intravenously for four 2-week cycles', ' cyclophosphamide: Postoperative: Given intravenously for four two-week cycles', ' paclitaxel: Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two week', ' Overall Number of Participants Analyzed: 51', ' Measure Type: Number', ' Unit of Measure: percentage of participants 16 (7 to 29)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/51 (0.00%)']}

576e519a-1ef3-43e5-a13c-6058ad71f388

Single

Intervention

NCT03374995

the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks.

Entailment

{'Clinical Trial ID': 'NCT03374995', 'Intervention': ['INTERVENTION 1: ', ' Group I (Topical Keratin)', ' Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks).', ' Quality-of-Life Assessment: Ancillary studies', ' Topical Keratin: Given topically', 'INTERVENTION 2: ', ' Group II (Standard of Care)', ' Patients receive standard of care as directed by radiation oncologist until the end of radiation therapy (approximately 3-6 weeks).', ' Best Practice: Receive standard of care', ' Quality-of-Life Assessment: Ancillary studies'], 'Eligibility': ['Inclusion Criteria:', ' Diagnosis of breast cancer, received chemotherapy, and scheduled to receive 4 to 6 weeks of radiation therapy (radiation protocol of 42 Gy+)', ' Area to be irradiated representing 1-10% of total body surface area (TBSA)', ' Able and willing to sign protocol consent form', ' Able and willing to document symptoms and treatment details as often as needed, not to exceed daily notes', ' Able and willing to have photographs of the affected area taken regularly', 'Exclusion Criteria:', ' Women who are pregnant, lactating/nursing or plan to become pregnant', ' Previous radiation therapy to the area to be treated with radiation therapy', ' Receiving palliative radiation therapy', ' Unhealed or infected surgical sites in the irradiation area', ' Patients undergoing cytotoxic chemotherapy or concurrent Herceptin as part of overall treatment plan (tamoxifen/aromatase inhibitor allowed)', ' Use of oral corticosteroids or topical corticosteroids in the irradiation area', ' Use of Erbitux', ' Autoimmune disease', ' Skin disease in target irradiation area', ' Smoker', ' Known allergy to the standard of care or ingredients in KeraStat Cream'], 'Results': ['Outcome Measurement: ', ' Incidence of Early Adverse Skin Reactions (EASRs)', ' The Modified ONS Criteria for Radiation-Induced Acute Skin Toxicity will be used for classification of EASRs related to the skin. Participants will report in a total of 7 visits any experience with Grade I (faint or dull erythema; dry desquamation or Grade II (tender or bright erythema, patchy, moist desquamation) acute radiation dermatitis using the RTOG (Radiation Therapy Oncology Group) grading system with Grade II considered the worse outcome. Comparative effectiveness will include the number or study participants in each arm that experience RTOG Grade I or Grade II radiation dermatitis and moist desquamation.', ' Time frame: Up to 4 weeks post-RT', 'Results 1: ', ' Arm/Group Title: Group I (Topical Keratin)', ' Arm/Group Description: Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks).', ' Quality-of-Life Assessment: Ancillary studies', ' Topical Keratin: Given topically', ' Overall Number of Participants Analyzed: 13', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Grade I Acute Radiation Dermatitis: 13 100.0%', ' Grade II Acute Radiation Dermatitis: 4 30.8%', 'Moist Desquamation: 1 7.7%', 'Results 2: ', ' Arm/Group Title: Group II (Standard of Care)', ' Arm/Group Description: Patients receive standard of care as directed by radiation oncologist until the end of radiation therapy (approximately 3-6 weeks).', ' Best Practice: Receive standard of care', ' Quality-of-Life Assessment: Ancillary studies', ' Overall Number of Participants Analyzed: 11', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Grade I Acute Radiation Dermatitis: 10 90.9%', ' Grade II Acute Radiation Dermatitis: 6 54.5%', 'Moist Desquamation: 0 0.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/13 (0.00%)', 'Adverse Events 2:', ' Total: 0/11 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

699d0cb5-1ebb-441d-aa7e-041a48923b00

Single

Eligibility

NCT01127373

Patients with T1N1M0, T2N1M0, T3N1M0 and TxN1M0 tumors are eliglbe for the primary trial.

Entailment

{'Clinical Trial ID': 'NCT01127373', 'Intervention': ['INTERVENTION 1: ', ' Radiation Therapy Via Multi-beam IMRT', ' This is a single-arm feasibility study of multi-beam IMRT with daily set-up verification in the treatment of women with node-positive breast cancer who will receive radiation to the breast/chest wall and regional lymph nodes, including the internal mammary lymph nodes.', ' Multi-Beam Intensity-Modulated Radiation Therapy: IMRT with multiple beams will be utilized to treat the breast or chest wall and axillary, supraclavicular and internal mammary lymph nodes. Treatment will be delivered once a day, 5 days a week for approximately 5 weeks. All missed radiation treatment visits will be made up. Daily set-up error will be checked prior to the delivery of every treatment.', ' BreastQ questionnaire-: MSKCC Department of Surgery. For patients who received a mastectomy with or without reconstruction, the questionnaire will be administered at baseline and 5-7 months after treatment.'], 'Eligibility': ['Inclusion Criteria:', ' Female gender', ' Age 18 years', ' An invasive primary breast cancer of any histology arising from breast parenchyma', ' Patient must be status post mastectomy or partial mastectomy with an assessment of axillary nodes via sentinel lymph node biopsy and/or axillary lymph node dissection', ' Pathologic confirmation of metastatic disease in at least one regional lymph node. Regional lymph nodes are defined as the ipsilateral axillary lymph nodes, ipsilateral supraclavicular lymph nodes, and ipsilateral internal mammary lymph nodes. Thus, any T stage is allowed as long as the N stage is 1 and M stage is 0.', ' Patient signed study-specific consent form.', 'Exclusion Criteria:', ' Patients with distant metastasis.', ' Patients who are pregnant or breastfeeding.', ' Patients with psychiatric or addictive disorders that would preclude obtaining informed consent.', ' Time between initial diagnosis of breast cancer and start of radiation therapy exceeds 13 months.', " Estimated life expectancy judged to be less than one year by patient's treating radiation oncologist.", ' Prior radiation therapy to the ipsilateral or contralateral breast or thorax.', ' Primary breast cancer is a lymphoma or sarcoma histology.', ' Patients with a history of non-skin malignancy <5 years prior to the diagnosis of breast cancer.', ' Patients requiring radiation to the bilateral breasts.'], 'Results': ['Outcome Measurement: ', ' Count of Participants Receiving Adjuvant Radiation Therapy Via Multi-beam IMRT Using Daily 3D Position Verification', ' The purpose of this pilot study is to assess the feasibility of utilizing multi-beam IMRT in the adjuvant treatment of the breast and regional lymph nodes of women with node-positive breast cancer requiring coverage of the internal mammary lymph nodes. A feasibility rate of at least 90% is required, ie, treatment can be successfully planned and delivered for at least 90% of the patients.', ' Time frame: 5 weeks', 'Results 1: ', ' Arm/Group Title: Radiation Therapy Via Multi-beam IMRT', ' Arm/Group Description: This is a single-arm feasibility study of multi-beam IMRT with daily set-up verification in the treatment of women with node-positive breast cancer who will receive radiation to the breast/chest wall and regional lymph nodes, including the internal mammary lymph nodes.', ' Multi-Beam Intensity-Modulated Radiation Therapy: IMRT with multiple beams will be utilized to treat the breast or chest wall and axillary, supraclavicular and internal mammary lymph nodes. Treatment will be delivered once a day, 5 days a week for approximately 5 weeks. All missed radiation treatment visits will be made up. Daily set-up error will be checked prior to the delivery of every treatment.', ' BreastQ questionnaire-: MSKCC Department of Surgery. For patients who received a mastectomy with or without reconstruction, the questionnaire will be administered at baseline and 5-7 months after treatment.', ' Overall Number of Participants Analyzed: 116', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Discontinued IMRT due to disease progression: 1 0.9%', ' Completed IMRT: 111 95.7%', ' Ineligible: 4 3.4%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 10/116 (8.62%)', ' Death not assoc w CTCAE term-Disease prog NOS 1/116 (0.86%)', ' Fever (in the absence of neutropenia) 1/116 (0.86%)', ' Pain - Chest/thorax NOS 1/116 (0.86%)', ' Breast Infection 1/116 (0.86%)', ' Back Pain 1/116 (0.86%)', ' Muscle weakness - Whole body/general 1/116 (0.86%)', ' Pain - Back 1/116 (0.86%)', ' Dysarthria 1/116 (0.86%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

6ec27be7-aa61-4ba8-b92a-98dcaee1eb0b

Single

Adverse Events

NCT00266799

None of the patients in cohort 1 of the primary trial had ACUTE VESTIBULAR or acute coronary syndrome.

Contradiction

{'Clinical Trial ID': 'NCT00266799', 'Intervention': ['INTERVENTION 1: ', ' Pegylated Liposomal Doxorubicin (PLD)', ' PLD 50 mg/m^2 was administered intravenously once every 28 days. Each cycle was repeated until progress or unacceptable toxicity.', 'INTERVENTION 2: ', ' Capecitabine', ' Capecitabine 1250 mg/m^2, in tablets of 150 mg and 500 mg, was administered orally twice daily (BID) for 14 consecutive days followed by a 7-day rest period. Each cycle was repeated every 21 days until progress or unacceptable toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Patients must be female.', ' Patients must have metastatic disease of a cytological or histological confirmed breast cancer.', ' Patients must be 18 years or older.', ' Patients should have evaluable disease (at least uni-dimensionally measurable lesion according to the RECIST criteria in at least one site that has not been irradiated), however, patients who only have non-measurable/evaluable disease are not excluded. Also patients with only bone metastasis are not excluded.', ' Patients must have an Eastern Cooperative Oncology Group (ECOG) 0-2.', ' Patients must have a sufficient life expectancy to be treated with chemotherapy.', ' Patients must be willing and able to complete study questionnaires.', ' Patients must have adequate renal function as evidenced by serum creatinine <=1.5 mg/dL, or a creatinine clearance of >=45 mL/min (if serum creatinine is > 1.5 mg/dL but <= 1.8 mg/dL).', ' Patients must have adequate bone marrow function as evidenced by leukocyte count greater than 3.5 g/L, hemoglobin >=9.0 g/dL, and platelet count >=100x10^9/L.', ' Patients must have adequate liver function as evidenced by bilirubin of <=1.5 times the upper limits of normal (ULN) and alkaline phosphatase <=3 times, ULN unless related to liver metastasis.', ' Patients must have Sodium and Potassium values within normal limits.', ' Patients whose clinical condition (co-morbidity) allows a treatment with monotherapy or who expressed their wish to be treated with monotherapy.', ' Patients must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.', 'Exclusion Criteria:', ' History of receiving prior chemotherapy in the metastatic setting (Note: patients may have had', ' hormonal therapy or chemotherapy in the adjuvant setting; patients may have received hormonal therapy in metastatic setting, patients may have received local radiotherapy).', ' Patients with positive estrogen- / progesterone-receptor status, where an endocrine therapy is indicated. However, patients progressing under hormonal therapy are not excluded.', ' Patients with known hypersensitivity to doxorubicinhydrochlorid or to any of the excipients OR known hypersensitivity to capecitabine or fluorouracil or to any of the excipients.', ' Patients with known DPD (dihydro pyrimidine dehydrogenase) deficiency.', ' Patients who are receiving a concomitant treatment with sorivudine or its chemically related analogues, such as brivudine.', ' Patients who are taking concomitant medications (except bisphosphonates) for metastatic disease, including hormonal therapy, radiation therapy, trastuzumab, or biologicals are also not permitted.', ' Patients with Human epidermal growth factor receptor 2 (Her-2/neu) overexpressing tumors with the most recent evaluation as the relevant result', ' immunologically Her2neu 3+ positive', ' Her2neu-2+ positive and ´Fluorescent in-situ hybridization (FISH)´ positive', ' History of treatment with capecitabine', ' History of treatment with anthracyclines in the adjuvant setting exceeding cumulative doses of anthracyclines by more than 360 mg/m^2 doxorubicin (or equivalents, i.e. 600mg/m^2 epirubicine).', ' Patients with anthracycline resistant disease are not permitted. Anthracycline resistance is defined as development of locally recurrent or metastatic disease while on adjuvant anthracycline therapy, or relapse less than 12 months after completion of anthracycline therapy.', ' Strong remission pressure that requires polychemotherapy with the exception of patients who are not suitable for a treatment with polychemotherapy or not accepting polychemotherapy.', ' Evidence of primary or metastatic malignancy involving the central nervous system unless previously treated and asymptomatic for 3 months or greater.', ' Patients with reduced liver functions (evidenced by bilirubin of above 1.5 times the upper limits of normal (ULN); alkaline phosphatase above 3 times ULN (except related to liver metastasis, in which case <=5 x ULN).', ' Dyspnea on exertion.', ' History of cardiac disease, with New York Heart Association Class II or greater, or clinical evidence of congestive heart failure or myocardial infarct within less than six months or an left ventricular ejection fraction (LVEF) below 50%.', ' Woman with childbearing potential with insufficient contraception [e.g. intra-uterine device (IUD) are regarded as sufficient] during the study period and the six months following the last study drug application. All methods based on hormonal contraception are not permitted.', ' Existing pregnancy or lactation (note on pregnancy test). A negative pregnancy test for women of childbearing potential has to be in place prior randomization (Note: A pregnancy test has to be done for patients who are not postmenopausal. Postmenopausal is defined as those not having a menstrual period for 12 months in a row).', ' Existing doubts on ability and willingness of the subject for cooperation.', ' Participation of the subject at a clinical study within the last 30 days.', ' Participation of the subject in the same clinical study at an earlier date.', ' Concomitant participation in another study than the one described here.', ' Abuse of drugs, alcohol, or pharmaceuticals.', ' Any condition, whether medical or non-medical, that may interfere, in the opinion of the investigator, with aim of this study.'], 'Results': ['Outcome Measurement: ', ' Time to Disease Progression (TTP) Using Response Evaluation Criteria in Solid Tumors (RECIST)', ' TTP was defined as the time from onset of treatment with study drug until first evidence/diagnosis of progressive disease or - in the absence of any diagnosis of progressive disease - until the participant´s death. Diagnosis of progressive disease was done according to RECIST (Version 1.0) and/or investigator assessment based on RECIST. RECIST criteria used changes in the largest diameter of target/non-target lesions. Target (measurable) lesions were up to a maximum of 5 per organ & >20 mm by clinical imaging (>=10 mm with spiral CT scan). Non-target lesions were all other lesions.', ' Time frame: From Day 1 (Cycle 1) until First Evidence/Diagnosis of Progressive Disease or Death', 'Results 1: ', ' Arm/Group Title: Pegylated Liposomal Doxorubicin (PLD)', ' Arm/Group Description: PLD 50 mg/m^2 was administered intravenously once every 28 days. Each cycle was repeated until progress or unacceptable toxicity.', ' Overall Number of Participants Analyzed: 98', ' Median (95% Confidence Interval)', ' Unit of Measure: Months By Investigator Assessment (ITT): 6.02 (5.10 to 8.19)', ' By RECIST Criteria (ITT): 6.58 (5.29 to 8.19)', ' By Investigator Assessment (TTP N = 63, N = 59): 5.85 (4.37 to 7.86)', ' By RECIST Criteria (TTP N = 63, N = 59): 6.02 (4.37 to 7.86)', 'Results 2: ', ' Arm/Group Title: Capecitabine', ' Arm/Group Description: Capecitabine 1250 mg/m^2, in tablets of 150 mg and 500 mg, was administered orally twice daily (BID) for 14 consecutive days followed by a 7-day rest period. Each cycle was repeated every 21 days until progress or unacceptable toxicity.', ' Overall Number of Participants Analyzed: 102', ' Median (95% Confidence Interval)', ' Unit of Measure: Months By Investigator Assessment (ITT): 6.05 (4.27 to 9.07)', ' By RECIST Criteria (ITT): 7.10 (4.77 to 9.53)', ' By Investigator Assessment (TTP N = 63, N = 59): 5.88 (2.99 to 8.98)', ' By RECIST Criteria (TTP N = 63, N = 59): 6.05 (4.08 to 9.27)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 30/98 (30.61%)', ' NEUTROPENIA 1/98 (1.02%)', ' ATRIAL FIBRILLATION 1/98 (1.02%)', ' CARDIAC FAILURE 1/98 (1.02%)', ' TACHYCARDIA 0/98 (0.00%)', ' ACUTE VESTIBULAR SYNDROME 1/98 (1.02%)', ' VERTIGO 0/98 (0.00%)', ' ABDOMINAL PAIN 0/98 (0.00%)', ' COLITIS 0/98 (0.00%)', ' DIARRHOEA 2/98 (2.04%)', ' FEMORAL HERNIA 0/98 (0.00%)', ' HAEMATEMESIS 0/98 (0.00%)', ' ILEUS 0/98 (0.00%)', ' NAUSEA 0/98 (0.00%)', 'Adverse Events 2:', ' Total: 46/102 (45.10%)', ' NEUTROPENIA 0/102 (0.00%)', ' ATRIAL FIBRILLATION 0/102 (0.00%)', ' CARDIAC FAILURE 0/102 (0.00%)', ' TACHYCARDIA 2/102 (1.96%)', ' ACUTE VESTIBULAR SYNDROME 0/102 (0.00%)', ' VERTIGO 1/102 (0.98%)', ' ABDOMINAL PAIN 2/102 (1.96%)', ' COLITIS 1/102 (0.98%)', ' DIARRHOEA 8/102 (7.84%)', ' FEMORAL HERNIA 1/102 (0.98%)', ' HAEMATEMESIS 1/102 (0.98%)', ' ILEUS 1/102 (0.98%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

6e882de6-e55f-40a4-95a1-bdb176e68a18

Single

Eligibility

NCT00834678

Patients with lymphopenia can participate in the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT00834678', 'Intervention': ['INTERVENTION 1: ', ' Bendamustine and Erlotinib', ' Participants in dose level I were administered 100 mg/m^2 IV of Bendamustine on days 1 and 2 and 100 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.', ' Participants in dose level II were administered 120 mg/m^2 IV of Bendamustine on days 1 and 2 and 150 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed breast cancer meeting 1 of the following criteria:', ' Unresectable stage IIIB or IIIC disease', ' Stage IV disease', ' Must be negative for all of the following:', ' Estrogen receptor (< 10%)', ' Progesterone receptor (<10%)', ' HER-2 (negative FISH, IHC 0 - 1+, or IHC +2 with negative FISH)', ' Measurable or evaluable disease', ' No symptomatic or progressive CNS (central nervous system) metastases', ' Previously treated CNS metastases allowed provided all of the following criteria are met:', ' At least 8 weeks since prior radiation to brain or CNS metastases', ' No concurrent steroids', ' No leptomeningeal disease', ' PATIENT CHARACTERISTICS:', ' Menopausal status not specified', ' ECOG (Eastern Cooperative Oncology Group) performance status 0-2', ' Life expectancy 6 months', ' WBC > 1,500/mm³', ' Platelet count > 100,000/mm³', ' Creatinine clearance > 40 mL/min', ' Normal electrolytes (i.e., Na, K, and Ca normal; minor deviations are allowed if they do not impact on patient safety in the clinical judgment of the treating physician)', ' Bilirubin 1.5 times upper limit of normal (ULN)', ' ALT and AST 2.5 times ULN ( 5 times ULN in the presence of documented liver metastases)', ' Alkaline phosphatase 2.5 times ULN ( 5 times ULN in the presence of liver or bone metastases)', ' Not pregnant or nursing', ' Fertile patients must use effective barrier contraception', ' No uncontrolled intercurrent illness', ' No active infection requiring systemic therapy', ' Able to swallow oral medications and with no medical problems or prior surgeries that may interfere with the absorption of oral medications including the following:', ' Uncontrolled nausea, vomiting, or diarrhea', ' Lack of the physical integrity of the upper gastrointestinal tract', ' Malabsorption syndrome', ' No known hypersensitivity to bendamustine hydrochloride, mannitol, or erlotinib hydrochloride', ' No prior malignancy in the past 5 years except for adequately treated basal cell or squamous cell skin carcinoma, or adequately treated stage I-II cancer for which the patient is in complete remission', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics', ' Prior adjuvant or neoadjuvant chemotherapy and 1 prior chemotherapy regimen in the metastatic setting allowed provided recovered from all acute toxicities', ' No prior bendamustine hydrochloride or EGFR-directed therapy', ' No other concurrent antineoplastic treatments, including radiotherapy, chemotherapy, biological therapy, hormonal therapy, immunotherapy, gene therapy, and surgery', ' Intravenous bisphosphonates allowed', ' No concurrent antiretroviral therapy for HIV-positive patients', ' No other concurrent investigational agents'], 'Results': ['Outcome Measurement: ', ' Maximum-tolerated Dose of Bendamustine Hydrochloride (Phase I)', ' 28 day cycle included intravenous bendamustine on days 1 and 2.', ' Time frame: Up to two years', 'Results 1: ', ' Arm/Group Title: Bendamustine and Erlotinib', ' Arm/Group Description: Participants in dose level I were administered 100 mg/m^2 IV of Bendamustine on days 1 and 2 and 100 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.', ' Participants in dose level II were administered 120 mg/m^2 IV of Bendamustine on days 1 and 2 and 150 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.', ' Overall Number of Participants Analyzed: 11', ' Measure Type: Number', ' Unit of Measure: mg/m^2 120'], 'Adverse Events': ['Adverse Events 1:', ' Total: 3/11 (27.27%)', ' Infection 3/11 (27.27%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

525ed182-07e9-4548-87b3-c831e0b7389e

Comparison

Adverse Events

NCT00110084

NCT01961544

the primary trial and the secondary trial both reported cases of Pseudomonal sepsis in their patients.

Contradiction

{'Clinical Trial ID': 'NCT00110084', 'Intervention': ['INTERVENTION 1: ', ' Nab-paclitaxel/Gemcitabine', ' Nab (nanoparticle albumin-bound)-Paclitaxel (125mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle and gemcitabine (1000 mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically or cytologically confirmed invasive breast cancer', ' - Clinical evidence of metastatic disease', ' + No bone metastases or other non-measurable disease as the only evidence of metastasis', ' Measurable disease, defined as at least 1 measurable lesion', ' - The following are considered non-measurable disease:', ' Small lesions (< 2 cm)', ' Bone lesions', ' Leptomeningeal disease', ' Ascites', ' Pleural or pericardial effusions', ' Inflammatory breast disease', ' Lymphangitis cutis or pulmonis', ' Abdominal masses that are not confirmed and followed by imaging techniques', ' Cystic lesions', ' HER2(human epidermal growth factor receptor 2)-positive disease allowed provided patient has received prior treatment with trastuzumab', ' No evidence of active brain metastasis, including leptomeningeal involvement', ' Hormone receptor status:', ' Not specified', ' PATIENT CHARACTERISTICS:', ' Age', ' 18 and over Sex', ' Female Menopausal status', ' Not specified Performance status', ' ECOG 0-1 Life expectancy', ' At least 12 weeks Hematopoietic', ' Absolute neutrophil count 1,500/mm^3', ' Platelet count 100,000/mm^3', ' Hemoglobin 9 g/dL Hepatic', ' AST and ALT 2.5 times upper limit of normal (ULN)', ' Bilirubin 1.5 times ULN Renal', ' Creatinine 1.5 mg/dL Other', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception during and for 30 days after completion of study treatment', ' No pre-existing peripheral neuropathy > grade 1', ' No other clinically significant illness or significant medical condition that would preclude study participation', ' No history of allergy or hypersensitivity to paclitaxel protein-bound particles in an injectable suspension, paclitaxel, gemcitabine, albumin, drug product excipients, or agents that are chemically similar to study drugs', ' No serious medical risk factors involving any of the major organ systems that would preclude study participation', ' No active stage III or IV invasive non-breast malignancy within the past 5 years', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy', ' See Disease Characteristics Chemotherapy', ' No more than 1 prior adjuvant chemotherapy regimen', ' No prior chemotherapy for metastatic disease', ' At least 6 months since prior adjuvant or neoadjuvant taxane', ' More than 2 weeks since prior cytotoxic chemotherapy', ' Prior neoadjuvant chemotherapy allowed', ' No other concurrent chemotherapy Endocrine therapy', ' Prior hormonal treatment as adjuvant therapy or for metastatic disease allowed Radiotherapy', ' Prior radiotherapy to target lesion allowed provided there is evidence of disease progression after completion of treatment', ' More than 2 weeks since prior radiotherapy, except radiotherapy to a non-target lesion only or single-dose palliative radiotherapy', ' No concurrent radiotherapy Surgery', ' Not specified Other', ' More than 2 weeks since prior investigational drugs', ' No concurrent participation in another clinical trial that is studying investigational procedures or therapies', ' Concurrent bisphosphonates (e.g., pamidronate or zoledronate) allowed for palliation of pain or lytic lesions from breast cancer'], 'Results': ['Outcome Measurement: ', ' Proportion of Patients With Confirmed Responses', ' Confirmed tumor response (complete and partial) as measured by RECIST(Response Evaluation Criteria In Solid Tumors) criteria on 2 consecutive evaluations at least 6 weeks apart.', ' Confirmed tumor response is at least a 30% decrease in the sum of the longest diameter of target lesions and no new lesions.', ' Time frame: Two consecutive evaluations at least 6 weeks apart', 'Results 1: ', ' Arm/Group Title: Nab-paclitaxel/Gemcitabine', ' Arm/Group Description: Nab (nanoparticle albumin-bound)-Paclitaxel (125mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle and gemcitabine (1000 mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle', ' Overall Number of Participants Analyzed: 50', ' Measure Type: Number', ' Unit of Measure: participants Confirmed response: 25', 'Assessable: 50'], 'Adverse Events': ['Adverse Events 1:', ' Total: 11/50 (22.00%)', ' Anemia 3/50 (6.00%)', ' Febrile neutropenia 1/50 (2.00%)', ' Arrythmia 1/50 (2.00%)', ' Ileus 1/50 (2.00%)', ' Nausea 1/50 (2.00%)', ' Pain-Abdominal 1/50 (2.00%)', ' Vomiting 1/50 (2.00%)', ' Bronchial infection 1/50 (2.00%)', ' Sepsis 1/50 (2.00%)', ' Neutropenia 2/50 (4.00%)', ' Platelet count decreased 1/50 (2.00%)', ' Dehydration 1/50 (2.00%)', ' Arthralgia 1/50 (2.00%)']}

{'Clinical Trial ID': 'NCT01961544', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/m^2', ' Participants received 1.4 milligrams per meters squared (mg/m^2) eribulin mesylate intravenously over the course of 2 to 5 minutes on Day 1 and Day 8 of each 21-day cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Female, Age greater or equal to 20 years', ' Patients with histologically or cytologically confirmed carcinoma of the breast', ' Patients with locally advance or metastatic carcinoma of the breast', ' Patients who have received two to five prior chemotherapeutic regimens including an antracycline and a taxane and 2 or more regimens for locally recurrent and/or metastatic disease', ' Patients must have proved refractory to the most recent chemotherapy on or within six (6) months of therapy', ' Patients who have assessable lesion according to RECIST v 1.1', ' Adequately maintained bone marrow function', ' absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9 /L', ' hemoglobin greater than or equal to 10.0 g/dl (a hemoglobin less than 10.0 g/dL is acceptable if it is corrected by erythropoietin or transfusion)', ' Platelet count greater than or equal to 100 x 10^9 /L', ' Adequately maintained liver function', ' Total bilirubin: less than or equal to 1.5 times the upper limits of normal (ULN) and', ' Alkaline phosphatase(ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 x ULN (in the case of liver metastases less than or equal to 5 x ULN)', ' Adequately maintained renal function', ' Serum creatinine less than or equal to 2.0 mg/dl or', ' Calculated creatinine clearance greater than or equal to 40 ml/min (Cockcroft and Gault formula)', ' Resolution of all chemotherapy or radiation-related toxicities to Grade 1 severity or lower, except for', ' alopecia', ' stable sensory neuropathy less than or equal to Grade 2', ' Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2', ' Life expectancy of greater than or equal to 3 months', ' Patients willing and able to comply with the study protocol for the duration of the study', ' Patients who have provided written consent to participate in this study', ' Exclusion Criteria', ' Patients who have received a chemotherapy, radiation, biologics, immunotherapy or hormonal therapy within three weeks before treatment start (but, palliative radiation can be enrolled)', ' Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen', ' Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least four weeks before starting treatment in this study. Any signs and/or symptoms of brain metastases must be stable for at least four weeks before starting study treatment', ' Patients with meningeal carcinomatosis', ' Significant cardiovascular impairment', ' Myocardial infarction within the past six months, unstable angina, history of congestive heart failure NYHA class III or IV, or serious cardiac arrhythmia', " QTc prolongation (Bazett's Formula greater than 480 msec) or congenital long QT syndrome", ' Severe/uncontrolled intercurrent illness/infection required administration of antibiotic injection', ' Patients who have processed a major surgery within four weeks before participation in this clinical trial', ' Patients who have had a prior malignancy within the past five years other than breast cancer (but, treated non-melanoma skin cancer and carcinoma in situ of the cervix will not be excluded)', ' Patients with known positive HIV status', ' Patients who have received genetic therapy or other investigational drug within 4 weeks before treatment start or expected to receive prohibited medication', ' Patients with prior allergies to Halichondrin B, its derivatives, active ingredient, or other diluting agent', ' Patients who have received this investigational product before registration for this study', ' Patients who are pregnant, who may possibly be pregnant, or are lactating', ' Patients who do not agree to practice contraception for the study periods', ' Patients who have participated in other clinical trial within 4 weeks before screening', ' Patients otherwise judged by investigator or sub investigator to be unsuitable for inclusion'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Treatment-emergent Serious Adverse Event (SAE)', " An AE is defined as any harmful, untoward sign (including abnormal laboratory value, etc.), symptom, or disease in a participant administered investigational product that does not necessarily have a causal relationship with treatment. An SAE is defined as an AE that is life threatening or results in death, results in hospitalization (initial or prolonged), results in a disability (significant, persistent, or permanent change, impairment, damage or disruption in the participant's body function/structure, physical activities, or quality of life), results in a congenital anomaly, or requires intervention to prevent permanent impairment or damage. TEAEs are defined as those events that started on or after the date and time of administration of the first dose of study drug and those events that were present prior to the administration of the first dose of study drug and increased in severity during the study.", ' Time frame: mean of 3.76 months', 'Results 1: ', ' Arm/Group Title: Eribulin Mesylate 1.4 mg/m^2', ' Arm/Group Description: Participants received 1.4 milligrams per meters squared (mg/m^2) eribulin mesylate intravenously over the course of 2 to 5 minutes on Day 1 and Day 8 of each 21-day cycle.', ' Overall Number of Participants Analyzed: 101', ' Measure Type: Number', ' Unit of Measure: Participants TEAE: 101', ' Treatment-emergent SAE: 20'], 'Adverse Events': ['Adverse Events 1:', ' Total: 20/101 (19.80%)', ' Neutropenia * 2/101 (1.98%)', ' Febrile neutropenia * 1/101 (0.99%)', ' Pericardial effusion * 2/101 (1.98%)', ' Abdominal distension * 1/101 (0.99%)', ' Abdominal pain * 1/101 (0.99%)', ' Ascites * 1/101 (0.99%)', ' Gastritis * 1/101 (0.99%)', ' Asthenia * 1/101 (0.99%)', ' Pyrexia * 1/101 (0.99%)', ' Pneumonia * 1/101 (0.99%)', ' Pseudomonal sepsis * 1/101 (0.99%)']}

233d2ec1-1383-4088-90af-c5a948847631

Single

Adverse Events

NCT00426556

There were an equal number of cases of Febrile neutropenia, Leukopenia and Neutropenia across cohorts in the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00426556', 'Intervention': ['INTERVENTION 1: ', ' Phase I - RAD001 5mg + PT, Daily', ' Daily dosing schedule of Everolimus 5mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab', 'INTERVENTION 2: ', ' Phase I - RAD001 10mg + PT, Daily', ' Daily dosing schedule of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab'], 'Eligibility': ['Inclusion Criteria:', ' Female or male patients 18 years old with WHO performance status 1', ' HER-2 over-expressing metastatic breast cancer cells confirmed by histology', ' Progressive disease on prior trastuzumab alone/or in combination with other anticancer agents, or relapsed any time after completion of this therapy (phase l)', ' Patient resistance to trastuzumab and taxanes (Phase ll)', ' Measurable disease according to RECIST (Phase ll)', ' Patients neurologically stable with adequate bone marrow, liver and renal function', 'Exclusion Criteria:', ' Patients receiving endocrine therapy for breast cancer 2 weeks prior to study treatment start', ' Patients currently receiving chemotherapy, immunotherapy or radiotherapy or who have received these 4 weeks prior to study treatment start or patients who have received lapatinib 2 weeks prior to study treatment start', ' Patients who have previously received mTOR inhibitors', ' Other protocol-defined inclusion/exclusion criteria may apply'], 'Results': ['Outcome Measurement: ', ' Phase II: Overall Response Rate', ' The primary objective of this phase II study was to evaluate the efficacy of the dose level/regimen of everolimus recommended from the Phase I with trastuzumab and paclitaxel (PT) therapy in patients with HER2-overexpressing metastatic breast cancer whose disease progressed on/after trastuzumab mono-and/or combination therapy based on the evaluation of objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Objective response rate (ORR) was defined as the proportion of patients with a best overall response (BOR) of complete response (CR) or partial response (PR). Only patients with measurable disease (the presence of at least one measurable lesion) at baseline were included in the study. CR = Disappearance of all target lesions; PR = At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.', ' Time frame: every 8 - 9 weeks until disease progression or a new lesion is identified', 'Results 1: ', ' Arm/Group Title: Phase I - RAD001 5mg + PT, Daily', ' Arm/Group Description: Daily dosing schedule of Everolimus 5mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab', ' Overall Number of Participants Analyzed: 0', ' Measure Type: Number', ' Unit of Measure: Percentage of Participants ', 'Results 2: ', ' Arm/Group Title: Phase I - RAD001 10mg + PT, Daily', ' Arm/Group Description: Daily dosing schedule of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab', ' Overall Number of Participants Analyzed: 0', ' Measure Type: Number', ' Unit of Measure: Percentage of Participants '], 'Adverse Events': ['Adverse Events 1:', ' Total: 3/6 (50.00%)', ' Febrile neutropenia 0/6 (0.00%)', ' Leukopenia 0/6 (0.00%)', ' Neutropenia 0/6 (0.00%)', ' Thrombocytopenia 0/6 (0.00%)', ' Cardio-respiratory arrest 0/6 (0.00%)', ' Cardiopulmonary failure 0/6 (0.00%)', ' Vertigo 0/6 (0.00%)', ' Visual impairment 0/6 (0.00%)', ' Abdominal pain 0/6 (0.00%)', ' Diarrhoea 0/6 (0.00%)', ' Dysphagia 0/6 (0.00%)', ' Gastric ulcer 0/6 (0.00%)', 'Adverse Events 2:', ' Total: 6/17 (35.29%)', ' Febrile neutropenia 0/17 (0.00%)', ' Leukopenia 0/17 (0.00%)', ' Neutropenia 0/17 (0.00%)', ' Thrombocytopenia 0/17 (0.00%)', ' Cardio-respiratory arrest 1/17 (5.88%)', ' Cardiopulmonary failure 0/17 (0.00%)', ' Vertigo 0/17 (0.00%)', ' Visual impairment 0/17 (0.00%)', ' Abdominal pain 0/17 (0.00%)', ' Diarrhoea 1/17 (5.88%)', ' Dysphagia 0/17 (0.00%)', ' Gastric ulcer 1/17 (5.88%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

8e3fe244-d47d-48ce-ab29-4a5226024aad

Single

Eligibility

NCT00005957

T4 N3 M0 adenocarcinoma of the breast are eligible for the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT00005957', 'Intervention': ['INTERVENTION 1: ', ' Standard Breast Irradiation', ' radiation therapy: Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.', 'INTERVENTION 2: ', ' Breast Radiation Plus Regional Radiation', ' regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)', ' Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically proven invasive carcinoma of the breast', ' No evidence of T4, N2-3, or M1 disease prior to surgery', ' Node positive or high-risk node negative', ' Prior breast-conserving therapy (BCT) (e.g., lumpectomy, partial mastectomy, or segmental mastectomy) and axillary node dissection or sentinel node biopsy required and must be a candidate for breast radiotherapy after BCT', ' Normally patients should have microscopically clear resection margins and those with positive margins should undergo reexcision', ' Patients with microscopically focally positive margins (defined as no greater than 3 times high power fields) are candidates for breast radiotherapy plus a boost to the lumpectomy site', ' Patients with prior sentinel node dissection eligible if node negative, but still meet high-risk criteria', ' If node positive, then a level I and II axillary dissection must be performed', ' No evidence of residual disease in axilla after dissection', ' Must be treated with currently accepted adjuvant systemic chemotherapy and/or hormonal therapy', ' High risk of regional and systemic recurrence due to one of the following:', ' Pathologically positive axillary lymph nodes', ' Pathologically negative axillary lymph nodes with one of the following:', ' Primary tumor greater than 5 cm', ' Primary tumor greater than 2 cm and less than 10 axillary lymph nodes excised and one of the following:', ' Estrogen receptor negative', ' Skarf-Bloom-Richardson grade 3', ' Lymphovascular invasion', ' Hormone receptor status:', ' Estrogen and progesterone receptor status known', ' PATIENT CHARACTERISTICS:', ' Age:', ' 16 and over', ' Sex:', ' Female', ' Menopausal status:', ' Premenopausal or postmenopausal', 'Performance status:', ' ECOG 0-2', ' Life expectancy:', ' At least 5 years', ' Hematopoietic:', ' Not specified', ' Hepatic:', ' SGOT and/or SGPT no greater than 3 times upper limit of normal (ULN)*', ' Alkaline phosphatase no greater than 3 times ULN* NOTE: * Patients with laboratory values greater than 3 times ULN may still be eligible if no metastatic disease by imaging examinations', ' Renal:', ' No serious nonmalignant renal disease', ' Cardiovascular:', ' No serious nonmalignant cardiovascular disease', ' Pulmonary:', ' No serious nonmalignant pulmonary disease', ' Other:', ' Not pregnant or nursing', ' Fertile patients must use effective contraception', ' No other serious nonmalignant disease (e.g., systemic lupus erythematosus or scleroderma) that would preclude definitive surgery or radiotherapy', ' No other malignancy except:', ' Nonmelanomatous skin cancer', ' Carcinoma in situ of the cervix or endometrium', ' Contralateral noninvasive breast cancer (unless prior radiotherapy to the contralateral breast)', ' Invasive carcinoma of the cervix, endometrium, colon, thyroid, or melanoma that was curatively treated at least 5 years prior to study participation', ' No psychiatric or addictive disorder that would preclude informed consent or study compliance', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy:', ' Not specified', ' Chemotherapy:', ' See Disease Characteristics', ' Concurrent standard adjuvant chemotherapy allowed', ' Endocrine therapy:', ' See Disease Characteristics', ' Concurrent standard adjuvant hormonal therapy allowed', ' Radiotherapy:', ' See Disease Characteristics', ' Surgery:', ' See Disease Characteristics'], 'Results': ['Outcome Measurement: ', ' Overall Survival', ' Duration of study', ' Time frame: 10 years', 'Results 1: ', ' Arm/Group Title: Standard Breast Irradiation', ' Arm/Group Description: radiation therapy: Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.', ' Overall Number of Participants Analyzed: 916', ' Measure Type: Number', ' Unit of Measure: percentage of alive at 10 years 82 (79 to 84)', 'Results 2: ', ' Arm/Group Title: Breast Radiation Plus Regional Radiation', ' Arm/Group Description: regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)', ' Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.', ' Overall Number of Participants Analyzed: 916', ' Measure Type: Number', ' Unit of Measure: percentage of alive at 10 years 83 (80 to 85)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/927 (0.11%)', ' Secondary Malignancy 1/927 (0.11%)', 'Adverse Events 2:', ' Total: 3/893 (0.34%)', ' Secondary Malignancy 3/893 (0.34%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

670443b0-89bf-4af4-a9ab-4cdff26d09a8

Comparison

Intervention

NCT00332709

NCT00659373

All the primary trial participants receive the same dose of Letrozole, only certain patients in the secondary trial are administered Exemestane.

Entailment

{'Clinical Trial ID': 'NCT00332709', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Letrozole 2.5 mg/day for 3 years', 'INTERVENTION 2: ', ' Letrozole + Zoledronic Acid', ' Letrozole 2.5mg/day for 3 years plus Zoledronic acid 4mg every 6 months'], 'Eligibility': ['Inclusion Criteria:', ' Compliant postmenopausal women with primary operable breast cancer after 4 to 6 years of therapy with tamoxifen (end of tamoxifen therapy within last 6 months)', ' Performance status 0-2 (Eastern Cooperative Oncology Group)', ' Patients without severe osteoporosis at study entry', ' No evidence of relapse at the time of randomization', ' Adequate function of bone marrow, kidney, and liver', 'Exclusion Criteria:', ' Estrogen- and progesterone-receptor status negative or unknown', ' Completion of adjuvant tamoxifen therapy more than 6 months prior to study start', ' Inflammatory breast cancer', ' Current/active dental problems including infection of the teeth or jawbone, dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw, of exposed bone in the mouth, or of slow healing after dental procedures.', ' Recent (within 6 weeks) or planned dental or jaw surgery', " History of diseases with influence on bone metabolism such as Paget's disease and primary overactive parathyroid", ' Prior or concomitant therapies: chemotherapy within the last 12 months, intravenous or oral bisphosphonates, systemic corticosteroids, anabolic steroids or growth hormones, Tibolone, parathyroid hormone, systemic sodium fluoride or any drugs known to affect the skeleton (such as calcitonin, mithramycin, or gallium nitrate)', ' Patients with previous or concomitant cancers (not breast cancer) within the past 5 years EXCEPT adequately treated basal or squamous cell skin cancers or in situ cancer of the cervix. Patients with previous other cancer(s) must have been disease-free for at least 5 years.', ' Patients currently receiving oral bisphosphonates must discontinue these at least 3 weeks prior to study start.', ' Additional protocol defined inclusion/exclusion criteria may apply.'], 'Results': ['Outcome Measurement: ', ' Change in Bone Mineral Density (BMD) From Baseline to Month 36', ' Change in bone mineral density (BMD) measured by dual X-ray absorptiometry (DXA) in lumbar spine (L1-L4). Change calculated by (Month 36 BMD-Baseline BMD)/Baseline BMD*100.', ' Time frame: at 36 months as compared to baseline', 'Results 1: ', ' Arm/Group Title: Letrozole', ' Arm/Group Description: Letrozole 2.5 mg/day for 3 years', ' Overall Number of Participants Analyzed: 21', ' Mean (Standard Deviation)', ' Unit of Measure: Percent -0.11 (0.14)', 'Results 2: ', ' Arm/Group Title: Letrozole + Zoledronic Acid', ' Arm/Group Description: Letrozole 2.5mg/day for 3 years plus Zoledronic acid 4mg every 6 months', ' Overall Number of Participants Analyzed: 20', ' Mean (Standard Deviation)', ' Unit of Measure: Percent 0.03 (0.08)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/40 (15.00%)', ' ACUTE MYOCARDIAL INFARCTION 0/40 (0.00%)', ' ANGINA PECTORIS 0/40 (0.00%)', ' ANGINA UNSTABLE 0/40 (0.00%)', ' CORONARY ARTERY STENOSIS 0/40 (0.00%)', ' SUPRAVENTRICULAR TACHYCARDIA 0/40 (0.00%)', ' VERTIGO POSITIONAL 1/40 (2.50%)', ' CONCOMITANT DISEASE PROGRESSION 1/40 (2.50%)', ' CHOLECYSTITIS 1/40 (2.50%)', ' DIVERTICULITIS 0/40 (0.00%)', ' CONTUSION 0/40 (0.00%)', 'Adverse Events 2:', ' Total: 7/41 (17.07%)', ' ACUTE MYOCARDIAL INFARCTION 1/41 (2.44%)', ' ANGINA PECTORIS 1/41 (2.44%)', ' ANGINA UNSTABLE 1/41 (2.44%)', ' CORONARY ARTERY STENOSIS 1/41 (2.44%)', ' SUPRAVENTRICULAR TACHYCARDIA 1/41 (2.44%)', ' VERTIGO POSITIONAL 0/41 (0.00%)', ' CONCOMITANT DISEASE PROGRESSION 0/41 (0.00%)', ' CHOLECYSTITIS 0/41 (0.00%)', ' DIVERTICULITIS 1/41 (2.44%)', ' CONTUSION 1/41 (2.44%)']}

{'Clinical Trial ID': 'NCT00659373', 'Intervention': ['INTERVENTION 1: ', ' Tamoxifen', ' Tamoxifen 20mg orally daily for 5 years', 'INTERVENTION 2: ', ' Ovarian Function Suppression', ' Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)', ' Note: Data were collected separately for the T+OFS and E+OFS participants in the parent study, IBCSG 24-02 (SOFT). The sample size for this Co-SOFT substudy was small, so the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed breast cancer', ' Completely resected disease', ' Registered for clinical trial IBCSG-2402, but not yet started protocol hormonal therapy', ' Has not yet received any of the following adjuvant endocrine therapy, either before or after registration on IBCSG-2402:', ' Tamoxifen, exemestane, or gonadotropin-releasing hormone (GnRH) agonist', ' Ovarian irradiation', ' Bilateral oophorectomy', ' Hormone receptor status:', ' Estrogen and/or progesterone receptor positive', ' Each tumor must be hormone receptor positive', ' PATIENT CHARACTERISTICS:', ' Premenopausal', ' Can speak and read the local language(s) fluently', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics'], 'Results': ['Outcome Measurement: ', ' Change in Cognitive Function Over 1 Year in Premenopausal Breast Cancer Patients Who Receive Adjuvant Tamoxifen (T) Alone Against Those Receive Adjuvant Tamoxifen (T+OFS) or Exemestane (E+OFS) With Ovarian Function Suppression (OFS)', ' Objective cognitive function measured with CogState, a computerized test battery of 7 tasks: Detection, Identification, Monitoring, Memory, Learning, International Shopping List Task (ISLT) and ISLT-Delayed Recall. Performance speed is measured for Detection/Identification/Monitoring and performance accuracy is measured for Memory/Learning/ISLT/ISLT-Delayed Recall. Performance speed calculated as mean of the log10 transformed reaction time for correct responses (lower score=better); performance accuracy calculated as arcsine transformation of the proportion of correct responses (higher scores=better). Main outcome measure is a composite score (average of task scores after transformation and standardization by age-specific norms). A positive standardized score indicates that a patient performed better than average; a negative standardized score indicates below average results. Patients complete assessments at baseline and 1 year after randomization to parent IBCSG 24-02 (SOFT) study.', ' Time frame: 1 year after patient randomization to parent IBCSG 24-02 study', 'Results 1: ', ' Arm/Group Title: Tamoxifen', ' Arm/Group Description: Tamoxifen 20mg orally daily for 5 years', ' Overall Number of Participants Analyzed: 20', ' Mean (Standard Deviation)', ' Unit of Measure: standardized units -.04 (0.49)', 'Results 2: ', ' Arm/Group Title: Ovarian Function Suppression', ' Arm/Group Description: Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)', ' Note: Data were collected separately for the T+OFS and E+OFS participants in the parent study, IBCSG 24-02 (SOFT). The sample size for this Co-SOFT substudy was small, so the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS.', ' Overall Number of Participants Analyzed: 54', ' Mean (Standard Deviation)', ' Unit of Measure: standardized units -0.21 (0.92)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/20 (0.00%)', 'Adverse Events 2:', ' Total: 0/54 (0.00%)']}

455748bf-8e12-4834-8126-ab77cab16200

Single

Results

NCT01808573

the primary trial Patients receiving Neratinib Plus Capecitabine had a Mean (95% Confidence Interval) Progression Free Survival more than 2 months longer than patients administered with Lapatinib Plus Capecitabine.

Entailment

{'Clinical Trial ID': 'NCT01808573', 'Intervention': ['INTERVENTION 1: ', ' Neratinib Plus Capecitabine', ' neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.', 'INTERVENTION 2: ', ' Lapatinib Plus Capecitabine', ' lapatinib 1250 mg orally, once daily, continuously in 21 day cycles, and capecitabine 2000 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Aged 18 years at signing of informed consent.', ' Histologically confirmed MBC, current stage IV.', ' Documented HER2 overexpression or gene-amplified tumor immunohistochemistry 3+ or 2+, with confirmatory fluorescence in situ hybridization (FISH) +.', ' Prior treatment with at least two (2) HER2-directed regimens for metastatic breast cancer.', 'Exclusion Criteria:', ' Received previous therapy with capecitabine, neratinib, lapatinib, or any other HER2 directed tyrosine kinase inhibitor.', ' Note: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.'], 'Results': ['Outcome Measurement: ', ' Centrally Assessed Progression Free Survival', ' Progression Free Survival (PFS), Measured in Months, for Randomized Subjects of the Central Assessment. The time interval from the date of randomization until the first date on which recurrence, progression (per Response Evaluation Criteria in Solid Tumors Criteria (RECIST) v1.1), or death due to any cause, is documented. For subjects without recurrence, progression or death, it is censored at the last valid tumor assessment. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to 24 months.', ' Time frame: From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.', 'Results 1: ', ' Arm/Group Title: Neratinib Plus Capecitabine', ' Arm/Group Description: neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.', ' Overall Number of Participants Analyzed: 307', ' Mean (95% Confidence Interval)', ' Unit of Measure: months 8.8 (7.8 to 9.8)', 'Results 2: ', ' Arm/Group Title: Lapatinib Plus Capecitabine', ' Arm/Group Description: lapatinib 1250 mg orally, once daily, continuously in 21 day cycles, and capecitabine 2000 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.', ' Overall Number of Participants Analyzed: 314', ' Mean (95% Confidence Interval)', ' Unit of Measure: months 6.6 (5.9 to 7.4)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 103/303 (33.99%)', ' Anaemia 1/303 (0.33%)', ' Febrile neutropenia 1/303 (0.33%)', ' Neutropenia 1/303 (0.33%)', ' Acute myocardial infarction 0/303 (0.00%)', ' Atrial fibrillation 1/303 (0.33%)', ' Cardiac arrest 0/303 (0.00%)', ' Cardiac tamponade 1/303 (0.33%)', ' Cardiomyopathy 1/303 (0.33%)', ' Palpitations 2/303 (0.66%)', ' Pericardial effusion 1/303 (0.33%)', ' Tachycardia 0/303 (0.00%)', 'Adverse Events 2:', ' Total: 93/311 (29.90%)', ' Anaemia 2/311 (0.64%)', ' Febrile neutropenia 3/311 (0.96%)', ' Neutropenia 0/311 (0.00%)', ' Acute myocardial infarction 1/311 (0.32%)', ' Atrial fibrillation 0/311 (0.00%)', ' Cardiac arrest 1/311 (0.32%)', ' Cardiac tamponade 1/311 (0.32%)', ' Cardiomyopathy 0/311 (0.00%)', ' Palpitations 0/311 (0.00%)', ' Pericardial effusion 1/311 (0.32%)', ' Tachycardia 1/311 (0.32%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

d29bd9dd-b52e-4b18-82ea-e2914dfb9579

Single

Results

NCT00337103

The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00337103', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/m^2', ' Eribulin mesylate 1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.', 'INTERVENTION 2: ', ' Capecitabine 2.5 g/m^2/Day', ' Capecitabine : Capecitabine 2.5 g/m^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days.'], 'Eligibility': ['Inclusion Criteria:', ' Female patients with histologically or cytologically confirmed carcinoma of the breast. Every effort should be made to ensure that paraffin embedded tissue or slides from the diagnostic biopsy or surgical specimen are available for confirmation of diagnosis.', ' Patients with locally advanced or metastatic disease who have received up to three prior chemotherapy regimens, and no more than two prior regimens for advanced and/or metastatic disease.', ' Regimens must have included an anthracycline (e.g., doxorubicin, epirubicin) and a taxane (e.g., paclitaxel, docetaxel), either in combination or in separate regimens.', ' Patients with known human epidermal growth factor 2 (HER2/neu) over-expressing tumors may additionally have been treated with trastuzumab in centers where this treatment is available.', ' Patients with known estrogen and/or progesterone receptor-expressing tumors may have additionally been treated with hormonal therapy.', ' Resolution of all chemotherapy or radiation-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy <= Grade 2 and alopecia.', ' Age >= 18 years.', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.', ' Life expectancy of >= 3 months.', ' Adequate renal function as evidenced by serum creatinine <1.5 mg/dL or calculated creatinine clearance > 50 mL/minute (min) per the Cockcroft and Gault formula.', ' Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) >= 1.5 x 10^9/L, hemoglobin >= 10.0 g/dL (a hemoglobin < 10.0 g/dL acceptable if it is corrected by growth factor or transfusion), and platelet count >= 100 x 10^9/L.', ' Adequate liver function as evidenced by bilirubin <= 1.5 times the upper limits of normal (ULN) and alkaline phosphatase, alanine transaminase (ALT), and aspartate transaminase (AST) <= 3 x ULN (in the case of liver metastases <= 5 x ULN), or in case of bone metastases, liver specific alkaline phosphatase <= 3 x ULN.', ' Patients willing and able to complete the EORTC (European Organization for Research on the Treatment of Cancer) quality of life questionnaire (QLQ-C30 with breast cancer module QLQ-BR23) and to record their pain level on the Visual Analog Scale (VAS).', ' Patients willing and able to comply with the study protocol for the duration of the study.', ' Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.', 'Exclusion Criteria:', ' Patients who have received more than three prior chemotherapy regimens for their disease, including adjuvant therapies, or patients who have received more than two prior chemotherapy regimens for advanced disease (other therapies are allowed e.g., anti-estrogens, trastuzumab and radiotherapy).', ' Patients who have received capecitabine as a prior therapy for their disease.', ' Patients who have received chemotherapy, radiation, or biological therapy within two weeks, or hormonal therapy, within one week before study treatment start, or any investigational drug within four weeks before study treatment start.', ' Radiation therapy encompassing > 30% of marrow.', ' Prior treatment with mitomycin C or nitrosourea.', ' Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.', ' Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment with study treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before starting study treatment; radiographic stability should be determined by comparing a contrast-enhanced Computed Tomography Scan (CT) or Magnetic Resonance Imaging (MRI) brain scan performed during screening to a prior scan performed at least 4 weeks earlier.', ' Patients with meningeal carcinomatosis.', ' Patients who are receiving anti-coagulant therapy with warfarin or related compounds, other than for line patency, and cannot be changed to heparin-based therapy, are not eligible. If a patient is to continue on mini-dose warfarin, then the prothrombin time (PT)/international normalized ratio (INR) must be closely monitored.', ' Women who are pregnant or breast-feeding; women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test; women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception (considered to be two methods of contraception, one of which must be a barrier method, e.g. condom, diaphragm or cervical cap). Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.', ' Severe/uncontrolled intercurrent illness/infection.', ' Significant cardiovascular impairment (history of congestive heart failure > New York Heart Association [NYHA] Grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia).', ' Patients with organ allografts requiring immunosuppression.', ' Patients with known positive human immunodeficiency virus (HIV) status.', ' Patients who have had a prior malignancy, other than carcinoma in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated >= 5 years previously with no subsequent evidence of recurrence.', ' Patients with pre-existing neuropathy > Grade 2.', ' Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative.', ' Patients who participated in a prior E7389 clinical trial.', " Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study."], 'Results': ['Outcome Measurement: ', ' Overall Survival (OS)', ' OS was measured from the date of randomization until the date of death from any cause, or the last date the participant was known to be alive. Participants who were lost to follow-up or who were alive at the date of data cutoff were censored. The censoring rules for OS were as follows: 1) if the participant was still alive at data cutoff, the date of data cutoff was considered the end date, and 2) if the participant was lost to follow-up before data cutoff, the date they were last known to be alive was considered the end date. Participants who survived past the end of the study were counted as in the full study period. If death occurred after data cutoff, the end date was to be censored at the time of data cutoff.', ' Time frame: From date of randomization until date of death from any cause, assessed up to data cutoff date of 12 Mar 2012, or up to approximately 6 years', 'Results 1: ', ' Arm/Group Title: Eribulin Mesylate 1.4 mg/m^2', ' Arm/Group Description: Eribulin mesylate 1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.', ' Overall Number of Participants Analyzed: 554', ' Median (95% Confidence Interval)', ' Unit of Measure: days 484 (462 to 536)', 'Results 2: ', ' Arm/Group Title: Capecitabine 2.5 g/m^2/Day', ' Arm/Group Description: Capecitabine : Capecitabine 2.5 g/m^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days.', ' Overall Number of Participants Analyzed: 548', ' Median (95% Confidence Interval)', ' Unit of Measure: days 440 (400 to 487)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 95/544 (17.46%)', ' Neutropenia 10/544 (1.84%)', ' Febrile Neutropenia 7/544 (1.29%)', ' Leukopenia 4/544 (0.74%)', ' Anaemia 3/544 (0.55%)', ' Pancytopenia 1/544 (0.18%)', ' Thrombocytopenia 0/544 (0.00%)', ' Cardiopulmonary Failure 1/544 (0.18%)', ' Myocardial Infarction 1/544 (0.18%)', ' Pericardial Effusion 1/544 (0.18%)', ' Angina Pectoris 1/544 (0.18%)', 'Adverse Events 2:', ' Total: 115/546 (21.06%)', ' Neutropenia 1/546 (0.18%)', ' Febrile Neutropenia 4/546 (0.73%)', ' Leukopenia 0/546 (0.00%)', ' Anaemia 0/546 (0.00%)', ' Pancytopenia 1/546 (0.18%)', ' Thrombocytopenia 1/546 (0.18%)', ' Cardiopulmonary Failure 1/546 (0.18%)', ' Myocardial Infarction 1/546 (0.18%)', ' Pericardial Effusion 1/546 (0.18%)', ' Angina Pectoris 0/546 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

2649c857-f98d-4529-9a4a-4f8b17813cb8

Single

Results

NCT00399802

The Single IV Infusion of ZA 4 mg group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group

Entailment

{'Clinical Trial ID': 'NCT00399802', 'Intervention': ['INTERVENTION 1: ', ' Single IV Infusion of ZA 4 mg', ' Participants received a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks.', 'INTERVENTION 2: ', ' Once-daily Odanacatib 5 mg', ' Participants received a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment.'], 'Eligibility': ['Inclusion Criteria:', ' Patient has histologically or cytologically-confirmed breast cancer', ' Patient has documented skeletal metastases', 'Exclusion Criteria:', ' Patient is undergoing current oral bisphosphonate therapy, or has a history of oral bisphosphonate use within 6 months of entry into study'], 'Results': ['Outcome Measurement: ', ' Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen (u-NTx) at Week 4', ' u-NTx is a biochemical index of bone resorption. Participants provided urine specimens on Day 1 (baseline) and at Week 4 for measurement of u-NTx.', ' Time frame: Baseline and Week 4', 'Results 1: ', ' Arm/Group Title: Single IV Infusion of ZA 4 mg', ' Arm/Group Description: Participants received a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks.', ' Overall Number of Participants Analyzed: 14', ' Mean (95% Confidence Interval)', ' Unit of Measure: Percentage change -73 (-80 to -62)', 'Results 2: ', ' Arm/Group Title: Once-daily Odanacatib 5 mg', ' Arm/Group Description: Participants received a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment.', ' Overall Number of Participants Analyzed: 27', ' Mean (95% Confidence Interval)', ' Unit of Measure: Percentage change -77 (-82 to -71)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/14 (14.29%)', ' Febrile neutropenia 0/14 (0.00%)', ' Ascites 0/14 (0.00%)', ' Breast cancer metastatic 1/14 (7.14%)', ' Metastases to bone 1/14 (7.14%)', 'Adverse Events 2:', ' Total: 4/29 (13.79%)', ' Febrile neutropenia 1/29 (3.45%)', ' Ascites 1/29 (3.45%)', ' Breast cancer metastatic 0/29 (0.00%)', ' Metastases to bone 2/29 (6.90%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

0a6e8720-ea47-4520-bd02-e0eb8fcd880f

Single

Results

NCT02679755

More patients in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events compared to patients in the Palbociclib+Letrozole India Cohort.

Contradiction

{'Clinical Trial ID': 'NCT02679755', 'Intervention': ['INTERVENTION 1: ', ' Palbociclib+Letrozole India Cohort', ' Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment ofr each 28-day cycle. Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information', 'INTERVENTION 2: ', ' Palbociclib+Letrozole Australia Cohort', ' Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle. Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information'], 'Eligibility': ['Inclusion Criteria:', ' Post-menopausal women (>=18 years of age) with proven diagnosis of advanced carcinoma of the breast (ER(+) and/or PgR(+) and HER2(-)) who are appropriate for letrozole therapy (in the first-line advanced/metastatic disease setting).', ' Eastern Cooperative Oncology Group (ECOG) performance status 0-2.', ' Adequate bone marrow, liver, and renal function.', 'Exclusion Criteria:', ' Prior treatment with any CDK inhibitor .', ' QTc >480 msec; history of QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes.', ' High cardiovascular risk, including, but not limited to myocardial infarction, severe/unstable angina, severe cardiac dysrhythmias, and symptomatic pulmonary embolism in the past 6 months of enrollment.'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Treatment-Emergent Adverse Events (All Causalities)', ' An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as treatment emergent adverse events (TEAEs). AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.', ' Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months', 'Results 1: ', ' Arm/Group Title: Palbociclib+Letrozole India Cohort', ' Arm/Group Description: Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment ofr each 28-day cycle. Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information', ' Overall Number of Participants Analyzed: 100', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Participants with adverse events: 92 92.0%', ' Participants with serious adverse events: 18 18.0%', ' Participants with grade 3 or 4 adverse events: 69 69.0%', ' Participants with grade 5 adverse events: 3 3.0%', ' Participants discontinued due to adverse events: 2 2.0%', 'Results 2: ', ' Arm/Group Title: Palbociclib+Letrozole Australia Cohort', ' Arm/Group Description: Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle. Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information', ' Overall Number of Participants Analyzed: 152', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Participants with adverse events: 152 100.0%', ' Participants with serious adverse events: 45 29.6%', ' Participants with grade 3 or 4 adverse events: 124 81.6%', ' Participants with grade 5 adverse events: 7 4.6%', ' Participants discontinued due to adverse events: 9 5.9%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 18/100 (18.00%)', ' Anaemia * 4/100 (4.00%)', ' Febrile neutropenia * 3/100 (3.00%)', ' Neutropenia * 1/100 (1.00%)', ' Pancytopenia * 0/100 (0.00%)', ' Thrombocytopenia * 1/100 (1.00%)', ' Acute coronary syndrome * 1/100 (1.00%)', ' Stress cardiomyopathy * 0/100 (0.00%)', ' Abdominal pain * 0/100 (0.00%)', ' Abdominal pain upper * 0/100 (0.00%)', ' Ascites * 1/100 (1.00%)', 'Adverse Events 2:', ' Total: 45/152 (29.61%)', ' Anaemia * 0/152 (0.00%)', ' Febrile neutropenia * 3/152 (1.97%)', ' Neutropenia * 1/152 (0.66%)', ' Pancytopenia * 1/152 (0.66%)', ' Thrombocytopenia * 0/152 (0.00%)', ' Acute coronary syndrome * 0/152 (0.00%)', ' Stress cardiomyopathy * 1/152 (0.66%)', ' Abdominal pain * 2/152 (1.32%)', ' Abdominal pain upper * 2/152 (1.32%)', ' Ascites * 0/152 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

ce6630d3-d3b7-4870-a486-9b6284a454f0

Comparison

Intervention

NCT00054028

NCT02162719

Both the primary trial and the secondary trial at least partly administer their interventions intravenously.

Entailment

{'Clinical Trial ID': 'NCT00054028', 'Intervention': ['INTERVENTION 1: ', ' Suramin and Paclitaxel', ' Suramin will be infused weekly over 30 minutes. Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin.'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have histologically or cytologically confirmed stage IIIB or IV metastatic breast cancer (MBC)', 'Prior chemotherapy:', ' Phase I: patients must have received prior paclitaxel or other taxanes in either the adjuvant or metastatic setting; prior chemotherapy, radiation or surgery must be completed at least 21 days before study entry; prior treatment with anthracyclines is not required', ' Phase II: up to two prior chemotherapy regimens for stage IIIB or IV MBC; patients must have received prior paclitaxel or other taxanes in either the adjuvant or metastatic setting; prior chemotherapy, radiation or surgery must be completed at least 21 days before study entry; prior treatment with anthracyclines is not required', ' Measurable disease (phase II)', ' No known brain metastases', ' Hormone receptor status:', ' Not specified', ' Performance status - Eastern Cooperative Oncology Group (ECOG) 0-2', ' White blood cell (WBC) at least 3,000/mm^3', ' Absolute neutrophil count at least 1,000/mm^3', ' Platelet count at least 100,000/mm^3', ' Hemoglobin at least 9.0 g/dL', ' Bilirubin no greater than 1.5 mg/dL', ' Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) no greater than 2.5 times upper limit of normal', ' Creatinine no greater than 1.5 mg/dL', ' Left ventricular ejection fraction (LVEF) at least lower limit of normal', ' No symptomatic congestive heart failure', ' No unstable angina pectoris', ' No cardiac arrhythmia', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception', ' No history of allergic reactions attributable to compounds of similar chemical or biological composition to Cremophor', ' No concurrent uncontrolled illness that would preclude study compliance', ' No ongoing or active infection', ' No uncontrolled diabetes mellitus', ' No psychiatric illness or social situations that would preclude study compliance', ' No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix', ' See Disease Characteristics', ' At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered', ' No more than 2 prior chemotherapy regimens for this malignancy (phase II)', ' No concurrent steroids or hormones except the following:', ' Steroids to prevent hypersensitivity reactions prior to paclitaxel administration', ' Hormones for nondisease-related conditions (e.g., insulin for diabetes)', ' At least 3 weeks since prior radiotherapy and recovered', ' At least 3 weeks since prior surgery and recovered', ' No concurrent combination antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients', ' No other concurrent investigational agents', ' Concurrent bisphosphonates (i.e., pamidronate or zoledronate) are allowed for the treatment of hypercalcemia or palliation of skeletal metastases'], 'Results': ['Outcome Measurement: ', ' Percentage of Patients That Achieved Target Suramin Concentrations in Plasma', ' Target suramin concentration was considered achieved, if at least 5 of 6 patients achieved the target plasma concentration of 10-50 µM over the duration of 8-48 hours when paclitaxel levels are therapeutic.', ' Time frame: Up to 5 years', 'Results 1: ', ' Arm/Group Title: Suramin and Paclitaxel', ' Arm/Group Description: Suramin will be infused weekly over 30 minutes. Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin.', ' Overall Number of Participants Analyzed: 9', ' Measure Type: Number', ' Unit of Measure: percent of patients 88'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/31 (3.23%)', ' Adult respiratory distress syndrome (ARDS) 1/31 (3.23%)']}

{'Clinical Trial ID': 'NCT02162719', 'Intervention': ['INTERVENTION 1: ', ' Ipatasertib and Paclitaxel', ' Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.', 'INTERVENTION 2: ', ' Placebo and Paclitaxel', ' Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with placebo matching ipatasertib, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically documented triple-negative adenocarcinoma of the breast that is inoperable locally advanced or metastatic and is not amenable to resection with curative intent', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', ' Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen, required prior to randomization', ' Measurable disease, according to the RECIST v1.1', ' Adequate hematologic and organ function within 14 days before the first study treatment', ' For female participants of childbearing potential, agreement (by both participant and partner) to use an effective form of contraception for the duration of the study and for 6 months after last dose of study treatment', 'Exclusion Criteria:', ' Any previous therapy, including chemotherapy or hormonal or targeted therapy, for inoperable locally advanced or metastatic triple-negative adenocarcinoma of the breast. Participants may have received prior neoadjuvant or adjuvant chemotherapy and/or radiation treatment for locally advanced triple negative adenocarcinoma, provided all treatments were completed greater than or equal to (>/=) 6 months prior to Cycle 1 Day 1. Locally recurrent disease must not be amenable to resection with curative intent', ' Any radiation treatment to metastatic site within 28 days of Cycle 1, Day 1', ' Known Human Epidermal Growth Factor Receptor 2 (HER2) positive, erythrocyte receptor (ER) positive, or progesterone receptor (PR) positive breast cancer', ' Previous therapy with Akt, PI3K, and/or mTOR inhibitors', ' Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study', ' Known presence of the brain or spinal cord metastasis, as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or prior radiographic assessments'], 'Results': ['Outcome Measurement: ', ' Progression Free Survival (PFS)', ' PFS was defined as the time from randomization to the first occurrence of disease progression, as determined by investigator review of tumor assessments by RECIST, v1.1 or death on study (<=30 days after the last dose of study treatment regimen) from any cause, whichever occurred first.', ' Time frame: Baseline up to 30 days after the last dose of study drug administration (Clinical Cut Off Date: 07 June 2016)', 'Results 1: ', ' Arm/Group Title: Ipatasertib and Paclitaxel', ' Arm/Group Description: Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.', ' Overall Number of Participants Analyzed: 62', ' Median (90% Confidence Interval)', ' Unit of Measure: Months 6.18 (4.57 to 7.33)', 'Results 2: ', ' Arm/Group Title: Placebo and Paclitaxel', ' Arm/Group Description: Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with placebo matching ipatasertib, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.', ' Overall Number of Participants Analyzed: 62', ' Median (90% Confidence Interval)', ' Unit of Measure: Months 4.93 (3.58 to 5.36)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 18/61 (29.51%)', ' Pancytopenia 0/61 (0.00%)', ' Febrile Neutropenia 2/61 (3.28%)', ' Constipation 0/61 (0.00%)', ' Diarrhoea 3/61 (4.92%)', ' Nausea 1/61 (1.64%)', ' Pancreatitis 1/61 (1.64%)', ' Death 0/61 (0.00%)', ' Pyrexia 2/61 (3.28%)', ' Cholestasis 0/61 (0.00%)', ' Atypical Pneumonia 1/61 (1.64%)', ' Cystitis 0/61 (0.00%)', ' Gastroenteritis 0/61 (0.00%)', ' Influenza 0/61 (0.00%)', 'Adverse Events 2:', ' Total: 12/62 (19.35%)', ' Pancytopenia 1/62 (1.61%)', ' Febrile Neutropenia 0/62 (0.00%)', ' Constipation 1/62 (1.61%)', ' Diarrhoea 0/62 (0.00%)', ' Nausea 0/62 (0.00%)', ' Pancreatitis 0/62 (0.00%)', ' Death 1/62 (1.61%)', ' Pyrexia 1/62 (1.61%)', ' Cholestasis 1/62 (1.61%)', ' Atypical Pneumonia 0/62 (0.00%)', ' Cystitis 1/62 (1.61%)', ' Gastroenteritis 1/62 (1.61%)', ' Influenza 1/62 (1.61%)']}

27e31574-5a73-4a68-997d-daa84797a65a

Single

Adverse Events

NCT00014222

Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events, whereas cohort two recorded 41.

Contradiction

{'Clinical Trial ID': 'NCT00014222', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: CEF', ' 6 cycles - q 28 days (6 months) - Cyclophosphamide 75 mg/m2 - po - Days 1-14 - Epirubicin 60 mg/m2 - IV - Days 1 and 8 - 5 Fluorouracil: 500mg/m2 - IV - Days 1 and 8 + Continuous Antibiotic Prophylaxis with Cotrimoxazole 960 mg (i.e.2x480 mg tablets) po-bid or Ciprofloxacin 500 mg - po-bid', ' cyclophosphamide: 75, 600 and 830 mg/m2', ' epirubicin hydrochloride: 60 mg/m2', ' fluorouracil: 500mg/m2', 'INTERVENTION 2: ', ' Arm 2: EC/T', ' 6 cycles - q 14 days (3 months) - Epirubicin 120 mg/m2 - IV - Day 1 - Cyclophosphamide 830 mg/m2 - IV - Day 1 - Filgrastim 5μg/kg/d - SC - Days 2 - 13 + Epoetin Alfa 40,000 IU - SC - once weekly (to begin within 1 week after start of protocol therapy as needed) 21 days from last administration of EC (EC/T) 4 cycles - q 21 days (3 months) - Adriamycin 60 mg/m2 - IV - Day 1 - Cyclophosphamide 600 mg/m2 - IV - Day 1 - 21 days from last administration of AC 4 cycles - q 21 days (3 months) - Paclitaxel 175 mg/m2 IV 3 hour infusion', ' epoetin alfa: 40,000 IU', ' filgrastim: 5 mg/kg/d - days 2-13', ' cyclophosphamide: 75, 600 and 830 mg/m2', ' doxorubicin hydrochloride: 60 mg/m2', ' paclitaxel: 175 mg/m2'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed adenocarcinoma of the breast that is potentially curable', ' T0-4 (dermal involvement on pathology assessment only), N0-2, M0', ' No clinical T4 disease', ' Previously treated with one of the following:', ' Total mastectomy and level II axillary node dissection', ' Partial mastectomy and level II axillary node dissection with planned breast radiotherapy after completion of adjuvant chemotherapy regimen*', ' Patients with a positive sentinel node biopsy must undergo level II axillary node dissection or sufficient nodal sampling', ' If microscopic residual in situ or invasive disease is present at total or partial mastectomy margins, planned radiotherapy must also include a boost to the tumor bed', ' No residual tumor in the axilla after dissection', ' Axillary node positive', ' Negative nodes allowed if the tumor is 1 cm and 1 or more of the following criteria defining high-risk node-negative disease are met:', ' Histological grade III or,', ' Estrogen receptor negative or,', ' Lymphatic/vascular invasion', ' Hormone receptor status:', ' Estrogen receptor status known', ' PATIENT CHARACTERISTICS:', ' Age:', ' 60 and under', ' Sex:', ' Female', ' Menopausal status:', ' Pre- or postmenopausal', 'Performance status:', ' ECOG 0-2', ' Life expectancy:', ' At least 5 years', ' Hematopoietic:', ' WBC 3,000/mm^3', ' Platelet count 100,000/mm^3', ' Hepatic:', ' Bilirubin 1.5 times upper limit of normal (ULN)', ' Renal:', ' Creatinine 1.5 times ULN', ' Cardiovascular:', ' LVEF limit of normal by MUGA or echocardiogram', ' No arrhythmia requiring ongoing treatment', ' No congestive heart failure', ' No documented coronary artery disease', ' Other:', ' No other malignancy except:', ' Adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix', ' Ductal or lobular carcinoma in situ that has been curatively treated by surgery alone', ' Other prior malignancies (except breast cancer) curatively treated more than 5 years prior to study entry', ' No serious underlying medical illness or psychiatric or addictive disorder that would preclude study compliance', ' No known hypersensitivity to E. coli-derived products, mammalian-cell derived products, or any study agents', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective non-hormonal contraception', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy:', ' No prior immunotherapy for breast cancer', ' No concurrent pegfilgrastim or darbepoetin alfa (Arm II)', ' Allowed on arms 1 and 3 if medically necessary', ' Chemotherapy:', ' No prior chemotherapy for breast cancer', ' Endocrine therapy:', ' No prior hormonal therapy for breast cancer', ' No concurrent hormone replacement therapy', ' No concurrent selective estrogen-receptor modulators (e.g., raloxifene for the treatment or prevention of osteoporosis)', ' No concurrent oral contraceptives (i.e., birth control pills)', ' No other concurrent aromatase inhibitors', ' Radiotherapy:', ' See Disease Characteristics', ' No prior radiotherapy for breast cancer', ' Surgery:', ' See Disease Characteristics', ' No more than 12 weeks since prior total or partial mastectomy (including re-excision of margins)', ' Other:', ' At least 30 days since prior investigational drugs', ' No other concurrent investigational drugs', ' Concurrent bisphosphonates for the treatment or prevention of osteoporosis allowed'], 'Results': ['Outcome Measurement: ', ' Disease Free Survival', ' Disease free survival was defined as the time from randomization to the time of recurrence of the primary disease. Local or nodal recurrence and metastatic disease were considered a recurrence of the primary tumour. Patients who had contralateral breast cancer or a second primary malignancy, or died from some cause other than disease were censored as relapse-free at the time of death. Patients who had not relapsed were censored at longest follow-up or at non-breast cancer death. As required, adjudication was used to assess reports of recurrence.', ' Time frame: 13 years', 'Results 1: ', ' Arm/Group Title: Arm 1: CEF', ' Arm/Group Description: 6 cycles - q 28 days (6 months) - Cyclophosphamide 75 mg/m2 - po - Days 1-14 - Epirubicin 60 mg/m2 - IV - Days 1 and 8 - 5 Fluorouracil: 500mg/m2 - IV - Days 1 and 8 + Continuous Antibiotic Prophylaxis with Cotrimoxazole 960 mg (i.e.2x480 mg tablets) po-bid or Ciprofloxacin 500 mg - po-bid', ' cyclophosphamide: 75, 600 and 830 mg/m2', ' epirubicin hydrochloride: 60 mg/m2', ' fluorouracil: 500mg/m2', ' Overall Number of Participants Analyzed: 701', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Disease Recurrence: 141 20.1%', ' No recurrence: 560 79.9%', 'Results 2: ', ' Arm/Group Title: Arm 2: EC/T', ' Arm/Group Description: 6 cycles - q 14 days (3 months) - Epirubicin 120 mg/m2 - IV - Day 1 - Cyclophosphamide 830 mg/m2 - IV - Day 1 - Filgrastim 5μg/kg/d - SC - Days 2 - 13 + Epoetin Alfa 40,000 IU - SC - once weekly (to begin within 1 week after start of protocol therapy as needed) 21 days from last administration of EC (EC/T) 4 cycles - q 21 days (3 months) - Adriamycin 60 mg/m2 - IV - Day 1 - Cyclophosphamide 600 mg/m2 - IV - Day 1 - 21 days from last administration of AC 4 cycles - q 21 days (3 months) - Paclitaxel 175 mg/m2 IV 3 hour infusion', ' epoetin alfa: 40,000 IU', ' filgrastim: 5 mg/kg/d - days 2-13', ' cyclophosphamide: 75, 600 and 830 mg/m2', ' doxorubicin hydrochloride: 60 mg/m2', ' paclitaxel: 175 mg/m2', ' Overall Number of Participants Analyzed: 701', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Disease Recurrence: 135 19.3%', ' No recurrence: 566 80.7%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 83/680 (12.21%)', ' Hemoglobin 11/680 (1.62%)', ' Transfusion: Platelets 0/680 (0.00%)', ' Transfusion: pRBCs 0/680 (0.00%)', ' Febrile neutropenia 49/680 (7.21%)', ' Edema 1/680 (0.15%)', ' Ischemia/infarction 0/680 (0.00%)', ' Palpitations 0/680 (0.00%)', ' Pericardial effusion 0/680 (0.00%)', ' Keratitis 1/680 (0.15%)', ' Double vision 1/680 (0.15%)', ' Colitis 1/680 (0.15%)', 'Adverse Events 2:', ' Total: 86/688 (12.50%)', ' Hemoglobin 15/688 (2.18%)', ' Transfusion: Platelets 1/688 (0.15%)', ' Transfusion: pRBCs 1/688 (0.15%)', ' Febrile neutropenia 41/688 (5.96%)', ' Edema 0/688 (0.00%)', ' Ischemia/infarction 0/688 (0.00%)', ' Palpitations 1/688 (0.15%)', ' Pericardial effusion 1/688 (0.15%)', ' Keratitis 0/688 (0.00%)', ' Double vision 0/688 (0.00%)', ' Colitis 0/688 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

e21171de-ad49-4fc5-9c5d-aa362ca61c8a

Single

Intervention

NCT02518191

Cohort 2 of the primary trial is the control group, as the Eligible patients with breast cancer treated with GnRHa every 28 days.

Contradiction

{'Clinical Trial ID': 'NCT02518191', 'Intervention': ['INTERVENTION 1: ', ' GnRHa (Gonadotrophin-releasing Hormone Analogues) Group', ' Eligible patients with breast cancer treated with GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy.', ' Goserelin 3.6mg, or leuprorelin 3.75mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.', 'INTERVENTION 2: ', ' None GnRHa (Gonadotrophin-releasing Hormone Analogues) Group', ' Eligible patients with breast cancer treated without GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy.'], 'Eligibility': ['Inclusion Criteria:', ' Premenopausal women 18 to 49 years of age are eligible for enrollment', ' Patients have operable stage I to IIIA breast cancer for which treatment with adjuvant or neoadjuvant cyclophosphamide-containing chemotherapy was planned.', ' Eligible participants had taken no estrogens, antiestrogens, selective estrogen-receptor modulators, aromatase inhibitors, or hormonal contraceptives within the month before enrollment.', ' Human chorionic gonadotropin negative by urine test before entering the group.', ' Informed consent, understanding and compliance with the requirements of the study.', ' No significant chronic disease and any organ dysfunction.', 'Exclusion Criteria:', ' Exceptions were made for the use of hormonal contraception in women younger than 35 years of age that was discontinued before randomization.', ' Use of hormonal treatment for up to 2 months for the purposes of in vitro fertilization and cryopreservation of embryos or oocytes before randomization.', ' Patients with metastatic lesions or history of bilateral ovariectomy,ovarian radiation were excluded.', ' Patients received previous adjuvant endocrine therapy for breast cancer are not suitable to this trial.', ' Patients with uterine and/or adnexal diseases needing medical or surgical treatment are not suitable.', ' Allergic to active or inactive excipients of GnRHa is an exclusion criterion.'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Premature Ovarian Insufficiency', ' The serum levels of anti-Müllerian hormone (AMH) were measured using human AMH ELISA kit (11351, Biofine)). POI (premature ovarian insufficiency) was defined as AMH<0.5ng/mL in this study.', ' Time frame: 1 years', 'Results 1: ', ' Arm/Group Title: GnRHa (Gonadotrophin-releasing Hormone Analogues) Group', ' Arm/Group Description: Eligible patients with breast cancer treated with GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy.', ' Goserelin 3.6mg, or leuprorelin 3.75mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.', ' Overall Number of Participants Analyzed: 165', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 10 6.1%', 'Results 2: ', ' Arm/Group Title: None GnRHa (Gonadotrophin-releasing Hormone Analogues) Group', ' Arm/Group Description: Eligible patients with breast cancer treated without GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy.', ' Overall Number of Participants Analyzed: 165', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 38 23.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/165 (0.00%)', 'Adverse Events 2:', ' Total: ']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

5dcdeac8-1c4a-4c24-9074-bbe93fcf4d32

Single

Results

NCT00684983

The Median length of time that a patient in Arm A of the primary trial lived with the disease without it getting worse was half a year.

Entailment

{'Clinical Trial ID': 'NCT00684983', 'Intervention': ['INTERVENTION 1: ', ' Arm A', ' Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Given PO and capecitabine: Given PO', 'INTERVENTION 2: ', ' Arm B', ' Patients receive capecitabine and lapatinib ditosylate as in arm I. Patients also receive cixutumumab IV over 1-1½ hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV, lapatinib ditosylate: Given PO and capecitabine: Given PO'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed, locally advanced: (a T4 primary tumor and stage IIIB or IIIC disease) or metastatic breast cancer that has progressed after treatment with regimens that included trastuzumab and either an anthracycline or a taxane or both', ' NOTE: Agents need not have been given concurrently, nor in the same regimen', ' NOTE: Prior treatment with trastuzumab is required unless there is a contraindication for trastuzumab treatment', ' Pre-treatment requirements:', ' Prior treatment with trastuzumab in the neo-adjuvant, adjuvant or metastatic setting is required', ' NOTE: Prior treatment with trastuzumab is required unless there is a contraindication for trastuzumab treatment', ' NOTE: Concomitant use of trastuzumab is not allowed in this study', ' Prior chemotherapy allowed in the neo-adjuvant, adjuvant, or metastatic setting; unlimited prior chemotherapy is allowed', ' Prior hormonal therapy allowed in the neo-adjuvant, adjuvant, or metastatic setting; unlimited prior hormonal therapy is allowed', ' HER2 positive, defined as:', ' Validated immunohistochemistry (IHC) assay score of 3+ (defined as uniform, intense staining of > 30% of invasive tumor cells)', ' -OR- Average HER2 gene copy number of > 6', ' -OR- Gene amplified (HER2:D17Z1 ratio > 2.20)', ' Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria', ' Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only', ' Hemoglobin > 9.0 g/dL (obtained =< 7 days prior to registration)', ' White blood cells (WBC) >= 3,000/mL (obtained =< 7 days prior to registration)', ' Absolute neutrophil count (ANC) >= 1500/mL (obtained =< 7 days prior to registration)', ' Platelet count >= 75,000/mL (obtained =< 7 days prior to registration)', ' Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 7 days prior to registration)', ' Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x ULN or SGOT (AST) and SGPT (ALT) =< 5 x ULN if elevations are due to liver metastases (obtained =< 7 days prior to registration)', ' Serum creatinine =< 1.5 x ULN (obtained =< 7 days prior to registration)', ' Creatinine clearance >= 30 mL/min (calculated according to Cockcroft and Gault) (obtained =< 7 days prior to registration)', ' NOTE: In patients with moderate renal impairment (calculated creatinine clearance 30-50 mL/min) at baseline, a dose reduction of the capecitabine starting dose is required', ' Fasting glucose < 120 mg/dL (obtained =< 7 days prior to registration)', ' NOTE: Patients with diabetes are allowed to participate, provided that their blood glucose is within the guidelines above upon enrollment', ' International normalization ratio (INR) =< 1.5 x ULN (obtained =< 7 days prior to registration)', ' Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2', ' Adequate cardiac function defined as an ejection fraction >= 50% as determined by multi gated acquisition scan (MUGA) or echocardiogram', ' Life expectancy > 3 months', ' Has written informed consent been obtained?', ' Willingness to return to a North Central Cancer Treatment Group (NCCTG) or other participating cooperative group institution for treatment and follow-up', ' Patient willing to provide tissue and blood samples for research purposes', ' Availability of diagnostic material (i.e., diagnostic slides confirming locally advanced/metastatic disease and HER2 stained slides) and operative and pathology reports from diagnosis of locally advanced or metastatic breast cancer', ' NOTE: Biopsy of recurrent disease and submission of these materials is not required if materials available from initial diagnosis of locally advanced/metastatic disease', ' Ability to complete questionnaire(s) by themselves or with assistance', 'Exclusion Criteria:', ' Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:', ' Pregnant women', ' Nursing women', ' Men or women of childbearing potential who are unwilling to employ adequate contraception (as determined by the treating physician)', ' Stage III or IV invasive cancer, other than breast cancer, in =< 5 years prior to registration', ' Actively being treated for other malignancy, excepting non-melanotic skin cancer or carcinoma-in-situ of the cervix; if there is a history of prior malignancy, patient must not be receiving other specific treatment for their cancer', ' New York Heart Association class III or IV cardiovascular disease', " Current, active hepatic or biliary disease except Gilbert's syndrome or asymptomatic gallstones", ' Evidence of active brain metastasis including leptomeningeal involvement; central nervous system (CNS) metastasis controlled by prior surgery and/or radiotherapy is allowed', ' NOTE: To be considered controlled, there must be at least 2 months of no symptoms or evidence of progression prior to study entry and corticosteroid therapy must have been discontinued', ' Major surgery, chemotherapy, or immunologic therapy =< 4 weeks prior to registration', ' Radiotherapy =< 4 weeks prior to registration, except if to a non-target lesion only; prior radiation to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed; if patient receives single dose radiation for palliation or radiation to non-target lesion, they may immediately proceed to registration without waiting; acute adverse events from radiation must have resolved to =< Common Terminology Criteria for Adverse Events (CTCAE) version (v) 3.0 grade 1', ' Prior treatment with any therapy targeting IGF-I, IGF-II or its receptors (either monoclonal antibody or tyrosine kinase inhibitor), including but not limited to any of the following (which would have been received on a previous clinical trial):', ' IMC-A12 (cixutumumab)', ' CP-751,871 (figitumumab)', ' AMG-479', ' INSM-18', ' MK0646 (h7C10)', ' SCH717454 (19D12, robatumumab)', ' R1507', ' OSI-906', ' BMS-754807', ' PPP', ' NVP-AEW541', ' AVE-1642', ' MEDI-573', ' Prior therapy with any therapy targeting HER1 (EGFR) and/or HER2 (either monoclonal antibody or tyrosine kinase) other than trastuzumab, including but not limited to any of the following:', ' Lapatinib (Tykerb)', ' Gefitinib (Iressa)', ' Erlotinib (Tarceva)', ' Cetuximab (Erbitux)', ' Panitumumab (Vectibix)', ' Currently receiving treatment with any agents that are contraindicated by study therapies:', ' IMC-A12 - none identified to date', ' Lapatinib - CYP3A4 inhibitors and inducers, including grapefruit and grapefruit juice', ' Capecitabine - warfarin (Coumadin), cimetidine (Tagamet), allopurinol (Lopurin), sorivudine (Usevir) or brivudine (Brivex), ketoconazole (Nizoral), itraconazole (Sporanox), ritonavir (Norvir), amprenavir (Agenerase) or indinavir (Crixivan)', ' Uncontrolled intercurrent illness including, but not limited to:', ' Poorly controlled diabetes', ' Ongoing or active infection', ' Symptomatic congestive heart failure', ' Unstable angina pectoris', ' Cardiac arrhythmia', ' Psychiatric illness/social situations that would limit compliance with study requirements', ' Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of the safety of the prescribed regimens', ' Currently receiving treatment in a different clinical study in which investigational procedures are performed or investigational therapies are administered', ' Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive with an acquired immune deficiency syndrome (AIDS)-defining illness; HIV positive patients with cluster of differentiation (CD) 4 count within institutional normal range and no history of an AIDS-defining illness are eligible; however, some antiviral/antiretroviral medications which have CYP3A4 interactions are prohibited on this study'], 'Results': ['Outcome Measurement: ', ' Progression-free Survival (PFS)', ' Analysis of the primary endpoint, PFS, will be performed using Cox regression with treatment group as a single covariate.', ' Time frame: From randomization to the earliest date of documentation of disease progression, up to 5 years', 'Results 1: ', ' Arm/Group Title: Arm A', ' Arm/Group Description: Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Given PO and capecitabine: Given PO', ' Overall Number of Participants Analyzed: 19', ' Median (95% Confidence Interval)', ' Unit of Measure: Median survival and CI in months 6.0 (4.3 to 8.6)', 'Results 2: ', ' Arm/Group Title: Arm B', ' Arm/Group Description: Patients receive capecitabine and lapatinib ditosylate as in arm I. Patients also receive cixutumumab IV over 1-1 hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV, lapatinib ditosylate: Given PO and capecitabine: Given PO', ' Overall Number of Participants Analyzed: 37', ' Median (95% Confidence Interval)', ' Unit of Measure: Median survival and CI in months 4.9 (2.9 to 8.5)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/19 (21.05%)', ' Hemoglobin decreased 0/19 (0.00%)', ' Hemolysis 0/19 (0.00%)', ' Diarrhea 2/19 (10.53%)', ' Ear, nose and throat examination abnormal 0/19 (0.00%)', ' Esophageal ulcer 0/19 (0.00%)', ' Gastritis 1/19 (5.26%)', ' Mucositis oral 0/19 (0.00%)', ' Nausea 1/19 (5.26%)', ' Vomiting 1/19 (5.26%)', ' Chest pain 0/19 (0.00%)', ' Chills 0/19 (0.00%)', ' Disease progression 1/19 (5.26%)', 'Adverse Events 2:', ' Total: 14/45 (31.11%)', ' Hemoglobin decreased 1/45 (2.22%)', ' Hemolysis 1/45 (2.22%)', ' Diarrhea 1/45 (2.22%)', ' Ear, nose and throat examination abnormal 1/45 (2.22%)', ' Esophageal ulcer 1/45 (2.22%)', ' Gastritis 1/45 (2.22%)', ' Mucositis oral 1/45 (2.22%)', ' Nausea 1/45 (2.22%)', ' Vomiting 1/45 (2.22%)', ' Chest pain 1/45 (2.22%)', ' Chills 1/45 (2.22%)', ' Disease progression 0/45 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

38f47a03-f71d-4072-a005-b954fb6069da

Single

Adverse Events

NCT00129376

More than 2% of patients in the primary trial experienced a clinically significant inflammation of the back of the throat.

Contradiction

{'Clinical Trial ID': 'NCT00129376', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin + Cyclophosphamide Followed Docetaxel', ' Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles (days 1, 22, 43 and 64). Three weeks later, docetaxel (36 mg/m2) was administered as a 30-min intravenous infusion, weekly for six weeks (days 85, 92, 99, 106, 113 and 120) followed by a 2-week resting period (8-week cycle). After that, patients received a second docetaxel cycle (infusions on days 141, 148, 155, 162, 169 and 176).'], 'Eligibility': ['Inclusion Criteria:', ' Written informed consent.', ' Patients with breast cancer stages II and IIIA, with histological diagnoses as per true-cut or open biopsy.', ' Negative extension study, including bilateral mammography, thoracic x-ray, computed tomography (CT)-scan or abdominal echography and bone scintigraphy.', ' Analysis of hormone receptor status in primary tumour. It is highly recommended to obtain a tumour tissue sample before start of treatment, and after definitive surgery. These samples will be analysed centrally by Spanish Breast Cancer Research Group (GEICAM).', ' Age >= 18 and <= 70 years old.', ' Performance status as per Karnofsky index >= 80.', ' Minimum life expectancy of 6 months.', ' Electrocardiogram (EKG) 12 weeks before registration to the study. If abnormalities are suspected, cardiac function must be assessed by left ventricular ejection fraction (LVEF).', ' Haematology: neutrophils >= 2.0 x10^9/l; platelets >= 100 x10^9/l; hemoglobin >=10 g/dl.', ' Hepatic function: total bilirubin <= 1 x upper normal limit (UNL); Aspartate aminotransferase (AST) (SGOT) and and Alanine aminotransferase (ALT) (SGPT) <= 2.5 x UNL; alkaline phosphatase <= 5 x UNL.', ' Renal function: creatinine <= 1.5 x UNL; creatinine clearance >= 60 ml/min.', ' Patients able to comply with study requirements.', ' Negative pregnancy test.', ' Adequate contraceptive method during the study and up to 3 months after definitive surgery.', 'Exclusion Criteria:', ' Previous systemic therapy for breast cancer treatment.', ' Previous treatments with anthracyclines or taxanes for any malignancy.', ' Previous radiotherapy for breast cancer.', ' Bilateral invasive breast cancer.', ' Pregnant or lactating women.', ' Previous motor or sensorial neurotoxicity grade >=2.', ' Other serious pathologies: congestive heart failure or angina pectoris; history of myocardial infarction in the previous year; uncontrolled hypertension (HT) or high risk arrhythmias.', ' History of neurological or psychiatric impairment, precluding patients from providing free informed consent.', ' Active infection.', ' Active peptic ulcer; unstable diabetes mellitus.', ' History of previous or current malignancies other than breast cancer, except for basal skin carcinoma, cervical in situ carcinoma, other tumour diagnosed and treated more than 10 years before, ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS).', ' Chronic treatment with corticoids unless the treatment started > 6 months before registration to the study, and low doses are administered.', ' Substitutive hormonal therapy. This treatment must be interrupted before inclusion in the study.', ' Concomitant treatment with other investigational products or administration in the 30 previous days.', 'Males.'], 'Results': ['Outcome Measurement: ', ' Pathological Complete Response (pCR) Rate', ' Pathological complete response was defined by the Miller & Payne criteria. pCR was defined as no invasive cells identifiable in breast sections at surgery. Response was measured by physical exam and breast imaging before surgery and was evaluated according to the World Health Organization (WHO) criteria. Pathological response after surgery, was based on the proportion of remaining tumor and postchemotherapy changes, evaluating separately the response in the breast and in the axilla lymph nodes.', ' Time frame: Up to 29 weeks', 'Results 1: ', ' Arm/Group Title: Doxorubicin + Cyclophosphamide Followed Docetaxel', ' Arm/Group Description: Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles (days 1, 22, 43 and 64). Three weeks later, docetaxel (36 mg/m2) was administered as a 30-min intravenous infusion, weekly for six weeks (days 85, 92, 99, 106, 113 and 120) followed by a 2-week resting period (8-week cycle). After that, patients received a second docetaxel cycle (infusions on days 141, 148, 155, 162, 169 and 176).', ' Overall Number of Participants Analyzed: 61', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 11 18.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 12/63 (19.05%)', ' Febrile neutropenia * [1]4/63 (6.35%)', ' Congestive heart failure * [2]1/63 (1.59%)', ' Cardiac-ischemia/infarction * 1/63 (1.59%)', ' Vomiting * [1]1/63 (1.59%)', ' Acute Pharyngitis * 1/63 (1.59%)', ' Infection * 3/63 (4.76%)', ' Neutrophil count decreased * [1]1/63 (1.59%)', ' Pneumonitis/pulmonary infiltrates * [3]1/63 (1.59%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

e41917b8-d921-4797-b845-0121a75104a4

Single

Results

NCT02513472

Cohort 1 patients in the primary trial surivied almost twice as long as those in cohort 2.

Contradiction

{'Clinical Trial ID': 'NCT02513472', 'Intervention': ['INTERVENTION 1: ', ' Stratum 1: Eribulin Mesylate + Pembrolizumab', ' Participants with mTNBC who were never treated with systemic anticancer therapy in the metastatic setting received eribulin mesylate 1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrolizumab 200 mg, intravenous infusion on Day 1 in Treatment Cycle 1 (safety run-in, Phase 1b) and then continued in each 21-days Treatment Cycles in the presence of clinical benefit until confirmed disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor in Phase 2 in the Stratum 1.', 'INTERVENTION 2: ', ' Stratum 2: Eribulin Mesylate + Pembrolizumab', ' Participants with mTNBC previously treated with 1 to 2 lines of systemic anticancer therapy in the metastatic setting received eribulin mesylate 1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrolizumab 200 mg, intravenous infusion on Day 1 in Treatment Cycle 1 (safety run-in, Phase 1b) and then continued in each 21-days Treatment Cycles in the presence of clinical benefit until confirmed disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor in Phase 2 in the Stratum 2.'], 'Eligibility': ['Inclusion Criteria:', ' Females or males, aged >=18 years at the time of signing the informed consent form (ICF).', ' mTNBC (confirmed from most recent tissue sample) meeting the following criteria:', ' Estrogen receptor (ER) and progesterone receptor negative (a tumor is ER and/or progesterone receptor positive if at least 1 percent (%) of the cells examined have estrogen and/or progesterone receptors) and human epidermal growth factor receptor 2 (HER2) negative (defined as immunohistochemistry [IHC] less than (<) 2+ or fluorescence in situ hybridization [FISH] negative).', ' Previously treated with 0 to 2 lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting. Hormonal therapy and bone metastases treatment (example, bisphosphonates, denosumab, etc) are not considered forms of systemic anticancer therapy.', ' Presence of measurable disease meeting the following criteria:', ' At least 1 lesion of >=10 millimeter (mm) in long axis diameter for nonlymph nodes or >=15 mm in short axis diameter for lymph nodes that is serially measurable according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) using computerized tomography (CT) or magnetic resonance imaging (MRI) or panoramic and close-up color photography.', ' Lesions that have had radiotherapy must show subsequent radiographic evidence of increased size to be deemed a target lesion.', ' Life expectancy of >=3 months.', ' Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.', ' Adequate renal function as evidenced by serum creatinine less than or equal to (<=) 1.5 milligram per deciliter (mg/dL) or calculated creatinine clearance >=50 millimeter per minute (mL/min) according to the Cockcroft and Gault formula.', ' Adequate bone marrow function, defined as:', ' Absolute neutrophil count (ANC) >=1.5*10^9/L.', ' Hemoglobin (Hb) >=10.0 gram per deciliter (g/dL) (can be corrected by growth factor or transfusion).', ' Platelet count >=100*10^9/L.', ' Adequate liver function, defined as:', ' Total bilirubin <=1.5*upper limit of normal (ULN).', ' Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) <=3*ULN unless there are bone metastases, in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase. ALT and AST <= 5*ULN if participant has liver metastases.', ' Resolution of all chemotherapy-related or radiation-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy (<= Grade 2) and alopecia.', ' Archived tissue sample or new biopsy sample.', ' Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta-human chorionic gonadotropin [B-hCG] (or human chorionic gonadotropin [hCG]) test with a minimum sensitivity of 25 International units per litre (IU/L) or equivalent units of B-hCG [or hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.', ' All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (that is, bilateral tubal ligation, total hysterectomy or bilateral oophorectomy, all with surgery at least 1 month before dosing).', ' Females of childbearing potential must not have had unprotected sexual intercourse within 30 days before study entry and must agree to use a highly effective method of contraception (example, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, a combination oral contraceptive (estrogen/progesterone), or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 120 days after study drug discontinuation. If currently abstinent, the participant must agree to use a double barrier method as described above if she becomes sexually active during the study period or for 120 days after study drug discontinuation. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 28 days before dosing and must continue to use the same contraceptive during the study and for 120 days after study drug discontinuation.', ' Males who have had a successful vasectomy (confirmed azoospermia) or they and their female partners meet the criteria above (that is, not of childbearing potential or practicing highly effective contraception throughout the study period or for 120 days after study drug discontinuation). No sperm donation is allowed during the study period or for 120 days after study drug discontinuation.', ' Willing and able to comply with all aspects of the treatment protocol.', ' Provide written informed consent.', 'Exclusion Criteria:', ' Previous treatment with eribulin mesylate or any anti-programmed death receptor-1 (anti-PD-1), programmed death receptor ligand-1 (PD-L1), or PD-L2 agent.', ' Active autoimmune disease that has required systemic treatment in the past 2 years (that is, with use of disease modifying agents, corticosteroids, or immunosuppresive drugs). Replacement therapy (example, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc) is not considered a form of systemic treatment.', ' Less than 6 months since prior adjuvant chemotherapy.', ' Current enrollment in another interventional clinical study or used any investigational drug or device within the past 28 days preceding informed consent.', ' Treatment with chemotherapy or biological therapy within the previous 3 weeks, radiation or small molecule targeted therapy within the previous 2 weeks.', ' Known central nervous system (CNS) disease, except for those participants with treated brain metastasis who are stable for at least 1 month, having no evidence of progression or hemorrhage after treatment and no ongoing requirement for corticosteroids, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period.', ' Known history of human immunodeficiency virus (HIV) positive.', ' Known active hepatitis B (example, HBsAg reactive) or hepatitis C (example, hepatitis C virus ribonucleic acid (HCV RNA) detected).', ' Existing anticancer treatment-related toxicities of Grades >= 2 (except for alopecia and Grade 2 sensory neuropathy) according to Common Terminology Criteria for Adverse Events (CTCAE v4.03).', ' Any other malignancy that required treatment or has shown evidence of recurrence (except for nonmelanoma skin cancer, or histologically confirmed complete excision of carcinoma in situ) during the 5 years prior to enrollment in this study.', ' History of significant cardiovascular disease, defined as:', ' congestive heart failure greater than New York Heart Association (NYHA) Class II according to the NYHA Functional Classification.', ' unstable angina or myocardial infarction within 6 months of enrollment.', ' serious cardiac arrhythmia.', ' Clinically significant electrocardiogram (ECG) abnormality, including a marked Baseline prolonged QT interval/corrected QT interval ([QT/QTc], example, a repeated demonstration of a QTc interval >500 millisecond [ms]).', " History of concomitant medical conditions or infectious diseases that, in the opinion of the investigator, would compromise the participant's ability to safely complete the study.", ' Hypersensitivity to the active substance or any other excipients of the eribulin mesylate drug product, or severe hypersensitivity (>=Grade 3) to pembrolizumab and/or any of its excipients.', ' Scheduled for major surgery during the study.', ' Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the sponsor.', ' Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.', ' Has a history of interstitial lung disease.', ' Has an active infection requiring systemic therapy.', ' Has received a live-virus vaccination within 30 days of planned start of study therapy. Seasonal flu vaccines that do not contain live virus are permitted.', " The investigator's belief that the participant is medically unfit to receive eribulin mesylate and pembrolizumab or unsuitable for any other reason."], 'Results': ['Outcome Measurement: ', ' Objective Response Rate (ORR)', ' ORR was defined as percentage of participants with confirmed best overall response (BOR) of complete response (CR) or partial response (PR) using independent imaging review (IIR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. BOR of CR and PR was confirmed by a subsequent CR assessment and CR or PR assessment, respectively at least 4 weeks later. CR: disappearance of all measurable, non-measurable lesions and no unequivocal new lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (<) 10 millimeter (mm). PR: at least a 30 percent (%) decrease in sum of diameters (SOD) of target lesions, taking as reference the baseline SOD and there are no unequivocal new lesions, and no progression of non-target disease. The 2-sided 95% confidence interval (CI) calculated by Clopper-Pearson method. As planned, data up to the primary completion date only were analyzed.', ' Time frame: From date of first dose of study drug administration to date of first documentation of disease progression or death, whichever occurred first (up to 3 years 11 months)', 'Results 1: ', ' Arm/Group Title: Stratum 1: Eribulin Mesylate + Pembrolizumab', ' Arm/Group Description: Participants with mTNBC who were never treated with systemic anticancer therapy in the metastatic setting received eribulin mesylate 1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrolizumab 200 mg, intravenous infusion on Day 1 in Treatment Cycle 1 (safety run-in, Phase 1b) and then continued in each 21-days Treatment Cycles in the presence of clinical benefit until confirmed disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor in Phase 2 in the Stratum 1.', ' Overall Number of Participants Analyzed: 66', ' Measure Type: Number', ' Unit of Measure: percentage of participant 25.8 (15.8 to 38.0)', 'Results 2: ', ' Arm/Group Title: Stratum 2: Eribulin Mesylate + Pembrolizumab', ' Arm/Group Description: Participants with mTNBC previously treated with 1 to 2 lines of systemic anticancer therapy in the metastatic setting received eribulin mesylate 1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrolizumab 200 mg, intravenous infusion on Day 1 in Treatment Cycle 1 (safety run-in, Phase 1b) and then continued in each 21-days Treatment Cycles in the presence of clinical benefit until confirmed disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor in Phase 2 in the Stratum 2.', ' Overall Number of Participants Analyzed: 101', ' Measure Type: Number', ' Unit of Measure: percentage of participant 21.8 (14.2 to 31.1)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 30/66 (45.45%)', ' Anaemia 1/66 (1.52%)', ' Febrile neutropenia 1/66 (1.52%)', ' Neutropenia 2/66 (3.03%)', ' Cardiac arrest 1/66 (1.52%)', ' Pericardial effusion 0/66 (0.00%)', ' Adrenal insufficiency 1/66 (1.52%)', ' Retinal detachment 0/66 (0.00%)', ' Abdominal pain upper 1/66 (1.52%)', ' Colitis 1/66 (1.52%)', ' Constipation 0/66 (0.00%)', ' Diarrhoea 1/66 (1.52%)', ' Duodenal ulcer 0/66 (0.00%)', 'Adverse Events 2:', ' Total: 57/101 (56.44%)', ' Anaemia 1/101 (0.99%)', ' Febrile neutropenia 3/101 (2.97%)', ' Neutropenia 3/101 (2.97%)', ' Cardiac arrest 0/101 (0.00%)', ' Pericardial effusion 1/101 (0.99%)', ' Adrenal insufficiency 1/101 (0.99%)', ' Retinal detachment 1/101 (0.99%)', ' Abdominal pain upper 0/101 (0.00%)', ' Colitis 1/101 (0.99%)', ' Constipation 1/101 (0.99%)', ' Diarrhoea 0/101 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

bcb2d4a9-f2da-4a51-861b-3d5a9fbb6541

Comparison

Adverse Events

NCT02491892

NCT00887575

Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial, this is due to the significant difference in cohort size.

Contradiction

{'Clinical Trial ID': 'NCT02491892', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab 420 mg', ' Participants received a loading dose of 840 mg via IV infusion at the first infusion of pertuzumab, followed by a maintenance dose of 420 mg every 3 weeks until unacceptable toxicity or disease progression.', 'INTERVENTION 2: ', ' Pertuzumab 1050 mg', ' Participants did not receive a loading dose, but received pertuzumab 1050 mg via IV infusion every 3 weeks until unacceptable toxicity or disease progression.'], 'Eligibility': ['Inclusion Criteria:', ' Females at least 18 years of age', ' Histologically-confirmed metastatic breast cancer with low HER2 expression and at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST)', ' Karnofsky performance status at least 80%', ' Disease progression on/after up to 2 different chemotherapy regimens, including an anthracycline-containing therapy', ' Left ventricular ejection fraction (LVEF) at least 50%', ' Adequate liver function', 'Exclusion Criteria:', ' Pleural effusions, ascites, or bone lesions as the only manifestation(s) of cancer', ' Pulmonary or central nervous system (CNS) metastases', ' Chemotherapy, radiotherapy, or immunotherapy within 4 weeks; or hormone therapy within 2 weeks of Day 1', ' Previous treatment with any drug that targets the HER2 receptor family', ' Previous treatment with corticosteroids as cancer therapy', ' History of significant cardiac disease', ' Major surgery or trauma within 4 weeks of Day 1', ' Pregnant or lactating women'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants Achieving a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR)', ' Objective tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed CR was defined as the disappearance of all target lesions, and confirmed PR was defined as at least at 30 percent (%) decrease in the sum of the longest diameters of target lesions. Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response. The percentage of participants achieving a best overall response of CR or PR was calculated as [number of participants meeting the above criteria divided by the number analyzed] multiplied by 100.', ' Time frame: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)', 'Results 1: ', ' Arm/Group Title: Pertuzumab 420 mg', ' Arm/Group Description: Participants received a loading dose of 840 mg via IV infusion at the first infusion of pertuzumab, followed by a maintenance dose of 420 mg every 3 weeks until unacceptable toxicity or disease progression.', ' Overall Number of Participants Analyzed: 41', ' Measure Type: Number', ' Unit of Measure: percentage of participants 4.9', 'Results 2: ', ' Arm/Group Title: Pertuzumab 1050 mg', ' Arm/Group Description: Participants did not receive a loading dose, but received pertuzumab 1050 mg via IV infusion every 3 weeks until unacceptable toxicity or disease progression.', ' Overall Number of Participants Analyzed: 37', ' Measure Type: Number', ' Unit of Measure: percentage of participants 0'], 'Adverse Events': ['Adverse Events 1:', ' Total: 10/41 (24.39%)', ' Cardiac failure * 1/41 (2.44%)', ' Pericardial effusion * 1/41 (2.44%)', ' Ascites * 1/41 (2.44%)', ' Diarrhoea * 0/41 (0.00%)', ' Dysphagia * 0/41 (0.00%)', ' Large intestinal obstruction * 0/41 (0.00%)', ' Lung infection * 1/41 (2.44%)', ' Pneumonia * 1/41 (2.44%)', ' Sepsis * 1/41 (2.44%)', ' Ejection fraction decreased * 2/41 (4.88%)', ' Neck pain * 1/41 (2.44%)', 'Adverse Events 2:', ' Total: 8/37 (21.62%)', ' Cardiac failure * 0/37 (0.00%)', ' Pericardial effusion * 0/37 (0.00%)', ' Ascites * 1/37 (2.70%)', ' Diarrhoea * 1/37 (2.70%)', ' Dysphagia * 1/37 (2.70%)', ' Large intestinal obstruction * 1/37 (2.70%)', ' Lung infection * 0/37 (0.00%)', ' Pneumonia * 0/37 (0.00%)', ' Sepsis * 0/37 (0.00%)', ' Ejection fraction decreased * 0/37 (0.00%)', ' Neck pain * 0/37 (0.00%)']}

{'Clinical Trial ID': 'NCT00887575', 'Intervention': ['INTERVENTION 1: ', ' Phase II- Sunitinib/Paclitaxel/Carboplatin', ' Systemic Therapy based on maximum tolerated dose (MTD) of the Phase I portion'], 'Eligibility': ['Inclusion Criteria:', ' Female patients, age 18 years', ' Histologically confirmed invasive ER-, PR-, and HER2-negative (triple-negative) adenocarcinoma of the breast', ' Triple-negative tumors are defined as:', ' For HER2-negative:', ' Fluorescence in situ hybridization (FISH)-negative (defined by ratio <2.2) OR', ' Immunohistochemical (IHC) 0, IHC 1+, OR', ' IHC 2+ or IHC 3+ and FISH-negative (defined by ratio <2.2)', ' For ER- and PR-negative: <10% tumor staining by immunohistochemistry (IHC)', ' Primary palpable disease confined to a breast and axilla on physical examination. For patients without clinically suspicious axillary adenopathy, the primary tumor must be larger than 2 cm in diameter by physical exam or imaging studies (clinical T2-T3, N0-N1, M0). For patients with clinically suspicious axillary adenopathy, the primary breast tumor can be any size (clinical T1-3, N1-2, M0). T1N0M0 lesions are excluded. Patients with metastatic disease are excluded.', ' Patients without clearly defined palpable breast mass or axillary lymph nodes but radiographically measurable tumor masses are eligible. Accepted procedures for measuring breast disease are mammography, MRI, and breast ultrasound. Patients with lesions measurable only by imaging will require repeat imaging after 3 cycles and prior to surgery', ' Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2', ' Neuropathy grade <1 by the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v 3.0)', ' Resolution of all acute effects of surgical procedures to grade 1.', ' For patients who had, or will have sentinel lymph node and/or axillary dissection prior to initiation of study treatment, completion at least 4 weeks prior to starting study treatment and well-healed wound is required', ' Adequate hematologic function with:', ' Absolute neutrophil count (ANC) >1500/μL', ' Platelets 100,000/μL', ' Hemoglobin 10 g/dL', ' Adequate hepatic and renal function with:', ' Serum bilirubin the institutional upper limit of normal (ULN)', ' Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 2.5 x institutional ULN', ' Alkaline phosphatase 2.5 x institutional ULN', ' Serum creatinine 1.5 x ULN or calculated creatinine clearance 40 mL/min', ' Left ventricular ejection fraction (LVEF) 50% by multigated acquisition (MUGA) or echocardiogram (ECHO)', ' Bilateral, synchronous breast cancer is allowed if one primary tumor meets the inclusion criteria', ' Knowledge of the investigational nature of the study and ability to provide consent for study participation', ' Ability and willingness to comply with study visits, treatment, testing, and other study procedures', 'Exclusion Criteria:', ' Previous treatment for this breast cancer', ' Previous treatment with paclitaxel or carboplatin', ' Previous treatment with sunitinib or other angiogenic inhibitors (including, but not limited to bevacizumab, sorafenib, thalidomide)', ' Any of the following within the 12 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident including transient ischemic attack, or pulmonary embolus', ' Uncontrolled hypertension (blood pressure >150/100 mmHg despite optimal medical therapy)', ' Ongoing cardiac dysrhythmias grade 2, atrial fibrillation of any grade, or prolongation of the QTc interval to >470 msec', ' Major surgery, significant traumatic injury, or radiation therapy within 4 weeks of starting study treatment. An interval of at least 1week is required following minor surgical procedures, with the exception of placement of a vascular access device', ' Grade 3 hemorrhage within 4 weeks of starting study treatment', ' Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication', ' Known human immunodeficiency virus (HIV) infection or other serious infection', ' Concomitant treatment with drugs having proarrhythmic potential including terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide, and flecainide', " Concurrent use of the potent CYP3A4 inhibitors ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, amprenavir, indinavir, nelfinavir, delavirdine and voriconazole and CYP3A4 inducers rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, St. John's Wort, and dexamethasone. Use of dexamethasone for study premedication is allowed. Grapefruit and grapefruit juice is prohibited. Alternative therapies should be used when available. If use of a potent CYP3A4 inhibitor or inducer is necessary, this must be approved by the Study Chair", ' Known or suspected hypersensitivity to drugs containing Cremophor®EL (polyoxyethylated castor oil) such as cyclosporine or teniposide', ' Pregnancy or breast-feeding. Negative serum pregnancy test is required within 7 days prior to first study treatment (Day 1, Cycle ) for all women of childbearing potential. Patients of childbearing potential must agree to use a birth control method that is approved by their study physician while receiving study treatment and for three months after the last dose of study treatment. Patients must agree to not breast-feed while receiving study treatment', ' Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator (SERM). Patients must have discontinued use of such agents prior to beginning study treatment', ' History of malignancy treated with curative intent within the previous 5 years with the exception of skin cancer, cervical carcinoma in situ, or follicular thyroid cancer. Patients with previous invasive cancers (including breast cancer) are eligible if the treatment was completed more than 5 years prior to initiating current study treatment, and there is no evidence of recurrent disease', ' Use of any investigational agent within 30 days of administration of the first dose of study drug or concurrent treatment on another clinical study', ' Requirement for radiation therapy concurrent with study anticancer treatment. Patients who require breast or chest wall radiation therapy after surgery are eligible, but will have maintenance sunitinib interrupted while receiving radiation', ' Any other disease(s), psychiatric condition, metabolic dysfunction, or findings from a physical examination or clinical laboratory test result that would cause reasonable suspicion of a disease or condition, that contraindicates the use of study drugs, that may increase the risk associated with study participation, that may affect the interpretation of the results, or that would make the patient inappropriate for this study'], 'Results': ['Outcome Measurement: ', ' Phase II: The Number of Subjects Exhibiting Pathologic Complete Response to Neoadjuvant Treatment With Sunitinib/Paclitaxel/Carboplatin', ' Pathologic complete response (PCR) is defined as no residual invasive breast cancer in final breast or axillary lymph node samples.', ' Time frame: at weeks 26-30', 'Results 1: ', ' Arm/Group Title: Phase II- Sunitinib/Paclitaxel/Carboplatin', ' Arm/Group Description: Systemic Therapy based on maximum tolerated dose (MTD) of the Phase I portion', ' Overall Number of Participants Analyzed: 32', ' Measure Type: Number', ' Unit of Measure: participants 12'], 'Adverse Events': ['Adverse Events 1:', ' Total: 3/41 (7.32%)', ' ANEMIA 1/41 (2.44%)', ' FEBRILE NEUTROPENIA 1/41 (2.44%)', ' LEUKOPENIA 1/41 (2.44%)', ' NEUTROPENIA 2/41 (4.88%)', ' THROMBOCYTOPENIA 2/41 (4.88%)', ' DIARRHEA 1/41 (2.44%)', ' DYSPEPSIA 1/41 (2.44%)', ' FLATULENCE 1/41 (2.44%)', ' MUCOSITIS 1/41 (2.44%)', ' NAUSEA 2/41 (4.88%)', ' VOMITING 2/41 (4.88%)', ' EDEMA 1/41 (2.44%)', ' FATIGUE 2/41 (4.88%)', ' PHARYNGITIS 1/41 (2.44%)']}

3e56c28c-6d5c-49c4-aaf7-b4e2cb3ca2d7

Single

Results

NCT01881230

The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group

Contradiction

{'Clinical Trial ID': 'NCT01881230', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Nab-Paclitaxel + Gemcitabine', ' Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle. Participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment', 'INTERVENTION 2: ', ' Arm B: Nab-Paclitaxel + Carboplatin', ' Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle. Participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment.'], 'Eligibility': ['Inclusion Criteria: A subject will be eligible for inclusion in this study only if all of the following criteria are met:', ' Female subjects, age 18 years at the time informed consent is signed', ' Pathologically confirmed adenocarcinoma of the breast', ' Pathologically confirmed as triple negative, source documented, defined as both of the following', ' Estrogen Receptor (ER) and Progesterone Receptor (PgR) negative: < 1% of tumor cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PgR (positive intrinsic controls)', ' Human Epidermal Growth Factor Receptor 2 (HER2) negative as per American Society of Clinical Oncology - College of American Pathologists (ASCO/CAP) guidelines i. Immunohistochemistry (IHC) 0 or 1 Fluorescence In Situ Hybridization (FISH) negative (or equivalent negative test). Subjects with IHC 2 must have a negative by Fluorescence In Situ Hybridization (FISH),, (or equivalent negative test).', ' Subjects with prior breast cancer history of different phenotypes (ie, ER/PgR/HER2 positive) must have pathologic confirmation of triple negative disease in at least one of the current sites of metastasis', " Subjects must have received prior adjuvant or neoadjuvant anthracycline therapy; unless (a) anthracycline treatment was not indicated or was not the best treatment option for the subject in the opinion of the treating physician; and (b) anthracycline treatment remains not indicated or, in the opinion of the treating physician, is not the best treatment option for the subject's metastatic disease.", ' a. Newly diagnosed subjects presenting with TNMBC are eligible for the study if anthracycline treatment is not indicated or is not the best treatment option for the subject in the opinion of the treating physician.', ' Subjects with measurable metastatic disease, defined by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) guidelines', ' Life expectancy 16 weeks from randomization', ' No prior cytotoxic chemotherapy for metastatic breast cancer. Prior immunotherapy and/or monoclonal antibody therapy are acceptable. Prior treatments must have been discontinued at least 30 days prior to start of study treatment and all related toxicities must have resolved to Grade 1 or less.', ' Prior neoadjuvant or adjuvant chemotherapy, if given, must have been completed at least 6 months before randomization with all related toxicities resolved, and documented evidence of disease progression per RECIST 1.1 guidelines is required.', ' a. If prior neoadjuvant or adjuvant chemotherapy contained taxane, gemcitabine, or platinum agents, the treatment must have completed at least 12 months before randomization', ' Prior radiotherapy must have completed before randomization, with full recovery from acute radiation side effects. At least one measurable lesion must be completely outside the radiation portal or there must be unequivocal radiologic or clinical exam proof of progressive disease within the radiation portal, in accordance with RECIST 1.1 guidelines', ' At least 30 days from major surgery before randomization, with full recovery', ' Eastern Cooperative Oncology Group (ECOG) performance status 0-1', ' Subject has the following blood counts at screening:', ' Absolute Neutrophil Count (ANC) 1500/mm^2 ;', ' Platelets 100,000/mm^2 ;', ' Hemoglobin (Hgb) 9 g/dL', ' Subject has the following blood chemistry levels at screening:', ' Aspartate aminotransferase (AST) Serum glutamic-oxaloacetic transaminase (SGOT), Alanine Aminotransferase (ALT ) Serum Glutamic Pyruvate Transaminase (SGPT) 2.5 x upper limit of normal range (ULN); if hepatic metastases present 5.0 x ULN', " Total serum bilirubin ULN; or total bilirubin 3.0 × ULN with direct bilirubin within normal range in subjects with documented Gilbert's Syndrome", ' Creatinine clearance > 60 mL/min (by Cockcroft-Gault)', ' Females of child-bearing potential [defined as a sexually mature women who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months)] must:', ' Demonstrate a negative serum pregnancy test result at screening (performed by central lab) confirmed by local negative urine pregnancy dipstick within 72 hours prior to the first dose of IP); pregnancy test with sensitivity of at least 25 mIU/mL; and', ' Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis) or agree to use, and be able to comply with, two physician approved effective contraception methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) without interruption for 28 days or longer as required by local guidelines, prior to starting study drug, during the study therapy (including dose interruptions), and for 28 days after discontinuation of the study or longer as required by local guidelines', ' Females must abstain from breastfeeding starting at randomization, during study participation and for 28 days or longer as required by local guidelines, after IP discontinuation', ' Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted', ' Able to adhere to the study visit schedule and other protocol requirements', 'Exclusion Criteria:', ' A subject will not be eligible for inclusion in this study if any of the following criteria apply:', ' Male subjects', ' Concurrent chemotherapy or any other anti tumor therapy for breast cancer. Prior immunotherapy & monoclonal antibody therapy are acceptable.', ' Subjects who received prior cytotoxic chemotherapy after incomplete resection of locoregional recurrent disease', ' History of, or known current evidence of brain metastasis, including leptomeningeal involvement.', ' Subjects with bone as the only site of metastatic disease', ' Subjects with regional lymph node as the only site of metastatic disease', ' Serious intercurrent medical or psychiatric illness, including serious active infection', ' History of class II-IV congestive heart failure or myocardial infarction within 6 months of randomization', ' History of other primary malignancy in the last 5 years prior to randomization. Subjects with prior breast cancer history are eligible, however, the most recently obtained biopsy must demonstrate triple negative disease (source documented). Subjects with prior history of in situ cancer or basal or localized squamous cell skin cancer are eligible.', ' Subjects with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple uncontrolled or unstable allergies which, in the opinion of the investigator, may lead to serious complications', ' Peripheral neuropathy Grade 2 by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0', ' Subjects who have received an investigational product within the previous 4 weeks prior to randomization', ' Subject is currently enrolled, or will enroll in a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study', ' Pregnant or nursing women', ' Subjects with prior hypersensitivity to nab-paclitaxel, gemcitabine, carboplatin or any other platin, or nucleoside analogue agents', ' Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study', ' Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if she were to participate in the study', ' Any condition that confounds the ability to interpret data from the study', ' History of seropositive human immunodeficiency virus (HIV)', ' Subjects who are receiving immunosuppressive or myelosuppressive medications that would, in the opinion of the investigator, increase the risk of serious neutropenic complications'], 'Results': ['Outcome Measurement: ', ' Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment.', ' PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause on or prior to the data cutoff date for the statistical analysis, whichever occurred earlier. Tumor responses were assessed every 6 weeks using, Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Stable disease is neither sufficient shrinkage to qualify for a PR nor sufficient increase of lesions to qualify for Progressive disease (PD); Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir.', ' Time frame: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C', 'Results 1: ', ' Arm/Group Title: Arm A: Nab-Paclitaxel + Gemcitabine', ' Arm/Group Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle. Participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment', ' Overall Number of Participants Analyzed: 61', ' Median (95% Confidence Interval)', ' Unit of Measure: months 5.5 (4.1 to 7.0)', 'Results 2: ', ' Arm/Group Title: Arm B: Nab-Paclitaxel + Carboplatin', ' Arm/Group Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle. Participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment.', ' Overall Number of Participants Analyzed: 64', ' Median (95% Confidence Interval)', ' Unit of Measure: months 8.3 (5.7 to 10.6)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 22/60 (36.67%)', ' Anaemia 2/60 (3.33%)', ' Febrile neutropenia 1/60 (1.67%)', ' Neutropenia 1/60 (1.67%)', ' Pancytopenia 0/60 (0.00%)', ' Thrombocytopenia 0/60 (0.00%)', ' Acute myocardial infarction 0/60 (0.00%)', ' Atrial fibrillation 1/60 (1.67%)', ' Cardiac failure 1/60 (1.67%)', ' Myocardial infarction 0/60 (0.00%)', ' Palpitations 1/60 (1.67%)', ' Pericardial effusion 0/60 (0.00%)', 'Adverse Events 2:', ' Total: 20/64 (31.25%)', ' Anaemia 2/64 (3.13%)', ' Febrile neutropenia 3/64 (4.69%)', ' Neutropenia 2/64 (3.13%)', ' Pancytopenia 0/64 (0.00%)', ' Thrombocytopenia 0/64 (0.00%)', ' Acute myocardial infarction 0/64 (0.00%)', ' Atrial fibrillation 0/64 (0.00%)', ' Cardiac failure 0/64 (0.00%)', ' Myocardial infarction 1/64 (1.56%)', ' Palpitations 0/64 (0.00%)', ' Pericardial effusion 0/64 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

27397dfc-b6cf-41a3-862c-a99ccd2ddd5d